

Atezolizumab for First-Line Treatment of Metastatic No

New England Journal of Medicine

378, 2288-2301

DOI: [10.1056/nejmoa1716948](https://doi.org/10.1056/nejmoa1716948)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Treatment of Advanced Non-Small-Cell Lung Cancer: From Chemotherapy to Chemoimmunotherapy. <i>Journal of Oncology Practice</i> , 2018, 14, 537-538.	2.5	13
2	Navigating Through New, First-Line Treatment Options for Lung Cancer. <i>Journal of Oncology Practice</i> , 2018, 14, 539-540.	2.5	0
3	Atezolizumab for first-line treatment of metastatic nonsquamous non-small cell lung cancer: what makes the difference?. <i>Journal of Thoracic Disease</i> , 2018, 10, S3241-S3243.	0.6	2
4	PD-1 and PD-L1 inhibitor toxicities in non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, S4034-S4037.	0.6	5
5	Challenges and unanswered questions for the next decade of immune-oncology research in NSCLC. <i>Translational Lung Cancer Research</i> , 2018, 7, 691-702.	1.3	8
6	Immunotherapy in tyrosine kinase inhibitor-naïve advanced epidermal growth factor receptor-mutant non-small cell lung cancer—driving down a precarious road in driver-mutated lung cancer. <i>Translational Lung Cancer Research</i> , 2018, 7, S377-S380.	1.3	3
7	Immunotherapies in the management of epidermal growth factor receptor mutated non-small cell lung cancer: a role will be found?. <i>Translational Lung Cancer Research</i> , 2018, 7, S370-S372.	1.3	2
9	A new era of treating advanced lung cancer is upon us. <i>Translational Lung Cancer Research</i> , 2018, 7, S202-S205.	1.3	2
10	Atezolizumab in non-squamous non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, S3155-S3159.	0.6	4
11	Identification of a novel therapeutic target in driver-negative non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2018, 7, S218-S220.	1.3	0
12	Reversal of resistance to chemotherapy following anti-programmed cell death-1 immunotherapy in metastatic lung adenocarcinoma. <i>Medicine (United States)</i> , 2018, 97, e13427.	0.4	1
13	A case report of remarkable response to association of radiofrequency ablation with subsequent Atezolizumab in stage IV nonsmall cell lung cancer. <i>Medicine (United States)</i> , 2018, 97, e13112.	0.4	14
14	Histology versus cytology: PD-L1 testing in non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2018, 7, S225-S227.	1.3	7
15	Do toxicity patterns vary between programmed death-1 and programmed death ligand-1 inhibitors?. <i>Journal of Thoracic Disease</i> , 2018, 10, S4069-S4072.	0.6	3
16	30-day mortality after the start of systemic anticancer therapy for lung cancer: is it really a useful performance indicator?. <i>ERJ Open Research</i> , 2018, 4, 00030-2018.	1.1	16
22	Advances in evidence-based medicine for immunotherapy of non-small cell lung cancer. <i>Journal of Evidence-Based Medicine</i> , 2018, 11, 278-287.	2.4	22
23	Checkpoint Inhibitor Pneumonitis—Real-World Incidence and Risk. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1812-1814.	0.5	10
24	Combination of PD-1 blockade and RetroNectin-activated cytokine-induced killer in preheavily treated non-small-cell lung cancer: a retrospective study. <i>Immunotherapy</i> , 2018, 10, 1315-1323.	1.0	6

#	ARTICLE	IF	CITATIONS
25	The efficacy and safety of immune checkpoint inhibitor combination therapy in lung cancer: a systematic review and meta-analysis. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 7369-7383.	1.0	19
26	Specialists to the Rescue of Oncologists for the Management of Toxicity Occurring Under Combination of Anticancer Therapies. <i>Journal of Thoracic Oncology</i> , 2018, 13, e231-e232.	0.5	1
27	ASCO 2018 NSCLC highlights combination therapy is key. <i>Memo - Magazine of European Medical Oncology</i> , 2018, 11, 266-271.	0.3	12
28	The prognostic significance of circulating tumor cells in head and neck and non-small cell lung cancer. <i>Cancer Medicine</i> , 2018, 7, 5910-5919.	1.3	91
29	Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for first-line treatment in advanced non-small cell lung carcinoma: a systematic review and meta-analysis. , 2018, 6, 155.		82
30	Multicenter phase II study on cisplatin, pemetrexed, and bevacizumab followed by maintenance with pemetrexed and bevacizumab for patients with advanced or recurrent nonsquamous non-small cell lung cancer: MAP study. <i>BMC Cancer</i> , 2018, 18, 1231.	1.1	10
31	Immunotherapy in Lung Cancer: A New Age in Cancer Treatment. <i>Advances in Experimental Medicine and Biology</i> , 2018, 995, 65-95.	0.8	49
33	L'immunothérapie de première ligne pour les CBNPC de stades avancés (sans addiction oncogénique). <i>Revue Des Maladies Respiratoires Actualités</i> , 2018, 10, 380-384.	0.0	0
36	CXCR4 Based Therapeutics for Non-Small Cell Lung Cancer (NSCLC). <i>Journal of Clinical Medicine</i> , 2018, 7, 303.	1.0	38
37	Therapeutic Strategies in EGFR Mutant Non-Small Cell Lung Cancer. <i>Current Treatment Options in Oncology</i> , 2018, 19, 58.	1.3	41
38	Profile of atezolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 2857-2873.	2.0	10
39	Hedgehog Signaling in Lung Cancer: From Oncogenesis to Cancer Treatment Resistance. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2835.	1.8	74
40	Multiplex Immuno-Liquid Chromatography-Mass Spectrometry-Parallel Reaction Monitoring (LC-MS-PRM) Quantitation of CD8A, CD4, LAG3, PD1, PD-L1, and PD-L2 in Frozen Human Tissues. <i>Journal of Proteome Research</i> , 2018, 17, 3932-3940.	1.8	15
41	Pembrolizumab for the treatment of gastric cancer. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 1177-1187.	1.1	13
42	Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2018, 29, iv192-iv237.	0.6	1,571
43	Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1436-1437.	0.5	7
44	Far upstream element-binding protein 1 is up-regulated in pancreatic cancer and modulates immune response by increasing programmed death ligand 1. <i>Biochemical and Biophysical Research Communications</i> , 2018, 505, 830-836.	1.0	10
46	Should chemotherapy plus immune checkpoint inhibition be the standard frontline therapy for patients with metastatic non-small cell lung cancer?. <i>Cancer</i> , 2018, 124, 4592-4596.	2.0	7

#	ARTICLE	IF	CITATIONS
47	Pneumonitis in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1930-1939.	0.5	282
48	Durvalumab in NSCLC: latest evidence and clinical potential. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591880415.	1.4	22
49	Immune Marker Profiling and Programmed Death Ligand 1 Expression Across NSCLC Mutations. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1884-1896.	0.5	78
50	Choosing the Best Chemotherapy Agent to Boost Immune Checkpoint Inhibition Activity. <i>Cancer Research</i> , 2018, 78, 5729-5730.	0.4	11
51	Immunotherapy for oncogenic-driven advanced non-small cell lung cancers: Is the time ripe for a change?. <i>Cancer Treatment Reviews</i> , 2018, 71, 47-58.	3.4	37
52	Combination of Crizotinib and Osimertinib or Erlotinib Might Overcome MET-Mediated Resistance to EGFR Tyrosine Kinase Inhibitor in EGFR-Mutated Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2018, 13, e232-e234.	0.5	21
53	Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. <i>New England Journal of Medicine</i> , 2018, 379, 2108-2121.	13.9	3,097
55	New strategies in immunotherapy for lung cancer: beyond PD-1/PD-L1. <i>Therapeutic Advances in Respiratory Disease</i> , 2018, 12, 175346661879413.	1.0	35
56	Strong Programmed Death Ligand 1 Expression Predicts Poor Response and De Novo Resistance to EGFR Tyrosine Kinase Inhibitors Among NSCLC Patients With EGFR Mutation. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1668-1675.	0.5	111
57	Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy. <i>JAMA Oncology</i> , 2018, 4, 1543.	3.4	567
58	Selecting immuno-oncology-based drug combinations - what should we be considering?. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 971-985.	1.3	5
60	Combinations of Bevacizumab With Cancer Immunotherapy. <i>Cancer Journal (Sudbury, Mass)</i> , 2018, 24, 193-204.	1.0	144
61	Atezolizumab Treatment of Nonsquamous NSCLC. <i>New England Journal of Medicine</i> , 2018, 379, 1187-1188.	13.9	10
62	Dabrafenib and trametinib for the treatment of non-small cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 1063-1068.	1.1	17
63	Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. <i>New England Journal of Medicine</i> , 2018, 379, e14.	13.9	164
64	EGFR TKIs and Immune Checkpoint Inhibitors: Is This an Optimal Combination?. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1245-1247.	0.5	1
65	Effectiveness and safety of PD-1/PD-L1 or CTLA4 inhibitors combined with chemotherapy as a first-line treatment for lung cancer: A meta-analysis. <i>Journal of Thoracic Disease</i> , 2018, 10, 6636-6652.	0.6	33
66	A Case of Nivolumab-induced Severe Neutropenia with Stomatitis, Enteritis and Liver Dysfunction. <i>Japanese Journal of Lung Cancer</i> , 2018, 58, 996-1000.	0.0	2

#	ARTICLE	IF	CITATIONS
67	Immune-checkpoint inhibitors in non-small cell lung cancer: A tool to improve patientsâ€™ selection. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 129, 27-39.	2.0	39
68	The changing scenario of 1st line therapy in non-oncogene addicted NSCLCs in the era of immunotherapy. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 130, 1-12.	2.0	16
69	Role of Immunotherapy for Oncogene-Driven Non-Small Cell Lung Cancer. <i>Cancers</i> , 2018, 10, 245.	1.7	34
70	Impact of PD-L1 Expression in EGFR-Positive NSCLC? The Answer Remains the Sameâ€¦. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1060-1061.	0.5	4
71	The Italian Nivolumab Expanded Access Program Confirms the Limitations of Single-Agent PD-1 Inhibition in EGFR-Mutant and Never-Smoking Patients with NSCLC. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1058-1059.	0.5	5
72	Therapeutic approaches for T790M mutation positive non-small-cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 1021-1030.	1.1	21
73	Monoclonal antibody therapy in cancer: When two is better (and considerably more expensive) than one. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2018, 43, 925-930.	0.7	5
74	RANBP9 affects cancer cells response to genotoxic stress and its overexpression is associated with worse response to platinum in NSCLC patients. <i>Oncogene</i> , 2018, 37, 6463-6476.	2.6	15
75	NCCN Guidelines Insights: Nonâ€“Small Cell Lung Cancer, Version 5.2018. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 807-821.	2.3	394
76	Frontline immunotherapy for NSCLC: alone or not alone?. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 593-594.	12.5	10
77	Is smoking history the truly best biomarker for immune checkpoint inhibitor treatment in advanced non-small cell lung cancer?. <i>ESMO Open</i> , 2018, 3, e000421.	2.0	9
78	Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors. <i>Molecular Cancer</i> , 2018, 17, 129.	7.9	536
79	Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced nonâ€“small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study. <i>Lung Cancer</i> , 2018, 125, 273-281.	0.9	69
80	Targeting oncogenic drivers in lung cancer: Recent progress, current challenges and future opportunities. , 2019, 193, 20-30.		49
81	Imaging of Precision Therapy for Lung Cancer: Current State of the Art. <i>Radiology</i> , 2019, 293, 15-29.	3.6	45
82	Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naïve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905). <i>Journal of Clinical Oncology</i> , 2019, 37, 2537-2547.	0.8	36
83	Rate of cancer progression as a predictive marker of efficacy of immunotherapy; an analysis in metastatic non-small-cell lung cancer. <i>Immunotherapy</i> , 2019, 11, 657-665.	1.0	1
84	Targeting Vascular Endothelial Growth Factor in Oesophagogastric Cancer: A Review of Progress to Date and Immunotherapy Combination Strategies. <i>Frontiers in Oncology</i> , 2019, 9, 618.	1.3	9

#	ARTICLE	IF	CITATIONS
85	Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients With Advanced EGFR-Mutant Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2019, 5, 1448.	3.4	94
89	Management of non-small cell lung cancer harboring epidermal growth factor receptor mutations in the era of first-line osimertinib. <i>Journal of Thoracic Disease</i> , 2019, 11, 2664-2668.	0.6	3
90	Immunotherapy for non-small cell lung cancer: from clinical trials to real-world practice. <i>Translational Lung Cancer Research</i> , 2019, 8, 202-207.	1.3	12
91	Editorial on "The AvaALL Randomized Clinical Trial". <i>Journal of Thoracic Disease</i> , 2019, 11, S1237-S1240.	0.6	1
93	Treatment of uncommon EGFR mutations in non-small cell lung cancer: new evidence and treatment. <i>Translational Lung Cancer Research</i> , 2019, 8, 302-316.	1.3	91
94	What the Oncologist Needs From the Pathologist for Tyrosine Kinase Inhibitor Therapies. <i>Archives of Pathology and Laboratory Medicine</i> , 2019, 143, 1089-1092.	1.2	4
95	Advances in the prediction of long-term effectiveness of immune checkpoint blockers for non-small-cell lung cancer. <i>Immunotherapy</i> , 2019, 11, 993-1003.	1.0	16
96	Predictive value of PD-L1 and other clinical factors for chemoimmunotherapy in advanced non-small-cell lung cancer. <i>Future Oncology</i> , 2019, 15, 2371-2383.	1.1	4
97	Non-small-cell lung cancer: what are the benefits and challenges of treating it with immune checkpoint inhibitors?. <i>Immunotherapy</i> , 2019, 11, 1149-1160.	1.0	9
98	Subgroup Analysis of Japanese Patients in a Phase III Study of Atezolizumab in Extensive-stage Small-cell Lung Cancer (IMpower133). <i>Clinical Lung Cancer</i> , 2019, 20, 469-476.e1.	1.1	26
99	Pemetrexed, Bevacizumab, or the Combination As Maintenance Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer: ECOG-ACRIN 5508. <i>Journal of Clinical Oncology</i> , 2019, 37, 2360-2367.	0.8	52
100	The interaction of immune checkpoint inhibitor plus chemotherapy in non-small-cell lung cancer: subadditivity, additivity or synergism?. <i>Immunotherapy</i> , 2019, 11, 913-920.	1.0	13
101	PD-L1 expression and EGFR status in advanced non-small-cell lung cancer patients receiving PD-1/PD-L1 inhibitors: a meta-analysis. <i>Future Oncology</i> , 2019, 15, 1667-1678.	1.1	13
102	Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment. <i>Mayo Clinic Proceedings</i> , 2019, 94, 1623-1640.	1.4	1,153
103	Comparison of tumor cell numbers and 22C3 PD-L1 expression between cryobiopsy and transbronchial biopsy with endobronchial ultrasonography-guide sheath for lung cancer. <i>Respiratory Research</i> , 2019, 20, 185.	1.4	21
104	Prospect of immunotherapy combined with anti-angiogenic agents in patients with advanced non-small cell lung cancer. <i>Cancer Management and Research</i> , 2019, Volume 11, 7707-7719.	0.9	45
105	Novel Delivery Systems for Checkpoint Inhibitors. <i>Medicines (Basel, Switzerland)</i> , 2019, 6, 74.	0.7	24
106	Removal of N-Linked Glycosylation Enhances PD-L1 Detection and Predicts Anti-PD-1/PD-L1 Therapeutic Efficacy. <i>Cancer Cell</i> , 2019, 36, 168-178.e4.	7.7	240

#	ARTICLE	IF	CITATIONS
107	<p>Profile of alectinib for the treatment of ALK-positive non-small cell lung cancer (NSCLC): patient selection and perspectives</p>. OncoTargets and Therapy, 2019, Volume 12, 4567-4575.	1.0	14
108	Tumor Vasculatures: A New Target for Cancer Immunotherapy. Trends in Pharmacological Sciences, 2019, 40, 613-623.	4.0	79
109	Targeting PD-1 in cancer: Biological insights with a focus on breast cancer. Critical Reviews in Oncology/Hematology, 2019, 142, 35-43.	2.0	18
110	Opportunities of circulating tumor DNA in lung cancer. Cancer Treatment Reviews, 2019, 78, 31-41.	3.4	16
111	Rational application of the first-line chemotherapy and immune checkpoint inhibitors in advanced nonsmall cell lung cancer: A meta-analysis. Cancer Medicine, 2019, 8, 5033-5046.	1.3	9
112	Heterogeneity analysis of PD-L1 expression and copy number status in EBUS-TBNA biopsy specimens of non-small cell lung cancer: Comparative assessment of primary and metastatic sites. Lung Cancer, 2019, 134, 202-209.	0.9	35
113	Baseline Absolute Lymphocyte Count and ECOG Performance Score Are Associated with Survival in Advanced Non-Small Cell Lung Cancer Undergoing PD-1/PD-L1 Blockade. Journal of Clinical Medicine, 2019, 8, 1014.	1.0	41
114	Targeted Therapies in Lung Cancer: Management Strategies for Nurses and Practitioners. , 2019, , .		0
115	New emerging targets in cancer immunotherapy: the role of TIM3. ESMO Open, 2019, 4, e000497.	2.0	72
116	Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer. JAMA Network Open, 2019, 2, e196879.	2.8	161
117	First-line atezolizumab in addition to bevacizumab plus chemotherapy for metastatic, nonsquamous non-small cell lung cancer: A United States-based cost-effectiveness analysis. Cancer, 2019, 125, 3526-3534.	2.0	87
118	Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small cell lung cancer treated with nivolumab. Journal of Clinical Laboratory Analysis, 2019, 33, e22964.	0.9	171
119	Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial. Lancet Oncology, The, 2019, 20, 1109-1123.	5.1	193
120	Resistance to immune checkpoint inhibitors. Next steps and combinational approaches. Memo - Magazine of European Medical Oncology, 2019, 12, 123-127.	0.3	6
121	Immuno-Oncological Treatment and Tumor Mass in Non-Small Cell Lung Cancer: Case-Control Analysis of Overall Survival in Routine Clinical Practice. Oncology, 2019, 97, 228-235.	0.9	13
122	The Impact and Toxicity of Checkpoint Inhibitors in Management of Lung Cancer. , 2019, , 65-84.		0
123	ROS1. Current Cancer Research, 2019, , 55-78.	0.2	0
124	PF-06439535 (a Bevacizumab Biosimilar) Compared with Reference Bevacizumab (Avastin®), Both Plus Paclitaxel and Carboplatin, as First-Line Treatment for Advanced Non-Squamous Non-Small-Cell Lung Cancer: A Randomized, Double-Blind Study. BioDrugs, 2019, 33, 555-570.	2.2	36

#	ARTICLE	IF	CITATIONS
125	Concomitant medications during immune checkpoint blockage in cancer patients: Novel insights in this emerging clinical scenario. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 142, 26-34.	2.0	49
126	Practical Application of Real-World Evidence in Developing Cancer Therapies. <i>JCO Clinical Cancer Informatics</i> , 2019, 3, 1-2.	1.0	6
127	Impact of baseline steroids on efficacy of programmed cell death-1 (PD-1) and programmed death-ligand 1 (PD-L1) blockade in patients with advanced non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2019, 8, S364-S368.	1.3	18
128	Correlation between the qualification for bevacizumab use and the survival of patients with non-small cell lung cancer harboring the epidermal growth factor receptor mutation: a retrospective analysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 2555-2564.	1.2	6
129	Inhaled Submicron Particle Paclitaxel (NanoPac) Induces Tumor Regression and Immune Cell Infiltration in an Orthotopic Athymic Nude Rat Model of Non-Small Cell Lung Cancer. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2019, 32, 266-277.	0.7	11
130	<p>Clinical utility of ramucirumab in non-small-cell lung cancer</p>. <i>Biologics: Targets and Therapy</i> , 2019, Volume 13, 133-137.	3.0	6
131	A Computational Model of Neoadjuvant PD-1 Inhibition in Non-Small Cell Lung Cancer. <i>AAPS Journal</i> , 2019, 21, 79.	2.2	53
132	<p>Combination pembrolizumab plus chemotherapy: a new standard of care for patients with advanced non-small-cell lung cancer</p>. <i>Lung Cancer: Targets and Therapy</i> , 2019, Volume 10, 47-56.	1.3	12
133	Determinants of immunological evasion and immuncheckpoint inhibition response in non-small cell lung cancer: the genetic front. <i>Oncogene</i> , 2019, 38, 5921-5932.	2.6	27
134	Potential immune escape mechanisms underlying the distinct clinical outcome of immune checkpoint blockades in small cell lung cancer. <i>Journal of Hematology and Oncology</i> , 2019, 12, 67.	6.9	54
135	Metastasis manners and the underlying mechanisms of ALK and ROS1 rearrangement lung cancer and current possible therapeutic strategies. <i>RSC Advances</i> , 2019, 9, 17921-17932.	1.7	2
136	Recent Findings in the Regulation of Programmed Death Ligand 1 Expression. <i>Frontiers in Immunology</i> , 2019, 10, 1337.	2.2	85
137	Durable Response After 2 Doses of Pembrolizumab in a Patient With Nonâ€“Small-Cell Lung Cancer With an Isolated Brain Metastasis. <i>Clinical Lung Cancer</i> , 2019, 20, e552-e554.	1.1	1
138	Treatment of metastatic non-small cell lung cancer: 2018 guidelines of the Italian Association of Medical Oncology (AIOM). <i>Tumori</i> , 2019, 105, 3-14.	0.6	9
139	Elevated platelet-to-lymphocyte corresponds with poor outcome in patients with advanced cancer receiving anti-PD-1 therapy. <i>International Immunopharmacology</i> , 2019, 74, 105707.	1.7	11
140	EGFR Targeted Therapy. <i>Current Cancer Research</i> , 2019, , 1-30.	0.2	2
141	Role of immune checkpoint inhibitors in the treatment of colorectal cancer: focus on nivolumab. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 1247-1263.	1.4	29
142	Adoptive cell therapy with tumour-infiltrating lymphocytes: the emerging importance of clonal neoantigen targets for next-generation products in non-small cell lung cancer. <i>Immuno-Oncology Technology</i> , 2019, 3, 1-7.	0.2	20

#	ARTICLE	IF	CITATIONS
144	Pemetrexed exposure predicts toxicity in advanced non-small-cell lung cancer: A prospective cohort study. <i>European Journal of Cancer</i> , 2019, 121, 64-73.	1.3	16
145	Checkpoint inhibitors plus chemotherapy for first-line treatment of advanced non-small cell lung cancer: a systematic review and meta-analysis of randomized controlled trials. <i>Future Science OA</i> , 2019, 5, FSO421.	0.9	26
146	<p>Recent advances and application of PD-1 blockade in sarcoma</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 6887-6896.	1.0	17
147	Prognostic Factors and Biomarkers of Responses to Immune Checkpoint Inhibitors in Lung Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4931.	1.8	44
148	Efficacy and safety profiles of programmed cell death-1/programmed cell death ligand-1 inhibitors in the treatment of triple-negative breast cancer: A comprehensive systematic review. <i>Oncology Reviews</i> , 2019, 13, 425.	0.8	14
149	Factors Influencing the Efficacy of Anti-PD-1 Therapy in Chinese Patients with Advanced Melanoma. <i>Journal of Oncology</i> , 2019, 2019, 1-8.	0.6	9
150	A novel superhydrophobic coating consisting of SiC nanowires. <i>Materials Research Express</i> , 2019, 6, 105094.	0.8	3
151	Impact of clinicopathological features on the efficacy of immune checkpoint inhibitors plus conventional treatment in patients with advanced lung cancer. <i>Journal of Thoracic Disease</i> , 2019, 11, 3794-3807.	0.6	3
152	FDA- and EMA-Approved Tyrosine Kinase Inhibitors in Advanced EGFR-Mutated Non-Small Cell Lung Cancer: Safety, Tolerability, Plasma Concentration Monitoring, and Management. <i>Biomolecules</i> , 2019, 9, 668.	1.8	80
153	Hyperprogressive Disease during Anti-PD-1 (PDCD1) / PD-L1 (CD274) Therapy: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2019, 11, 1699.	1.7	81
155	Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater. <i>Lung Cancer</i> , 2019, 138, 88-94.	0.9	54
156	Comparisons between tumor burden and other prognostic factors that influence survival of patients with non-small cell lung cancer treated with immune checkpoint inhibitors. <i>Thoracic Cancer</i> , 2019, 10, 2259-2266.	0.8	18
157	The Levels of Interferon-gamma Release as a Biomarker for Non-small-cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors. <i>Anticancer Research</i> , 2019, 39, 6231-6240.	0.5	30
158	Translational Research and Onco-Omics Applications in the Era of Cancer Personal Genomics. <i>Advances in Experimental Medicine and Biology</i> , 2019, , .	0.8	0
159	The Differences in the Safety and Tolerability of Immune Checkpoint Inhibitors as Treatment for Non-small Cell Lung Cancer and Melanoma: Network Meta-Analysis and Systematic Review. <i>Frontiers in Pharmacology</i> , 2019, 10, 1260.	1.6	18
160	Adverse Events of Concurrent Immune Checkpoint Inhibitors and Antiangiogenic Agents: A Systematic Review. <i>Frontiers in Pharmacology</i> , 2019, 10, 1173.	1.6	35
162	Incidence of Immune Checkpoint Inhibitor-Associated Diabetes: A Meta-Analysis of Randomized Controlled Studies. <i>Frontiers in Pharmacology</i> , 2019, 10, 1453.	1.6	24
163	Immunogenicity of Del19 EGFR mutations in Chinese patients affected by lung adenocarcinoma. <i>BMC Immunology</i> , 2019, 20, 43.	0.9	6

#	ARTICLE	IF	CITATIONS
164	Efficacy of immune checkpoint inhibitors in cancer patients of different ages: a meta-analysis. <i>Future Oncology</i> , 2019, 15, 3633-3646.	1.1	8
165	Therapeutic Monoclonal Antibodies Targeting Immune Checkpoints for the Treatment of Solid Tumors. <i>Antibodies</i> , 2019, 8, 51.	1.2	32
166	Immune checkpoint inhibitors for head and neck squamous cell carcinoma: Current landscape and future directions. <i>Head and Neck</i> , 2019, 41, 4-18.	0.9	40
167	A prospective phase II study of carboplatin and nab-paclitaxel in patients with advanced non-small cell lung cancer and concomitant interstitial lung disease (HOT1302). <i>Lung Cancer</i> , 2019, 138, 65-71.	0.9	32
168	PLGA Nanoparticles Codelivering siRNAs against Programmed Cell Death Protein-1 and Its Ligand Gene for Suppression of Colon Tumor Growth. <i>Molecular Pharmaceutics</i> , 2019, 16, 4940-4953.	2.3	29
169	A modified recursive partitioning analysis for predicting overall survival in patients with non-small cell lung cancer and central nervous system metastases. <i>Journal of Thoracic Disease</i> , 2019, 11, 3909-3919.	0.6	2
170	Therapy Line and Associated Predictors of Response to PD-1/PD-L1-Inhibitor Monotherapy in Advanced Non-small-Cell Lung Cancer: A Retrospective Bi-centric Cohort Study. <i>Targeted Oncology</i> , 2019, 14, 707-717.	1.7	15
171	Treatment effect and safety profile of salvage chemotherapy following immune checkpoint inhibitors in lung cancer. <i>Lung Cancer Management</i> , 2019, 8, LMT12.	1.5	10
173	Theoretical and Practical Implications of Treating Cachexia in Advanced Lung Cancer Patients. <i>Cancers</i> , 2019, 11, 1619.	1.7	9
174	High mortality and poor treatment efficacy of immune checkpoint inhibitors in patients with severe grade checkpoint inhibitor pneumonitis in non-small cell lung cancer. <i>Thoracic Cancer</i> , 2019, 10, 2006-2012.	0.8	52
175	The efficacy of immune checkpoint inhibitors in anaplastic lymphoma kinase-positive non-small cell lung cancer. <i>Thoracic Cancer</i> , 2019, 10, 2117-2123.	0.8	9
176	Impact of tumor microenvironment on the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with EGFR-mutant non-small cell lung cancer. <i>Cancer Science</i> , 2019, 110, 3244-3254.	1.7	32
177	Urinary NGAL and RBP Are Biomarkers of Normoalbuminuric Renal Insufficiency in Type 2 Diabetes Mellitus. <i>Journal of Immunology Research</i> , 2019, 2019, 1-11.	0.9	24
178	Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 764.	3.8	720
179	Safety and efficacy of PD-1 blockade-activated multiple antigen-specific cellular therapy alone or in combination with apatinib in patients with advanced solid tumors: a pooled analysis of two prospective trials. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1467-1477.	2.0	19
180	Optimizing outcomes and treatment sequences in EGFR mutation-positive non-small-cell lung cancer: recent updates. <i>Future Oncology</i> , 2019, 15, 2983-2997.	1.1	27
181	New Insights into Mechanisms of Cisplatin Resistance: From Tumor Cell to Microenvironment. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4136.	1.8	249
182	Pretreatment prognostic nutritional index as a novel biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors. <i>Lung Cancer</i> , 2019, 136, 45-51.	0.9	84

#	ARTICLE	IF	CITATIONS
184	A Phase I, Randomized, Single-Dose Study Evaluating the Biosimilarity of TAB008 to Bevacizumab in Healthy Volunteers. <i>Frontiers in Pharmacology</i> , 2019, 10, 905.	1.6	9
185	Diagnosis and Treatment of ALK Aberrations in Metastatic NSCLC. <i>Current Treatment Options in Oncology</i> , 2019, 20, 79.	1.3	34
186	Tumor-induced peripheral immunosuppression promotes brain metastasis in patients with non-small cell lung cancer. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1501-1513.	2.0	39
187	Immune checkpoint inhibitors of PD-L1 as cancer therapeutics. <i>Journal of Hematology and Oncology</i> , 2019, 12, 92.	6.9	485
188	A phase II study of pembrolizumab and paclitaxel in patients with relapsed or refractory small-cell lung cancer. <i>Lung Cancer</i> , 2019, 136, 122-128.	0.9	38
189	First-line immune checkpoint inhibitors for advanced non-small cell lung cancer with wild-type epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK): a systematic review and network meta-analysis. <i>Journal of Thoracic Disease</i> , 2019, 11, 2899-2912.	0.6	15
190	Plasma Biomarkers and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: New Tools for Better Patient Selection?. <i>Cancers</i> , 2019, 11, 1269.	1.7	25
191	The Association Between the Incidence Risk of Peripheral Neuropathy and PD-1/PD-L1 Inhibitors in the Treatment for Solid Tumor Patients: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2019, 9, 866.	1.3	25
192	The evolving immuno-oncology landscape in advanced lung cancer: first-line treatment of non-small cell lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591987036.	1.4	45
193	Engineered T Cell Therapy for Cancer in the Clinic. <i>Frontiers in Immunology</i> , 2019, 10, 2250.	2.2	267
194	Real-World Clinical and Economic Outcomes and the Role of Bevacizumab in Patients With Non-Small-Cell Lung Cancer With Liver Metastases. <i>Journal of Oncology Practice</i> , 2019, 15, e878-e887.	2.5	8
195	Chemoimmunotherapy for stage IV non-small-cell lung cancer. <i>Lancet Oncology</i> , The, 2019, 20, e466.	5.1	5
196	Immune Checkpoint Inhibitors as Switch or Continuation Maintenance Therapy in Solid Tumors: Rationale and Current State. <i>Targeted Oncology</i> , 2019, 14, 505-525.	1.7	40
197	Chemoimmunotherapy for stage IV non-small-cell lung cancer – Authors' reply. <i>Lancet Oncology</i> , The, 2019, 20, e467.	5.1	0
198	New options for combination therapy for advanced non-squamous NSCLC. <i>Expert Review of Respiratory Medicine</i> , 2019, 13, 1095-1107.	1.0	15
199	Comparing three different anti-PD-L1 antibodies for immunohistochemical evaluation of small cell lung cancer. <i>Lung Cancer</i> , 2019, 137, 108-112.	0.9	10
200	An update on immunotherapy options for urothelial cancer. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 1265-1274.	1.4	14
201	Qualifying antibodies for image-based immune profiling and multiplexed tissue imaging. <i>Nature Protocols</i> , 2019, 14, 2900-2930.	5.5	92

#	ARTICLE	IF	CITATIONS
202	Osimertinib in first line setting: for Asian patients. <i>Translational Lung Cancer Research</i> , 2019, 8, 550-552.	1.3	0
203	Using Machine Learning to Bend the Cost Curve—Addressing High-Cost Targeted Therapeutics. <i>JAMA Network Open</i> , 2019, 2, e1911913.	2.8	1
204	Cost-effectiveness of Atezolizumab Combination Therapy for First-Line Treatment of Metastatic Nonsquamous Non—Small Cell Lung Cancer in the United States. <i>JAMA Network Open</i> , 2019, 2, e1911952.	2.8	47
205	<p>A multi-center, Phase II trial of nab-paclitaxel and gemcitabine in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 7135-7140.	0.9	5
206	New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness. <i>Frontiers in Oncology</i> , 2019, 9, 953.	1.3	97
207	Predictors of benefits from frontline chemoimmunotherapy in stage IV non-small-cell lung cancer: a meta-analysis. <i>Oncimmunology</i> , 2019, 8, e1665974.	2.1	14
208	Retrospective analysis of docetaxel in combination with ramucirumab for previously treated non-small cell lung cancer patients. <i>Translational Lung Cancer Research</i> , 2019, 8, 450-460.	1.3	18
209	The association of PD-L1 expression with the efficacy of anti-PD-1/PD-L1 immunotherapy and survival of non-small cell lung cancer patients: a meta-analysis of randomized controlled trials. <i>Translational Lung Cancer Research</i> , 2019, 8, 413-428.	1.3	95
210	Tumour Microenvironment and Immune Evasion in EGFR Addicted NSCLC: Hurdles and Possibilities. <i>Cancers</i> , 2019, 11, 1419.	1.7	54
211	Cardiovascular Toxicities of Immune—Checkpoint—Inhibitors. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1714-1727.	1.2	124
212	Nivolumab plus Ipilimumab in Advanced Non—Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 2020-2031.	13.9	1,866
213	Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer. <i>Drug Resistance Updates</i> , 2019, 46, 100644.	6.5	133
214	Clinical significance of PD-L1-positive cancer-associated fibroblasts in pNOMO non-small cell lung cancer. <i>Lung Cancer</i> , 2019, 137, 56-63.	0.9	43
215	Biomarkers for immune checkpoint inhibitors in advanced nonsmall cell lung cancer. <i>Current Opinion in Oncology</i> , 2019, 31, 24-28.	1.1	17
216	First-line checkpoint inhibitors for wild-type advanced non-small-cell cancer: a pair-wise and network meta-analysis. <i>Immunotherapy</i> , 2019, 11, 311-320.	1.0	8
217	The evolving role of immuno—oncology for the treatment of head and neck cancer. <i>Laryngoscope Investigative Otolaryngology</i> , 2019, 4, 62-69.	0.6	3
218	Regulatory T cells in cancer immunosuppression — implications for anticancer therapy. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 356-371.	12.5	872
219	Early fatal hemoptysis after first-dose, first-line pembrolizumab in a central lung cancer: did tumor shrinkage matter?. <i>Immunotherapy</i> , 2019, 11, 161-166.	1.0	5

#	ARTICLE	IF	CITATIONS
220	Immune checkpoint inhibitors and non-small-cell lung cancer management: 2018 update. <i>Immunotherapy</i> , 2019, 11, 149-153.	1.0	8
222	Overexpressed histone acetyltransferase 1 regulates cancer immunity by increasing programmed death-ligand 1 expression in pancreatic cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 47.	3.5	63
223	Pembrolizumab plus chemotherapy for first-line treatment of metastatic nonsquamous non-small-cell lung cancer: a network meta-analysis. <i>Immunotherapy</i> , 2019, 11, 407-428.	1.0	53
224	Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. <i>Annals of Oncology</i> , 2019, 30, 1321-1328.	0.6	842
226	<p>Incidence risk of PD-1/PD-L1 related diarrhea in non-small cell lung cancer (NSCLC) patients: a systematic review and meta-analysis</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 3957-3969.	0.9	5
227	Emerging angiogenesis inhibitors for non-small cell lung cancer. <i>Expert Opinion on Emerging Drugs</i> , 2019, 24, 71-81.	1.0	10
228	Recent advances in the clinical development of immune checkpoint blockade therapy. <i>Cellular Oncology (Dordrecht)</i> , 2019, 42, 609-626.	2.1	76
229	Can Immunogenic Chemotherapies Relieve Cancer Cell Resistance to Immune Checkpoint Inhibitors?. <i>Frontiers in Immunology</i> , 2019, 10, 1181.	2.2	20
230	Targeted Therapies in Non-small-Cell Lung Cancer. <i>Cancer Treatment and Research</i> , 2019, 178, 3-43.	0.2	16
231	Drug resistance in non-small cell lung Cancer (NSCLC): Impact of genetic and non-genetic alterations on therapeutic regimen and responsiveness. , 2019, 202, 140-148.		43
233	Uveal Melanoma, Angiogenesis and Immunotherapy, Is There Any Hope?. <i>Cancers</i> , 2019, 11, 834.	1.7	41
234	Highlights of thoracic oncology from the 2018 ERS International Congress. <i>ERJ Open Research</i> , 2019, 5, 00222-2018.	1.1	0
235	Prospects for a personalized peptide vaccine against lung cancer. <i>Expert Review of Vaccines</i> , 2019, 18, 703-709.	2.0	9
236	Homologous recombination and DNA repair mutations in patients treated with carboplatin and nab-paclitaxel for metastatic non-small cell lung cancer. <i>Lung Cancer</i> , 2019, 134, 167-173.	0.9	9
237	Immune checkpoint inhibitor treatment in patients with oncogene-addicted non-small cell lung cancer (NSCLC): summary of a multidisciplinary round-table discussion. <i>ESMO Open</i> , 2019, 4, e000498.	2.0	38
238	First-line immune checkpoint blockade for advanced non-small-cell lung cancer: Travelling at the speed of light. <i>Lung Cancer</i> , 2019, 134, 245-253.	0.9	35
239	Cancer immunotherapy: the art of targeting the tumor immune microenvironment. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 227-240.	1.1	50
240	Advanced-Stage Non-“Small Cell Lung Cancer: Advances in Thoracic Oncology 2018. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1134-1155.	0.5	61

#	ARTICLE	IF	CITATIONS
241	Early serum tumor marker dynamics predict progression-free and overall survival in single PD-1/PD-L1 inhibitor treated advanced NSCLC—A retrospective cohort study. <i>Lung Cancer</i> , 2019, 134, 59-65.	0.9	31
242	Clinical associations and prognostic value of site-specific metastases in non-small cell lung cancer: A population-based study. <i>Oncology Letters</i> , 2019, 17, 5590-5600.	0.8	22
243	Current status of immune checkpoint inhibition in early-stage NSCLC. <i>Annals of Oncology</i> , 2019, 30, 1244-1253.	0.6	98
244	Abandoning the Notion of Non-Small Cell Lung Cancer. <i>Trends in Molecular Medicine</i> , 2019, 25, 585-594.	3.5	207
245	<p>Nivolumab plus ipilimumab combination therapy for the first-line treatment NSCLC: evidence to date</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 4893-4904.	0.9	10
246	Disorder of Coagulation-Fibrinolysis System: An Emerging Toxicity of Anti-PD-1/PD-L1 Monoclonal Antibodies. <i>Journal of Clinical Medicine</i> , 2019, 8, 762.	1.0	53
247	From Hope to Reality: Durable Overall Survival With Immune Checkpoint Inhibitors for Advanced Lung Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 2511-2513.	0.8	22
248	Comparative safety analysis of immunotherapy combined with chemotherapy versus monotherapy in solid tumors: a meta-analysis of randomized clinical trials. <i>Oncotarget</i> , 2019, 10, 3294-3301.	0.8	13
249	Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer. <i>Lung Cancer</i> , 2019, 134, 259-267.	0.9	28
250	Association between peripheral blood markers and immune-related factors on tumor cells in patients with resected primary lung adenocarcinoma. <i>PLoS ONE</i> , 2019, 14, e0217991.	1.1	5
251	Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis. <i>Lung Cancer</i> , 2019, 134, 127-140.	0.9	156
252	Microtubule-targeting agents in the treatment of non-small cell lung cancer: insights on new combination strategies and investigational compounds. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 513-523.	1.9	21
253	The role of combination chemo-immunotherapy in advanced non-small cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 561-568.	1.1	58
254	EGFR mutation subtype impacts efficacy of immune checkpoint inhibitors in non-small-cell lung cancer. <i>Annals of Oncology</i> , 2019, 30, 1190-1192.	0.6	4
255	Lack of clearly defined role for anti-programmed death-(ligand) 1 therapy in epidermal growth factor receptor mutated non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2019, 8, 195-197.	1.3	2
256	Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop. , 2019, 7, 131.		64
257	Nivolumab plus ipilimumab in non-small-cell lung cancer. <i>Future Oncology</i> , 2019, 15, 2287-2302.	1.1	42
258	Advanced Non-small Cell Lung Cancer: Sequencing Agents in the EGFR-Mutated/ALK-Rearranged Populations. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, e187-e197.	1.8	33

#	ARTICLE	IF	CITATIONS
259	Reprogramming the Tumor Microenvironment to Improve Immunotherapy: Emerging Strategies and Combination Therapies. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 165-174.	1.8	123
260	Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncology, The, 2019, 20, 924-937.	5.1	1,133
261	Immune checkpoint inhibitors and neuropathy: A new dawn. Clinical Neurophysiology, 2019, 130, 1401-1402.	0.7	0
262	Sex-Based Heterogeneity in Response to Lung Cancer Immunotherapy: A Systematic Review and Meta-Analysis. Journal of the National Cancer Institute, 2019, 111, 772-781.	3.0	144
263	Efficacy and safety of nivolumab plus apatinib in advanced liver carcinosarcoma: A case report. Immunotherapy, 2019, 11, 651-656.	1.0	15
264	A Novel Paradigm Between Leukocytosis, G-CSF Secretion, Neutrophil-to-Lymphocyte Ratio, Myeloid-Derived Suppressor Cells, and Prognosis in Non-small Cell Lung Cancer. Frontiers in Oncology, 2019, 9, 295.	1.3	47
265	A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients With Small Cell Lung Cancer: Results From the IFCT-1603 Trial. Journal of Thoracic Oncology, 2019, 14, 903-913.	0.5	132
266	PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 2019, 14, 1021-1031.	0.5	79
267	Phase II trial of S-1 plus cisplatin combined with bevacizumab for advanced non-squamous non-small cell lung cancer (TCOG LC-1202). Japanese Journal of Clinical Oncology, 2019, 49, 749-754.	0.6	2
268	AVAILABLE NIS " AVASTIN" in lung cancer treatment in routine oncology practice in Germany. BMC Cancer, 2019, 19, 433.	1.1	9
269	IMpassion132 Phase III trial: atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer. Future Oncology, 2019, 15, 1951-1961.	1.1	58
270	Focus on Recommendations for the Management of Non-small Cell Lung Cancer. CardioVascular and Interventional Radiology, 2019, 42, 1230-1239.	0.9	2
271	Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker. BioMed Research International, 2019, 2019, 1-15.	0.9	37
272	Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 147-164.	1.8	459
273	PD(L)1 inhibitors vs chemotherapy vs their combination in front-line treatment for NSCLC: An indirect comparison. International Journal of Cancer, 2019, 145, 3011-3021.	2.3	15
274	The ABCs of preventing hyperprogressive disease after immunotherapy: awareness, biomarkers, and combination. Journal of Thoracic Disease, 2019, 11, S347-S351.	0.6	6
275	Resistance to epidermal growth factor receptor tyrosine kinase inhibitors in mutated non-small cell lung cancer: new avenues and strategies to overcome resistance. Memo - Magazine of European Medical Oncology, 2019, 12, 128-135.	0.3	1
276	A single-arm phase II trial of weekly nanoparticle albumin-bound paclitaxel (nab-paclitaxel) monotherapy after standard of chemotherapy for previously treated advanced non-small cell lung cancer. Cancer Chemotherapy and Pharmacology, 2019, 84, 351-358.	1.1	8

#	ARTICLE	IF	CITATIONS
277	Efficacy and safety of combination immunotherapy for malignant solid tumors: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 138, 178-189.	2.0	31
278	Strategies to Improve Cancer Immune Checkpoint Inhibitors Efficacy, Other Than Abscopal Effect: A Systematic Review. <i>Cancers</i> , 2019, 11, 539.	1.7	45
279	LKB1 and Tumor Metabolism: The Interplay of Immune and Angiogenic Microenvironment in Lung Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1874.	1.8	39
280	The role of osimertinib in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2019, 11, S448-S452.	0.6	7
281	Recent progress in nanomaterials for nucleic acid delivery in cancer immunotherapy. <i>Biomaterials Science</i> , 2019, 7, 2640-2651.	2.6	34
282	Chemotherapy in Combination With Immune Checkpoint Inhibitors for the First-Line Treatment of Patients With Advanced Non-small Cell Lung Cancer: A Systematic Review and Literature-Based Meta-Analysis. <i>Frontiers in Oncology</i> , 2019, 9, 264.	1.3	87
283	Beyond PD-L1 Markers for Lung Cancer Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1915.	1.8	61
284	Checkpoint blockade and nanosonosensitizer-augmented noninvasive sonodynamic therapy combination reduces tumour growth and metastases in mice. <i>Nature Communications</i> , 2019, 10, 2025.	5.8	404
285	Phase II Study of S-1 and Paclitaxel Combination Therapy in Patients with Previously Treated Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2019, 24, 1033-e617.	1.9	3
286	The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV. <i>International Journal of Clinical Oncology</i> , 2019, 24, 731-770.	1.0	100
287	Enhancing Antitumor Immunity with Antiangiogenic Therapy: A Clinical Model in Renal Cell Carcinoma?. <i>Oncologist</i> , 2019, 24, 725-727.	1.9	5
288	Feasibility study of metabolically supported chemotherapy with weekly carboplatin/paclitaxel combined with ketogenic diet, hyperthermia and hyperbaric oxygen therapy in metastatic non-small cell lung cancer. <i>International Journal of Hyperthermia</i> , 2019, 36, 445-454.	1.1	47
289	Immunotherapy in Non-Small-Cell Lung Cancer Patients With Performance Status 2: Clinical Decision Making With Scant Evidence. <i>Journal of Clinical Oncology</i> , 2019, 37, 1863-1867.	0.8	76
290	Exploring a Tumor-Intrinsic PD-L1 Signal with Proximity-Dependent Biotin Identification in Lung Cancer Cells. <i>Biochemistry</i> , 2019, 58, 2293-2296.	1.2	7
291	Emerging therapies for non-small cell lung cancer. <i>Journal of Hematology and Oncology</i> , 2019, 12, 45.	6.9	111
292	KEYNOTE-024: goodbye to chemotherapy?. <i>Journal of Thoracic Disease</i> , 2019, 11, S428-S432.	0.6	3
293	Treatment of patients with recurrent epithelial ovarian cancer for whom platinum is still an option. <i>Annals of Oncology</i> , 2019, 30, 721-732.	0.6	53
294	Redefining Treatment Paradigms in First-line Advanced Non-Small-Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 4881-4887.	3.2	10

#	ARTICLE	IF	CITATIONS
295	Pharmacokinetic Study of Osimertinib in Cancer Patients with Mild or Moderate Hepatic Impairment. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2019, 369, 291-299.	1.3	13
296	Next Generation Sequencing and Genetic Alterations in Squamous Cell Lung Carcinoma: Where Are We Today?. <i>Frontiers in Oncology</i> , 2019, 9, 166.	1.3	61
297	First-Line Therapy for Wild-Type Patients. , 2019, , 87-102.		1
298	Epidermal Growth Factor Receptorâ€“Mutant Nonâ€“Small-Cell Lung Cancer. , 2019, , 115-131.		0
299	Genomic correlates of response to immune checkpoint blockade. <i>Nature Medicine</i> , 2019, 25, 389-402.	15.2	346
300	VEGF in Signaling and Disease: Beyond Discovery and Development. <i>Cell</i> , 2019, 176, 1248-1264.	13.5	1,468
301	Carboplatin Plus Nab-paclitaxel in Performance Status 2 Patients With Advanced Non-small-cell Lung Cancer. <i>Anticancer Research</i> , 2019, 39, 1463-1468.	0.5	5
302	Immunotherapy in Nonâ€“Small Cell Lung Cancer: Facts and Hopes. <i>Clinical Cancer Research</i> , 2019, 25, 4592-4602.	3.2	447
303	Impact of early inflammatory cytokine elevation after commencement of PD-1 inhibitors to predict efficacy in patients with non-small cell lung cancer. <i>Medical Oncology</i> , 2019, 36, 33.	1.2	66
304	First-Line Treatment of Non-Small-Cell Lung Cancer (NSCLC) with Immuneâ€“Checkpoint Inhibitors. <i>BioDrugs</i> , 2019, 33, 159-171.	2.2	40
305	PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions. <i>Oncologist</i> , 2019, 24, S31-S41.	1.9	239
306	Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1431.	1.8	77
307	How to make the best use of immunotherapy as first-line treatment of advanced/metastatic non-small-cell lung cancer. <i>Annals of Oncology</i> , 2019, 30, 884-896.	0.6	78
308	Combined Checkpoint Inhibition and Chemotherapy: New Era of 1st-Line Treatment for Non-Small-Cell Lung Cancer. <i>Molecular Therapy - Oncolytics</i> , 2019, 13, 1-6.	2.0	26
309	Tumor Neovascularization and Developments in Therapeutics. <i>Cancers</i> , 2019, 11, 316.	1.7	85
310	From Whole-Brain Radiotherapy to Immunotherapy: A Multidisciplinary Approach for Patients with Brain Metastases from NSCLC. <i>Journal of Oncology</i> , 2019, 2019, 1-12.	0.6	12
311	Strategies to overcome acquired resistance to EGFR TKI in the treatment of non-small cell lung cancer. <i>Clinical and Translational Oncology</i> , 2019, 21, 1287-1301.	1.2	73
312	<p>Complete response associated with immune checkpoint inhibitors in advanced non-small-cell lung cancer: a meta-analysis of nine randomized controlled trials</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 1623-1629.	0.9	19

#	ARTICLE	IF	CITATIONS
313	Finally, after decades, immune checkpoint inhibitors dethroned the standard of care of small-cell lung cancer. <i>Immunotherapy</i> , 2019, 11, 457-460.	1.0	5
314	Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study. <i>Lancet Respiratory Medicine</i> , 2019, 7, 347-357.	5.2	137
315	The role of immune checkpoint inhibitors in advanced non-small cell lung cancer. <i>Expert Review of Respiratory Medicine</i> , 2019, 13, 435-447.	1.0	7
316	Toxicity patterns associated with chemotherapy/immune checkpoint inhibitor combinations: a meta-analysis. <i>Immunotherapy</i> , 2019, 11, 543-554.	1.0	11
317	Recent clinical trials of immunotherapy in non-small-cell lung cancer. <i>Immunotherapy</i> , 2019, 11, 461-466.	1.0	5
318	Clinical Cancer Advances 2019: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2019, 37, 834-849.	0.8	66
319	Using clinical genomic sequencing to guide personalized cancer therapy in China. <i>Personalized Medicine</i> , 2019, 16, 287-299.	0.8	2
320	Bevacizumab in EGFR-positive NSCLC: time to change first-line treatment?. <i>Lancet Oncology</i> , 2019, 20, 602-603.	5.1	4
321	Heterogeneous tumor features and treatment outcome between males and females with lung cancer (LC): Do gender and sex matter?. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 138, 87-103.	2.0	16
322	Are we ready to describe response or progression to immunotherapy in lung cancer?. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 138, 112-119.	2.0	10
323	A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab. <i>Journal of Translational Medicine</i> , 2019, 17, 99.	1.8	52
324	A Changing of the Guard: Immune Checkpoint Inhibitors With and Without Chemotherapy as First Line Treatment for Metastatic Non-small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 195.	1.3	48
325	Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. <i>Lancet Respiratory Medicine</i> , 2019, 7, 387-401.	5.2	704
326	Searching for a chemoimmunotherapy signal in patients with non-small-cell lung cancer and EGFR mutations. <i>Lancet Respiratory Medicine</i> , 2019, 7, 366-367.	5.2	5
327	Programmed Cell Death Ligand 1 Immunohistochemistry: A Concordance Study Between Surgical Specimen, Biopsy, and Tissue Microarray. <i>Clinical Lung Cancer</i> , 2019, 20, 258-262.e1.	1.1	23
328	Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out. <i>Cancer Treatment Reviews</i> , 2019, 75, 39-51.	3.4	124
329	The prognostic value of PKM2 and its correlation with tumour cell PD-L1 in lung adenocarcinoma. <i>BMC Cancer</i> , 2019, 19, 289.	1.1	21
330	Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment. <i>Molecular Cancer</i> , 2019, 18, 60.	7.9	361

#	ARTICLE	IF	CITATIONS
331	Outcome of Patients with Nonâ€“Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1244-1254.	0.5	178
332	Metabolic enzymes expressed by cancer cells impact the immune infiltrate. <i>Oncolmunology</i> , 2019, 8, e1571389.	2.1	15
333	Association between depth of response and survival in patients with advancedâ€“stage nonâ€“small cell lung cancer treated with firstâ€“line chemotherapy. <i>Cancer</i> , 2019, 125, 2394-2399.	2.0	8
334	Crizotinib-induced immunogenic cell death in non-small cell lung cancer. <i>Nature Communications</i> , 2019, 10, 1486.	5.8	189
335	Trials in progress: IMagyn050/GOG 3015/ENGOT-OV39. A Phase III, multicenter, randomized study of atezolizumab versus placebo administered in combination with paclitaxel, carboplatin, and bevacizumab to patients with newly-diagnosed stage III or stage IV ovarian, fallopian tube, or primary peritoneal cancer. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 430-433.	1.2	33
336	The Intersection between Tumor Angiogenesis and Immune Suppression. <i>Clinical Cancer Research</i> , 2019, 25, 5449-5457.	3.2	300
337	<i>EGFR</i>-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes. <i>Journal of Clinical Oncology</i> , 2019, 37, 278-285.	0.8	286
338	Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Nonâ€“Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater. <i>Journal of Clinical Oncology</i> , 2019, 37, 537-546.	0.8	1,144
339	Sequential therapy with ramucirumab and/or checkpoint inhibitors for non-small-cell lung cancer in routine practice. <i>Future Oncology</i> , 2019, 15, 2915-2931.	1.1	30
340	Comparative efficacy and safety of firstâ€“line treatments for advanced nonâ€“small cell lung cancer with immune checkpoint inhibitors: A systematic review and metaâ€“analysis. <i>Thoracic Cancer</i> , 2019, 10, 607-623.	0.8	22
341	Nivolumab-refractory patients with advanced non-small-cell lung cancer. <i>Lung Cancer</i> , 2019, 130, 128-134.	0.9	16
342	Efficacy of nintedanib and docetaxel in patients with advanced lung adenocarcinoma treated with first-line chemotherapy and second-line immunotherapy in the nintedanib NPU program. <i>Clinical and Translational Oncology</i> , 2019, 21, 1270-1279.	1.2	38
343	Targeting Immune Checkpoints in Lung Cancer: Current Landscape and Future Prospects. <i>Clinical Drug Investigation</i> , 2019, 39, 341-353.	1.1	28
344	Low-Dose Apatinib Optimizes Tumor Microenvironment and Potentiates Antitumor Effect of PD-1/PD-L1 Blockade in Lung Cancer. <i>Cancer Immunology Research</i> , 2019, 7, 630-643.	1.6	217
345	<p>Brigatinib for ALK-positive metastatic non-small-cell lung cancer: design, development and place in therapy</p>. <i>Drug Design, Development and Therapy</i> , 2019, Volume 13, 569-580.	2.0	17
346	Checkpoint Inhibitor Pneumonitis: Too Clinically Serious For Benefit?. <i>Journal of Thoracic Oncology</i> , 2019, 14, 332-335.	0.5	7
347	Immune Modulation of Head and Neck Squamous Cell Carcinoma and the Tumor Microenvironment by Conventional Therapeutics. <i>Clinical Cancer Research</i> , 2019, 25, 4211-4223.	3.2	85
348	Current views on tumor mutational burden in patients with non-small cell lung cancer treated by immune checkpoint inhibitors. <i>Journal of Thoracic Disease</i> , 2019, 11, S71-S80.	0.6	71

#	ARTICLE	IF	CITATIONS
349	Molecular markers and prediction of response to immunotherapy in non-small cell lung cancer, an update. <i>Journal of Thoracic Disease</i> , 2019, 11, S25-S36.	0.6	51
350	The Role of Angiogenesis Inhibitors in the Era of Immune Checkpoint Inhibitors and Targeted Therapy in Metastatic Non-Small Cell Lung Cancer. <i>Current Treatment Options in Oncology</i> , 2019, 20, 21.	1.3	27
351	Soluble immune checkpoint molecules: Serum markers for cancer diagnosis and prognosis. <i>Cancer Reports</i> , 2019, 2, e1160.	0.6	26
352	Defining aggressive or early progressing nononcogene-addicted non-small-cell lung cancer: a separate disease entity?. <i>Future Oncology</i> , 2019, 15, 1363-1383.	1.1	10
353	The Role of Molecular Profiling to Predict the Response to Immune Checkpoint Inhibitors in Lung Cancer. <i>Cancers</i> , 2019, 11, 201.	1.7	49
354	Biological therapies in lung cancer treatment: using our immune system as an ally to defeat the malignancy. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 457-467.	1.4	7
355	How I treat ALK-positive non-small cell lung cancer. <i>ESMO Open</i> , 2019, 4, e000524.	2.0	31
356	New emerging targets in cancer immunotherapy beyond CTLA-4, PD-1 and PD-L1: Introducing an "ESMO Open" Cancer Horizons Series. <i>ESMO Open</i> , 2019, 4, e000501.	2.0	6
357	Immune checkpoint inhibitors and driver oncogenes in non-small cell lung cancer. <i>Translational Cancer Research</i> , 2019, 8, S628-S632.	0.4	3
358	Anti-angiogenesis boosts chemo-immunotherapy in patients with EGFR mutations or baseline liver metastases: insights from IMpower150 study. <i>Translational Cancer Research</i> , 2019, 8, S612-S617.	0.4	10
359	Clinical Features of Liver Injury Induced by Immune Checkpoint Inhibitors in Japanese Patients. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2019, 2019, 1-12.	0.8	43
360	Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors. <i>Oncologist</i> , 2019, 24, 1128-1136.	1.9	156
361	Traitements de première ligne dans les CBNPC avancés, en l'absence d'addiction oncogénique (incluant) Tj ETQq0 0 0 rgBT 2019, 11, 342-354.	0.0	0
362	Analysis of the association between prior chemotherapy regimens and outcomes of subsequent anti-PD-(L)1 monotherapy in advanced non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2019, 8, 920-928.	1.3	1
363	Addition of atezolizumab to nab-paclitaxel plus carboplatin is a new standard option for the first-line treatment for non-squamous non-small cell lung cancer. <i>Translational Cancer Research</i> , 2019, 8, E11-E14.	0.4	0
364	Latest Immunotherapy Methods in Non-small Cell Lung Cancer Treatment. <i>Juntendo Medical Journal</i> , 2019, 65, 444-450.	0.1	1
365	Combination immune checkpoint inhibitors with platinum-based chemotherapy in advanced non-small cell lung cancer: what's known and what's next. <i>Translational Lung Cancer Research</i> , 2019, 8, S447-S450.	1.3	12
366	How to recognize and manage hyper-progression and pseudo-progression during immune checkpoint blockade in non-small cell lung cancer. <i>Precision Cancer Medicine</i> , 2019, 2, 35-35.	1.8	3

#	ARTICLE	IF	CITATIONS
367	Immunotherapy in EGFR mutant non-small cell lung cancer: when, who and how?. <i>Translational Lung Cancer Research</i> , 2019, 8, 710-714.	1.3	11
368	Clinicopathological values of PD-L1 expression in HER2-positive breast cancer. <i>Scientific Reports</i> , 2019, 9, 16662.	1.6	33
369	Immune checkpoint inhibitors win the 2018 Nobel Prize. <i>Biomedical Journal</i> , 2019, 42, 299-306.	1.4	62
370	KEYNOTE-042: is lowering the PD-L1 threshold for first-line pembrolizumab monotherapy a good idea?. <i>Translational Lung Cancer Research</i> , 2019, 8, 723-727.	1.3	4
371	The impact of previous therapy strategy on the efficiency of anlotinib hydrochloride as a third-line treatment on patients with advanced non-small cell lung cancer (NSCLC): a subgroup analysis of ALTER0303 trial. <i>Translational Lung Cancer Research</i> , 2019, 8, 575-583.	1.3	27
372	Atezolizumab First-Line Combination Therapy: A Review in Metastatic Nonsquamous NSCLC. <i>Targeted Oncology</i> , 2019, 14, 759-768.	1.7	21
373	Highly multiplexed immunofluorescence images and single-cell data of immune markers in tonsil and lung cancer. <i>Scientific Data</i> , 2019, 6, 323.	2.4	39
374	Prise en charge diagnostique et thérapeutique du mésothéliome pleural malin en 2019. <i>Revue Des Maladies Respiratoires Actualites</i> , 2019, 11, 306-314.	0.0	0
375	Cancer du poumon. <i>Revue Des Maladies Respiratoires Actualites</i> , 2019, 11, S29-S35.	0.0	0
376	Immunothérapie pratique, pratique de l'immunothérapie: de la prise en charge initiale au suivi. <i>Revue Des Maladies Respiratoires Actualites</i> , 2019, 11, S502-S507.	0.0	0
377	Odds ratio of programmed cell death-1 or ligand 1 inhibitor-related endocrine dysfunction in patients with lung cancer. <i>Medicine (United States)</i> , 2019, 98, e18310.	0.4	2
378	Combined Antiangiogenic Therapy and Immunotherapy Is Effective for Pancreatic Cancer With Mismatch Repair Proficiency but High Tumor Mutation Burden. <i>Pancreas</i> , 2019, 48, 1232-1236.	0.5	15
379	Safety and Efficacy Results of a Phase I, Open-Label Study of Concurrent and Delayed Nivolumab in Combination With nab-Paclitaxel and Carboplatin in Advanced Non-small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 1256.	1.3	10
380	Maximum Somatic Allele Frequency in Combination With Blood-Based Tumor Mutational Burden to Predict the Efficacy of Atezolizumab in Advanced Non-small Cell Lung Cancer: A Pooled Analysis of the Randomized POPLAR and OAK Studies. <i>Frontiers in Oncology</i> , 2019, 9, 1432.	1.3	27
381	Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer. , 2019, 7, 316.		102
382	Immune-Checkpoint Inhibitors as the First Line Treatment of Advanced Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials. <i>Journal of Cancer</i> , 2019, 10, 6261-6268.	1.2	22
383	Durvalumab for the treatment of non-small cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 1009-1016.	1.1	20
384	Is the game over for PD-1 inhibitors in EGFR mutant non-small cell lung cancer?. <i>Translational Lung Cancer Research</i> , 2019, 8, S339-S342.	1.3	13

#	ARTICLE	IF	CITATIONS
385	Immune Checkpoint Inhibition in Non-metastatic Non-small Cell Lung Cancer: Chance for Cure?. <i>Drugs</i> , 2019, 79, 1937-1945.	4.9	4
386	KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591988554.	1.4	25
387	Immune checkpoint inhibitors in gastrointestinal malignancies: what can we learn from experience with other tumors?. <i>Translational Gastroenterology and Hepatology</i> , 2019, 4, 73-73.	1.5	4
388	Analysis of key clinical features for achieving complete remission in stage III and IV non-small cell lung cancer patients. <i>Respiratory Research</i> , 2019, 20, 263.	1.4	5
389	Population pharmacokinetics, exposure-safety, and immunogenicity of atezolizumab in pediatric and young adult patients with cancer. , 2019, 7, 314.		30
390	The Kinetic Changes of Systemic Inflammatory Factors during Bevacizumab Treatment and Its Prognostic Role in Advanced Non-small Cell Lung Cancer Patients. <i>Journal of Cancer</i> , 2019, 10, 5082-5089.	1.2	19
391	Second-line treatment of EGFR T790M-negative non-small cell lung cancer patients. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591989028.	1.4	28
392	Development and clinical applications of cancer immunotherapy against PD-1 signaling pathway. <i>Journal of Biomedical Science</i> , 2019, 26, 96.	2.6	26
394	Facial Palsy Induced by Checkpoint Blockade: A Single Center Retrospective Study. <i>Journal of Immunotherapy</i> , 2019, 42, 94-96.	1.2	9
395	Treatment of oncogene-driven non-small cell lung cancer. <i>Current Opinion in Pulmonary Medicine</i> , 2019, 25, 300-307.	1.2	7
396	The overall safety evaluation of programmed cell death/programmed cell death ligand 1 (PD-1/PD-L1) treatment for lung cancer patients. <i>Medicine (United States)</i> , 2019, 98, e16439.	0.4	1
397	Afatinib, an irreversible ErbB family blocker for the treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer. <i>European Journal of Oncology Pharmacy</i> , 2019, 2, e18.	0.5	1
398	PD-L1 for selecting non-small-cell lung cancer patients for first-line immuno-chemotherapy combination: a systematic review and meta-analysis. <i>Immunotherapy</i> , 2019, 11, 921-930.	1.0	8
399	MicroRNAs in non-small cell lung cancer: Gene regulation, impact on cancer cellular processes, and therapeutic potential. <i>Pharmacology Research and Perspectives</i> , 2019, 7, e00528.	1.1	58
400	Pulmonary complications of immune checkpoint inhibitors in patients with nonsmall cell lung cancer. <i>European Respiratory Review</i> , 2019, 28, 190058.	3.0	73
401	The Tumor Vessel Targeting Strategy: A Double-Edged Sword in Tumor Metastasis. <i>Cells</i> , 2019, 8, 1602.	1.8	24
402	Checkpoints inhibitors in the (neo)adjuvant setting of solid tumors. <i>Current Opinion in Oncology</i> , 2019, 31, 439-444.	1.1	3
403	The KEY to the end of the chemotherapy in advanced non-small cell lung cancer, or not yet?. <i>Translational Lung Cancer Research</i> , 2019, 8, 731-737.	1.3	1

#	ARTICLE	IF	CITATIONS
404	A case report of immune checkpoint inhibitor nivolumab combined with anti-angiogenesis agent anlotinib for advanced esophageal squamous cell carcinoma. <i>Medicine (United States)</i> , 2019, 98, e17164.	0.4	9
405	Interpretation of ceritinib clinical trial results and future combination therapy strategies for ALK-rearranged NSCLC. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 1061-1075.	1.1	7
406	Maintenance Therapy in Metastatic Solid Tumors. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 615-623.	0.6	4
407	Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy. <i>Journal of Hematology and Oncology</i> , 2019, 12, 134.	6.9	296
409	Approach to stage IV non-small-cell lung cancer. <i>Current Opinion in Pulmonary Medicine</i> , 2019, Publish Ahead of Print, 311-320.	1.2	1
411	Tumor Mutational Burden Is Site Specific in Non-Small-Cell Lung Cancer and Is Highest in Lung Adenocarcinoma Brain Metastases. <i>JCO Precision Oncology</i> , 2019, 3, 1-13.	1.5	13
413	Advances in clinical trials of targeted therapy and immunotherapy of lung cancer in 2018. <i>Translational Lung Cancer Research</i> , 2019, 8, 1091-1106.	1.3	27
414	Usefulness of complementary next-generation sequencing and quantitative immunohistochemistry panels for predicting brain metastases and selecting treatment outcomes of non-small cell lung cancer. <i>Human Pathology</i> , 2019, 83, 177-191.	1.1	5
415	Impact of Checkpoint Inhibitor Pneumonitis on Survival in NSCLC Patients Receiving Immune Checkpoint Immunotherapy. <i>Journal of Thoracic Oncology</i> , 2019, 14, 494-502.	0.5	114
416	Desperately seeking Models to find the right partner and the best use for checkpoint inhibitors. <i>British Journal of Cancer</i> , 2019, 120, 139-140.	2.9	2
417	Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS. <i>Annals of Oncology</i> , 2019, 30, 171-210.	0.6	214
418	A Cautionary Analysis of Immunotherapy Prior to Targeted Therapy. <i>Journal of Thoracic Oncology</i> , 2019, 14, 8-10.	0.5	10
419	Predicting Treatment Response Based on RNA Expression in Large Datasets. <i>Clinical Cancer Research</i> , 2019, 25, 1443-1445.	3.2	1
420	SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018). <i>Clinical and Translational Oncology</i> , 2019, 21, 3-17.	1.2	110
421	Inhibition of oncogenic cap-dependent translation by 4EGI-1 reduces growth, enhances chemosensitivity and alters genome-wide translation in non-small cell lung cancer. <i>Cancer Gene Therapy</i> , 2019, 26, 157-165.	2.2	9
422	Evaluation of objective response, disease control and progression-free survival as surrogate end-points for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials. <i>European Journal of Cancer</i> , 2019, 106, 1-11.	1.3	37
423	Immunotherapy for the First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 2691-2698.	3.2	78
424	Induction of Peripheral Effector CD8 T-cell Proliferation by Combination of Paclitaxel, Carboplatin, and Bevacizumab in Non-small Cell Lung Cancer Patients. <i>Clinical Cancer Research</i> , 2019, 25, 2219-2227.	3.2	32

#	ARTICLE	IF	CITATIONS
425	A Phase II Study of Nivolumab in Patients With Advanced Nonâ€“small-cell Lung Cancer who Responded to Prior PD-1/L1 Inhibitors: West Japan Oncology Group 9616L (WJOG9616L). <i>Clinical Lung Cancer</i> , 2019, 20, 139-141.	1.1	5
426	Advancements in Small-cell Lung Cancer: The Changing Landscape Following IMpower-133. <i>Clinical Lung Cancer</i> , 2019, 20, 148-160.e2.	1.1	27
427	Co-expression of IDO1 and PD-L1 in lung squamous cell carcinoma: Potential targets of novel combination therapy. <i>Lung Cancer</i> , 2019, 128, 26-32.	0.9	24
428	Comparative and combined effectiveness of innovative therapies in cancer: a literature review. <i>Journal of Comparative Effectiveness Research</i> , 2019, 8, 205-216.	0.6	3
429	Immunotherapy alone or chemo-immunotherapy as front-line treatment for advanced non-small cell lung cancer. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 225-232.	1.4	22
430	Therapeutic impact of Nintedanib with paclitaxel and/or a PD-L1 antibody in preclinical models of orthotopic primary or metastatic triple negative breast cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 16.	3.5	27
431	Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up. <i>JAMA Oncology</i> , 2019, 5, 334.	3.4	206
432	PD-1 Blockade in Early-Stage Lung Cancer. <i>Annual Review of Medicine</i> , 2019, 70, 425-435.	5.0	29
433	Recurrent grade 4 panuveitis with serous retinal detachment related to nivolumab treatment in a patient with metastatic renal cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 85-95.	2.0	32
434	Role of Clinical Pharmacodynamics Studies in the Era of Precision Medicines Against Cancer. , 2019, , 1-18.		1
435	A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2). <i>Gastric Cancer</i> , 2019, 22, 344-354.	2.7	60
436	Treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer: update and perspectives. <i>Current Opinion in Oncology</i> , 2019, 31, 8-12.	1.1	7
437	Prospective exosomeâ€“focused translational research for afatinib study of nonâ€“small cell lung cancer patients expressing EGFR (EXTRA study). <i>Thoracic Cancer</i> , 2019, 10, 395-400.	0.8	10
438	Cost-effectiveness and Budgetary Consequence Analysis of Durvalumab Consolidation Therapy vs No Consolidation Therapy After Chemoradiotherapy in Stage III Nonâ€“Small Cell Lung Cancer in the Context of the US Health Care System. <i>JAMA Oncology</i> , 2019, 5, 358.	3.4	48
439	Metal Drugs and the Anticancer Immune Response. <i>Chemical Reviews</i> , 2019, 119, 1519-1624.	23.0	237
440	Multidisciplinary treatment of lung cancer in older patients: A review. <i>Journal of Geriatric Oncology</i> , 2019, 10, 405-410.	0.5	17
441	Adjuvant Therapy in Patients With Completely Resected Nonâ€“small-cell Lung Cancer: Current Status and Perspectives. <i>Clinical Lung Cancer</i> , 2019, 20, 1-6.	1.1	36
442	Reasoning the effect of immunotherapy after chemoradiation in the PACIFIC trial. <i>Future Oncology</i> , 2019, 15, 81-94.	1.1	2

#	ARTICLE	IF	CITATIONS
443	Amplifying Outcomes: Checkpoint Inhibitor Combinations in First-Line Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2020, 25, 64-77.	1.9	30
444	Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer. <i>Seminars in Cancer Biology</i> , 2020, 61, 167-179.	4.3	302
445	Combination therapy with PD-1 or PD-L1 inhibitors for cancer. <i>International Journal of Clinical Oncology</i> , 2020, 25, 818-830.	1.0	86
446	Oncolysis without viruses "inducing systemic anticancer immune responses with local therapies. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 49-64.	12.5	92
447	Treatment options beyond immunotherapy in patients with wild-type lung adenocarcinoma: a Delphi consensus. <i>Clinical and Translational Oncology</i> , 2020, 22, 759-771.	1.2	11
448	Differences Between the East and the West in Managing Advanced-Stage Non-small Cell Lung Cancer. <i>Clinical Oncology</i> , 2020, 32, e1-e9.	0.6	6
449	Dual Programmed Death Receptor-1 and Vascular Endothelial Growth Factor Receptor-2 Blockade Promotes Vascular Normalization and Enhances Antitumor Immune Responses in Hepatocellular Carcinoma. <i>Hepatology</i> , 2020, 71, 1247-1261.	3.6	247
450	Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer. <i>Clinical and Translational Oncology</i> , 2020, 22, 708-716.	1.2	6
451	Efficacy of anti-PD-1 therapy for recurrence after chemoradiotherapy in locally advanced NSC LC. <i>International Journal of Clinical Oncology</i> , 2020, 25, 67-73.	1.0	6
452	The landscape of immune checkpoint inhibitor plus chemotherapy versus immunotherapy for advanced non-small cell lung cancer: A systematic review and meta-analysis. <i>Journal of Cellular Physiology</i> , 2020, 235, 4913-4927.	2.0	48
453	Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. <i>Clinical and Translational Oncology</i> , 2020, 22, 989-1003.	1.2	59
454	The Journey of an EGFR-Mutant Lung Adenocarcinoma through Erlotinib, Osimertinib and ABCP Immunotherapy Regimens: Sensitivity and Resistance. <i>Case Reports in Oncology</i> , 2020, 12, 765-776.	0.3	9
455	Neuropsychiatric Immune-related Adverse Events Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma and Systemic Lupus Erythematosus. <i>Internal Medicine</i> , 2020, 59, 569-572.	0.3	8
456	Biomarkers for immune checkpoint inhibition in non-small cell lung cancer (NSCLC). <i>Cancer</i> , 2020, 126, 260-270.	2.0	202
457	First-line PD-1/PD-L1 inhibitor plus chemotherapy vs chemotherapy alone for negative or PD-L1-expressing metastatic non-small-cell lung cancers. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 441-448.	1.2	8
458	Immune-related adverse reactions in the hepatobiliary system: second-generation checkpoint inhibitors highlight diverse histological changes. <i>Histopathology</i> , 2020, 76, 470-480.	1.6	52
459	Association of PD-L1 expression status with the efficacy of PD-1/PD-L1 inhibitors and overall survival in solid tumours: A systematic review and meta-analysis. <i>International Journal of Cancer</i> , 2020, 147, 116-127.	2.3	53
460	Efficacy of Anti-PD1/PD-L1 Therapy (IO) in KRAS Mutant Non-small Cell Lung Cancer Patients: A Retrospective Analysis. <i>Anticancer Research</i> , 2020, 40, 427-433.	0.5	16

#	ARTICLE	IF	CITATIONS
461	Combined Atezolizumab and Chemotherapy for a Patient With Double Primary Cancers. <i>In Vivo</i> , 2020, 34, 389-392.	0.6	4
462	Atezolizumab for use in PD-L1-positive unresectable, locally advanced or metastatic triple-negative breast cancer. <i>Future Oncology</i> , 2020, 16, 4439-4453.	1.1	29
463	<p>Immunotherapy for the Treatment of Breast Cancer: Emerging New Data</p>. <i>Breast Cancer: Targets and Therapy</i> , 2019, Volume 11, 321-328.	1.0	25
464	Targeted therapy of oncogenic-driven advanced non-small cell lung cancer: recent advances and new perspectives. <i>Expert Review of Respiratory Medicine</i> , 2020, 14, 367-383.	1.0	21
465	Immune-resistant mechanisms in cancer immunotherapy. <i>International Journal of Clinical Oncology</i> , 2020, 25, 810-817.	1.0	39
466	Current issues and perspectives in PD-1 blockade cancer immunotherapy. <i>International Journal of Clinical Oncology</i> , 2020, 25, 790-800.	1.0	120
467	Recent progress in supramolecular peptide assemblies as virus mimics for cancer immunotherapy. <i>Biomaterials Science</i> , 2020, 8, 1045-1057.	2.6	20
468	Efficacy and safety of first-line pembrolizumab monotherapy in elderly patients (aged ≤75–years) with non-small cell lung cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 457-466.	1.2	21
469	Vessel co-option and resistance to anti-angiogenic therapy. <i>Angiogenesis</i> , 2020, 23, 55-74.	3.7	77
470	Occult Gastrointestinal Perforation in a Patient With EGFR-Mutant Non–Small-Cell Lung Cancer Receiving Combination Chemotherapy With Atezolizumab and Bevacizumab: Brief–Report. <i>Clinical Lung Cancer</i> , 2020, 21, e57-e60.	1.1	5
471	Treatment of advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	2.0	39
472	PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee. <i>Journal of Thoracic Oncology</i> , 2020, 15, 499-519.	0.5	203
473	Chemotherapy remains a cornerstone in the treatment of nonsmall cell lung cancer. <i>Current Opinion in Oncology</i> , 2020, 32, 63-67.	1.1	52
474	Twenty–five years of <i>Respirology</i>: Advances in lung cancer. <i>Respirology</i> , 2020, 25, 26-31.	1.3	2
476	PD-1 disrupted CAR-T cells in the treatment of solid tumors: Promises and challenges. <i>Biomedicine and Pharmacotherapy</i> , 2020, 121, 109625.	2.5	92
477	Precision Medicine in Lung Cancer Treatment. <i>Surgical Oncology Clinics of North America</i> , 2020, 29, 15-21.	0.6	23
478	Optimized antiangiogenic reprogramming of the tumor microenvironment potentiates CD40 immunotherapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 541-551.	3.3	66
479	Prognostic value of PD-L1 expression on tumor cells combined with CD8+ TIL density in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy. <i>Radiation Oncology</i> , 2020, 15, 5.	1.2	28

#	ARTICLE	IF	CITATIONS
480	Predictors of Survival Benefit From Immune Checkpoint Inhibitors in Patients With Advanced Nonâ€“small-cell Lung Cancer: A Systematic Review and Meta-analysis. <i>Clinical Lung Cancer</i> , 2020, 21, 106-113.e5.	1.1	22
481	Frontline immunotherapy for NSCLC â€” the tale of the tail. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 73-74.	12.5	35
482	Immune checkpoint blockade for nonâ€“small cell lung cancer: What is the role in the special populations?. <i>European Journal of Cancer</i> , 2020, 125, 1-11.	1.3	31
483	Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer, including patients with EGFR mutations. <i>Expert Review of Respiratory Medicine</i> , 2020, 14, 125-136.	1.0	51
484	Immunotherapy at any line of treatment improves survival in patients with advanced metastatic nonâ€“small cell lung cancer (NSCLC) compared with chemotherapy (Quijoteâ€“CLICaP). <i>Thoracic Cancer</i> , 2020, 11, 353-361.	0.8	36
485	The immunotherapeutic landscape in nonâ€“small cell lung cancer and its surgical horizons. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2020, 159, 1616-1623.	0.4	21
486	Angiogenesis inhibition in non-small cell lung cancer: a critical appraisal, basic concepts and updates from American Society for Clinical Oncology 2019. <i>Current Opinion in Oncology</i> , 2020, 32, 44-53.	1.1	18
487	New insight in endocrine-related adverse events associated to immune checkpoint blockade. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2020, 34, 101370.	2.2	60
488	Acquired Resistance in Lung Cancer. <i>Annual Review of Cancer Biology</i> , 2020, 4, 279-297.	2.3	13
489	Antidrug Antibodies Against Immune Checkpoint Blockers: Impairment of Drug Efficacy or Indication of Immune Activation?. <i>Clinical Cancer Research</i> , 2020, 26, 787-792.	3.2	44
490	Immune-Related Adverse Events in the Setting of PD-1/L1 Inhibitor Combination Therapy. <i>Oncologist</i> , 2020, 25, e398-e404.	1.9	10
491	Predictive impact of antibiotics in patients with advanced non small-cell lung cancer receiving immune checkpoint inhibitors. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 121-131.	1.1	45
492	Patient-Reported Outcomes From Patients Receiving Immunotherapy or Chemoimmunotherapy for Metastatic Nonâ€“Small-Cell Lung Cancer in Clinical Practice. <i>Clinical Lung Cancer</i> , 2020, 21, 255-263.e4.	1.1	28
493	Influence of age on the efficacy of immune checkpoint inhibitors in advanced cancers: a systematic review and meta-analysis. <i>Acta Oncologica</i> , 2020, 59, 249-256.	0.8	28
494	Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced nonâ€“small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort study. <i>Investigational New Drugs</i> , 2020, 38, 211-218.	1.2	31
495	Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria. <i>Clinical Cancer Research</i> , 2020, 26, 1846-1855.	3.2	70
496	Impact of PDâ€“L1 expression and human papillomavirus status in antiâ€“PD1/PDL1 immunotherapy for head and neck squamous cell carcinomaâ€”Systematic review and metaâ€“analysis. <i>Head and Neck</i> , 2020, 42, 774-786.	0.9	52
497	Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 44-59.	5.1	826

#	ARTICLE	IF	CITATIONS
498	Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre phase 1–2 study. <i>Lancet Oncology</i> , The, 2020, 21, 134-144.	5.1	103
499	Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Non–Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2020, 21, e191-e204.	1.1	26
500	Phase II Trial of Concurrent Atezolizumab With Chemoradiation for Unresectable NSCLC. <i>Journal of Thoracic Oncology</i> , 2020, 15, 248-257.	0.5	97
501	Randomized Phase III Study of Continuation Maintenance Bevacizumab With or Without Pemetrexed in Advanced Nonsquamous Non–Small-Cell Lung Cancer: COMPASS (WJOG5610L). <i>Journal of Clinical Oncology</i> , 2020, 38, 793-803.	0.8	28
502	Real-World Adherence to Guideline-Recommended Treatment for Small Cell Lung Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 236-242.	0.6	14
503	Benign lymph node microenvironment is associated with response to immunotherapy. <i>Precision Clinical Medicine</i> , 2020, 3, 44-53.	1.3	10
504	Immune checkpoint blockade and biomarkers of clinical response in non–small cell lung cancer. <i>Scandinavian Journal of Immunology</i> , 2020, 92, e12980.	1.3	14
505	To Continue or Not to Continue? That Is the Question. <i>Journal of Clinical Oncology</i> , 2020, 38, 3830-3832.	0.8	2
506	Immunotherapy in advanced non-small-cell lung cancer with EGFR mutations. <i>Immunotherapy</i> , 2020, 12, 1195-1207.	1.0	2
507	Smoking status-based efficacy difference in anti-PD-1/PD-L1 immunotherapy: a systematic review and meta-analysis. <i>Immunotherapy</i> , 2020, 12, 1313-1324.	1.0	5
508	Safety, Antitumor Activity, and Pharmacokinetics of Toripalimab, a Programmed Cell Death 1 Inhibitor, in Patients With Advanced Non–Small Cell Lung Cancer. <i>JAMA Network Open</i> , 2020, 3, e2013770.	2.8	34
509	The potential of 18F-FDG PET/CT in predicting PDL1 expression status in pulmonary lesions of untreated stage IIIB-IV non-small-cell lung cancer. <i>Lung Cancer</i> , 2020, 150, 44-52.	0.9	5
510	Superior efficacy of immunotherapy–based combinations over monotherapy for EGFR –mutant non–small cell lung cancer acquired resistance to EGFR–TKIs. <i>Thoracic Cancer</i> , 2020, 11, 3501-3509.	0.8	9
511	Understanding EGFR heterogeneity in lung cancer. <i>ESMO Open</i> , 2020, 5, e000919.	2.0	32
512	Identification and Utilization of Biomarkers to Predict Response to Immune Checkpoint Inhibitors. <i>AAPS Journal</i> , 2020, 22, 132.	2.2	27
513	Treatment after progression in the era of immunotherapy. <i>Lancet Oncology</i> , The, 2020, 21, e463-e476.	5.1	115
514	MicroRNA –200b is a potential biomarker of the expression of PD–L1 in patients with lung cancer. <i>Thoracic Cancer</i> , 2020, 11, 2975-2982.	0.8	12
515	Landscape of immune checkpoint inhibitor-related adverse events in Chinese population. <i>Scientific Reports</i> , 2020, 10, 15567.	1.6	20

#	ARTICLE	IF	CITATIONS
516	First-Line Immune Checkpoint Inhibition for Advanced Non-Small-Cell Lung Cancer: State of the Art and Future Directions. <i>Drugs</i> , 2020, 80, 1783-1797.	4.9	12
517	Alternative splicing of HER2: a novel mediator of EGFR TKI resistance. <i>Translational Lung Cancer Research</i> , 2020, 9, 1606-1612.	1.3	1
518	<p>Management of Immune Checkpoint Inhibitor Toxicities</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 9139-9158.	0.9	18
519	Predictive biomarkers for immunotherapy efficacy in non-small-cell lung cancer: current status and future perspectives. <i>Biomarkers in Medicine</i> , 2020, 14, 1383-1392.	0.6	16
520	Biomarkers for immune checkpoint therapy targeting programmed death 1 and programmed death ligand 1. <i>Biomedicine and Pharmacotherapy</i> , 2020, 130, 110621.	2.5	8
521	The incidence risk of programmed cell death-1/programmed cell death ligand 1 inhibitor-related alopecia for cancer patients. <i>Medicine (United States)</i> , 2020, 99, e22555.	0.4	2
522	Mechanisms of resistance to immune checkpoint inhibitors and strategies to reverse drug resistance in lung cancer. <i>Chinese Medical Journal</i> , 2020, 133, 2444-2455.	0.9	7
523	HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric or gastroesophageal junction cancer: a multicenter, single-arm phase II trial. , 2020, 8, e001279.		11
524	Utility of immune checkpoint inhibitors in nonâ€smallâ€cell lung cancer patients with poor performance status. <i>Cancer Science</i> , 2020, 111, 3739-3746.	1.7	20
525	Deep immunophenotyping at the single-cell level identifies a combination of anti-IL-17 and checkpoint blockade as an effective treatment in a preclinical model of data-guided personalized immunotherapy. , 2020, 8, e001358.		44
526	Severe delayed pulmonary toxicity following PDâ€L1â€specific CARâ€T cell therapy for nonâ€small cell lung cancer. <i>Clinical and Translational Immunology</i> , 2020, 9, e1154.	1.7	12
527	Harmonization of Molecular Testing for Non-Small Cell Lung Cancer: Emphasis on PD-L1. <i>Frontiers in Oncology</i> , 2020, 10, 549198.	1.3	2
529	The relationship between pneumonitis and programmed cell death-1/programmed cell death ligand 1 inhibitors among cancer patients. <i>Medicine (United States)</i> , 2020, 99, e22567.	0.4	5
530	Blood-Based Biomarkers for Predicting Immunotherapy Benefit in Lung Cancer. <i>Cell</i> , 2020, 183, 303-304.	13.5	4
531	The Resistance Mechanisms of Lung Cancer Immunotherapy. <i>Frontiers in Oncology</i> , 2020, 10, 568059.	1.3	47
532	Tislelizumab: an investigational anti-PD-1 antibody for the treatment of advanced non-small cell lung cancer (NSCLC). <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 1355-1364.	1.9	39
533	Emerging and investigational targeted chemotherapy and immunotherapy agents for metastatic brain tumors. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 1389-1406.	1.9	4
534	The prospect of combination therapy with immune checkpoint inhibitors and chemotherapy for squamous cell carcinoma of the lung. <i>Translational Lung Cancer Research</i> , 2020, 9, 811-815.	1.3	3

#	ARTICLE	IF	CITATIONS
535	Neoadjuvant chemotherapy and Avelumab in early stage resectable nonsmall cell lung cancer. <i>Cancer Medicine</i> , 2020, 9, 8406-8411.	1.3	31
537	Les CBNPC de stades avancés hors addiction oncogénique : les traitements systémiques de deuxième ligne. <i>Revue Des Maladies Respiratoires Actualites</i> , 2020, 12, 2S185-2S194.	0.0	0
538	Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition. <i>Cell</i> , 2020, 183, 363-376.e13.	13.5	206
539	Are antiangiogenics a good "partner" for immunotherapy in ovarian cancer?. <i>Angiogenesis</i> , 2020, 23, 543-557.	3.7	10
540	Antiemetics: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2020, 38, 2782-2797.	0.8	201
541	Targeting Immunometabolism Mediated by CD73 Pathway in EGFR-Mutated Non-small Cell Lung Cancer: A New Hope for Overcoming Immune Resistance. <i>Frontiers in Immunology</i> , 2020, 11, 1479.	2.2	30
542	Angiogenesis and Its Role in the Tumour Microenvironment: A Target for Cancer Therapy. , 2020, , .		2
543	Dramatic Response to Teriprilumab and Anlotinib Combination Therapy in a patient with EGFR-Mutant Lung Adenocarcinoma Who Experienced Small-Cell Transformation Mediated Erlotinib Resistance After Failure of Chemotherapy. <i>JTO Clinical and Research Reports</i> , 2020, 1, 100010.	0.6	0
544	Resistance to immune checkpoint inhibitors in non-small cell lung cancer: biomarkers and therapeutic strategies. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592093790.	1.4	49
545	Efficacy and safety of PD-1/PD-L1 inhibitors plus nab-paclitaxel for patients with non-small cell lung cancer who have progressed after platinum-based chemotherapy. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592093688.	1.4	17
546	Potential Benefits of Bevacizumab Combined With Platinum-Based Chemotherapy in Advanced Non-Small-Cell Lung Cancer Patients With EGFR Mutation. <i>Clinical Lung Cancer</i> , 2020, 21, 273-280.e4.	1.1	21
547	Selected highlights of the 2019 Pulmonary Pathology Society Biennial Meeting: PD-L1 test harmonization studies. <i>Translational Lung Cancer Research</i> , 2020, 9, 906-916.	1.3	3
548	Insights from Pharmacovigilance: Gastrointestinal-Related Immune Checkpoint Inhibitor Adverse Events. <i>Gastroenterology</i> , 2020, 159, 1195-1200.e1.	0.6	5
549	Efficacy and safety of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer (NSCLC): a systematic literature review. <i>Oncolimmunology</i> , 2020, 9, 1774314.	2.1	34
552	Association between tumor mutation burden and immune infiltration in ovarian cancer. <i>International Immunopharmacology</i> , 2020, 89, 107126.	1.7	26
553	Hypothesis generative head-to-head study comparing efficacy of afatinib and osimertinib based on immunological biomarkers in Japanese NSCLC patients with EGFR mutations (Heat on Beat study). <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592096725.	1.4	6
554	Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07). <i>Nature Communications</i> , 2020, 11, 5824.	5.8	42
555	Radiotherapy for non-small cell lung cancer in the immunotherapy era: the opportunity and challenge—a narrative review. <i>Translational Lung Cancer Research</i> , 2020, 9, 2120-2136.	1.3	16

#	ARTICLE	IF	CITATIONS
556	Prognostic factors for patients with metastatic or recurrent thymic carcinoma receiving palliative-intent chemotherapy. <i>Lung Cancer</i> , 2020, 148, 122-128.	0.9	7
557	FLAURA strikes again: efficacy of osimertinib is independent of PD-L1 expression. <i>Translational Lung Cancer Research</i> , 2020, 9, 2165-2172.	1.3	0
558	A Window of Opportunity: Targeting Cancer Endothelium to Enhance Immunotherapy. <i>Frontiers in Immunology</i> , 2020, 11, 584723.	2.2	22
559	A narrative review of synergistic drug administration in unresectable locally advanced non-small cell lung cancer: current landscape and future prospects in the era of immunotherapy. <i>Translational Lung Cancer Research</i> , 2020, 9, 2082-2096.	1.3	4
560	A pathological complete response to neoadjuvant chemotherapy and immunotherapy in a non-small cell lung cancer patient. <i>Translational Lung Cancer Research</i> , 2020, 9, 2157-2160.	1.3	5
561	Pan-cancer population pharmacokinetics and exposure-safety and efficacy analyses of atezolizumab in patients with high tumor mutational burden. <i>Pharmacology Research and Perspectives</i> , 2020, 8, e00685.	1.1	8
562	CCL7 recruits cDC1 to promote antitumor immunity and facilitate checkpoint immunotherapy to non-small cell lung cancer. <i>Nature Communications</i> , 2020, 11, 6119.	5.8	53
563	Comprehensive Evaluation of Immune-Checkpoint DNA Cancer Vaccines in a Rat Cholangiocarcinoma Model. <i>Vaccines</i> , 2020, 8, 703.	2.1	8
564	Impact of preexisting antinuclear antibodies on combined immunotherapy and chemotherapy in advanced non-small cell lung cancer patients. <i>Medical Oncology</i> , 2020, 37, 111.	1.2	13
565	Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial. <i>Breast Cancer Research</i> , 2020, 22, 124.	2.2	21
566	Imperfect Predictors for Lung Cancer Immunotherapy—A Field for Further Research. <i>Frontiers in Oncology</i> , 2020, 10, 568174.	1.3	14
567	Vascular Heterogeneity With a Special Focus on the Hepatic Microenvironment. <i>Frontiers in Physiology</i> , 2020, 11, 591901.	1.3	6
568	Immune Checkpoint Inhibitor-Related Pneumonitis. <i>Respiration</i> , 2020, 99, 932-942.	1.2	30
569	Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC). <i>BMC Cancer</i> , 2020, 20, 1185.	1.1	75
570	<p>Anti-Angiogenic Therapy in the Treatment of Non-Small Cell Lung Cancer</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 12113-12129.	1.0	25
571	Première ligne des CBNPC avancés sans addiction oncogénique : quel traitement pour quel patient ?. <i>Revue Des Maladies Respiratoires Actualites</i> , 2020, 12, 2S329-2S338.	0.0	0
572	Tolérance de l'immunothérapie en combinaison dans le cancer bronchique non à petites cellules. <i>Revue Des Maladies Respiratoires Actualites</i> , 2020, 12, 2S344-2S351.	0.0	0
573	Immunotherapy for extensive stage small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2020, 12, 6212-6224.	0.6	3

#	ARTICLE	IF	CITATIONS
574	Immune Escape Mechanisms in Non Small Cell Lung Cancer. <i>Cancers</i> , 2020, 12, 3605.	1.7	92
575	The Immune Checkpoint PD-1 in Natural Killer Cells: Expression, Function and Targeting in Tumour Immunotherapy. <i>Cancers</i> , 2020, 12, 3285.	1.7	85
576	First line Immunotherapy for Non-Small Cell Lung Cancer. <i>Pharmaceuticals</i> , 2020, 13, 373.	1.7	49
577	CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592095299.	1.4	23
578	Systematic Assessment of Risk of Fever in Solid Tumor Patients Treated With PD-1/PD-L1 Inhibitors: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 570080.	1.3	5
579	Therapy-Induced Modulation of the Tumor Microenvironment: New Opportunities for Cancer Therapies. <i>Frontiers in Oncology</i> , 2020, 10, 582884.	1.3	23
580	Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 725-741.	12.5	701
581	First-line immune-chemotherapy combination for squamous NSCLC is already a reality. <i>Translational Lung Cancer Research</i> , 2020, 9, 819-823.	1.3	1
582	Role of Clinical Pharmacodynamics Studies in the Era of Precision Medicines Against Cancer. , 2020, , 343-360.		0
583	Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology) Tj ETQq1 1 0.784314288 /Over	1.4	23
584	The Gut Microbiome Associates with Immune Checkpoint Inhibition Outcomes in Patients with Advanced Non-€"Small Cell Lung Cancer. <i>Cancer Immunology Research</i> , 2020, 8, 1243-1250.	1.6	154
585	Atezolizumab in a <u>C</u><u>H</u>ort of pretreated, advanced, non-small cell lung cancer patients with rare HistologiCal Subtyp<u>E</u>s (CHANCE trial). <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592091598.	1.4	5
586	Current management of <i>RET</i> rearranged non-small cell lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592092863.	1.4	31
587	Comparative risk of serious and fatal treatment-related adverse events caused by 19 immune checkpoint inhibitors used in cancer treatment: a network meta-analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592094092.	1.4	11
588	Immunoradiotherapy as an Effective Therapeutic Strategy in Lung Cancer: From Palliative Care to Curative Intent. <i>Cancers</i> , 2020, 12, 2178.	1.7	25
589	Clinical burden of immune checkpoint inhibitor-induced pneumonitis. <i>Respiratory Investigation</i> , 2020, 58, 305-319.	0.9	11
590	Antibiotics impair immune checkpoint inhibitor effectiveness in Hispanic patients with non-€"small cell lung cancer (<sc>ABâ€"CLICaP</sc>). <i>Thoracic Cancer</i> , 2020, 11, 2552-2560.	0.8	12
591	Clinical features affecting survival in metastatic NSCLC treated with immunotherapy: A critical review of published data. <i>Cancer Treatment Reviews</i> , 2020, 89, 102085.	3.4	41

#	ARTICLE	IF	CITATIONS
592	IMpower 131: The Exception to the Rule. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1258-1260.	0.5	1
593	Emerging drugs for small cell lung cancer: a focused review on immune checkpoint inhibitors. <i>Expert Opinion on Emerging Drugs</i> , 2020, 25, 353-366.	1.0	5
594	Myeloid Cells as Clinical Biomarkers for Immune Checkpoint Blockade. <i>Frontiers in Immunology</i> , 2020, 11, 1590.	2.2	50
595	Immunotherapy in older patients with non-small cell lung cancer: Young International Society of Geriatric Oncology position paper. <i>British Journal of Cancer</i> , 2020, 123, 874-884.	2.9	15
596	Cavitation and fatal hemoptysis after immunotherapy for advanced lung adenocarcinoma: A case report. <i>Thoracic Cancer</i> , 2020, 11, 2727-2730.	0.8	6
597	Do Elderly Lung Cancer Patients Aged ≥75 Years Benefit from Immune Checkpoint Inhibitors?. <i>Cancers</i> , 2020, 12, 1995.	1.7	8
598	Systemic Therapy of Common Tumours in Older Patients: Challenges and Opportunities. A Young International Society of Geriatric Oncology Review Paper. <i>Current Oncology Reports</i> , 2020, 22, 98.	1.8	3
599	Immunotherapy Alone or in Combination with Chemotherapy as First-Line Treatment of Non-Small Cell Lung Cancer. <i>Current Treatment Options in Oncology</i> , 2020, 21, 69.	1.3	20
600	SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges. <i>Journal of Hematology and Oncology</i> , 2020, 13, 105.	6.9	73
601	The Potential of Immune Modulation in Therapeutic HIV-1 Vaccination. <i>Vaccines</i> , 2020, 8, 419.	2.1	2
602	Apatinib in combination with pemetrexed-platinum chemotherapy for chemo-naïve non-squamous non-small cell lung cancer: a phase II clinical study. <i>Lung Cancer</i> , 2020, 147, 229-236.	0.9	9
603	Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non-small cell lung cancer and a poor performance status. , 2020, 8, e001007.		36
604	Update on Targeted Therapies for Advanced Non-Small Cell Lung Cancer: Durvalumab in Context. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 6885-6896.	1.0	1
605	Next-Generation Sequencing at High Sequencing Depth as a Tool to Study the Evolution of Metastasis Driven by Genetic Change Events of Lung Squamous Cell Carcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 1215.	1.3	7
606	Modulation of Determinant Factors to Improve Therapeutic Combinations with Immune Checkpoint Inhibitors. <i>Cells</i> , 2020, 9, 1727.	1.8	8
607	Platinum-Based Chemotherapy in Older Patients with Non-Small Cell Lung Cancer: What to Expect in the Real World. <i>Drugs and Aging</i> , 2020, 37, 677-689.	1.3	1
608	Phase II Study of Immunotherapy With Tecemotide and Bevacizumab After Chemoradiation in Patients With Unresectable Stage III Non-Squamous Non-Small-Cell Lung Cancer (NS-NSCLC): A Trial of the ECOG-ACRIN Cancer Research Group (E6508). <i>Clinical Lung Cancer</i> , 2020, 21, 520-526.	1.1	8
609	Clinical and molecular characteristics associated with survival among cancer patients receiving first-line anti-PD-1/PD-L1-based therapies. <i>Biomarkers</i> , 2020, 25, 441-448.	0.9	1

#	ARTICLE	IF	CITATIONS
610	Programmed cell death 1 (PD-1)/PD-L1 inhibitors-related pneumonitis in patients with advanced non-small cell lung cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 16, 299-304.	0.7	10
611	A Phase 2 Study of Tislelizumab in Combination With Platinum-Based Chemotherapy as First-line Treatment for Advanced Lung Cancer in Chinese Patients. <i>Lung Cancer</i> , 2020, 147, 259-268.	0.9	31
612	Multimodal synergistic treatment based on tumour immunological contexture for advanced non-driver non-small cell lung cancer: A myth or reality?. <i>European Journal of Cancer Care</i> , 2020, 29, e13291.	0.7	1
613	Baseline metabolic tumor volume as a strong predictive and prognostic biomarker in patients with non-small cell lung cancer treated with PD1 inhibitors: a prospective study. , 2020, 8, e000645.		54
614	Ferroptosis, necroptosis, and pyroptosis in anticancer immunity. <i>Journal of Hematology and Oncology</i> , 2020, 13, 110.	6.9	698
615	The frequency and inter-relationship of PD-L1 expression and tumour mutational burden across multiple types of advanced solid tumours in China. <i>Experimental Hematology and Oncology</i> , 2020, 9, 17.	2.0	21
616	Prognostic role of targeted therapy in patients with multiple-site metastases from non-small-cell lung cancer. <i>Future Oncology</i> , 2020, 16, 1957-1967.	1.1	5
617	Choosing the best first-line therapy: NSCLC with no actionable oncogenic driver. <i>Lung Cancer Management</i> , 2020, 9, LMT36.	1.5	19
618	Targeting the immune milieu in gastrointestinal cancers. <i>Journal of Gastroenterology</i> , 2020, 55, 909-926.	2.3	7
619	Targeting PD-L1 in non-small cell lung cancer using CAR T cells. <i>Oncogenesis</i> , 2020, 9, 72.	2.1	48
620	Risk factors of immune checkpoint inhibitor-related interstitial lung disease in patients with lung cancer: a single-institution retrospective study. <i>Scientific Reports</i> , 2020, 10, 13773.	1.6	42
621	Adverse impact of bone metastases on clinical outcomes of patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors. <i>Thoracic Cancer</i> , 2020, 11, 2812-2819.	0.8	23
622	Normalizing the Tumor Microenvironment for Radiosensitization. <i>Cancer Drug Discovery and Development</i> , 2020, , 301-338.	0.2	4
623	Immune Oncology Biomarkers in Lung Cancer: an Overview. <i>Current Oncology Reports</i> , 2020, 22, 107.	1.8	8
624	Association of immune checkpoint inhibitor with survival in patients with cancers with protein tyrosine phosphatase receptor T mutation. <i>Clinical and Translational Medicine</i> , 2020, 10, e214.	1.7	6
625	First-Line Immune-Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Landscape and Future Progress. <i>Frontiers in Pharmacology</i> , 2020, 11, 578091.	1.6	51
626	LKB1 mutations are not associated with the efficacy of first-line and second-line chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC): a post hoc analysis of the TAILOR trial. <i>ESMO Open</i> , 2020, 5, e000748.	2.0	2
627	Clinical Outcomes for PD-1 Inhibitor Plus Chemotherapy as Second-Line or Later Therapy Compared to PD-1/PD-L1 Inhibitor Alone in Advanced Non-small-cell Lung Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 556275.	1.3	6

#	ARTICLE	IF	CITATIONS
628	Microbiota and Lung Cancer. Opportunities and Challenges for Improving Immunotherapy Efficacy. <i>Frontiers in Oncology</i> , 2020, 10, 568939.	1.3	15
629	Old Player-New Tricks: Non Angiogenic Effects of the VEGF/VEGFR Pathway in Cancer. <i>Cancers</i> , 2020, 12, 3145.	1.7	42
630	Id1 and PD-1 Combined Blockade Impairs Tumor Growth and Survival of KRAS-mutant Lung Cancer by Stimulating PD-L1 Expression and Tumor Infiltrating CD8+ T Cells. <i>Cancers</i> , 2020, 12, 3169.	1.7	10
631	Impact of PET/CT for Assessing Response to Immunotherapy—A Clinical Perspective. <i>Journal of Clinical Medicine</i> , 2020, 9, 3483.	1.0	26
632	Ramucirumab in Combination with Pembrolizumab in Treatment-Naïve Advanced Gastric or GEJ Adenocarcinoma: Safety and Antitumor Activity from the Phase 1a/b JVDF Trial. <i>Cancers</i> , 2020, 12, 2985.	1.7	21
633	Exploratory Analysis of Lenvatinib Therapy in Patients with Unresectable Hepatocellular Carcinoma Who Have Failed Prior PD-1/PD-L1 Checkpoint Blockade. <i>Cancers</i> , 2020, 12, 3048.	1.7	37
634	Efficacy and safety of immune checkpoint blockade in self-identified Black patients with advanced non-small cell lung cancer. <i>Cancer</i> , 2020, 126, 5040-5049.	2.0	12
635	Immune-related pneumonitis associated with immune checkpoint inhibitors in lung cancer: a network meta-analysis. , 2020, 8, e001170.		28
636	Challenges associated with systemic therapy for older patients with inoperable non-small cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 2185-2194.	0.9	1
637	Phase II study on first-line treatment of NIVolumab in combination with folfoxiri/bevacizumab in patients with Advanced COloRectal cancer RAS or BRAF mutated — NIVACOR trial (GOIRC-03-2018). <i>BMC Cancer</i> , 2020, 20, 822.	1.1	13
638	Cost effectiveness of immune checkpoint inhibitors for treatment of non-small cell lung cancer: A systematic review. <i>PLoS ONE</i> , 2020, 15, e0238536.	1.1	34
639	Characterization of a novel HDAC/RXR/HtrA1 signaling axis as a novel target to overcome cisplatin resistance in human non-small cell lung cancer. <i>Molecular Cancer</i> , 2020, 19, 134.	7.9	44
640	Immune checkpoint inhibitor efficacy and safety in older non-small cell lung cancer patients. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 1447-1453.	0.6	14
641	Impact of Age on the Efficacy of Immune Checkpoint Inhibitor-Based Combination Therapy for Non-small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 1671.	1.3	25
642	Recent advances in the development of protein-protein interactions modulators: mechanisms and clinical trials. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 213.	7.1	387
643	Another Brick in the Wall: Sintilimab Plus Chemotherapy in Advanced Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1556-1558.	0.5	5
644	Immunotherapy Breakthroughs in the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. <i>Cancers</i> , 2020, 12, 2691.	1.7	39
645	Recurrence of Immune-Related Adverse Events After Immune Checkpoint Inhibitor Rechallenge. <i>JAMA Oncology</i> , 2020, 6, 1813.	3.4	0

#	ARTICLE	IF	CITATIONS
646	Non-interventional LUME-BioNIS study of nintedanib plus docetaxel after chemotherapy in adenocarcinoma non-small cell lung cancer: A subgroup analysis in patients with prior immunotherapy. <i>Lung Cancer</i> , 2020, 148, 159-165.	0.9	17
647	Brain metastases: lessons and challenges in the targeted therapy and immunotherapy era. <i>Journal of Thoracic Disease</i> , 2020, 12, 4527-4530.	0.6	3
648	Efficacy and safety of recombinant human endostatin combined with radiotherapy or chemoradiotherapy in patients with locally advanced non-small cell lung cancer: a pooled analysis. <i>Radiation Oncology</i> , 2020, 15, 205.	1.2	10
649	An update on the immune landscape in lung and head and neck cancers. <i>Ca-A Cancer Journal for Clinicians</i> , 2020, 70, 505-517.	157.7	93
650	Tumor Endothelial Cells (TECs) as Potential Immune Directors of the Tumor Microenvironment – New Findings and Future Perspectives. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 766.	1.8	99
651	Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer. <i>Nature Communications</i> , 2020, 11, 4607.	5.8	69
652	PD-L1-mediated gasdermin C expression switches apoptosis to pyroptosis in cancer cells and facilitates tumour necrosis. <i>Nature Cell Biology</i> , 2020, 22, 1264-1275.	4.6	508
653	A novel scoring method based on RNA-seq immunograms describing individual cancer-immunity interactions. <i>Cancer Science</i> , 2020, 111, 4031-4040.	1.7	32
654	PD-1 Inhibitor Therapy in a Patient with Preexisting P-ANCA Vasculitis: A Case Report and Review of the Literature. <i>Case Reports in Oncological Medicine</i> , 2020, 2020, 1-5.	0.2	1
655	ctDNA Concentration, MIK167 Mutations and Hyper-Progressive Disease Related Gene Mutations Are Prognostic Markers for Camrelizumab and Apatinib Combined Multiline Treatment in Advanced NSCLC. <i>Frontiers in Oncology</i> , 2020, 10, 1706.	1.3	17
656	Radiotherapy Scheme Effect on PD-L1 Expression for Locally Advanced Rectal Cancer. <i>Cells</i> , 2020, 9, 2071.	1.8	10
657	Adverse Effects of Anti-PD-1/PD-L1 Therapy in Non-small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 554313.	1.3	32
658	Efficacy of Docetaxel Plus Ramucirumab as Palliative Third-Line Therapy Following Second-Line Immune-Checkpoint-Inhibitor Treatment in Patients With Non-Small-Cell Lung Cancer Stage IV. <i>Clinical Medicine Insights: Oncology</i> , 2020, 14, 117955492095135.	0.6	24
659	Combined Methylome and Transcriptome Analyses Reveals Potential Therapeutic Targets for EGFR Wild Type Lung Cancers with Low PD-L1 Expression. <i>Cancers</i> , 2020, 12, 2496.	1.7	11
660	Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity. <i>Experimental and Molecular Medicine</i> , 2020, 52, 1475-1485.	3.2	306
661	Efficacy and safety of first-line avelumab in patients with advanced non-small cell lung cancer: results from a phase Ib cohort of the JAVELIN Solid Tumor study. , 2020, 8, e001064.		16
663	Striving toward Improved Outcomes for Surgically Resectable Non-Small Cell Lung Cancer: the Promise and Challenges of Neoadjuvant Immunotherapy. <i>Current Oncology Reports</i> , 2020, 22, 109.	1.8	10
664	Suppressing neutrophil-dependent angiogenesis abrogates resistance to anti-VEGF antibody in a genetic model of colorectal cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 21598-21608.	3.3	46

#	ARTICLE	IF	CITATIONS
665	Current status and future potential of predictive biomarkers for immune checkpoint inhibitors in gastric cancer. <i>ESMO Open</i> , 2020, 5, e000791.	2.0	25
666	Identification of a 4-lncRNA signature predicting prognosis of patients with non-small cell lung cancer: a multicenter study in China. <i>Journal of Translational Medicine</i> , 2020, 18, 320.	1.8	7
667	Bispecific Targeting of PD-1 and PD-L1 Enhances T-cell Activation and Antitumor Immunity. <i>Cancer Immunology Research</i> , 2020, 8, 1300-1310.	1.6	39
668	Anti-PD-1 and Anti-PD-L1 Monoclonal Antibodies in People Living with HIV and Cancer. <i>Current HIV/AIDS Reports</i> , 2020, 17, 547-556.	1.1	21
669	Variants of SLC22A16 Predict the Efficacy of Platinum Combination Chemotherapy in Advanced Non-small-cell Lung Cancer. <i>Anticancer Research</i> , 2020, 40, 4245-4251.	0.5	4
670	C-Reactive Protein (CRP) Levels in Immune Checkpoint Inhibitor Response and Progression in Advanced Non-Small Cell Lung Cancer: A Bi-Center Study. <i>Cancers</i> , 2020, 12, 2319.	1.7	52
671	Exosomes in Angiogenesis and Anti-angiogenic Therapy in Cancers. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5840.	1.8	143
672	PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5918.	1.8	15
673	Development of EGFR TKIs and Options to Manage Resistance of Third-Generation EGFR TKI Osimertinib: Conventional Ways and Immune Checkpoint Inhibitors. <i>Frontiers in Oncology</i> , 2020, 10, 602762.	1.3	59
674	A narrative review of the role of fibroblasts in the growth and development of neurogenic tumors. <i>Annals of Translational Medicine</i> , 2020, 8, 1462-1462.	0.7	4
675	Immune-Related Neurological Toxicities of PD-1/PD-L1 Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis. <i>Frontiers in Immunology</i> , 2020, 11, 595655.	2.2	8
676	The Emerging Therapeutic Landscape of ALK Inhibitors in Non-Small Cell Lung Cancer. <i>Pharmaceuticals</i> , 2020, 13, 474.	1.7	51
677	Applicability of the PACIFIC trial results in patients not eligible for the PACIFIC trial: Canadian rapid consensus statement and recommendations.. <i>Cancer Treatment and Research Communications</i> , 2020, 25, 100265.	0.7	3
678	Outcome of Patients with NSCLC and Brain Metastases Treated with Immune Checkpoint Inhibitors in a "Real-Life" Setting. <i>Cancers</i> , 2020, 12, 3707.	1.7	12
679	The Value of PD-L1 Expression in Predicting the Efficacy of Anti-PD-1 or Anti-PD-L1 Therapy in Patients with Cancer: A Systematic Review and Meta-Analysis. <i>Disease Markers</i> , 2020, 2020, 1-14.	0.6	13
680	Heterogeneous Tumor-Immune Microenvironments between Primary and Metastatic Tumors in a Patient with ALK Rearrangement-Positive Large Cell Neuroendocrine Carcinoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9705.	1.8	12
681	A case of simultaneous occurrence of hepatitis and pancreatitis during the combination immunochemotherapy for non-small cell lung carcinoma. <i>Respiratory Medicine Case Reports</i> , 2020, 31, 101266.	0.2	7
682	Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma. <i>Cancer Communications</i> , 2020, 40, 711-720.	3.7	68

#	ARTICLE	IF	CITATIONS
683	PD-L1 expression in the microenvironment and the response to checkpoint inhibitors in head and neck squamous cell carcinoma. <i>Oncolmmunology</i> , 2020, 9, 1844403.	2.1	18
684	What Is the Standard First-Line Treatment for Advanced Non-Small Cell Lung Cancer?. <i>Cancer Journal (Sudbury, Mass)</i> , 2020, 26, 485-495.	1.0	5
685	Immune Modulation in Lung Cancer: Current Concepts and Future Strategies. <i>Respiration</i> , 2020, 99, 903-929.	1.2	18
686	Tumor Vessel Normalization: A Window to Enhancing Cancer Immunotherapy. <i>Technology in Cancer Research and Treatment</i> , 2020, 19, 153303382098011.	0.8	20
687	A phase III, randomized, double-blind, controlled trial of carboxyamidotriazole plus chemotherapy for the treatment of advanced non-small cell lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592096584.	1.4	7
688	Changing paradigm in advanced and metastatic non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2020, 12, 6992-7001.	0.6	3
689	Radiation and immunotherapy: emerging mechanisms of synergy. <i>Journal of Thoracic Disease</i> , 2020, 12, 7011-7023.	0.6	28
690	Beyond chemoradiotherapy: improving treatment outcomes for patients with stage III unresectable non-small-cell lung cancer through immuno-oncology and durvalumab (Imfinzi® 1/4, AstraZeneca UK) Tj ETQq1 2017843143gBT /Ove	1.2	14
691	Immunotherapy in EGFR-Mutant and ALK-Positive Lung Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2020, 26, 517-524.	1.0	18
692	Opioids impair nivolumab outcomes: a retrospective propensity score analysis in non-small-cell lung cancer. <i>BMJ Supportive and Palliative Care</i> , 2023, 13, e185-e189.	0.8	10
693	Durable Remission of Human Papillomavirus-Positive JAK2/PDL1/PDL2-Amplified Urethral Squamous Carcinoma With Sequential Chemotherapy and Immune Checkpoint Inhibitor Therapy. <i>JCO Precision Oncology</i> , 2020, 4, 860-864.	1.5	0
694	PD-L1 Immunohistochemistry Comparability and Their Correlation with Clinical Characteristics in NSCLC. <i>Analytical Cellular Pathology</i> , 2020, 2020, 1-7.	0.7	3
695	Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities. <i>Frontiers in Immunology</i> , 2020, 11, 598877.	2.2	133
696	A reply to "ROS1-mutant cancer and immune checkpoint inhibitors: A large database analysis". <i>Lung Cancer</i> , 2020, 150, 254-255.	0.9	0
697	Efficacy of local therapy for oligoprogressive disease after programmed cell death 1 blockade in advanced non-small cell lung cancer. <i>Cancer Science</i> , 2020, 111, 4442-4452.	1.7	25
698	Tobacco exposure and immunotherapy response in PD-L1 positive lung cancer patients. <i>Lung Cancer</i> , 2020, 150, 159-163.	0.9	33
699	Präzisionsmedizin bei NSCLC im Zeitalter der Immuntherapie: Neue Biomarker zur Selektion der am besten geeigneten Therapie oder des am besten geeigneten Patienten. <i>Karger Kompass Pneumologie</i> , 2020, 8, 300-317.	0.0	1
700	Biomarkers in immunotherapy: literature review and future directions. <i>Journal of Thoracic Disease</i> , 2020, 12, 5119-5127.	0.6	7

#	ARTICLE	IF	CITATIONS
701	A Holistic Perspective: Exosomes Shuttle between Nerves and Immune Cells in the Tumor Microenvironment. <i>Journal of Clinical Medicine</i> , 2020, 9, 3529.	1.0	10
702	New Target Therapies in Advanced Non-Small Cell Lung Cancer: A Review of the Literature and Future Perspectives. <i>Journal of Clinical Medicine</i> , 2020, 9, 3543.	1.0	28
703	Update 2020: Management of Non-Small Cell Lung Cancer. <i>Lung</i> , 2020, 198, 897-907.	1.4	270
704	Survival-Inferred Fragility Index of Phase 3 Clinical Trials Evaluating Immune Checkpoint Inhibitors. <i>JAMA Network Open</i> , 2020, 3, e2017675.	2.8	20
705	Checkpoint Inhibitors in Gynecological Malignancies: Are we There Yet?. <i>BioDrugs</i> , 2020, 34, 749-762.	2.2	5
706	Future of immune checkpoint inhibitors: focus on tumor immune microenvironment. <i>Annals of Translational Medicine</i> , 2020, 8, 1095-1095.	0.7	27
707	Cancer Immunotherapy Dosing: A Pharmacokinetic/Pharmacodynamic Perspective. <i>Vaccines</i> , 2020, 8, 632.	2.1	23
708	Safety evaluation of durvalumab for the treatment of non-small-cell lung cancer. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 653-659.	1.0	7
709	First-line combination immunotherapy for metastatic non-small cell lung cancer. <i>Journal of the Chinese Medical Association</i> , 2020, 83, 433-441.	0.6	2
710	Ongoing challenges of using immunotherapy in special populations: Poor performance status patients, elderly patients, and people living with HIV. <i>Lung Cancer</i> , 2020, 145, 71-75.	0.9	10
711	Breakthrough 5-year survival with pembrolizumab in Keynote-001 study: horizon shifting in advanced non-small cell lung cancer with immune check point inhibition. <i>Annals of Translational Medicine</i> , 2020, 8, 555-555.	0.7	8
712	Combination treatments with immunotherapy in brain metastases patients. <i>Future Oncology</i> , 2020, 16, 1691-1705.	1.1	2
713	Checkpoint Blockade in Lung Cancer With Driver Mutation: Choose the Road Wisely. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, 372-384.	1.8	64
714	An advanced non-small cell lung cancer patient with epidermal growth factor receptor sensitizing mutation responded to toripalimab in combination with chemotherapy after resistance to osimertinib: a case report. <i>Translational Lung Cancer Research</i> , 2020, 9, 354-359.	1.3	7
715	Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review. <i>Thoracic Cancer</i> , 2020, 11, 1927-1933.	0.8	47
716	Association of immune-related pneumonitis with the efficacy of PD-1/PD-L1 inhibitors in non-small cell lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592092203.	1.4	26
717	What's the Price? Toxicities of Targeted Therapies in Breast Cancer Care. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, 55-70.	1.8	13
718	Chemotherapy and immune checkpoint inhibitor combination, a new standard in squamous non-small cell lung cancer?. <i>Translational Lung Cancer Research</i> , 2020, 9, 401-405.	1.3	1

#	ARTICLE	IF	CITATIONS
719	Immune Checkpoint Blockade in Oncogene-Driven Non-Small-Cell Lung Cancer. <i>Drugs</i> , 2020, 80, 883-892.	4.9	5
720	Precision Medicine for NSCLC in the Era of Immunotherapy: New Biomarkers to Select the Most Suitable Treatment or the Most Suitable Patient. <i>Cancers</i> , 2020, 12, 1125.	1.7	43
721	Scientifically based combination therapies with immuno-oncology checkpoint inhibitors. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1711-1725.	1.1	6
722	Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 786-795.	5.1	419
723	Anti-angiogenic agents in the age of resistance to immune checkpoint inhibitors: Do they have a role in non-oncogene-addicted non-small cell lung cancer?. <i>Lung Cancer</i> , 2020, 144, 76-84.	0.9	29
724	Immune Checkpoint Inhibitors for Lung Cancer Treatment: A Review. <i>Journal of Clinical Medicine</i> , 2020, 9, 1362.	1.0	102
725	Keynote 42: Pembrolizumab, PD-L1, and where to draw the line. <i>Annals of Translational Medicine</i> , 2020, 8, 517-517.	0.7	2
726	The impact of immune-inflammation-nutritional parameters on the prognosis of non-small cell lung cancer patients treated with atezolizumab. <i>Journal of Thoracic Disease</i> , 2020, 12, 1520-1528.	0.6	52
727	A Randomized Phase II Study of Maintenance Bevacizumab, Pemetrexed or Bevacizumab Plus Pemetrexed for Advanced Non-squamous Non-small Cell Lung Cancer. <i>Anticancer Research</i> , 2020, 40, 2981-2987.	0.5	4
728	Pseudoprogression and Hyperprogression as New Forms of Response to Immunotherapy. <i>BioDrugs</i> , 2020, 34, 463-476.	2.2	49
729	Mechanistic Learning for Combinatorial Strategies With Immuno-oncology Drugs: Can Model-Informed Designs Help Investigators?. <i>JCO Precision Oncology</i> , 2020, 4, 486-491.	1.5	9
730	Neoadjuvant immunotherapy with resectable non-small cell lung cancer: recent advances and future challenges. <i>Journal of Thoracic Disease</i> , 2020, 12, 1615-1620.	0.6	18
731	The Impact of EGFR Mutation Status and Brain Metastasis for Non-Small Cell Lung Cancer Treated with Ramucirumab plus Docetaxel. <i>Oncology</i> , 2020, 98, 661-668.	0.9	7
732	Efficacy of immune checkpoint inhibitors and age in cancer patients. <i>Immunotherapy</i> , 2020, 12, 587-603.	1.0	21
733	Early-onset meningitis associated with atezolizumab treatment for non-small cell lung cancer: case report and literature review. <i>Investigational New Drugs</i> , 2020, 38, 1901-1905.	1.2	4
734	Exploiting immune-dependent effects of microtubule-targeting agents to improve efficacy and tolerability of cancer treatment. <i>Cell Death and Disease</i> , 2020, 11, 361.	2.7	30
735	Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. <i>Lancet</i> , The, 2020, 395, 1547-1557.	6.3	546
736	Treatment Rationale and Design for APPLE (WJOG11218L): A Multicenter, Open-Label, Randomized Phase 3 Study of Atezolizumab and Platinum/Pemetrexed With or Without Bevacizumab for Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2020, 21, 472-476.	1.1	12

#	ARTICLE	IF	CITATIONS
737	Addition of ramucirumab enhances docetaxel efficacy in patients who had received anti-PD-1/PD-L1 treatment. <i>Lung Cancer</i> , 2020, 144, 71-75.	0.9	21
738	The safety of atezolizumab plus chemotherapy for the treatment of metastatic lung cancer. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 775-783.	1.0	2
739	The hypoxic tumour microenvironment: A safe haven for immunosuppressive cells and a therapeutic barrier to overcome. <i>Cancer Letters</i> , 2020, 487, 34-44.	3.2	32
740	Principles of Immunotherapy in Non-Small Cell Lung Cancer. <i>Thoracic Surgery Clinics</i> , 2020, 30, 187-198.	0.4	19
741	Immuno-Oncology—The New Paradigm of Lung Cancer Treatment. <i>Current Oncology</i> , 2020, 27, 78-86.	0.9	18
743	The Efficacy and Safety of PD-1/PD-L1 Inhibitors in Combination with Conventional Therapies for Advanced Solid Tumors: A Meta-Analysis. <i>BioMed Research International</i> , 2020, 2020, 1-10.	0.9	8
744	Efficacy of immune checkpoint inhibitor monotherapy for patients with massive non-small-cell lung cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 2957-2966.	1.2	14
745	Anaplastic Lymphoma Kinase Mutation—Positive Non—Small Cell Lung Cancer. <i>Thoracic Surgery Clinics</i> , 2020, 30, 137-146.	0.4	8
746	Tepotinib in Non—Small-Cell Lung Cancer with <i>MET</i> Exon 14 Skipping Mutations. <i>New England Journal of Medicine</i> , 2020, 383, 931-943.	13.9	500
747	Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non—Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 2530-2542.	0.8	47
748	RAS-targeted therapies: is the undruggable drugged?. <i>Nature Reviews Drug Discovery</i> , 2020, 19, 533-552.	21.5	569
749	Durvalumab vs placebo consolidation therapy after chemoradiotherapy in stage III non-small-cell lung cancer: An updated PACIFIC trial-based cost-effectiveness analysis. <i>Lung Cancer</i> , 2020, 146, 42-49.	0.9	25
750	Identification of PD1-mediated regulation of antitumor antigen response in patients with NSCLC using the trans vivo DTH assay. , 2020, 8, e000152.		0
751	Cost-effectiveness of atezolizumab plus chemotherapy for advanced non-small-cell lung cancer. <i>International Journal of Clinical Pharmacy</i> , 2020, 42, 1175-1183.	1.0	31
752	Application of immune checkpoint inhibitors in EGFR-mutant non-small-cell lung cancer: from bed to bench. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592093033.	1.4	25
753	The Importance of Imaging Studies in the Assessment of Response to Immunotherapy in Lung Cancer. <i>Archivos De Bronconeumología</i> , 2020, 56, 380-389.	0.4	1
754	Immunotherapy in non-small-cell lung cancer: from targeted molecules to resistance patterns. <i>Pharmacogenomics</i> , 2020, 21, 705-720.	0.6	9
755	IConMHC: a deep learning convolutional neural network model to predict peptide and MHC-I binding affinity. <i>Immunogenetics</i> , 2020, 72, 295-304.	1.2	4

#	ARTICLE	IF	CITATIONS
756	Development of Severe Heart Failure in a Patient with Squamous Non-small-cell Lung Cancer During Nivolumab Treatment. <i>Internal Medicine</i> , 2020, 59, 2003-2008.	0.3	10
757	Imaging-Based Prediction of Molecular Therapy Targets in NSCLC by Radiogenomics and AI Approaches: A Systematic Review. <i>Diagnostics</i> , 2020, 10, 359.	1.3	51
758	Canadian Consensus: A New Systemic Treatment Algorithm for Advanced EGFR-Mutated Non-Small-Cell Lung Cancer. <i>Current Oncology</i> , 2020, 27, 146-155.	0.9	14
759	Immunotherapy in Advanced Non-Small Cell Lung Cancer. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2020, 41, 400-408.	0.8	4
760	Long-term survivors with immunotherapy in advanced NSCLC: is "cure"™ within reach?. <i>Translational Cancer Research</i> , 2020, 9, 409-414.	0.4	3
761	Advances in the Treatment of Non-Small Cell Lung Cancer. <i>Clinics in Chest Medicine</i> , 2020, 41, 237-247.	0.8	50
762	Targeted Therapy for Non-Small Cell Lung Cancer. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2020, 41, 409-434.	0.8	11
763	Pulmonary Complications of Immunotherapy. <i>Clinics in Chest Medicine</i> , 2020, 41, 295-305.	0.8	1
764	Real-world treatment efficacy of anti-programmed death-1 combined with anti-angiogenesis therapy in non-small cell lung cancer patients. <i>Medicine (United States)</i> , 2020, 99, e20545.	0.4	18
765	Quality of life with second or third line nab-paclitaxel-based regimens in advanced non-small-cell lung cancer. <i>Future Oncology</i> , 2020, 16, 749-762.	1.1	0
766	Immune microenvironment composition in non-small cell lung cancer and its association with survival. <i>Clinical and Translational Immunology</i> , 2020, 9, e1142.	1.7	119
767	Emerging Treatment Paradigms for EGFR-Mutant Lung Cancers Progressing on Osimertinib: A Review. <i>Journal of Clinical Oncology</i> , 2020, 38, 2926-2936.	0.8	107
768	Clinical consideration for choosing combination therapies in advanced non-small-cell lung cancer: age, Eastern Cooperative Organization performance status 2, steroids and antibiotics. <i>Future Oncology</i> , 2020, 16, 1683-1690.	1.1	4
769	Association of Programmed Cell Death Ligand 1 Expression Status With Receipt of Immune Checkpoint Inhibitors in Patients With Advanced Non-Small Cell Lung Cancer. <i>JAMA Network Open</i> , 2020, 3, e207205.	2.8	19
770	Looking for the Optimal PD-1/PD-L1 Inhibitor in Cancer Treatment: A Comparison in Basic Structure, Function, and Clinical Practice. <i>Frontiers in Immunology</i> , 2020, 11, 1088.	2.2	61
771	Hepatotoxicity in patients with solid tumors treated with PD-1/PD-L1 inhibitors alone, PD-1/PD-L1 inhibitors plus chemotherapy, or chemotherapy alone: systematic review and meta-analysis. <i>European Journal of Clinical Pharmacology</i> , 2020, 76, 1345-1354.	0.8	16
772	Spectrum and Clinical Activity of PD-1/PD-L1 Inhibitors: Regulatory Approval and Under Development. <i>Current Oncology Reports</i> , 2020, 22, 70.	1.8	11
773	Predictive value of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis. <i>International Immunopharmacology</i> , 2020, 85, 106677.	1.7	61

#	ARTICLE	IF	CITATIONS
774	<i>ALK</i> -Rearranged Non-Small Cell Lung Cancer in 2020: Real-World Triumphs in an Era of Multigeneration ALK-Inhibitor Sequencing Informed by Drug Resistance Profiling. <i>Oncologist</i> , 2020, 25, 641-649.	1.9	8
775	Phase I/II study of carboplatin plus weekly nab-paclitaxel in patients aged ≥75 years with squamous-cell lung cancer: TOR1322. <i>Lung Cancer</i> , 2020, 146, 182-188.	0.9	1
776	Afatinib for the treatment of <i>EGFR</i> mutation-positive NSCLC: A review of clinical findings. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 1461-1474.	0.5	61
777	Advances in targeting acquired resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors. <i>Journal of Thoracic Disease</i> , 2020, 12, 2859-2876.	0.6	11
778	The Risk Ratio of Immune-Related Colitis, Hepatitis, and Pancreatitis in Patients With Solid Tumors Caused by PD-1/PD-L1 Inhibitors: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 261.	1.3	11
779	Minimally Invasive Lobectomy for Residual Primary Tumors of Advanced Non-Small-Cell Lung Cancer After Treatment With Immune Checkpoint Inhibitors: Case Series and Clinical Considerations. <i>Clinical Lung Cancer</i> , 2020, 21, e265-e269.	1.1	7
780	Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 1505-1517.	0.8	710
781	Acquired resistance to targeted therapies in NSCLC: Updates and evolving insights. , 2020, 210, 107522.		56
782	Addressing Recent Failures in Immuno-Oncology Trials to Guide Novel Immunotherapeutic Treatment Strategies. <i>Pharmaceutical Medicine</i> , 2020, 34, 83-91.	1.0	9
783	Deep neural network classification based on somatic mutations potentially predicts clinical benefit of immune checkpoint blockade in lung adenocarcinoma. <i>Oncimmunology</i> , 2020, 9, 1734156.	2.1	21
784	Patterns of response in metastatic NSCLC during PD-1 or PD-L1 inhibitor therapy: Comparison of the RECIST 1.1 and iRECIST criteria. <i>Thoracic Cancer</i> , 2020, 11, 1068-1075.	0.8	15
785	Docetaxel Upregulates HMGB1 Levels in Non-small Cell Lung Cancer. <i>Biological and Pharmaceutical Bulletin</i> , 2020, 43, 399-403.	0.6	10
786	Combining Immune Checkpoint Inhibitors with Anti-Angiogenic Agents. <i>Journal of Clinical Medicine</i> , 2020, 9, 675.	1.0	57
787	Combining Immunotherapy and Chemotherapy for Non-Small Cell Lung Cancer. <i>Thoracic Surgery Clinics</i> , 2020, 30, 199-206.	0.4	30
788	ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer. <i>Annals of Oncology</i> , 2020, 31, 609-618.	0.6	100
789	Safety and efficacy of pembrolizumab in combination with S-1 plus oxaliplatin as a first-line treatment in patients with advanced gastric/gastroesophageal junction cancer: Cohort 1 data from the KEYNOTE-659 phase IIb study. <i>European Journal of Cancer</i> , 2020, 129, 97-106.	1.3	48
790	Melanoma immunotherapy: strategies to overcome pharmacological resistance. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 289-304.	1.1	13
791	Efficacy and safety of immune checkpoint inhibitor monotherapy in pretreated elderly patients with non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 761-771.	1.1	32

#	ARTICLE	IF	CITATIONS
792	Cost-Effectiveness Analysis of Atezolizumab Plus Chemotherapy in the First-Line Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer. <i>Advances in Therapy</i> , 2020, 37, 2116-2126.	1.3	24
793	The Story of Angiogenesis Inhibitors in Non-small-cell Lung Cancer: The Past, Present, and Future. <i>Clinical Lung Cancer</i> , 2020, 21, 308-313.	1.1	26
794	Conquering lung cancer: current status and prospects for the future. <i>Pulmonology</i> , 2020, 26, 283-290.	1.0	51
795	Immunotherapy: From Advanced NSCLC to Early Stages, an Evolving Concept. <i>Frontiers in Medicine</i> , 2020, 7, 90.	1.2	31
796	Apatinib Monotherapy or Combination Therapy for Non-Small Cell Lung Cancer Patients With Brain Metastases. <i>Oncology Research</i> , 2020, 28, 127-133.	0.6	5
797	Tumor Microenvironment. <i>Cancer Treatment and Research</i> , 2020, , .	0.2	12
798	Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations. <i>Journal of Thoracic Oncology</i> , 2020, 15, 914-947.	0.5	119
799	A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial. <i>Clinical Cancer Research</i> , 2020, 26, 1896-1904.	3.2	9
800	Association of Steroids Use with Survival in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2020, 12, 546.	1.7	177
801	The safety and efficacy of pembrolizumab for the treatment of non-small cell lung cancer. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 233-242.	1.0	7
802	Observed versus modelled lifetime overall survival of targeted therapies and immunotherapies for advanced non-small cell lung cancer patients – A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 153, 103035.	2.0	5
803	Recent updates on the resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors and resistance reversion strategies in lung cancer. <i>Medicinal Research Reviews</i> , 2020, 40, 2132-2176.	5.0	35
804	Role of Serum Vascular Endothelial Growth Factor (VEGF) as a Potential Biomarker of Response to Immune Checkpoint Inhibitor Therapy in Advanced Melanoma: Results of a Pilot Study. <i>Frontiers in Oncology</i> , 2020, 10, 1041.	1.3	12
805	Rechallenge Strategy in Cancer Therapy. <i>Oncology</i> , 2020, 98, 669-679.	0.9	9
806	Telomere Stress Potentiates STING-Dependent Anti-tumor Immunity. <i>Cancer Cell</i> , 2020, 38, 400-411.e6.	7.7	70
807	Do systemic treatments delivered after Nivolumab result in better outcomes? A bicentric case-control study. <i>Respiratory Medicine and Research</i> , 2020, 77, 100-105.	0.4	1
808	Economic Evaluations of Immune Checkpoint Inhibitors for Patients with Non-Small Cell Lung Cancer: A Systematic Review. <i>Cancer Management and Research</i> , 2020, Volume 12, 4503-4518.	0.9	5
809	Tumor evolution in epidermal growth factor receptor mutated non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2020, 12, 2896-2909.	0.6	5

#	ARTICLE	IF	CITATIONS
810	The safety of first and subsequent lines of PD-1/PD-L1 inhibitors monotherapy in non-small cell lung cancer patients: a meta-analysis. <i>Translational Cancer Research</i> , 2020, 9, 3231-3241.	0.4	5
811	Tumor Mutational Burden and PD-L1 Expression in Non-Small-Cell Lung Cancer (NSCLC) in Southwestern China. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 5191-5198.	1.0	3
812	Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic. <i>Cancer Treatment Reviews</i> , 2020, 89, 102067.	3.4	48
813	PD-(L)1 Inhibitors in Combination with Chemotherapy as First-Line Treatment for Non-Small-Cell Lung Cancer: A Pairwise Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2020, 9, 2093.	1.0	13
814	Immunotherapy for Non-small Cell Lung Cancer: Current Landscape and Future Perspectives. <i>Immune Network</i> , 2020, 20, e10.	1.6	86
816	Clinical Outcomes of Anti-programmed Death-1 Antibody-Related Pneumonitis in Patients with Non-Small Cell Lung Cancer. <i>SN Comprehensive Clinical Medicine</i> , 2020, 2, 570-578.	0.3	8
817	Sequential ctDNA whole-exome sequencing in advanced lung adenocarcinoma with initial durable tumor response on immune checkpoint inhibitor and late progression. , 2020, 8, e000527.		24
818	Anlotinib or platinum-pemetrexed as second-line therapy in EGFR T790M-negative lung cancer. <i>Annals of Palliative Medicine</i> , 2020, 9, 1681-1687.	0.5	7
819	Medical Treatment of Lung Cancer: Can Immune Cells Predict the Response? A Systematic Review. <i>Frontiers in Immunology</i> , 2020, 11, 1036.	2.2	10
820	Immuno-Metabolism and Microenvironment in Cancer: Key Players for Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4414.	1.8	87
821	Combination of Ipilimumab and Nivolumab in Cancers: From Clinical Practice to Ongoing Clinical Trials. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4427.	1.8	67
822	Optimal Management of Patients with Advanced NSCLC Harboring High PD-L1 Expression and Driver Mutations. <i>Current Treatment Options in Oncology</i> , 2020, 21, 60.	1.3	6
823	Clinical Activity and Safety of Atezolizumab in a Phase 1 Study of Patients With Relapsed/Refractory Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2020, 21, 455-463.e4.	1.1	13
824	Unique Genetic Characteristics and Clinical Prognosis of Female Patients with Lung Cancer Harboring RET Fusion Gene. <i>Scientific Reports</i> , 2020, 10, 10387.	1.6	8
825	Successful continuous nivolumab therapy for metastatic non-small cell lung cancer after local treatment of oligometastatic lesions. <i>Thoracic Cancer</i> , 2020, 11, 2357-2360.	0.8	8
826	Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer – a randomized phase III trial (AGO-OVAR 2.29/ENGOT-ov34). <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1997-2001.	1.2	11
827	Efficacy of Joungal in preventing febrile neutropenia induced by platinum-based doublet chemotherapy in lung cancer. <i>Annals of Palliative Medicine</i> , 2020, 9, 1688-1695.	0.5	0
828	Organoid Models of Tumor Immunology. <i>Trends in Immunology</i> , 2020, 41, 652-664.	2.9	210

#	ARTICLE	IF	CITATIONS
829	Immunotherapy combinations for the treatment of patients with solid tumors. <i>Future Oncology</i> , 2020, 16, 1715-1736.	1.1	6
830	The impact of PD-L1 N-linked glycosylation on cancer therapy and clinical diagnosis. <i>Journal of Biomedical Science</i> , 2020, 27, 77.	2.6	89
831	Immune checkpoint inhibitors: Key trials and an emerging role in breast cancer. <i>Seminars in Cancer Biology</i> , 2022, 79, 44-57.	4.3	104
832	Atezolizumab-associated encephalitis in metastatic lung adenocarcinoma: a case report. <i>Journal of Medical Case Reports</i> , 2020, 14, 88.	0.4	16
833	Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 251-266.	12.5	408
834	PET/CT and the Response to Immunotherapy in Lung Cancer. <i>Current Radiopharmaceuticals</i> , 2020, 13, 177-184.	0.3	17
835	Clinical efficacy and safety of anti-PD-1/PD-L1 inhibitors for the treatment of advanced or metastatic cancer: a systematic review and meta-analysis. <i>Scientific Reports</i> , 2020, 10, 2083.	1.6	124
836	Immunotherapy for nonsmall cell lung cancer: a new therapeutic algorithm. <i>European Respiratory Journal</i> , 2020, 55, 1901907.	3.1	27
837	Immunotherapy in lung cancer: the chemotherapy conundrum. <i>Chinese Clinical Oncology</i> , 2020, 9, 59-59.	0.4	15
838	Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update Summary. <i>JCO Oncology Practice</i> , 2020, 16, e844-e848.	1.4	18
839	Use of Programmed Death Receptor-1 and/or Programmed Death Ligand 1 Inhibitors for the Treatment of Brain Metastasis of Lung Cancer. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 667-683.	1.0	24
840	Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas. <i>Annals of Oncology</i> , 2020, 31, 599-608.	0.6	183
841	Synergizing systemic responses by combining immunotherapy with radiotherapy in metastatic non-small cell lung cancer: The potential of the abscopal effect. <i>Lung Cancer</i> , 2020, 142, 106-113.	0.9	28
843	New advances in antiangiogenic combination therapeutic strategies for advanced non-small cell lung cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 631-645.	1.2	50
844	A phase I and extension study of S-1 and carboplatin for previously untreated patients aged 75 years or more with advanced non-small cell lung cancer -TCOG 1101-. <i>International Journal of Clinical Oncology</i> , 2020, 25, 867-875.	1.0	1
845	Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression $\geq 50\%$. <i>Annals of Oncology</i> , 2020, 31, 404-411.	0.6	79
847	Fatal Adverse Events Associated With Programmed Cell Death Ligand 1 Inhibitors: A Systematic Review and Meta-Analysis. <i>Frontiers in Pharmacology</i> , 2020, 11, 5.	1.6	12
848	The Biology of Lung Cancer. <i>Clinics in Chest Medicine</i> , 2020, 41, 25-38.	0.8	52

#	ARTICLE	IF	CITATIONS
849	A novel cyclic peptide targeting LAG-3 for cancer immunotherapy by activating antigen-specific CD8+ T cell responses. <i>Acta Pharmaceutica Sinica B</i> , 2020, 10, 1047-1060.	5.7	50
850	Real-World Efficacy of First-Line Pembrolizumab in Patients With Advanced or Recurrent Nonâ€“Small-Cell Lung Cancer and High PD-L1 Tumor Expression. <i>Clinical Lung Cancer</i> , 2020, 21, e366-e379.	1.1	26
851	A phase IB study of durvalumab with or without tremelimumab and platinum-doublet chemotherapy in advanced solid tumours: Canadian Cancer Trials Group Study IND226. <i>Lung Cancer</i> , 2020, 143, 1-11.	0.9	19
852	Treatment of Patients With Nonâ€“Small-Cell Lung Cancer Harboring Rare Oncogenic Mutations. <i>Clinical Lung Cancer</i> , 2020, 21, 395-406.	1.1	2
853	Current status and progress of concurrent chemoradiotherapy in patients with locally advanced nonâ€“small cell lung cancer prior to the approval of durvalumab. <i>Thoracic Cancer</i> , 2020, 11, 1005-1014.	0.8	10
854	Current challenges in the management of nonsmall cell lung cancer brain metastases. <i>European Respiratory Journal</i> , 2020, 55, 1901686.	3.1	2
855	Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases. <i>Journal of Thoracic Oncology</i> , 2020, 15, 803-815.	0.5	178
856	Overcoming immunotherapeutic resistance by targeting the cancer inflammation cycle. <i>Seminars in Cancer Biology</i> , 2020, 65, 38-50.	4.3	34
857	Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration. <i>Nature Medicine</i> , 2020, 26, 47-51.	15.2	255
858	Immunosurveillance and Immunoediting of Lung Cancer: Current Perspectives and Challenges. <i>International Journal of Molecular Sciences</i> , 2020, 21, 597.	1.8	58
859	Immune checkpoint inhibitors in advanced nonâ€“small cell lung cancer: A metacentric experience from India. <i>Current Problems in Cancer</i> , 2020, 44, 100549.	1.0	4
860	Pharmacodynamics of current and emerging PD-1 and PD-L1 inhibitors for the treatment of non-small cell lung cancer. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020, 16, 87-96.	1.5	5
861	ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients. <i>European Journal of Cancer</i> , 2020, 127, 52-66.	1.3	52
862	Nanoparticles modified by triple single chain antibodies for MRI examination and targeted therapy in pancreatic cancer. <i>Nanoscale</i> , 2020, 12, 4473-4490.	2.8	22
863	Precision Management of Advanced Nonâ€“Small Cell Lung Cancer. <i>Annual Review of Medicine</i> , 2020, 71, 117-136.	5.0	101
864	Codelivery of Antiâ€“PDâ€“1 Antibody and Paclitaxel with Matrix Metalloproteinase and pH Dualâ€“Sensitive Micelles for Enhanced Tumor Chemoimmunotherapy. <i>Small</i> , 2020, 16, e1906832.	5.2	80
865	Therapy for Stage IV Nonâ€“Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update. <i>Journal of Clinical Oncology</i> , 2020, 38, 1608-1632.	0.8	301
866	Cost-effectiveness of pembrolizumab for advanced non-small cell lung cancer patients with varying comorbidity burden. <i>PLoS ONE</i> , 2020, 15, e0228288.	1.1	12

#	ARTICLE	IF	CITATIONS
885	Weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous non-small-cell lung cancer: Results of the IFCT-1103 ULTIMATE study. <i>European Journal of Cancer</i> , 2020, 131, 27-36.	1.3	44
886	Immune checkpoint inhibitors in special populations. A focus on advanced lung cancer patients. <i>Lung Cancer</i> , 2020, 144, 1-9.	0.9	10
887	Atezolizumab for the treatment of renal cell carcinoma. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 679-686.	1.4	0
888	Thyroid Toxicity Following Immune Checkpoint Inhibitor Treatment in Advanced Cancer. <i>Thyroid</i> , 2020, 30, 1458-1469.	2.4	44
889	Exploratory analysis of front-line therapies in REVEL: a randomised phase 3 study of ramucirumab plus docetaxel versus docetaxel for the treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy. <i>ESMO Open</i> , 2020, 5, e000567.	2.0	7
890	Propensity score-weighted analysis of chemotherapy after PD-1 inhibitors versus chemotherapy alone in patients with non-small cell lung cancer (WJOG10217L). <i>J Clin Oncol</i> , 2020, 38, e000350.		42
891	Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook. <i>Cancer Treatment Reviews</i> , 2020, 86, 102017.	3.4	573
892	Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial. <i>BMC Cancer</i> , 2020, 20, 352.	1.1	24
893	An update on angiogenesis targeting in head and neck squamous cell carcinoma. <i>Cancers of the Head & Neck</i> , 2020, 5, 5.	6.2	31
894	Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Non-Small-Cell Lung Cancer with ALK Rearrangement. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2623.	1.8	28
895	Effectiveness of PD-1/PD-L1 inhibitors in the treatment of lung cancer: Brightness and challenge. <i>Science China Life Sciences</i> , 2020, 63, 1499-1514.	2.3	20
896	Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1351-1360.	0.5	379
897	Efficacy of immune check-point inhibitors (ICPi) in large cell neuroendocrine tumors of lung (LCNEC). <i>Lung Cancer</i> , 2020, 143, 40-46.	0.9	38
898	Immunotherapy in Lung Cancer: From a Minor God to the Olympus. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1244, 69-92.	0.8	15
899	PD-1+ natural killer cells in human non-small cell lung cancer can be activated by PD-1/PD-L1 blockade. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1505-1517.	2.0	58
900	Identifying optimal first-line interventions for advanced non-small cell lung carcinoma according to PD-L1 expression: a systematic review and network meta-analysis. <i>Oncol Immunology</i> , 2020, 9, 1746112.	2.1	26
901	Immune Checkpoint Inhibitors for Brain Metastases: A Primer for Neurosurgeons. <i>Neurosurgery</i> , 2020, 87, E281-E288.	0.6	22
902	Mechanism-based treatment of cancer with immune checkpoint inhibitor therapies. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1690-1702.	1.1	26

#	ARTICLE	IF	CITATIONS
903	Pemetrexed sensitizes human lung cancer cells to cytotoxic immune cells. <i>Cancer Science</i> , 2020, 111, 1910-1920.	1.7	21
904	Durvalumab in frail and elderly patients with stage four non-small cell lung cancer: Study protocol of the randomized phase II DURATION trial. <i>Trials</i> , 2020, 21, 352.	0.7	7
905	Thyroid Dysfunction Related to the Antiangiogenic VEGFR2-Binding Monoclonal Antibody Ramucirumab: A Series of 14 Cases and a Descriptive Study. <i>Biological and Pharmaceutical Bulletin</i> , 2020, 43, 752-756.	0.6	3
906	Prospective Feasibility Study of Amrubicin and Bevacizumab Therapy for Patients With Previously Treated Advanced NSCLC. <i>Anticancer Research</i> , 2020, 40, 1571-1578.	0.5	0
907	Long-Term Gemcitabine Treatment Reshapes the Pancreatic Tumor Microenvironment and Sensitizes Murine Carcinoma to Combination Immunotherapy. <i>Cancer Research</i> , 2020, 80, 3101-3115.	0.4	77
908	Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC. <i>Clinical Cancer Research</i> , 2020, 26, 2849-2858.	3.2	74
909	Treatment rationale and design of the PROLONG study: safety and efficacy of pembrolizumab as first-line therapy for elderly patients with non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2020, 12, 1079-1084.	0.6	5
910	Chemotherapy and/or immune checkpoint inhibitors in NSCLC first-line setting: what is the best approach?. <i>Lung Cancer Management</i> , 2020, 9, LMT22.	1.5	15
911	Landscape and Future Perspectives of Immunotherapy in Neuroendocrine Neoplasia. <i>Cancers</i> , 2020, 12, 832.	1.7	27
912	Immunotherapy for Uterine Cervical Cancer Using Checkpoint Inhibitors: Future Directions. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2335.	1.8	52
913	EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 36-48.	0.5	153
914	Advances in Small-Cell Lung Cancer (SCLC) Translational Research. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2021, 11, a038240.	2.9	34
915	A multidisciplinary consensus on the morphological and functional responses to immunotherapy treatment. <i>Clinical and Translational Oncology</i> , 2021, 23, 434-449.	1.2	6
916	Trends in Drug Costs and Overall Survival in Patients with Metastatic Non-small Cell Lung Cancer in The Netherlands Diagnosed from 2008 Through 2014. <i>Pharmacoeconomics - Open</i> , 2021, 5, 121-127.	0.9	2
917	Prospective Observational Study of Treatment Resistance-related Gene Screening Using Plasma Circulating Tumor DNA in Third-generation EGFR-TKI Osimertinib Therapy (Elucidator). <i>Clinical Lung Cancer</i> , 2021, 22, e336-e341.	1.1	2
918	The role of ramucirumab and pembrolizumab combination in patients with advanced non-small cell lung cancer, gastroesophageal adenocarcinoma, or urothelial carcinoma. <i>Chinese Clinical Oncology</i> , 2021, 10, 30-30.	0.4	1
919	PD-L1 versus tumor mutation burden: Which is the better immunotherapy biomarker in advanced non-small cell lung cancer?. <i>Journal of Gene Medicine</i> , 2021, 23, e3294.	1.4	14
920	Nanomedicine in lung cancer: Current states of overcoming drug resistance and improving cancer immunotherapy. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2021, 13, e1654.	3.3	21

#	ARTICLE	IF	CITATIONS
921	Newly emerged immunogenic neoantigens in established tumors enable hosts to regain immunosurveillance in a T-cell-dependent manner. <i>International Immunology</i> , 2021, 33, 39-48.	1.8	4
922	Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 245-251.	1.2	47
923	Polypharmacy among older advanced lung cancer patients taking EGFR tyrosine kinase inhibitors. <i>Journal of Geriatric Oncology</i> , 2021, 12, 64-71.	0.5	14
924	Combination therapy with PD-1/PD-L1 blockade in non-small cell lung cancer: strategies and mechanisms. , 2021, 219, 107694.		79
925	Clinical strategies for optimizing infusion center care through a pandemic. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 165-179.	0.5	3
926	Impact of previous thoracic radiation therapy on the efficacy of immune checkpoint inhibitors in advanced non-small-cell lung cancer. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 279-286.	0.6	7
927	Programmed death-1 or programmed death ligand-1 inhibitors? A meta-analysis of differential efficacy as compared to chemotherapy in advanced non-small cell lung cancer. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 405-413.	0.5	2
928	Bevacizumab-associated events in Japanese women with cervical cancer: a multi-institutional survey of Obstetrical Gynecological Society of Kinki district, Japan. <i>International Journal of Clinical Oncology</i> , 2021, 26, 598-605.	1.0	6
929	Enrichment of circulating tumor-derived extracellular vesicles from human plasma. <i>Journal of Immunological Methods</i> , 2021, 490, 112936.	0.6	19
930	PDL1 high expression without TP53, KEAP1 and EPHA5 mutations could better predict survival for patients with NSCLC receiving atezolizumab. <i>Lung Cancer</i> , 2021, 151, 76-83.	0.9	10
931	Tumour targetable and microenvironment-responsive nanoparticles simultaneously disrupt the PD-1/PD-L1 pathway and MAPK/ERK/JNK pathway for efficient treatment of colorectal cancer. <i>Journal of Drug Targeting</i> , 2021, 29, 454-465.	2.1	6
932	Exploring the knowledge gap of immune checkpoint inhibitors in chronic renal failure: A systematic review of the literature. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103169.	2.0	14
933	Treatment patterns and clinical outcomes in patients with advanced non-small cell lung cancer initiating first-line treatment in the US community oncology setting: a real-world retrospective observational study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 671-690.	1.2	30
934	Low-dose carboplatin reprograms tumor immune microenvironment through STING signaling pathway and synergizes with PD-1 inhibitors in lung cancer. <i>Cancer Letters</i> , 2021, 500, 163-171.	3.2	55
935	Adverse events reporting in phase 3 oncology clinical trials of checkpoint inhibitors: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103162.	2.0	1
936	Checkpoint inhibitors in NSCLC for the elderly: current challenges and perspectives. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 315-323.	1.1	7
937	Multicenter Phase I/II Study of Nivolumab Combined with Paclitaxel Plus Ramucirumab as Second-line Treatment in Patients with Advanced Gastric Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 1029-1036.	3.2	46
938	Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2021, 16, 223-249.	9.6	956

#	ARTICLE	IF	CITATIONS
939	Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma. <i>Clinical Cancer Research</i> , 2021, 27, 1048-1057.	3.2	129
940	Brain metastases in metastatic cancer: a review of recent advances in systemic therapies. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 325-339.	1.1	10
941	Clinical outcomes of immune checkpoint blockades and the underlying immune escape mechanisms in squamous and adenocarcinoma NSCLC. <i>Cancer Medicine</i> , 2021, 10, 3-14.	1.3	28
942	Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer overexpressing PD-L1: results of the exploratory "FoRECATT" study. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1583-1592.	2.0	12
943	The cutting-edge progress of immune-checkpoint blockade in lung cancer. <i>Cellular and Molecular Immunology</i> , 2021, 18, 279-293.	4.8	102
944	Outcome and risk factor of immune-related adverse events and pneumonitis in patients with advanced or postoperative recurrent non-small cell lung cancer treated with immune checkpoint inhibitors. <i>Thoracic Cancer</i> , 2021, 12, 153-164.	0.8	28
945	Immunotherapy Treatment Patterns and Outcomes Among ALK-Positive Patients With Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2021, 22, 49-57.	1.1	39
946	The optimal immune checkpoint inhibitors combined with chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis. <i>Clinical and Translational Oncology</i> , 2021, 23, 1117-1127.	1.2	3
947	2020 Innovation-Based Optimism for Lung Cancer Outcomes. <i>Oncologist</i> , 2021, 26, e454-e472.	1.9	17
948	Molecular testing and targeted therapy for non-small cell lung cancer: Current status and perspectives. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103194.	2.0	260
949	Combination of Immunotherapy and Antiangiogenic Therapy in Cancer—a Rational Approach. <i>Journal of Thoracic Oncology</i> , 2021, 16, 178-182.	0.5	8
950	Immunotherapy combinations in advanced nonsmall cell lung cancer. <i>Current Opinion in Oncology</i> , 2021, 33, 73-79.	1.1	5
951	Combined Immunotherapy and Stereotactic Radiotherapy Improves Neurologic Outcomes in Patients with Non-small-cell Lung Cancer Brain Metastases. <i>Clinical Lung Cancer</i> , 2021, 22, 110-119.	1.1	27
952	Potential predictive value of change in inflammatory cytokines levels subsequent to initiation of immune checkpoint inhibitor in patients with advanced non-small cell lung cancer. <i>Cytokine</i> , 2021, 138, 155363.	1.4	20
953	Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial. <i>Journal of Thoracic Oncology</i> , 2021, 16, 653-664.	0.5	251
954	Expanding the nanotherapeutic toolbox for non-small-cell lung cancer. <i>Annals of Oncology</i> , 2021, 32, 9-11.	0.6	8
955	Triplet combination of durvalumab, tremelimumab, and paclitaxel in biliary tract carcinomas: Safety run-in results of the randomized IMMUNOBIL PRODIGE 57 phase II trial. <i>European Journal of Cancer</i> , 2021, 143, 55-63.	1.3	32
956	Comparative Efficacy and Safety of PD-1/PD-L1 Inhibitors for Patients with Solid Tumors: A Systematic Review and Bayesian Network Meta-analysis. <i>Journal of Cancer</i> , 2021, 12, 1133-1143.	1.2	14

#	ARTICLE	IF	CITATIONS
957	Effect of Treatment with the PD-1/PD-L1 Inhibitors on Key Health Outcomes of Cancer Patients. <i>BioDrugs</i> , 2021, 35, 61-73.	2.2	1
958	Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naïve patients with advanced non-squamous non-small-cell lung cancer (Camel): a randomised, open-label, multicentre, phase 3 trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 305-314.	5.2	277
959	Evaluation of the effect of prospective biomarker testing on progression-free survival in diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2021, 62, 999-1002.	0.6	0
960	Current status of PD-1/PD-L1 blockade immunotherapy in breast cancer. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 321-332.	0.6	22
961	Efficacy and Biomarker Analysis of Camrelizumab in Combination with Apatinib in Patients with Advanced Nonsquamous NSCLC Previously Treated with Chemotherapy. <i>Clinical Cancer Research</i> , 2021, 27, 1296-1304.	3.2	79
962	Comparative efficacy of chemoimmunotherapy versus immunotherapy for advanced non-small cell lung cancer: A network meta-analysis of randomized trials. <i>Cancer</i> , 2021, 127, 709-719.	2.0	16
963	The rediscovery of platinum-based cancer therapy. <i>Nature Reviews Cancer</i> , 2021, 21, 37-50.	12.8	452
964	Predictors of survival among Japanese patients receiving first-line chemoimmunotherapy for advanced non-small cell lung cancer. <i>Thoracic Cancer</i> , 2021, 12, 97-105.	0.8	20
965	Immunotherapy in nonsmall-cell lung cancer: current status and future prospects for liquid biopsy. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1177-1188.	2.0	60
966	Optimizing therapy sequence to prevent patient attrition in EGFR mutation-positive advanced or metastatic NSCLC. <i>Future Oncology</i> , 2021, 17, 471-486.	1.1	11
967	Differential Efficacy of Pembrolizumab According to Metastatic Sites in Patients With PD-L1 Strongly Positive (TPS ≥ 50%) NSCLC. <i>Clinical Lung Cancer</i> , 2021, 22, 127-133.e3.	1.1	9
968	Physiologic colonic uptake of 18F-FDG on PET/CT is associated with clinical response and gut microbiome composition in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1550-1559.	3.3	15
969	Alternative nivolumab duration and scheduling in advanced nonsmall cell lung cancer: A real-world evidence. <i>International Journal of Cancer</i> , 2021, 148, 1183-1191.	2.3	1
970	Platinum-based chemotherapy in combination with PD-1/PD-L1 inhibitors: preclinical and clinical studies and mechanism of action. <i>Expert Opinion on Drug Delivery</i> , 2021, 18, 187-203.	2.4	66
971	Targeted drug therapy in non-small cell lung cancer: Clinical significance and possible solutions-Part I. <i>Expert Opinion on Drug Delivery</i> , 2021, 18, 73-102.	2.4	13
972	Anti-PD-1/L1 plus anti-angiogenesis therapy as second-line or later treatment in advanced lung adenocarcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 881-891.	1.2	13
973	Immune landscape and therapeutic strategies: new insights into PD-L1 in tumors. <i>Cellular and Molecular Life Sciences</i> , 2021, 78, 867-887.	2.4	9
974	Selection of optimal first-line immuno-related therapy based on specific pathological characteristics for patients with advanced driver-gene wild-type non-small cell lung cancer: a systematic review and network meta-analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110185.	1.4	12

#	ARTICLE	IF	CITATIONS
975	Impact of Advantage in Tumor Response on the Correlation Between Progression-Free Survival and Overall Survival: Meta-Analysis of Clinical Trials in Patients with Advanced Non-Small Cell Lung Cancer. <i>Pharmaceutical Medicine</i> , 2021, 35, 81-92.	1.0	1
976	Tumor β -catenin expression is associated with immune evasion in non-small cell lung cancer with high tumor mutation burden. <i>Oncology Letters</i> , 2021, 21, 203.	0.8	13
977	Predictive biomarkers for response to immune checkpoint inhibitors in lung cancer: PD-L1 and beyond. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 478, 31-44.	1.4	23
978	Real-world efficacy of atezolizumab in non-small cell lung cancer: A multicenter cohort study focused on performance status and retreatment after failure of anti-PD-1 antibody. <i>Thoracic Cancer</i> , 2021, 12, 613-618.	0.8	16
979	Detecting Resistance to Therapeutic ALK Inhibitors in Tumor Tissue and Liquid Biopsy Markers: An Update to a Clinical Routine Practice. <i>Cells</i> , 2021, 10, 168.	1.8	28
980	A case of remarkable response to atezolizumab in ALK-translocated metastatic lung adenocarcinoma. <i>Respiratory Medicine Case Reports</i> , 2021, 34, 101478.	0.2	5
981	Comparative incidence of immune-related adverse events and hyperprogressive disease in patients with non-small cell lung cancer receiving immune checkpoint inhibitors with and without chemotherapy. <i>Investigational New Drugs</i> , 2021, 39, 1150-1158.	1.2	14
982	miRNA-Based Therapeutics in the Era of Immune-Checkpoint Inhibitors. <i>Pharmaceuticals</i> , 2021, 14, 89.	1.7	9
983	Response Rate and Survival at Key Timepoints With PD-1 Blockade vs Chemotherapy in PD-L1 Subgroups: Meta-Analysis of Metastatic NSCLC Trials. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab012.	1.4	16
984	Immunotherapy as a treatment strategy in advanced stage and recurrent endometrial cancer: review of current phase III immunotherapy clinical trials. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110011.	1.4	5
985	Impact of cancer cachexia on the therapeutic outcome of combined chemoimmunotherapy in patients with non-small cell lung cancer: a retrospective study. <i>Oncolimmunology</i> , 2021, 10, 1950411.	2.1	22
986	Smoking history and the efficacy of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer: a systematic review and meta-analysis. <i>Journal of Thoracic Disease</i> , 2021, 13, 220-231.	0.6	9
987	Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge" (December 4th-5th), Tj ETQq0 0 0,rgBT /Over 1.8	1.8	3
988	Induction therapy with Erlotinib (E) and Gemcitabine/Platinum (GP) in stage III NSCLC. <i>Journal of Pulmonology and Respiratory Research</i> , 2021, 5, 001-018.	0.0	0
990	Emerging role of circulating tumor cells in immunotherapy. <i>Theranostics</i> , 2021, 11, 8057-8075.	4.6	19
991	The Impact of Priming Effect of Immune Checkpoint Inhibitor Therapy for Advanced Stage Non-Small Cell Lung Cancer: A Meta-Epidemiological Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
992	The Multiple Potential Biomarkers for Predicting Immunotherapy Response"Finding the Needle in the Haystack. <i>Cancers</i> , 2021, 13, 277.	1.7	16
993	Molecular Therapeutics of Non-Small Cell Lung Cancer (NSCLC) and Challenges in Repeat Tissue Biopsy. <i>Advances in Lung Cancer (Irvine)</i> , 2021, 10, 21-39.	0.2	2

#	ARTICLE	IF	CITATIONS
994	Old but gold: the role of drug combinations in improving response to immune check-point inhibitors in thoracic malignancies beyond NSCLC. Exploration of Targeted Anti-tumor Therapy, 0, , .	0.5	0
995	<i>KRAS/LKB1</i> and <i>KRAS/TP53</i> co-mutations create divergent immune signatures in lung adenocarcinomas. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110069.	1.4	32
996	Colon cancer and immunotherapy“can we go beyond microsatellite instability?. Translational Gastroenterology and Hepatology, 2021, 6, 12-12.	1.5	19
997	Efficacy of immune-checkpoint inhibitors in advanced non-small cell lung cancer patients with different metastases. Annals of Translational Medicine, 2021, 9, 34-34.	0.7	22
998	High expression of Stabilin-2 predicts poor prognosis in non-small-cell lung cancer. Bioengineered, 2021, 12, 3426-3433.	1.4	2
999	Induction treatment in patients with stage III non-small cell lung cancer. Translational Lung Cancer Research, 2021, 10, 539-554.	1.3	8
1000	Auswirkungen von Chemotherapeutika auf zirkulierende Leukozytenpopulationen: Mögliche Implikationen für den Erfolg von CAR-T-Zell-Therapien. Karger Kompass Onkologie, 2021, 8, 116-127.	0.0	0
1001	The Role of Anti-angiogenesis in the Treatment Landscape of Non-small Cell Lung Cancer “ New Combinational Approaches and Strategies of Neovessel Inhibition. Frontiers in Cell and Developmental Biology, 2020, 8, 610903.	1.8	24
1002	A phase II study of cisplatin plus vinorelbine combined with atezolizumab as adjuvant therapy for completely resected non-small-cell lung cancer with EGFR mutation (West Japan Oncology Group) Tj ETQq0 0 0 rgBI4Overlock 10 Tf 50		
1003	Antiangiogenic Therapies for Mesothelioma: What Is the Role in Mesothelioma Treatment?. Respiratory Disease Series, 2021, , 243-252.	0.1	0
1004	Efficacy and safety of immune checkpoint inhibitor monotherapy in elderly patients with non-small cell lung cancer. Aging Medicine (Milton (N S W)), 2021, 4, 42-46.	0.9	4
1005	Case Series of Pleomorphic Carcinoma of the Lung Treated With Immune Checkpoint Inhibitors. In Vivo, 2021, 35, 1687-1692.	0.6	2
1006	The Influence of KDR Genetic Variation on the Efficacy and Safety of Patients With Advanced NSCLC Receiving First-Line Bevacizumab Plus Chemotherapy Regimen. Technology in Cancer Research and Treatment, 2021, 20, 153303382110194.	0.8	9
1007	Clinical course and prognosis of patients with lung cancer who develop anticancer therapy-related pneumonitis. Journal of Cancer Research and Clinical Oncology, 2021, 147, 1857-1864.	1.2	1
1009	Surgery after neoadjuvant immunotherapy in patients with resectable non-small cell lung cancer. Translational Lung Cancer Research, 2021, 10, 563-580.	1.3	14
1010	Nephrotoxicity in patients with solid tumors treated with anti-PD-1/PD-L1 monoclonal antibodies: a systematic review and meta-analysis. Investigational New Drugs, 2021, 39, 860-870.	1.2	12
1011	Nanoparticle-Mediated Delivery of Inhaled Immunotherapeutics for Treating Lung Metastasis. Advanced Materials, 2021, 33, e2007557.	11.1	89
1012	Efficacy and safety of anti-PD-1/PD-L1 combinations versus standard of care in cancer: a systematic review and meta-analysis.. OncoImmunology, 2021, 10, 1878599.	2.1	11

#	ARTICLE	IF	CITATIONS
1013	Inhibition of galectin-3 augments the antitumor efficacy of PD-L1 blockade in non-small cell lung cancer. <i>FEBS Open Bio</i> , 2021, 11, 911-920.	1.0	12
1014	Carcinoma de pulmão no microcítico. <i>Medicine</i> , 2021, 13, 1377-1387.	0.0	2
1015	Monoclonal Antibodies: A Prospective and Retrospective View. <i>Current Medicinal Chemistry</i> , 2021, 28, 435-471.	1.2	8
1016	Real Impact of Novel Immunotherapy Drugs in Cancer. The Experience of 10 Last Years. <i>Toxins</i> , 2021, 13, 149.	1.5	6
1017	Reconsidering Dexamethasone for Antiemesis when Combining Chemotherapy and Immunotherapy. <i>Oncologist</i> , 2021, 26, 269-273.	1.9	22
1018	Immunotherapy in non-small cell lung cancer: advancements and challenges. <i>Chinese Medical Journal</i> , 2021, 134, 1135-1137.	0.9	4
1019	Nutritional status and symptom burden in advanced non-small cell lung cancer: results of the dietetic assessment and intervention in lung cancer (DAIL) trial. <i>BMJ Supportive and Palliative Care</i> , 2023, 13, e213-e219.	0.8	6
1020	First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 198-211.	5.1	773
1021	Anti-PD1 versus anti-PD-L1 immunotherapy in first-line therapy for advanced non-small cell lung cancer: A systematic review and meta-analysis. <i>Thoracic Cancer</i> , 2021, 12, 1058-1066.	0.8	18
1022	IMpower132: Atezolizumab plus platinum-based chemotherapy vs chemotherapy for advanced NSCLC in Japanese patients. <i>Cancer Science</i> , 2021, 112, 1534-1544.	1.7	24
1023	Optimal Therapy for Advanced Non-Small Cell Lung Cancer Without Driver Alterations. <i>JNCI Cancer Spectrum</i> , 2021, 5, prab014.	1.4	0
1024	Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. <i>Lancet</i> , The, 2021, 397, 592-604.	6.3	441
1025	C-reactive protein reduction post treatment is associated with improved survival in atezolizumab (anti-PD-L1) treated non-small cell lung cancer patients. <i>PLoS ONE</i> , 2021, 16, e0246486.	1.1	6
1026	FDA Approval Summary: Nivolumab with Ipilimumab and Chemotherapy for Metastatic Non-small Cell Lung Cancer, A Collaborative Project Orbis Review. <i>Clinical Cancer Research</i> , 2021, 27, 3522-3527.	3.2	32
1027	Fatal Adverse Events Associated With Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer: A Systematic Review and Meta-Analysis. <i>Frontiers in Medicine</i> , 2021, 8, 627089.	1.2	9
1028	Immune checkpoint inhibitors: Significant advancements in non-small cell lung cancer treatment. <i>American Journal of Health-System Pharmacy</i> , 2021, 78, 769-780.	0.5	11
1029	Immune-Checkpoint Inhibitors Combinations in Metastatic NSCLC: New Options on the Horizon?. <i>ImmunoTargets and Therapy</i> , 2021, Volume 10, 9-26.	2.7	14
1030	PD-L1 as a biomarker of response to immune-checkpoint inhibitors. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 345-362.	12.5	646

#	ARTICLE	IF	CITATIONS
1031	Programmed death-ligand 1 expression level as a predictor of EGFR tyrosine kinase inhibitor efficacy in lung adenocarcinoma. <i>Translational Lung Cancer Research</i> , 2021, 10, 699-711.	1.3	12
1032	Practical Issues in the Use of Atezolizumab for Patients with Non-Small Cell Lung Cancer: Case Reports and Literature Review. <i>Oncology and Therapy</i> , 2021, 9, 41-53.	1.0	2
1033	Effectiveness of a Reverse Manual for Immune-related Adverse Events. <i>Japanese Journal of Lung Cancer</i> , 2021, 61, 17-23.	0.0	0
1034	nab-Paclitaxel Plus Durvalumab in Patients With Previously Treated Advanced Stage Non-small Cell Lung Cancer (ABOUND.2L+). <i>Frontiers in Oncology</i> , 2020, 10, 569715.	1.3	3
1035	Thyroid function abnormality induced by PD-1 inhibitors have a positive impact on survival in patients with non-small cell lung cancer. <i>International Immunopharmacology</i> , 2021, 91, 107296.	1.7	20
1036	Comparative Efficacy and Safety of Immunotherapeutic Regimens with PD-1/PD-L1 Inhibitors for Previously Untreated Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis. <i>Current Oncology</i> , 2021, 28, 1094-1113.	0.9	12
1037	Second-line therapy improves overall survival in primary refractory non-small cell lung cancer (NSCLC) patients. <i>ESMO Open</i> , 2021, 6, 100013.	2.0	2
1038	Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lung. , 2021, 9, e001999.		26
1040	Management of brain metastases from lung cancer in the era of immunotherapy: a review of the literature. <i>Future Oncology</i> , 2021, 17, 597-609.	1.1	3
1041	The European Medicines Agency review of the initial application of atezolizumab and the role of PD-L1 expression as biomarker for checkpoint inhibitors. <i>ESMO Open</i> , 2021, 6, 100008.	2.0	5
1042	Safety and Clinical Activity of Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase I Study. <i>Clinical Cancer Research</i> , 2021, 27, 3360-3369.	3.2	47
1043	Efficacy and safety of carboplatin and pemetrexed followed by maintenance with pemetrexed for elderly patients with advanced non-squamous non-small cell lung cancer: A single-arm, open-label, multicenter, phase II study. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021, 17, 486-494.	0.7	1
1044	Anlotinib combined with durvalumab in a patient with recurrent multifocal brain metastases of small cell lung cancer after definitive concurrent chemoradiotherapy and palliative radiotherapy of the lung and brain: a case report. <i>Annals of Palliative Medicine</i> , 2021, 10, 2379-2386.	0.5	4
1045	Incidence risk of PD-1/PD-L1-related pneumonia and diarrhea in non-small cell lung cancer (NSCLC) patients: a systematic review and meta-analysis of randomized controlled trials. <i>European Journal of Clinical Pharmacology</i> , 2021, 77, 1079-1088.	0.8	9
1047	Immunotherapy in lung cancer. <i>Journal of Surgical Oncology</i> , 2021, 123, 718-729.	0.8	7
1048	Anlotinib combined with PD-1 blockade for the treatment of lung cancer: a real-world retrospective study in China. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2517-2528.	2.0	34
1049	Immunotherapy in advanced Non-Small Cell Lung Cancer patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkers. <i>Lung Cancer</i> , 2021, 152, 165-173.	0.9	23
1050	Chemotherapeutic and targeted agents can modulate the tumor microenvironment and increase the efficacy of immune checkpoint blockades. <i>Molecular Cancer</i> , 2021, 20, 27.	7.9	54

#	ARTICLE	IF	CITATIONS
1051	Perspective of Immune Checkpoint Inhibitors in Thymic Carcinoma. <i>Cancers</i> , 2021, 13, 1065.	1.7	5
1052	Results of a Dose-Finding Phase 1b Study of Subcutaneous Atezolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer. <i>Clinical Pharmacology in Drug Development</i> , 2021, 10, 1142-1155.	0.8	8
1053	Efficacy and Safety of S-1 Compared With Docetaxel in Elderly Patients With Advanced NSCLC Previously Treated With Platinum-Based Chemotherapy: A Subgroup Analysis of the EAST-LC Trial. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100142.	0.6	1
1055	Inmunoterapia, cĂncer y PET. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2021, 40, 123-135.	0.0	0
1056	Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial. <i>Cancers</i> , 2021, 13, 1176.	1.7	16
1057	A Randomized Phase II Trial Comparing the Efficacy and Safety of Pioglitazone, Clarithromycin and Metronomic Low-Dose Chemotherapy with Single-Agent Nivolumab Therapy in Patients with Advanced Non-small Cell Lung Cancer Treated in Second or Further Line (ModuLung). <i>Frontiers in Pharmacology</i> , 2021, 12, 599598.	1.6	10
1058	Long-term efficacy of immune checkpoint inhibitors in non-small cell lung cancer patients harboring MET exon 14 skipping mutations. <i>International Journal of Clinical Oncology</i> , 2021, 26, 1065-1072.	1.0	3
1059	The KRASG12C Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 975-985.	1.9	79
1060	Immunotherapy for ALK-Rearranged Non-Small Cell Lung Cancer: Challenges Inform Promising Approaches. <i>Cancers</i> , 2021, 13, 1476.	1.7	21
1061	Immuno-oncology: a narrative review of gastrointestinal and hepatic toxicities. <i>Annals of Translational Medicine</i> , 2021, 9, 423-423.	0.7	6
1062	Peripheral Blood Autoantibodies Against to Tumor-Associated Antigen Predict Clinical Outcome to Immune Checkpoint Inhibitor-Based Treatment in Advanced Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 625578.	1.3	8
1063	Systemic immunity markers associated with lymphocytes predict the survival benefit from paclitaxel plus bevacizumab in HER2 negative advanced breast cancer. <i>Scientific Reports</i> , 2021, 11, 6328.	1.6	15
1064	The folate cycle enzyme MTHFD2 induces cancer immune evasion through PD-L1 up-regulation. <i>Nature Communications</i> , 2021, 12, 1940.	5.8	76
1065	Effect of corticosteroids on the outcome of patients with advanced non-small cell lung cancer treated with immune-checkpoint inhibitors. <i>European Journal of Cancer</i> , 2021, 145, 245-254.	1.3	52
1066	Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update. <i>Journal of Clinical Oncology</i> , 2021, 39, 1040-1091.	0.8	192
1067	Immunotherapy in Advanced Biliary Tract Cancers. <i>Cancers</i> , 2021, 13, 1569.	1.7	19
1068	Immune-Based Cancer Treatment: Addressing Disparities in Access and Outcomes. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, 66-78.	1.8	23
1069	Patients With Short PFS to EGFR-TKIs Predicted Better Response to Subsequent Anti-PD-1/PD-L1 Based Immunotherapy in EGFR Common Mutation NSCLC. <i>Frontiers in Oncology</i> , 2021, 11, 639947.	1.3	24

#	ARTICLE	IF	CITATIONS
1070	The histological diagnosis and molecular testing of lung cancer by surgical biopsy for intrathoracic lesions. <i>General Thoracic and Cardiovascular Surgery</i> , 2021, 69, 1185-1191.	0.4	0
1071	Identification of Proteins Deregulated by Platinum-Based Chemotherapy as Novel Biomarkers and Therapeutic Targets in Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 615967.	1.3	6
1072	Adaptive Mechanisms of Tumor Therapy Resistance Driven by Tumor Microenvironment. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 641469.	1.8	76
1073	The role of Anti-PD-1/PD-L1 monotherapy as first-line treatment of metastatic NSCLC without targetable mutations and PD-L1 TPS 1â€“49%. <i>Precision Cancer Medicine</i> , 0, 4, 9-9.	1.8	1
1074	Association between ¹⁸ F-FDG metabolic activity and programmed death ligand-1 (PD-L1) expression using 22C3 immunohistochemistry assays in non-small cell lung cancer (NSCLC) resection specimens. <i>British Journal of Radiology</i> , 2021, 94, 20200397.	1.0	8
1075	Impact of body mass index on survival and serious adverse events in advanced non-small cell lung cancer treated with bevacizumab: a meta-analysis of randomized clinical trials. <i>Current Medical Research and Opinion</i> , 2021, 37, 811-817.	0.9	7
1076	Nivolumab plus ipilimumab for the first-line treatment of metastatic NSCLC. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 705-713.	1.1	4
1077	Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Nonâ€“Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 723-733.	0.8	329
1078	If Virchow and Ehrlich Had Dreamt Together: What the Future Holds for KRAS-Mutant Lung Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3025.	1.8	5
1079	Correlation of Clinical Parameters with Intracranial Outcome in Non-Small Cell Lung Cancer Patients with Brain Metastases Treated with Pd-1/Pd-L1 Inhibitors as Monotherapy. <i>Cancers</i> , 2021, 13, 1562.	1.7	10
1080	Efficacy and safety of first-line treatments with immune checkpoint inhibitors plus chemotherapy for non-squamous non-small cell lung cancer: a meta-analysis and indirect comparison. <i>Annals of Palliative Medicine</i> , 2021, 10, 2766-2775.	0.5	8
1081	Immune-Related Adverse Events and Their Association With the Effectiveness of PD-1/PD-L1 Inhibitors in Non-Small Cell Lung Cancer: A Real-World Study From China. <i>Frontiers in Oncology</i> , 2021, 11, 607531.	1.3	18
1082	A retrospective analysis of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy for advanced or recurrent nonâ€“small cell lung cancer. <i>Thoracic Cancer</i> , 2021, 12, 1387-1397.	0.8	6
1083	Comparative Efficacy and Safety of Immunotherapy Alone and in Combination With Chemotherapy for Advanced Non-small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 611012.	1.3	16
1084	Chasing the Target: New Phenomena of Resistance to Novel Selective RET Inhibitors in Lung Cancer. Updated Evidence and Future Perspectives. <i>Cancers</i> , 2021, 13, 1091.	1.7	21
1085	Outcomes of patients with non-small cell lung cancer and poor performance status treated with immune checkpoint inhibitors in the real-world setting. <i>International Journal of Clinical Oncology</i> , 2021, 26, 1057-1064.	1.0	2
1086	NCCN Guidelines Insights: Nonâ€“Small Cell Lung Cancer, Version 2.2021. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 254-266.	2.3	628
1087	An expanded universe of cancer targets. <i>Cell</i> , 2021, 184, 1142-1155.	13.5	135

#	ARTICLE	IF	CITATIONS
1088	The role of immunotherapy in fusion-driven lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 461-464.	1.1	3
1089	Paradigms on Immunotherapy Combinations with Chemotherapy. <i>Cancer Discovery</i> , 2021, 11, 1353-1367.	7.7	197
1090	Immunotherapy, cancer and PET. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2021, 40, 123-135.	0.1	1
1091	Active and latent tuberculosis infections in patients treated with immune checkpoint inhibitors in a non-endemic tuberculosis area. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 3105-3111.	2.0	4
1092	Significance of PD-L1 expression in the cytological samples of non-small cell lung cancer patients treated with immune checkpoint inhibitors. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 3749-3755.	1.2	6
1094	CheckMate 743: A Glimmer of Hope for Malignant Pleural Mesothelioma. <i>Clinical Lung Cancer</i> , 2021, 22, 71-73.	1.1	4
1096	KRAS G12C inhibition and innate immune targeting. <i>Expert Opinion on Therapeutic Targets</i> , 2021, 25, 1-8.	1.5	6
1097	PD-(L)1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer Patients with High PD-L1 Expression: A Network Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2021, 10, 1365.	1.0	13
1098	Efficacy and Safety of Anti-PD-1 Plus Anlotinib in Patients With Advanced Non-Small-Cell Lung Cancer After Previous Systemic Treatment Failure: A Retrospective Study. <i>Frontiers in Oncology</i> , 2021, 11, 628124.	1.3	39
1099	Immune-Related Adverse Events Are Associated With Clinical Benefit in Patients With Non-Small-Cell Lung Cancer Treated With Immunotherapy Plus Chemotherapy: A Retrospective Study. <i>Frontiers in Oncology</i> , 2021, 11, 630136.	1.3	17
1100	Anti-Tumor Efficacy of PD-L1 Targeted Alpha-Particle Therapy in a Human Melanoma Xenograft Model. <i>Cancers</i> , 2021, 13, 1256.	1.7	6
1101	Complete Response of Bone Metastasis in Non-small Cell Lung Cancer With Pembrolizumab: Two Case Reports. <i>Anticancer Research</i> , 2021, 41, 1693-1699.	0.5	9
1102	Beyond immune checkpoint blockade: emerging immunological strategies. <i>Nature Reviews Drug Discovery</i> , 2021, 20, 899-919.	21.5	208
1103	Vascular reconstitution in the tumor for more effective tumor immunotherapy. <i>Cancer Science</i> , 2021, 112, 1348-1356.	1.7	8
1104	First-line Immunotherapy for Advanced Non-small-cell Lung Cancer. <i>Japanese Journal of Lung Cancer</i> , 2021, 61, 88-94.	0.0	0
1105	Clinical option of pemetrexed-based versus paclitaxel-based first-line chemotherapeutic regimens in combination with bevacizumab for advanced non-squamous non-small-cell lung cancer and optimal maintenance therapy: evidence from a meta-analysis of randomized control trials. <i>BMC Cancer</i> , 2021, 21, 426.	1.1	6
1106	Efficacy, Safety and Immunogenicity of MB02 (Bevacizumab Biosimilar) versus Reference Bevacizumab in Advanced Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study (STELLA). <i>BioDrugs</i> , 2021, 35, 429-444.	2.2	15
1107	Efficacy of Combination Docetaxel and Nintedanib in Advanced Non-Small Cell Lung Cancer in Thailand: A Multicenter Study. <i>Frontiers in Oncology</i> , 2021, 11, 572740.	1.3	4

#	ARTICLE	IF	CITATIONS
1108	Overcoming therapy resistance in EGFR-mutant lung cancer. <i>Nature Cancer</i> , 2021, 2, 377-391.	5.7	198
1109	Response Efficacy of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 562315.	1.3	38
1110	Phase 1b Study of Sintilimab Plus Anlotinib as First-line Therapy in Patients With Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 643-652.	0.5	123
1111	Too Good to be True?. <i>Journal of Thoracic Oncology</i> , 2021, 16, 507-508.	0.5	2
1112	Anti-angiogenic agents “overcoming tumour endothelial cell anergy and improving immunotherapy outcomes. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 527-540.	12.5	162
1113	Current medical and surgical management of lung cancer. <i>Journal of Surgery and Surgical Research</i> , 2021, , 052-056.	0.1	0
1114	From CheckMate 227 to CheckMate 9LA: rethinking the status of chemotherapy in the immunotherapy era “chemo-free or chemo-reform?. <i>Translational Lung Cancer Research</i> , 2021, 10, 1924-1927.	1.3	7
1115	Development of Immunotherapy Combination Strategies in Cancer. <i>Cancer Discovery</i> , 2021, 11, 1368-1397.	7.7	130
1116	Impact of Renin “angiotensin System Inhibitors on the Efficacy of Anti-PD-1/PD-L1 Antibodies in NSCLC Patients. <i>Anticancer Research</i> , 2021, 41, 2093-2100.	0.5	12
1117	How can we manage the cardiac toxicity of immune checkpoint inhibitors?. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 1-10.	1.0	8
1118	IMpower 132: Loses Power at the Finish Line. <i>Journal of Thoracic Oncology</i> , 2021, 16, 512-514.	0.5	0
1119	Perilesional edema in brain metastases as predictive factor of response to systemic therapy in non-small cell lung cancer patients: a preliminary study. <i>Annals of Translational Medicine</i> , 2021, 9, 648-648.	0.7	2
1120	Deciphering molecular mechanisms of metastasis: novel insights into targets and therapeutics. <i>Cellular Oncology (Dordrecht)</i> , 2021, 44, 751-775.	2.1	5
1121	Resistance to Immune Checkpoint Blockade in Uterine Leiomyosarcoma: What Can We Learn from Other Cancer Types?. <i>Cancers</i> , 2021, 13, 2040.	1.7	4
1122	The Next Decade of Immune Checkpoint Therapy. <i>Cancer Discovery</i> , 2021, 11, 838-857.	7.7	363
1123	Anti-Angiogenic Therapy: Current Challenges and Future Perspectives. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3765.	1.8	136
1124	Emerging principles of brain immunology and immune checkpoint blockade in brain metastases. <i>Brain</i> , 2021, 144, 1046-1066.	3.7	24
1125	EGFR L718V (+)/T790M (“) as a Mechanism of Resistance in Patients with Metastatic Non “small-cell Lung Cancer with EGFR L858R Mutations. <i>Clinical Lung Cancer</i> , 2021, 22, e817-e819.	1.1	4

#	ARTICLE	IF	CITATIONS
1126	Impact of docetaxel plus ramucirumab on metastatic site in previously treated patients with non-small cell lung cancer: a multicenter retrospective study. <i>Translational Lung Cancer Research</i> , 2021, 10, 1642-1652.	1.3	11
1127	Co-Occurring Alteration of NOTCH and DDR Pathways Serves as Novel Predictor to Efficacious Immunotherapy in NSCLC. <i>Frontiers in Oncology</i> , 2021, 11, 659321.	1.3	11
1128	Cost-Effectiveness Analysis of Atezolizumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer With Different PD-L1 Expression Status. <i>Frontiers in Oncology</i> , 2021, 11, 669195.	1.3	19
1129	What a general practitioner should know about bronchogenic carcinoma. <i>MedicĀna Pro Praxi</i> , 2021, 18, 63-67.	0.0	0
1130	Pembrolizumab Plus Chemotherapy or Anlotinib vs. Pembrolizumab Alone in Patients With Previously Treated EGFR-Mutant NSCLC. <i>Frontiers in Oncology</i> , 2021, 11, 671228.	1.3	13
1131	Addressing resistance to immune checkpoint inhibitor therapy:Ān urgent unmet need. <i>Future Oncology</i> , 2021, 17, 1401-1439.	1.1	17
1132	Strategies to overcome resistance to immune checkpoint blockade in lung cancer. <i>Lung Cancer</i> , 2021, 154, 151-160.	0.9	25
1133	Combination of Immune Checkpoint Inhibitors and Anti-Angiogenic Agents in Brain Metastases From Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 670313.	1.3	9
1134	Effects of Chemotherapy Agents on Circulating Leukocyte Populations: Potential Implications for the Success of CAR-T Cell Therapies. <i>Cancers</i> , 2021, 13, 2225.	1.7	21
1135	Exploration of the Tumor-Suppressive Immune Microenvironment by Integrated Analysis in EGFR-Mutant Lung Adenocarcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 591922.	1.3	8
1136	Immune checkpoint inhibitors combined with chemotherapy/bevacizumab therapy for patients with advanced lung cancer and heavily treated with EGFR mutation: a retrospective analysis. <i>Journal of Thoracic Disease</i> , 2021, 13, 2959-2967.	0.6	2
1137	Recurrent spindle cell carcinoma of the lung successfully treated by chemoimmunotherapy. <i>Respirology Case Reports</i> , 2021, 9, e00757.	0.3	4
1138	PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors. <i>Tumori</i> , 2022, 108, 47-55.	0.6	8
1139	Association of Dynamic Changes inĀPeripheral Blood Indexes With Response to PD-1 Inhibitor-Based Combination Therapy and Survival Among Patients With Advanced Non-Small Cell Lung Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 672271.	2.2	21
1140	Immunotherapy for non-small cell lung cancer in the elderly population: a generic protocol. <i>The Cochrane Library</i> , 0, , .	1.5	0
1141	Treatment-Related Serious Adverse Events of Immune Checkpoint Inhibitors in Clinical Trials: A Systematic Review. <i>Frontiers in Oncology</i> , 2021, 11, 621639.	1.3	12
1142	Emerging biological therapies for the treatment of malignant pleural mesothelioma. <i>Expert Opinion on Emerging Drugs</i> , 2021, 26, 179-192.	1.0	3
1143	DLL1 orchestrates CD8⁺T cells to induce long-term vascular normalization and tumor regression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	32

#	ARTICLE	IF	CITATIONS
1144	Control of Tumor Progression by Angiocrine Factors. <i>Cancers</i> , 2021, 13, 2610.	1.7	19
1145	Current advances in the treatment of lung cancer with immune checkpoint inhibitors. <i>Journal of the Korean Medical Association</i> , 2021, 64, 333-341.	0.1	0
1146	Immune checkpoint inhibitors and chemotherapy in first-line NSCLC: a meta-analysis. <i>Immunotherapy</i> , 2021, 13, 621-631.	1.0	35
1147	Narrative review of immune checkpoint inhibitors and radiation therapy for brain metastases. <i>Translational Cancer Research</i> , 2021, 10, 2527-2536.	0.4	1
1148	Evidence for frequent concurrent DCUN1D1, FGFR1, BCL9 gene copy number amplification in squamous cell lung cancer. <i>Pathology Research and Practice</i> , 2021, 221, 153412.	1.0	4
1149	Angiogenesis Inhibitors in Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 655316.	1.3	38
1150	The Impact of VEGF Inhibition on Clinical Outcomes in Patients With Advanced Non-Small Cell Lung Cancer Treated With Immunotherapy: A Retrospective Cohort Study. <i>Frontiers in Oncology</i> , 2021, 11, 663612.	1.3	8
1152	Safety and Efficacy of Neoadjuvant Immune Checkpoint Inhibitor Therapy in Patients with Resectable Non-small-Cell Lung Cancer: A Systematic Review. <i>Targeted Oncology</i> , 2021, 16, 425-434.	1.7	16
1153	Comprehensive analysis of blood-based biomarkers for predicting immunotherapy benefits in patients with advanced non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 2103-2117.	1.3	12
1154	Immune Checkpoint Inhibitor-Associated Pneumonitis in Non-Small Cell Lung Cancer: Current Understanding in Characteristics, Diagnosis, and Management. <i>Frontiers in Immunology</i> , 2021, 12, 663986.	2.2	50
1155	Molecular and Clinical Features of Hospital Admissions in Patients with Thoracic Malignancies on Immune Checkpoint Inhibitors. <i>Cancers</i> , 2021, 13, 2653.	1.7	2
1156	The Efficacy and Safety of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Combined With Thymosin in Advanced Non-Small Cell Lung Cancer Patients Harboring Active Epidermal Growth Factor Receptor Mutations. <i>Frontiers in Oncology</i> , 2021, 11, 659065.	1.3	3
1157	Recognition and Management of Toxicities from Immunotherapy and Targeted Therapy in Elderly Patients with Lung Cancer. <i>Advances in Oncology</i> , 2021, 1, 73-84.	0.1	0
1158	Microenvironmental regulation of tumour immunity and response to immunotherapy. <i>Journal of Pathology</i> , 2021, 254, 374-383.	2.1	17
1159	Baseline Serum Cholesterol Levels Predict the Response of Patients with Advanced Non-Small Cell Lung Cancer to Immune Checkpoint Inhibitor-Based Treatment. <i>Cancer Management and Research</i> , 2021, Volume 13, 4041-4053.	0.9	11
1160	Immunotherapy in Treating EGFR-Mutant Lung Cancer: Current Challenges and New Strategies. <i>Frontiers in Oncology</i> , 2021, 11, 635007.	1.3	76
1161	PD-L1 Expression Status Predicting Survival in Pulmonary Pleomorphic Carcinoma. <i>Anticancer Research</i> , 2021, 41, 2501-2509.	0.5	1
1162	Bevacizumab-Containing Chemoimmunotherapy for Recurrent Non-Small-Cell Lung Cancer after Chemoradiotherapy: Case Report. <i>Medicina (Lithuania)</i> , 2021, 57, 547.	0.8	0

#	ARTICLE	IF	CITATIONS
1163	Assessment of the Clinical Trials Safety Profile of PD-1/PD-L1 Inhibitors Among Patients With Cancer: An Updated Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 662392.	1.3	3
1164	Immune subgroup analysis for non-small cell lung cancer may be a good choice for evaluating therapeutic efficacy and prognosis. <i>Aging</i> , 2021, 13, 12691-12709.	1.4	1
1165	IMpower 132: Is the Second Exception to the Rule No Longer an Exception?. <i>Journal of Thoracic Oncology</i> , 2021, 16, e29-e30.	0.5	2
1166	Clinical Perspectives to Overcome Acquired Resistance to Anti-Programmed Death-1 and Anti-Programmed Death Ligand-1 Therapy in Non-Small Cell Lung Cancer. <i>Molecules and Cells</i> , 2021, 44, 363-373.	1.0	13
1167	The influence of monoclonal antibodies for cancer treatment on the endocrine system. <i>Postepy Higieny I Medycyny Doswiadczalnej</i> , 2021, 75, 317-327.	0.1	0
1168	Cytotoxic chemotherapeutic agents and the EGFR-TKI osimertinib induce calreticulin exposure in non-small cell lung cancer. <i>Lung Cancer</i> , 2021, 155, 144-150.	0.9	9
1169	Turning tumors from cold to inflamed to improve immunotherapy response. <i>Cancer Treatment Reviews</i> , 2021, 101, 102227.	3.4	42
1170	Immunotherapy in non-small cell lung cancer harbouring driver mutations. <i>Cancer Treatment Reviews</i> , 2021, 96, 102179.	3.4	56
1172	Pembrolizumab+chemotherapy versus atezolizumab+chemotherapy+bevacizumab for the first-line treatment of non-squamous NSCLC: A matching-adjusted indirect comparison. <i>Lung Cancer</i> , 2021, 155, 175-182.	0.9	11
1173	Analysis of Real-World Data to Investigate the Impact of Race and Ethnicity on Response to Programmed Cell Death-1 and Programmed Cell Death-Ligand 1 Inhibitors in Advanced Non-Small Cell Lung Cancers. <i>Oncologist</i> , 2021, 26, e1226-e1239.	1.9	17
1174	Organoid models of the tumor microenvironment and their applications. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 5829-5841.	1.6	27
1175	Predictability of early changes in derived neutrophil-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors. <i>Journal of Thoracic Disease</i> , 2021, 13, 2824-2832.	0.6	9
1176	Circulating PD-L1 levels change during bevacizumab-based treatment in recurrent glioma. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 3643-3650.	2.0	10
1177	Adoption of multiple primary endpoints in phase III trials of systemic treatments in patients with advanced solid tumours. A systematic review. <i>European Journal of Cancer</i> , 2021, 149, 49-60.	1.3	1
1178	Classification of Non-Small Cell Lung Cancer's Tumor Immune Micro-Environment and Strategies to Augment Its Response to Immune Checkpoint Blockade. <i>Cancers</i> , 2021, 13, 2924.	1.7	18
1179	Post-immunotherapy imaging in lung cancer. <i>Clinical Radiology</i> , 2022, 77, 44-57.	0.5	3
1180	Early Progression in Non-Small Cell Lung Cancer (NSCLC) with High PD-L1 Treated with Pembrolizumab in First-Line Setting: A Prognostic Scoring System Based on Clinical Features. <i>Cancers</i> , 2021, 13, 2935.	1.7	13
1182	Improving antitumor immunity using antiangiogenic agents: Mechanistic insights, current progress, and clinical challenges. <i>Cancer Communications</i> , 2021, 41, 830-850.	3.7	42

#	ARTICLE	IF	CITATIONS
1183	Two Complementarity Immunotherapeutics in Non-Small-Cell Lung Cancer Patientsâ€™ Mechanism of Action and Future Concepts. <i>Cancers</i> , 2021, 13, 2836.	1.7	3
1184	Meta-analysis of immune-related adverse events in phase 3 clinical trials assessing immune checkpoint inhibitors for lung cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 162, 103351.	2.0	24
1185	Risk factors for adverse events induced by immune checkpoint inhibitors in patients with non-small-cell lung cancer: a systematic review and meta-analysis. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 3069-3080.	2.0	31
1186	International consensus on severe lung cancerâ€™the first edition. <i>Translational Lung Cancer Research</i> , 2021, 10, 2633-2666.	1.3	6
1187	Cardiovascular Complications Associated with Contemporary Lung Cancer Treatments. <i>Current Treatment Options in Oncology</i> , 2021, 22, 71.	1.3	3
1188	Advances in siRNA delivery strategies for the treatment of MDR cancer. <i>Life Sciences</i> , 2021, 274, 119337.	2.0	21
1189	Immune Checkpoint Inhibition for Unresectable Malignant Pleural Mesothelioma. <i>Drugs</i> , 2021, 81, 971-984.	4.9	5
1190	Precise medicine of programmed cell death-1/programmed cell death 1 ligand 1 inhibitor immunotherapy combined radiotherapy for inoperable advanced lung cancer. <i>Medicine (United States)</i> , 2021, 100, e26367.	0.4	0
1191	Ang2 inhibitors and Tie2 activators: potential therapeutics in perioperative treatment of early stage cancer. <i>EMBO Molecular Medicine</i> , 2021, 13, e08253.	3.3	18
1192	Is there any opportunity for immune checkpoint inhibitor therapy in non-small cell lung cancer patients with brain metastases?. <i>Translational Lung Cancer Research</i> , 2021, 10, 2868-2875.	1.3	1
1193	Immunotherapy in oncogene addicted non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 2736-2751.	1.3	7
1194	The Tumor Microenvironment Factors That Promote Resistance to Immune Checkpoint Blockade Therapy. <i>Frontiers in Oncology</i> , 2021, 11, 641428.	1.3	32
1195	Advances in Immunotherapy and Implications for Current Practice in Nonâ€™Small-Cell Lung Cancer. <i>JCO Oncology Practice</i> , 2021, 17, 662-668.	1.4	14
1196	Immune Checkpoint and Anti-Angiogenic Antibodies for the Treatment of Non-Small Cell Lung Cancer in the European Union and United States. <i>Pharmaceutics</i> , 2021, 13, 912.	2.0	2
1197	Dramatic response to pembrolizumab with chemotherapy followed by salvage surgery in a lung cancer patient. <i>Thoracic Cancer</i> , 2021, 12, 2217-2220.	0.8	4
1198	Molecular determinants of response to PD-L1 blockade across tumor types. <i>Nature Communications</i> , 2021, 12, 3969.	5.8	79
1199	Immunotherapy for Advanced Nonâ€™Small Cell Lung Cancer: A Decade of Progress. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, e105-e127.	1.8	67
1200	Sex-related differences in the efficacy of immune checkpoint inhibitors in malignancy: a systematic review and meta-analysis. <i>Aging</i> , 2021, 13, 15413-15432.	1.4	9

#	ARTICLE	IF	CITATIONS
1201	Prediction of outcome in patients with non-small cell lung cancer treated with second line PD-1/PDL-1 inhibitors based on clinical parameters: Results from a prospective, single institution study. <i>PLoS ONE</i> , 2021, 16, e0252537.	1.1	20
1202	Role of sex hormones in lung cancer. <i>Experimental Biology and Medicine</i> , 2021, 246, 2098-2110.	1.1	22
1203	The Application of Combined Immune Checkpoint Inhibitor Modalities in Previously Treated Non-Small Cell Lung Cancer Patients and the Associations Thereof With the Lung Immune Prognostic Index. <i>Frontiers in Oncology</i> , 2021, 11, 690093.	1.3	5
1204	Durable Response to the Combination of Atezolizumab With Platinum-Based Chemotherapy in an Untreated Non-Smoking Lung Adenocarcinoma Patient With BRAF V600E Mutation: A Case Report. <i>Frontiers in Oncology</i> , 2021, 11, 634920.	1.3	7
1205	Emerging Biomarkers for the Selection of Advanced NSCLC-Affected Immunotherapy Patients. <i>Journal of Molecular Pathology</i> , 2021, 2, 197-206.	0.5	2
1206	The Position of EGF Deprivation in the Management of Advanced Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 639745.	1.3	9
1207	The prognostic impact of tumor mutational burden (TMB) in the first-line management of advanced non-oncogene addicted non-small-cell lung cancer (NSCLC): a systematic review and meta-analysis of randomized controlled trials. <i>ESMO Open</i> , 2021, 6, 100124.	2.0	75
1208	Incidence and risk factors for pneumonitis among patients with lung cancer who received immune checkpoint inhibitors after palliative thoracic radiotherapy. <i>Journal of Radiation Research</i> , 2021, 62, 669-675.	0.8	6
1209	Real-world outcomes of immunotherapy-based regimens in first-line advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2021, 156, 41-49.	0.9	66
1210	Targeting the Epidermal Growth Factor Receptor in EGFR-Mutated Lung Cancer: Current and Emerging Therapies. <i>Cancers</i> , 2021, 13, 3164.	1.7	35
1211	Immune Checkpoint Inhibitors in Ovarian Cancer: Can We Bridge the Gap Between IMagynation and Reality?. <i>Journal of Clinical Oncology</i> , 2021, 39, 1833-1838.	0.8	17
1212	Increased plasma levels of damage-associated molecular patterns during systemic anticancer therapy in patients with advanced lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 2475-2486.	1.3	13
1213	Evaluation of efficacy and toxicity of nivolumab combined with or without docetaxel in patients with advanced NSCLC. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 267-276.	2.0	2
1214	The effect of adding immune checkpoint inhibitors on the risk of pneumonitis for solid tumours: a meta-analysis of phase III randomised controlled trials. <i>European Journal of Cancer</i> , 2021, 150, 168-178.	1.3	11
1215	Nelfinavir restricts A549 cell growth by inhibiting STAT3 signaling. <i>Journal of International Medical Research</i> , 2021, 49, 030006052110149.	0.4	1
1216	Prognostic effect of coexisting TP53 and ZFH3 mutations in non-small cell lung cancer patients treated with immune checkpoint inhibitors. <i>Scandinavian Journal of Immunology</i> , 2021, 94, e13087.	1.3	7
1217	Atezolizumab and Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma: Pharmacokinetic and Safety Assessments Based on Hepatic Impairment Status and Geographic Region. <i>Liver Cancer</i> , 2021, 10, 485-499.	4.2	8
1218	Immune checkpoint inhibitors in therapy of non-small cell lung cancer (a review). <i>ZaporoÅ¼skij Medicinskij Å½urnal</i> , 2021, 23, 417-424.	0.0	0

#	ARTICLE	IF	CITATIONS
1219	A narrative review of combined stereotactic ablative radiotherapy and immunotherapy in metastatic non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 2766-2778.	1.3	9
1220	ICI plus chemotherapy prolonged survival over ICI alone in patients with previously treated advanced NSCLC. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 219-228.	2.0	5
1221	Immunotherapy in the treatment of lymphoma. <i>World Journal of Stem Cells</i> , 2021, 13, 503-520.	1.3	3
1222	Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 625-644.	12.5	148
1223	Subacute Cutaneous Lupus Erythematosus-Like Eruption Induced by EGFR-Tyrosine Kinase Inhibitor in EGFR-Mutated Non-small Cell Lung Cancer: A Case Report. <i>Frontiers in Medicine</i> , 2021, 8, 570921.	1.2	2
1224	Characterization of Circulating T Cell Receptor Repertoire Provides Information about Clinical Outcome after PD-1 Blockade in Advanced Non-Small Cell Lung Cancer Patients. <i>Cancers</i> , 2021, 13, 2950.	1.7	12
1225	Anti-PD1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer with Actionable Oncogenic Driver Mutations. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6288.	1.8	51
1226	“High Tumor Burden” in Metastatic Non-Small Cell Lung Cancer: Defining the Concept. <i>Cancer Management and Research</i> , 2021, Volume 13, 4665-4670.	0.9	5
1227	Immunotherapy and Vaccination in Surgically Resectable Non-Small Cell Lung Cancer (NSCLC). <i>Vaccines</i> , 2021, 9, 689.	2.1	9
1228	The Effect of Asymptomatic and/or Treated Brain Metastases on Efficacy of Immune Checkpoint Inhibitors in Metastatic Non-Small Cell Lung Cancer: A Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 702924.	1.3	6
1229	The changing landscape of anti-lung cancer drug clinical trials in mainland China from 2005 to 2020. <i>The Lancet Regional Health - Western Pacific</i> , 2021, 11, 100151.	1.3	13
1230	Immune checkpoint inhibitors in oncogene-addicted non-small cell lung cancer: a systematic review and meta-analysis. <i>Translational Lung Cancer Research</i> , 2021, 10, 2890-2916.	1.3	21
1231	The Correlation Between SPP1 and Immune Escape of EGFR Mutant Lung Adenocarcinoma Was Explored by Bioinformatics Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 592854.	1.3	13
1232	Atezolizumab Monotherapy or Plus Chemotherapy in First-Line Treatment for Advanced Non-Small Cell Lung Cancer Patients: A Meta-Analysis. <i>Frontiers in Immunology</i> , 2021, 12, 666909.	2.2	2
1233	Therapeutic Advances in the Management of Patients with Advanced RET Fusion-Positive Non-Small Cell Lung Cancer. <i>Current Treatment Options in Oncology</i> , 2021, 22, 72.	1.3	9
1234	Immunotherapy in gastroenteropancreatic neuroendocrine neoplasia. <i>Neuroendocrinology</i> , 2021, , .	1.2	3
1235	Immune checkpoint inhibitors in elderly patients treated for a lung cancer: a narrative review. <i>Translational Lung Cancer Research</i> , 2021, 10, 3014-3028.	1.3	9
1236	Genetic variation associated with thyroid autoimmunity shapes the systemic immune response to PD-1 checkpoint blockade. <i>Nature Communications</i> , 2021, 12, 3355.	5.8	40

#	ARTICLE	IF	CITATIONS
1237	Binimetinib, pemetrexed and cisplatin, followed by maintenance of binimetinib and pemetrexed in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations. The phase 1B SAKK 19/16 trial. <i>Lung Cancer</i> , 2021, 156, 91-99.	0.9	11
1238	Case Report: Durvalumab-Associated Encephalitis in Extensive-Stage Small Cell Lung Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 693279.	1.3	3
1239	Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 251-265.	2.0	22
1240	A Phase Ib Open-Label, Multicenter Study of Inhaled DV281, a TLR9 Agonist, in Combination with Nivolumab in Patients with Advanced or Metastatic Non-small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 4566-4573.	3.2	13
1241	Exploring the immune-checkpoint inhibitors™ efficacy/tolerability in special non-small cell lung cancer (NSCLC) populations: focus on steroids and autoimmune disease. <i>Translational Lung Cancer Research</i> , 2021, 10, 2876-2889.	1.3	2
1242	Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first-line treatment for Chinese patients with unresectable, metastatic, or recurrent non-squamous non-small cell lung cancer: A multicenter, randomized, double-blind, phase III trial. <i>Cancer Communications</i> , 2021, 41, 889-903.	3.7	16
1243	Recent Progress on Tubulin Inhibitors with Dual Targeting Capabilities for Cancer Therapy. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 7963-7990.	2.9	69
1244	Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39). <i>Journal of Clinical Oncology</i> , 2021, 39, 1842-1855.	0.8	183
1245	A vision of immuno-oncology: the Siena think tank of the Italian network for tumor biotherapy (NIBIT) foundation. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 240.	3.5	3
1247	Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1-Selected NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1872-1882.	0.5	85
1248	Role of PD-L1 assessment in advanced NSCLC. <i>Anti-Cancer Drugs</i> , 2021, Publish Ahead of Print, 1084-1085.	0.7	1
1249	The Effectiveness and Safety of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer Patients With Stage III/IV: A Multicenter Study. <i>Frontiers in Oncology</i> , 2021, 11, 671127.	1.3	2
1250	Real-world efficacy of docetaxel plus nintedanib after chemo-immunotherapy failure in advanced pulmonary adenocarcinoma. <i>Future Oncology</i> , 2021, 17, 3965-3976.	1.1	6
1251	Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics. <i>European Journal of Cancer</i> , 2021, 151, 211-220.	1.3	24
1252	Anti-programmed cell death ligand 1-based immunotherapy in recurrent hepatocellular carcinoma with inferior vena cava tumor thrombus and metastasis: Three case reports. <i>World Journal of Clinical Cases</i> , 2021, 9, 5988-5998.	0.3	2
1253	Cardiovascular toxicity of angiogenesis inhibitors and immune checkpoint inhibitors: synergistic anti-tumour effects at the cost of increased cardiovascular risk?. <i>Clinical Science</i> , 2021, 135, 1649-1668.	1.8	10
1254	Dramatic response to osimertinib combined with crizotinib in EGFR T790M mutation only in blood and Met amplification only in tumor tissue expressive non-small cell lung cancer. <i>Medicine (United Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 97</i>	0.5	1
1255	IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1909-1924.	0.5	212

#	ARTICLE	IF	CITATIONS
1256	Risk of Infection with Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. Targeted Oncology, 2021, 16, 553-568.	1.7	13
1257	Genetic evidence for the causal association between programmed death-ligand 1 and lung cancer. Journal of Cancer Research and Clinical Oncology, 2021, 147, 3279-3288.	1.2	3
1258	Real-world study of PD-L1 testing patterns and treatment distribution in patients with metastatic non-small-cell lung cancer in Israel. Immunotherapy, 2021, 13, 851-861.	1.0	2
1259	Combining liquid biopsy and radiomics for personalized treatment of lung cancer patients. State of the art and new perspectives. Pharmacological Research, 2021, 169, 105643.	3.1	13
1260	Effects of MicroRNA-22 (miR-222) on Non-Small-Cell Lung Carcinoma (NSCLC) Cells Apoptosis and Proliferation Through Protein Kinase B/Mammalian Target of Rapamycin (AKT/mTOR) Signaling Pathway. Journal of Biomaterials and Tissue Engineering, 2021, 11, 1346-1351.	0.0	0
1261	Blockade of the CD93 pathway normalizes tumor vasculature to facilitate drug delivery and immunotherapy. Science Translational Medicine, 2021, 13, .	5.8	54
1262	Antibody Drug Conjugates in Lung Cancer: State of the Current Therapeutic Landscape and Future Developments. Clinical Lung Cancer, 2021, 22, 483-499.	1.1	11
1263	Antiangiogenic therapy reverses the immunosuppressive breast cancer microenvironment. Biomarker Research, 2021, 9, 59.	2.8	32
1264	Myeloid-Derived Suppressor Cells: Implications in the Resistance of Malignant Tumors to T Cell-Based Immunotherapy. Frontiers in Cell and Developmental Biology, 2021, 9, 707198.	1.8	17
1265	Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study. Lancet Oncology, The, 2021, 22, 959-969.	5.1	222
1266	Tumor microenvironment disparity in multiple primary lung cancers: Impact of non-intrinsic factors, histological subtypes, and genetic aberrations. Translational Oncology, 2021, 14, 101102.	1.7	8
1267	Efficacy of docetaxel plus ramucirumab as palliative second-line therapy following first-line chemotherapy plus immune-checkpoint-inhibitor combination treatment in patients with non-small cell lung cancer (NSCLC) UICC stage IV. Translational Lung Cancer Research, 2021, 10, 3093-3105.	1.3	23
1268	Bevacizumab plus platinum-based chemotherapy in advanced non-squamous non-small-cell lung cancer: a randomized, open-label phase 2 study (CLEAR). Translational Lung Cancer Research, 2021, 10, 3059-3070.	1.3	2
1269	Efficacy and Safety of First-Line Immunotherapy Combinations for Advanced NSCLC: A Systematic Review and Network Meta-Analysis. Journal of Thoracic Oncology, 2021, 16, 1099-1117.	0.5	64
1270	Anti-angiogenesis Revisited: Combination with Immunotherapy in Solid Tumors. Current Oncology Reports, 2021, 23, 100.	1.8	26
1271	Cutaneous adverse events associated with immune checkpoint blockade: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2021, 163, 103376.	2.0	9
1272	Photodynamic Therapy and Hyperthermia in Combination Treatmentâ€”Neglected Forces in the Fight against Cancer. Pharmaceutics, 2021, 13, 1147.	2.0	18
1273	Immunotherapy in Older Adults With Cancer. Journal of Clinical Oncology, 2021, 39, 2115-2127.	0.8	33

#	ARTICLE	IF	CITATIONS
1274	Differential Dermatologic Adverse Events Associated With Checkpoint Inhibitor Monotherapy and Combination Therapy: A Meta-Analysis of Randomized Control Trials. <i>Frontiers in Pharmacology</i> , 2021, 12, 640099.	1.6	3
1275	Positron Emission Tomographic Imaging of Tumor Cell Death Using Zirconium-89-Labeled APOMAB® Following Cisplatin Chemotherapy in Lung and Ovarian Cancer Xenograft Models. <i>Molecular Imaging and Biology</i> , 2021, 23, 914-928.	1.3	3
1276	Targeting EGFR Exon 20 Insertions in Non-Small Cell Lung Cancer: Recent Advances and Clinical Updates. <i>Cancer Discovery</i> , 2021, 11, 2145-2157.	7.7	54
1277	Elevated Eosinophil Count Following Pembrolizumab Treatment for Non-Small Cell Lung Cancer. <i>Cureus</i> , 2021, 13, e16266.	0.2	4
1280	Is there any place for PD-1/CTLA-4 inhibitors combination in the first-line treatment of advanced NSCLC? a trial-level meta-analysis in PD-L1 selected subgroups. <i>Translational Lung Cancer Research</i> , 2021, 10, 3106-3119.	1.3	28
1281	Predictors of Response, Progression-Free Survival, and Overall Survival in Patients With Lung Cancer Treated With Immune Checkpoint Inhibitors. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1086-1098.	0.5	53
1282	Changes in expression of PD-L1 on peripheral T cells in patients with melanoma and lung cancer treated with PD-1 inhibitors. <i>Scientific Reports</i> , 2021, 11, 15312.	1.6	15
1283	The efficacy and safety of combination therapy with immune checkpoint inhibitors in non-small cell lung cancer: A meta-analysis. <i>International Immunopharmacology</i> , 2021, 96, 107594.	1.7	11
1284	Atezolizumab with bevacizumab, paclitaxel and carboplatin was effective for patients with SMARCA4-deficient thoracic sarcoma. <i>Immunotherapy</i> , 2021, 13, 799-806.	1.0	29
1285	Pathological Complete Response after Immune-Checkpoint Inhibitor Followed by Salvage Surgery for Clinical Stage IV Pulmonary Adenocarcinoma with Continuous Low Neutrophil-to-Lymphocyte Ratio: A Case Report. <i>Case Reports in Oncology</i> , 2021, 14, 1124-1133.	0.3	3
1286	Safety and Clinical Activity of Atezolizumab Plus Ipilimumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer: Results From a Phase 1b Trial. <i>Clinical Lung Cancer</i> , 2022, 23, 273-281.	1.1	6
1287	Prospective Multicenter Study of Chemotherapy-Induced Clostridium (Clostridioides) difficile Infection in Patients With Lung Cancer: North Japan Lung Cancer Study Group Trial 1204. <i>Frontiers in Oncology</i> , 2021, 11, 685320.	1.3	3
1288	The Risk of Immune-Related Thyroid Dysfunction Induced by PD-1/PD-L1 Inhibitors in Cancer Patients: An Updated Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 667650.	1.3	8
1289	Independent action models and prediction of combination treatment effects for response rate, duration of response and tumor size change in oncology drug development. <i>Contemporary Clinical Trials</i> , 2021, 106, 106434.	0.8	7
1290	Pyroptosis, a New Breakthrough in Cancer Treatment. <i>Frontiers in Oncology</i> , 2021, 11, 698811.	1.3	29
1291	Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score \geq 50%. <i>Journal of Clinical Oncology</i> , 2021, 39, 2339-2349.	0.8	468
1292	Paradigm shift in the management of metastatic nonsmall cell lung cancer. <i>International Journal of Clinical Practice</i> , 2021, 75, e14533.	0.8	0
1293	Efficacy of pembrolizumab combined with anlotinib in 3 patients with advanced non-small cell lung cancer. <i>Food Science and Technology</i> , 0, 42, .	0.8	0

#	ARTICLE	IF	CITATIONS
1294	Efficacy and safety profile of combining programmed cell death-1 (PD-1) inhibitors and antiangiogenic targeting agents as subsequent therapy for advanced or metastatic non-small cell lung cancer (NSCLC). <i>Thoracic Cancer</i> , 2021, 12, 2360-2368.	0.8	4
1295	Local ablative therapies in oligometastatic NSCLC-upfront or outback? a narrative review. <i>Translational Lung Cancer Research</i> , 2021, 10, 3446-3456.	1.3	7
1296	A narrative review of primary research endpoints of neoadjuvant therapy for lung cancer: past, present and future. <i>Translational Lung Cancer Research</i> , 2021, 10, 3264-3275.	1.3	12
1297	Three-dimensional CRISPR screening reveals epigenetic interaction with anti-angiogenic therapy. <i>Communications Biology</i> , 2021, 4, 878.	2.0	6
1298	Update on recent key publications in lung oncology: picking up speed. <i>European Respiratory Review</i> , 2021, 30, 200300.	3.0	1
1299	Estrogen Promotes Resistance to Bevacizumab in Murine Models of NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 2051-2064.	0.5	6
1300	Systematic Review of PD-1/PD-L1 Inhibitors in Oncology: From Personalized Medicine to Public Health. <i>Oncologist</i> , 2021, 26, e1786-e1799.	1.9	52
1301	Chronic Pleuritis and Recurrent Pleural Effusion After Atezolizumab for Small Cell Lung Cancer. <i>American Journal of Case Reports</i> , 2021, 22, e933396.	0.3	1
1302	Cancer immunotherapy from biology to nanomedicine. <i>Journal of Controlled Release</i> , 2021, 336, 410-432.	4.8	12
1303	18F-FDG PET/CT for monitoring anti-PD-1 therapy in patients with non-small cell lung cancer using SUV harmonization of results obtained with various types of PET/CT scanners used at different centers. <i>Annals of Nuclear Medicine</i> , 2021, 35, 1253-1263.	1.2	5
1304	Reporting quality of randomized, controlled trials evaluating immunotherapy in lung cancer. <i>Thoracic Cancer</i> , 2021, 12, 2732-2739.	0.8	4
1305	Infiltration of NK and plasma cells is associated with a distinct immune subset in non-small cell lung cancer. <i>Journal of Pathology</i> , 2021, 255, 243-256.	2.1	17
1306	Cancer-associated fibroblasts in non-small cell lung cancer: Recent advances and future perspectives. <i>Cancer Letters</i> , 2021, 514, 38-47.	3.2	30
1307	First-Line Treatment of Metastatic Non-Small Cell Lung Cancer in the Elderly. <i>Current Oncology Reports</i> , 2021, 23, 119.	1.8	4
1308	Comparison of the outcome between immunotherapy alone or in combination with chemotherapy in EGFR-mutant non-small cell lung cancer. <i>Scientific Reports</i> , 2021, 11, 16122.	1.6	13
1309	Lung cancer. <i>Lancet, The</i> , 2021, 398, 535-554.	6.3	896
1310	The current issues and future perspective of artificial intelligence for developing new treatment strategy in non-small cell lung cancer: harmonization of molecular cancer biology and artificial intelligence. <i>Cancer Cell International</i> , 2021, 21, 454.	1.8	19
1311	Treatment patterns in patients with metastatic non-small-cell lung cancer in the era of immunotherapy. <i>Future Oncology</i> , 2021, 17, 2940-2949.	1.1	11

#	ARTICLE	IF	CITATIONS
1312	Clinical observation of the efficacy of PD-1/PD-L1 inhibitors in the treatment of patients with advanced solid tumors. <i>Immunity, Inflammation and Disease</i> , 2021, 9, 1584-1595.	1.3	4
1313	Combination strategies of immunotherapy in non-small cell lung cancer: facts and challenges. <i>Chinese Medical Journal</i> , 2021, 134, 1908-1919.	0.9	2
1314	Toward personalized treatment approaches for non-small-cell lung cancer. <i>Nature Medicine</i> , 2021, 27, 1345-1356.	15.2	338
1315	Phase 1, pharmacogenomic, dose-expansion study of pegargiminas plus pemetrexed and cisplatin in patients with ASS1-deficient non-squamous non-small cell lung cancer. <i>Cancer Medicine</i> , 2021, 10, 6642-6652.	1.3	11
1316	PD-L1 Expression in Non-Small Cell Lung Cancer: Data from a Referral Center in Spain. <i>Diagnostics</i> , 2021, 11, 1452.	1.3	5
1317	Myocarditis occurrence with cancer immunotherapy across indications in clinical trial and post-marketing data. <i>Scientific Reports</i> , 2021, 11, 17324.	1.6	24
1318	Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker study. <i>Npj Breast Cancer</i> , 2021, 7, 110.	2.3	20
1319	First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis. <i>Annals of Oncology</i> , 2021, 32, 983-993.	0.6	205
1320	Anti-PD-(L)1 for KRAS-mutant advanced non-small-cell lung cancers: a meta-analysis of randomized-controlled trials. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 719-726.	2.0	33
1321	Immunotherapy in elderly patients. <i>Meditinskiy Sovet</i> , 2021, , 26-32.	0.1	0
1322	Antibody engineering and its therapeutic applications. <i>International Reviews of Immunology</i> , 2023, 42, 156-183.	1.5	5
1323	PD-(L)1 inhibitors as single-agent or in combination with chemotherapy for advanced, PD-L1-high non-small cell lung cancer: a meta-analysis. <i>Future Oncology</i> , 2021, 17, 4415-4424.	1.1	6
1324	Clinical efficacy and safety of maintenance therapy for advanced non-small cell lung cancer: a retrospective real-world study. <i>World Journal of Surgical Oncology</i> , 2021, 19, 231.	0.8	6
1325	Effect of Systemic Steroid Use for Immune-Related Adverse Events in Patients with Non-Small Cell Lung Cancer Receiving PD-1 Blockade Drugs. <i>Journal of Clinical Medicine</i> , 2021, 10, 3744.	1.0	11
1326	Maintenance treatment of combination with bevacizumab vs single agent for advanced non-squamous non-small cell lung cancer. <i>Medicine (United States)</i> , 2021, 100, e26862.	0.4	2
1327	Alliance Foundation Trial 09: A Randomized, Multicenter, Phase 2 Trial Evaluating Two Sequences of Pembrolizumab and Standard Platinum-Based Chemotherapy in Patients With Metastatic NSCLC. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100208.	0.6	0
1328	Real-world efficacy of osimertinib in previously EGFR-TKI treated NSCLC patients without identification of T790M mutation. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, , 1.	1.2	3
1329	Predictive Role of Prior Radiotherapy and Immunotherapy-Related Adverse Effects in Advanced NSCLC Patients Receiving Anti-PD-1/L1 Therapy. <i>Journal of Clinical Medicine</i> , 2021, 10, 3719.	1.0	2

#	ARTICLE	IF	CITATIONS
1330	Predicted outcomes of subdividing M1-stage metastatic lung cancer based on the prognosis and the response to local consolidative therapy. <i>Annals of Translational Medicine</i> , 2021, 9, 1293-1293.	0.7	0
1331	Immune checkpoint inhibitor combined with anti-angiogenesis agent inhibits metastasis of advanced adenoid cystic carcinoma of the tongue base to the lung: a case report. <i>Annals of Translational Medicine</i> , 2021, 9, 1353-1353.	0.7	1
1332	Research Progress on the Drug Resistance of ALK Kinase Inhibitors. <i>Current Medicinal Chemistry</i> , 2022, 29, 2456-2475.	1.2	3
1333	Efficacy and safety of treatment modalities across EGFR selected/unselected populations with non-small cell lung cancer and brain metastases: A systematic review and Bayesian network meta-analysis. <i>Lung Cancer</i> , 2021, 158, 74-84.	0.9	8
1334	Non-Small Cell Lung Cancer: Challenge and Improvement of Immune Drug Resistance. <i>Frontiers in Oncology</i> , 2021, 11, 739191.	1.3	6
1335	Cost-effectiveness analysis of the use of immunotherapy in metastatic solid tumours in Austria by applying the ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) version 1.1. <i>ESMO Open</i> , 2021, 6, 100198.	2.0	6
1336	Current status and quality of radiomic studies for predicting immunotherapy response and outcome in patients with non-small cell lung cancer: a systematic review and meta-analysis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 49, 345-360.	3.3	39
1337	Immunotherapy for locally advanced non-small cell lung cancer: current evidence and future perspectives. <i>Current Challenges in Thoracic Surgery</i> , 0, 3, 25-25.	0.2	0
1338	Immune checkpoint inhibitors for brain metastases in non-small-cell lung cancer: from rationale to clinical application. <i>Immunotherapy</i> , 2021, 13, 1031-1051.	1.0	14
1339	Bevacizumab for stereotactic radiosurgery-induced radiation necrosis in patients with non-small cell lung cancer treated with immune check-point inhibitors. <i>Journal of the Neurological Sciences</i> , 2021, 427, 117556.	0.3	4
1340	The landscape of immune checkpoint inhibitor therapy in advanced lung cancer. <i>BMC Cancer</i> , 2021, 21, 968.	1.1	12
1341	The best regimens for chemo-naïve incurable non-squamous non-small cell lung cancer with a programmed death-ligand 1 ≥49%: a network meta-analysis. <i>Translational Lung Cancer Research</i> , 2021, 10, 3550-3566.	1.3	4
1342	Prediction of overall survival in patients across solid tumors following atezolizumab treatments: A tumor growth inhibition-based overall survival modeling framework. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021, 10, 1171-1182.	1.3	15
1343	Current Status of Immune Checkpoint Inhibitor Immunotherapy for Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 704336.	1.3	29
1344	Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial. , 2021, 9, e002804.		5
1345	Overcoming microenvironmental resistance to PD-1 blockade in genetically engineered lung cancer models. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	44
1346	Sex-based heterogeneity in non-small cell lung cancer (NSCLC) and response to immune checkpoint inhibitors (ICIs): a narrative review. <i>Precision Cancer Medicine</i> , 0, 4, 26-26.	1.8	1
1348	The Predictive Value of Clinical and Molecular Characteristics or Immunotherapy in Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials. <i>Frontiers in Oncology</i> , 2021, 11, 732214.	1.3	11

#	ARTICLE	IF	CITATIONS
1349	Early discontinuation of induction therapy in chemoimmunotherapy as an effective alternative to the standard regimen in patients with non-small cell lung cancer: a retrospective study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 2437-2446.	1.2	4
1350	Polyclonal on- and off-target resistance mutations in an <i>EML4-ALK</i> positive non-small cell lung cancer patient under ALK inhibition. <i>Oncotarget</i> , 2021, 12, 1946-1952.	0.8	3
1351	Immune checkpoint inhibitors for first-line treatment of advanced non-small cell lung cancer: A systematic review and network meta-analysis. <i>Thoracic Cancer</i> , 2021, 12, 2873-2885.	0.8	10
1352	Anti-VEGF antibody protects against alveolar exudate leakage caused by vascular hyperpermeability, resulting in mitigation of pneumonitis induced by immunotherapy. <i>Molecular Cancer Therapeutics</i> , 2021, 20, molcanther.MCT-21-0031-E.2021.	1.9	6
1353	Intravoxel Incoherent Motion Diffusion-Weighted Imaging for Predicting and Monitoring the Response of Anti-Angiogenic Treatment in the Orthotopic Nude Mouse Model of Lung Adenocarcinoma. <i>Journal of Magnetic Resonance Imaging</i> , 2022, 55, 1202-1210.	1.9	4
1354	Atezolizumab: an investigational agent for the treatment of biliary tract cancer. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 1007-1015.	1.9	2
1355	The Right Partner in Crime: Unlocking the Potential of the Anti-EGFR Antibody Cetuximab via Combination With Natural Killer Cell Chartering Immunotherapeutic Strategies. <i>Frontiers in Immunology</i> , 2021, 12, 737311.	2.2	28
1357	PD-L1 heterogeneity in patients with non-small cell lung cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2022, 18, .	0.7	2
1358	Characterization of KRAS Mutation Subtypes in Non-small Cell Lung Cancer. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 2577-2584.	1.9	66
1360	From Anti-PD-1/PD-L1 to CTLA-4 and to MUC1: Is the Better Response to Treatment in Smokers of Cancer Patients Drug Specific?. <i>Journal of Personalized Medicine</i> , 2021, 11, 914.	1.1	2
1361	Improving Biologics™ Effectiveness in Clinical Oncology: From the Combination of Two Monoclonal Antibodies to Oligoclonal Antibody Mixtures. <i>Cancers</i> , 2021, 13, 4620.	1.7	9
1362	Immune checkpoint inhibitors at any treatment line in advanced NSCLC: Real-world overall survival in a large Italian cohort. <i>Lung Cancer</i> , 2021, 159, 145-152.	0.9	7
1363	Combination atezolizumab, bevacizumab, pemetrexed and carboplatin for metastatic EGFR mutated NSCLC after TKI failure. <i>Lung Cancer</i> , 2021, 159, 18-26.	0.9	46
1364	Development and Performance of a CD8 Gene Signature for Characterizing Inflammation in the Tumor Microenvironment across Multiple Tumor Types. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 1159-1173.	1.2	7
1365	Clinical characteristics of advanced non-small cell lung cancer patients with EGFR exon 20 insertions. <i>Scientific Reports</i> , 2021, 11, 18762.	1.6	13
1366	Therapeutic Rigid Bronchoscopy Intervention for Malignant Central Airway Obstruction Improves Performance Status to Allow Systemic Treatment. <i>Journal of Bronchology and Interventional Pulmonology</i> , 2022, 29, 93-98.	0.8	2
1367	A Phase 2 Study of Rovalpituzumab Tesirine in Combination With Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Extensive-Stage SCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1559-1569.	0.5	41
1368	Immunotherapy with toripalimab for lung adenocarcinoma in a real-world patient with an Eastern Cooperative Oncology Group performance status (ECOG PS) score of 4: a case report. <i>Annals of Palliative Medicine</i> , 2021, 10, 10114-10123.	0.5	0

#	ARTICLE	IF	CITATIONS
1369	Tumor Immunology and Immunotherapy of Non-Small-Cell Lung Cancer. Cold Spring Harbor Perspectives in Medicine, 2022, 12, a037895.	2.9	24
1370	Clinical Efficacy and Future Prospects of Immunotherapy in Lung Cancer. Life, 2021, 11, 1029.	1.1	8
1371	Simultaneous targeting of TGF- β 2/PD-L1 synergizes with radiotherapy by reprogramming the tumor microenvironment to overcome immune evasion. Cancer Cell, 2021, 39, 1388-1403.e10.	7.7	92
1372	The Neutrophil-to-Lymphocyte Ratio (NLR) Predicts the Prognosis of Unresectable Intermediate and Advanced Hepatocellular Carcinoma Treated with Apatinib. Cancer Management and Research, 2021, Volume 13, 6989-6998.	0.9	5
1373	Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches. Annals of Oncology, 2021, 32, 1101-1110.	0.6	134
1374	NSCLC Biomarkers to Predict Response to Immunotherapy with Checkpoint Inhibitors (ICI): From the Cells to In Vivo Images. Cancers, 2021, 13, 4543.	1.7	14
1375	Dramatic Response to Pembrolizumab Monotherapy in a Patient With ARID1A-Mutant Lung Adenocarcinoma: Case Report. Clinical Lung Cancer, 2021, 22, e708-e711.	1.1	0
1376	Biomarkers of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Beyond PD-L1. Clinical Lung Cancer, 2021, 22, 381-389.	1.1	4
1377	ER expression associates with poor prognosis in male lung squamous carcinoma after radical resection. BMC Cancer, 2021, 21, 1043.	1.1	2
1378	Triple negative breast cancer and non-small cell lung cancer: Clinical challenges and nano-formulation approaches. Journal of Controlled Release, 2021, 337, 27-58.	4.8	44
1379	Phase 3 Trial Comparing Nanoparticle Albumin-Bound Paclitaxel With Docetaxel for Previously Treated Advanced NSCLC. Journal of Thoracic Oncology, 2021, 16, 1523-1532.	0.5	57
1380	Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer. JAMA Oncology, 2021, 7, 1368.	3.4	57
1381	Prognostic significance of volume-based 18F-FDG PET/CT parameters and correlation with PD-L1 expression in patients with surgically resected lung adenocarcinoma. Medicine (United States), 2021, 100, e27100.	0.4	4
1382	Co-targeting the VEGF axis and immune checkpoints in NSCLC: back to the future. Annals of Oncology, 2021, 32, 1075-1076.	0.6	2
1383	Current state of knowledge on immunotherapy in ECOG PS 2 patients. A systematic review. Advances in Medical Sciences, 2021, 66, 381-387.	0.9	5
1384	Cardiac Toxicity Associated with Cancer Immunotherapy and Biological Drugs. Cancers, 2021, 13, 4797.	1.7	12
1385	Successful Re-administration of Atezolizumab for a Non-small-cell Lung Cancer Patient after Cardiac Tamponade Development as a Manifestation of Pseudo-progression Induced by Combination Treatment with Atezolizumab and Cytotoxic Chemotherapy. Internal Medicine, 2021, 60, 3009-3013.	0.3	1
1386	Atezolizumab-associated Dermatomyositis in Advanced Small-cell Lung Carcinoma. Internal Medicine, 2021, 60, 3025-3029.	0.3	10

#	ARTICLE	IF	CITATIONS
1387	Winds From the ORIENT: New Data to Inform RATIONAL Choice?. Journal of Thoracic Oncology, 2021, 16, 1434-1436.	0.5	0
1388	Association of HLA class I homozygosity with unfavorable clinical outcomes in patients with non-small cell lung cancer treated with chemo-immunotherapy or immunotherapy as first-line therapy. Heliyon, 2021, 7, e07916.	1.4	4
1389	Direct Comparison Between the Addition of Pembrolizumab or Bevacizumab for Chemotherapy-Based First-Line Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer Lacking Driver Mutations. Frontiers in Oncology, 2021, 11, 752545.	1.3	3
1390	EGFR mutation status in non-small cell lung cancer receiving PD-1/PD-L1 inhibitors and its correlation with PD-L1 expression: a meta-analysis. Cancer Immunology, Immunotherapy, 2022, 71, 1001-1016.	2.0	8
1391	Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer. Annals of Oncology, 2021, 32, 1137-1147.	0.6	94
1392	PD-1/PD-L1 expression in pancreatic cancer and its implication in novel therapies. Medicine and Pharmacy Reports, 0, , .	0.2	10
1393	The Value of 18F-FDG PET/CT in Predicting the Response to PD-1 Blocking Immunotherapy in Advanced NSCLC Patients with High-Level PD-L1 Expression. Clinical Lung Cancer, 2021, 22, 432-440.	1.1	16
1394	A Long-Term Extension Study of Bevacizumab in Patients With Solid Tumors. Oncologist, 2021, 26, e2254-e2264.	1.9	12
1395	Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial. Journal of Thoracic Oncology, 2021, 16, 1512-1522.	0.5	127
1396	Atezolizumab in Metastatic Triple-Negative Breast Cancer—No Contradiction in the Eyes of a Dispassionate Observer. JAMA Oncology, 2021, 7, 1285.	3.4	8
1397	Risk factors for immune-related adverse events from anti-PD-1 or anti-PD-L1 treatment in an Asian cohort of nonsmall cell lung cancer patients. International Journal of Cancer, 2022, 150, 636-644.	2.3	20
1398	Combination strategies to maximize the benefits of cancer immunotherapy. Journal of Hematology and Oncology, 2021, 14, 156.	6.9	202
1399	Pembrolizumab Plus Chemotherapy for Chinese Patients With Metastatic Squamous Non-Small-Cell Lung Cancer in KEYNOTE-407. JTO Clinical and Research Reports, 2021, 2, 100225.	0.6	13
1400	Impact of weight loss on treatment with PD-1/PD-L1 inhibitors plus chemotherapy in advanced non-small-cell lung cancer. Supportive Care in Cancer, 2022, 30, 1633-1641.	1.0	6
1401	The Role of Immunotherapy in the Treatment of Advanced Cervical Cancer: Current Status and Future Perspectives. Journal of Clinical Medicine, 2021, 10, 4523.	1.0	12
1402	Immune checkpoints and immunotherapy in non-small cell lung cancer: Novel study progression, challenges and solutions (Review). Oncology Letters, 2021, 22, 787.	0.8	8
1403	Comprehensive assessment of PD-L1 expression, tumor mutational burden and oncogenic driver alterations in non-small cell lung cancer patients treated with immune checkpoint inhibitors. Lung Cancer, 2021, 159, 128-134.	0.9	13
1404	Programmed Cell Death Protein-1 Inhibitors Versus Programmed Death-Ligand 1 Inhibitors in Addition to Chemotherapy for the First-Line Treatment of Advanced NSCLC: A Systematic Review and Meta-Analysis. JTO Clinical and Research Reports, 2021, 2, 100214.	0.6	3

#	ARTICLE	IF	CITATIONS
1405	Cisplatin or carboplatin for advanced non-small cell lung cancer: does it really matter?. <i>Translational Lung Cancer Research</i> , 2021, 10, 3705-3708.	1.3	0
1406	Arsenic sulfide reverses cisplatin resistance in non-small cell lung cancer in vitro and in vivo through targeting PD-L1 . <i>Thoracic Cancer</i> , 2021, 12, 2551-2563.	0.8	5
1407	Influence of Performance Status on the Effectiveness of Pembrolizumab Monotherapy in First-Line for Advanced Non-Small-Cell Lung Cancer: Results in a Real-World Population. <i>Biology</i> , 2021, 10, 890.	1.3	4
1408	A case of suspected autoimmune encephalitis after the introduction of atezolizumab + bevacizumab therapy for hepatocellular carcinoma. <i>Acta Hepatologica Japonica</i> , 2021, 62, 590-592.	0.0	2
1409	Selective Histone Deacetylase Inhibitor ACY-241 (Citarinostat) Plus Nivolumab in Advanced Non-Small Cell Lung Cancer: Results From a Phase Ib Study. <i>Frontiers in Oncology</i> , 2021, 11, 696512.	1.3	22
1410	Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-III A non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. <i>Lancet</i> , 2021, 398, 1344-1357.	6.3	689
1411	Sintilimab Plus Platinum and Gemcitabine as First-Line Treatment for Advanced or Metastatic Squamous NSCLC: Results From a Randomized, Double-Blind, Phase 3 Trial (ORIENT-12). <i>Journal of Thoracic Oncology</i> , 2021, 16, 1501-1511.	0.5	158
1412	Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer. <i>ESMO Open</i> , 2021, 6, 100254.	2.0	35
1413	Pharmacology-based ranking of anti-cancer drugs to guide clinical development of cancer immunotherapy combinations. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 311.	3.5	26
1414	Recent advances in immune checkpoint therapy in non-small cell lung cancer and opportunities for nanoparticle-based therapy. <i>European Journal of Pharmacology</i> , 2021, 909, 174404.	1.7	18
1415	Research Progress and Challenges in the Treatment of Central Nervous System Metastasis of Non-Small Cell Lung Cancer. <i>Cells</i> , 2021, 10, 2620.	1.8	10
1416	Vascular events with immune checkpoint inhibitors in melanoma or non-small cell lung cancer: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2021, 100, 102280.	3.4	10
1417	Ocular side effects of checkpoint inhibitors. <i>Survey of Ophthalmology</i> , 2021, 66, 951-959.	1.7	16
1418	Will the clinical development of 4th-generation double mutant active ALK TKIs (TPX-0131 and NVL-655) change the future treatment paradigm of ALK+ NSCLC?. <i>Translational Oncology</i> , 2021, 14, 101191.	1.7	24
1419	Clinical impact of pembrolizumab combined with chemotherapy in elderly patients with advanced non-small-cell lung cancer. <i>Lung Cancer</i> , 2021, 161, 26-33.	0.9	31
1420	PI3K inhibitor plus radiation enhances the antitumour immune effect of PD-1 blockade in syngenic murine breast cancer and humanised patient-derived xenograft model. <i>European Journal of Cancer</i> , 2021, 157, 450-463.	1.3	13
1421	Management of Advanced Disease in NSCLC. , 2022, , 912-920.		0
1422	Current Role of Immunotherapy. , 2022, , 905-911.		0

#	ARTICLE	IF	CITATIONS
1423	Systemic treatments other than TKI: Reflections on chemotherapy, immunotherapy and antiangiogenic agents in ALK-driven NSCLC. , 2021, , 55-69.		1
1424	Immunotherapy in non-small cell lung cancer: update and new insights. Journal of Clinical and Translational Research, 0, ,	0.3	23
1425	Therapeutic strategies to overcome ALK resistance in lung cancer. , 2021, , 123-139.		0
1426	Febrile neutropenia in a patient with non-small-cell lung cancer treated with atezolizumab: A case report. Respiratory Medicine Case Reports, 2021, 33, 101439.	0.2	4
1427	Synchronous Primary Lung Adenocarcinoma and Hepatocellular Carcinoma Successfully Treated with a Combination of Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel. Internal Medicine, 2021, 60, 3273-3277.	0.3	2
1428	Emerging immune checkpoint inhibitors for the treatment of hepatocellular carcinoma. Expert Opinion on Emerging Drugs, 2021, 26, 39-52.	1.0	9
1429	Antitumour immunity regulated by aberrant ERBB family signalling. Nature Reviews Cancer, 2021, 21, 181-197.	12.8	141
1430	Immune Therapy: What Can We Learn From Acquired Resistance?. Current Cancer Research, 2021, , 75-114.	0.2	0
1431	A Method for the Establishment of Human Lung Adenocarcinoma Patient-Derived Xenografts in Mice. Methods in Molecular Biology, 2021, 2279, 165-173.	0.4	1
1432	Immunotherapy response modeling by ex-vivo organ culture for lung cancer. Cancer Immunology, Immunotherapy, 2021, 70, 2223-2234.	2.0	9
1434	Identification of an Immunologic Signature of Lung Adenocarcinomas Based on Genome-Wide Immune Expression Profiles. Frontiers in Molecular Biosciences, 2020, 7, 603701.	1.6	7
1435	Surgical challenges in multimodal treatment of N2-stage IIIA non-small cell lung cancer. Japanese Journal of Clinical Oncology, 2021, 51, 333-344.	0.6	6
1436	Cytokine Release Syndrome Induced by Immune-checkpoint Inhibitor Therapy for Non-small-cell Lung Cancer. Internal Medicine, 2021, 60, 3459-3462.	0.3	10
1437	Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data. OncoImmunology, 2021, 10, 1865653.	2.1	24
1438	Frontline pembrolizumab for the treatment of RET-rearranged non-small cell lung cancer: A case report. Cancer Treatment and Research Communications, 2021, 28, 100423.	0.7	3
1439	Inhalation delivery dramatically improves the efficacy of topotecan for the treatment of local and distant lung cancer. Drug Delivery, 2021, 28, 767-775.	2.5	8
1440	Atezolizumab-induced Sclerosing Cholangitis in a patient with lung cancer: A case report. Cancer Treatment and Research Communications, 2021, 26, 100270.	0.7	13
1441	Combination therapy of cisplatin with cilastatin enables an increased dose of cisplatin, enhancing its antitumor effect by suppression of nephrotoxicity. Scientific Reports, 2021, 11, 750.	1.6	16

#	ARTICLE	IF	CITATIONS
1442	IMbrave 151: a randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110365.	1.4	24
1443	The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592199296.	1.4	40
1444	Great Strides in Precision Medicine: Personalized Oncology, Immunotherapies, and Molecular Diagnostics. , 2021, , 141-417.		0
1445	Durvalumab, Tremelimumab Alone or in Combination With Low-Dose or Hypofractionated Targeted Radiotherapy in Metastatic Non-Small Cell Lung Cancer Refractory to Prior PD-1 Therapy: A Multicentre, Open-Label, Randomized, Phase 2 Trial. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1446	Therapeutic Sequencing in ALK+ NSCLC. <i>Pharmaceuticals</i> , 2021, 14, 80.	1.7	38
1447	Tumor mutational burden on cytological samples: A pilot study. <i>Cancer Cytopathology</i> , 2021, 129, 460-467.	1.4	34
1448	LncRNA PART1 promotes cell proliferation and progression in non-small cell lung cancer cells via sponging miR-17-5p. <i>Journal of Cellular Biochemistry</i> , 2021, 122, 315-325.	1.2	18
1449	Status of Immune Oncology: Challenges and Opportunities. <i>Methods in Molecular Biology</i> , 2020, 2055, 3-21.	0.4	6
1450	Multiplex Immunofluorescence Assays. <i>Methods in Molecular Biology</i> , 2020, 2055, 467-495.	0.4	44
1451	Immuno-Oncology in the Era of Personalized Medicine. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1168, 117-129.	0.8	4
1452	Translational Biomarkers and Rationale Strategies to Overcome Resistance to Immune Checkpoint Inhibitors in Solid Tumors. <i>Cancer Treatment and Research</i> , 2020, 180, 251-279.	0.2	15
1453	The Role of the VEGF Signaling Pathway in Tumor Angiogenesis. , 2019, , 211-226.		5
1455	Importancia de la imagen en la valoración de la respuesta al tratamiento con inmunoterapia del cáncer de pulmón. <i>Archivos De Bronconeumología</i> , 2020, 56, 380-389.	0.4	4
1456	Double immune checkpoint blockade in advanced NSCLC. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 152, 102980.	2.0	12
1457	The progress and confusion of anti-PD1/PD-L1 immunotherapy for patients with advanced non-small cell lung cancer. <i>International Immunopharmacology</i> , 2020, 80, 106247.	1.7	28
1458	Pembrolizumab alone or with chemotherapy for squamous cell carcinoma of the head and neck: A cost-effectiveness analysis from Chinese perspective. <i>Oral Oncology</i> , 2020, 107, 104754.	0.8	7
1460	Challenges and Chances in the Preclinical to Clinical Translation of Anticancer Metallodrugs. 2-Oxoglutarate-Dependent Oxygenases, 2019, , 308-347.	0.8	14
1461	Treatment- and immune-related adverse events of immune checkpoint inhibitors in advanced lung cancer. <i>Bioscience Reports</i> , 2020, 40, .	1.1	29

#	ARTICLE	IF	CITATIONS
1462	Vascular toxicity associated with anti-angiogenic drugs. <i>Clinical Science</i> , 2020, 134, 2503-2520.	1.8	33
1463	Atezolizumab for First-Line Treatment of PD-L1 ⁺ Selected Patients with NSCLC. <i>New England Journal of Medicine</i> , 2020, 383, 1328-1339.	13.9	959
1464	Anti-PD-1 antibody HX008 combined with oxaliplatin plus capecitabine for advanced gastric or esophagogastric junction cancer: a multicenter, single-arm, open-label, phase Ib trial. <i>Oncolmmunology</i> , 2021, 10, 1864908.	2.1	9
1465	Durvalumab for the treatment of PD-L1 non-small cell lung cancer. <i>Expert Review of Precision Medicine and Drug Development</i> , 2021, 6, 95-105.	0.4	1
1466	A randomized phase III study comparing continuation and discontinuation of PD-1 pathway inhibitors for patients with advanced non-small-cell lung cancer (JCOG1701, SAVE study). <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 821-825.	0.6	15
1467	Moving Immunotherapy Into Early-Stage Lung Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2020, 26, 543-547.	1.0	5
1469	Five-year safety and efficacy data from a phase Ib study of nivolumab and chemotherapy in advanced non-small cell lung cancer. <i>Cancer Science</i> , 2020, 111, 1933-1942.	1.7	13
1470	Supplementation of L-arginine boosts the therapeutic efficacy of anticancer chemoimmunotherapy. <i>Cancer Science</i> , 2020, 111, 2248-2258.	1.7	31
1471	Multiorgan Signaling Mobilizes Tumor-Associated Erythroid Cells Expressing Immune Checkpoint Molecules. <i>Molecular Cancer Research</i> , 2021, 19, 507-515.	1.5	16
1472	Enapotamab vedotin, an AXL-specific antibody-drug conjugate, shows preclinical antitumor activity in non-small cell lung cancer. <i>JCI Insight</i> , 2019, 4, .	2.3	42
1473	EPHB2 carried on small extracellular vesicles induces tumor angiogenesis via activation of ephrin reverse signaling. <i>JCI Insight</i> , 2019, 4, .	2.3	88
1474	Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients. <i>JCI Insight</i> , 2018, 3, .	2.3	156
1475	U3-1402 sensitizes HER3-expressing tumors to PD-1 blockade by immune activation. <i>Journal of Clinical Investigation</i> , 2019, 130, 374-388.	3.9	43
1476	Time to dissect the autoimmune etiology of cancer antibody immunotherapy. <i>Journal of Clinical Investigation</i> , 2020, 130, 51-61.	3.9	66
1477	Evolution of Lung Cancer in the Context of Immunotherapy. <i>Clinical Medicine Insights: Oncology</i> , 2020, 14, 117955492097969.	0.6	6
1478	Emerging therapeutic agents for advanced non-small cell lung cancer. <i>Journal of Hematology and Oncology</i> , 2020, 13, 58.	6.9	161
1479	Colonization with multi-drug-resistant organisms negatively impacts survival in patients with non-small cell lung cancer. <i>PLoS ONE</i> , 2020, 15, e0242544.	1.1	10
1480	First Report of Severe Acute Graft-Versus-Host Disease After Allogeneic Stem Cell Transplant in a Patient With Myelodysplastic Syndrome Treated With Atezolizumab: Literature Review. <i>World Journal of Oncology</i> , 2020, 11, 112-115.	0.6	5

#	ARTICLE	IF	CITATIONS
1481	THERAPY OF ENDOCRINE DISEASE Immunotherapy of advanced thyroid cancer: from bench to bedside. European Journal of Endocrinology, 2020, 183, R41-R55.	1.9	20
1482	New treatment options for advanced urothelial cancer: a combination of atezolizumab with chemotherapy. Onkourologiya, 2020, 16, 104-117.	0.1	1
1483	The clinicopathological significance and prognostic value of programmed death-ligand 1 in prostate cancer: a meta-analysis of 3133 patients. Aging, 2021, 13, 2279-2293.	1.4	4
1484	A global immune gene expression signature for human cancers. Oncotarget, 2019, 10, 1993-2005.	0.8	9
1485	Survival correlation of immune response in human cancers. Oncotarget, 2019, 10, 6885-6897.	0.8	3
1486	Resistance to chemoimmunotherapy in non-small-cell lung cancer. , 2020, 3, 445-453.		3
1487	Clinical characteristics of colitis induced by taxane-based chemotherapy. Annals of Gastroenterology, 2019, 33, 59-67.	0.4	12
1488	The mechanism and risk factors for immune checkpoint inhibitor pneumonitis in non-small cell lung cancer patients. Cancer Biology and Medicine, 2020, 17, 599-611.	1.4	45
1489	Combination of immunotherapy with chemotherapy in first line treatment of metastatic gastric cancer? Too much, too little or just right?. Annals of Translational Medicine, 2020, 8, 1692-1692.	0.7	1
1490	VEGF inhibitors in EGFR-mutated lung cancer: a never-ending story?. Annals of Translational Medicine, 2018, 6, 446-446.	0.7	10
1491	Systemic therapy of elderly patients with advanced non-small cell lung cancerâ€”individualized treatment is key. Annals of Translational Medicine, 2019, 7, S48-S48.	0.7	3
1492	Combining immunotherapy and epidermal growth factor receptor kinase inhibitors: worth the risk?. Annals of Translational Medicine, 2019, 7, S76-S76.	0.7	5
1493	Pembrolizumab monotherapy for PD-L1 â‰¥50% non-small cell lung cancer, undisputed first choice?. Annals of Translational Medicine, 2019, 7, S140-S140.	0.7	11
1494	Are we facing a cure in lung cancer?â€”KEYNOTE-001 insights. Annals of Translational Medicine, 2019, 7, S215-S215.	0.7	7
1495	Five-year overall survival of pembrolizumab in advanced non-small cell lung cancer: another step from care to cure?. Annals of Translational Medicine, 2019, 7, S212-S212.	0.7	5
1496	Clinical significance of the immune cell landscape in hepatocellular carcinoma patients with different degrees of fibrosis. Annals of Translational Medicine, 2019, 7, 528-528.	0.7	26
1497	Challenges of the phase I drug development in non-small cell lung cancer. Chinese Clinical Oncology, 2019, 8, 25-25.	0.4	10
1498	EGFR first- and second-generation TKIsâ€”there is still place for them in EGFR-mutant NSCLC patients. Translational Cancer Research, 2018, 8, S23-S47.	0.4	48

#	ARTICLE	IF	CITATIONS
1499	Atezolizumab plus platinum-based regimen and bevacizumab: is it time to consider immunotherapy in a concurrent approach for lung cancer?. <i>Translational Cancer Research</i> , 2019, 8, S103-S105.	0.4	2
1500	Integrating immune checkpoint inhibitors and targeted therapies in the treatment of early stage non-small cell lung cancer: a narrative review. <i>Translational Lung Cancer Research</i> , 2020, 9, 2656-2673.	1.3	16
1501	Is there any place for immune-checkpoint inhibitors in the treatment algorithm of fusion-driven non-small cell lung cancer?â€”a literature review. <i>Translational Lung Cancer Research</i> , 2020, 9, 2674-2685.	1.3	2
1502	Overcoming TKI resistance in fusion-driven NSCLC: new generation inhibitors and rationale for combination strategies. <i>Translational Lung Cancer Research</i> , 2020, 9, 2581-2598.	1.3	11
1503	<p>Serum Tumor Marker Dynamics as Predictive Biomarkers in NSCLC Chemo-Immunotherapy and Mono-Immunotherapy Maintenance: A Registry-Based Descriptive Study</p>. <i>Lung Cancer: Targets and Therapy</i> , 2020, Volume 11, 113-121.	1.3	7
1504	<p>PD-1/PD-L1 Inhibitor Combined with Chemotherapy Can Improve the Survival of Non-Small Cell Lung Cancer Patients with Brain Metastases</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 12777-12786.	1.0	7
1505	Immuno-related endocrinopathy in patients treated with immune checkpoint inhibitors. <i>Meditinskiy Sovet</i> , 2020, , 16-24.	0.1	2
1506	Anti-tumor Drug Targets Analysis: Current Insight and Future Prospect. <i>Current Drug Targets</i> , 2019, 20, 1180-1202.	1.0	13
1507	PD-L1 Inhibitors for the Treatment of Prostate Cancer. <i>Current Drug Targets</i> , 2020, 21, 1558-1565.	1.0	4
1508	Safety Profiles and Pharmacovigilance Considerations for Recently Patented Anticancer Drugs: Lung Cancer. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2019, 14, 242-257.	0.8	5
1511	Tumor immune microenvironment of <i>EGFR</i>-mutant non-small-cell lung cancer and its impact on therapeutic efficacy. <i>Immunotherapy</i> , 2020, 12, 431-437.	1.0	4
1512	MiR-181a reduces radiosensitivity of non-small-cell lung cancer via inhibiting PTEN. <i>Panminerva Medica</i> , 2022, 64, .	0.2	6
1513	The LIPI score and inflammatory biomarkers for selection of patients with solid tumors treated with checkpoint inhibitors. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 64, 162-174.	0.4	38
1514	Combinations using checkpoint blockade to overcome resistance. <i>Ecancermedalscience</i> , 2020, 14, 1148.	0.6	11
1515	Case Report: A Case of Pituitary Carcinoma Treated With Sequential Dual Immunotherapy and Vascular Endothelial Growth Factor Inhibition Therapy. <i>Frontiers in Endocrinology</i> , 2020, 11, 576027.	1.5	20
1516	Novel Nuclear Medicine Imaging Applications in Immuno-Oncology. <i>Cancers</i> , 2020, 12, 1303.	1.7	6
1517	Plasma Biomarkers Screening by Multiplex ELISA Assay in Patients with Advanced Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors. <i>Cancers</i> , 2021, 13, 97.	1.7	6
1518	ABL001, a Bispecific Antibody Targeting VEGF and DLL4, with Chemotherapy, Synergistically Inhibits Tumor Progression in Xenograft Models. <i>International Journal of Molecular Sciences</i> , 2021, 22, 241.	1.8	26

#	ARTICLE	IF	CITATIONS
1522	Value of TTF-1 expression in non-squamous non-small cell lung cancer for assessing docetaxel monotherapy after chemotherapy failure. <i>Molecular and Clinical Oncology</i> , 2020, 13, 9.	0.4	6
1523	Biomarkers of immunotherapy in non-small cell lung cancer (Review). <i>Oncology Letters</i> , 2020, 20, 1-1.	0.8	8
1524	Early palliative care of non-small cell lung cancer in the context of immunotherapy. <i>Oncology Letters</i> , 2020, 20, 396.	0.8	1
1525	Mechanistic insight of predictive biomarkers for antitumor PD-1/PD-L1 blockade: A paradigm shift towards immune evaluation (Review). <i>Oncology Reports</i> , 2020, 44, 424-437.	1.2	18
1526	Current Status of Immunotherapy for Lung Cancer and Future Perspectives. <i>Tuberculosis and Respiratory Diseases</i> , 2020, 83, 14.	0.7	19
1527	Are anti-PD1 and anti-PD-L1 alike? The non-small-cell lung cancer paradigm. <i>Oncology Reviews</i> , 2020, 14, 490.	0.8	36
1528	Low doses in immunotherapy: Are they effective?. <i>Cancer Research Statistics and Treatment</i> , 2019, 2, 54.	0.1	12
1529	Immunotherapy in breast cancer. <i>Journal of Carcinogenesis</i> , 2019, 18, 2.	2.5	56
1530	Camrelizumab combined with microwave ablation improves the objective response rate in advanced non-small cell lung cancer. <i>Journal of Cancer Research and Therapeutics</i> , 2019, 15, 1629.	0.3	23
1531	Immune checkpoint inhibitor-induced diarrhea/colitis: Endoscopic and pathologic findings. <i>World Journal of Gastrointestinal Pathophysiology</i> , 2019, 10, 17-28.	0.5	26
1532	Immunotherapy – new perspective in lung cancer. <i>World Journal of Clinical Oncology</i> , 2020, 11, 250-259.	0.9	10
1533	Comparative Effectiveness of Carboplatin/Pemetrexed With Versus Without Bevacizumab for Advanced Nonsquamous Non-Small Cell Lung Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 469-477.	2.3	16
1534	NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 1.2020. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 1464-1472.	2.3	556
1536	TGF- β 2 inhibition combined with cytotoxic nanomedicine normalizes triple negative breast cancer microenvironment towards anti-tumor immunity. <i>Theranostics</i> , 2020, 10, 1910-1922.	4.6	110
1537	The safety and efficacy of immunotherapy with anti-programmed cell death 1 monoclonal antibody for lung cancer complicated with Mycobacterium tuberculosis infection. <i>Translational Lung Cancer Research</i> , 2021, 10, 3929-3942.	1.3	6
1538	The efficacy of immune checkpoint inhibitors in thoracic malignancies. <i>European Respiratory Review</i> , 2021, 30, 200387.	3.0	5
1539	First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial. <i>Journal of Thoracic Oncology</i> , 2022, 17, 289-308.	0.5	173
1540	Dispositional hope as a potential outcome parameter among patients with advanced malignancy: An analysis of the ENABLE database. <i>Cancer</i> , 2022, 128, 401-409.	2.0	9

#	ARTICLE	IF	CITATIONS
1541	Cost-Effectiveness of Cemiplimab Versus Standard of Care in the United States for First-Line Treatment of Advanced Non-small Cell Lung Cancer With Programmed Death-Ligand 1 Expression $\geq 50\%$. <i>Value in Health</i> , 2022, 25, 203-214.	0.1	11
1542	A Multicenter, Randomized Phase III Study Comparing Platinum Combination Chemotherapy Plus Pembrolizumab With Platinum Combination Chemotherapy Plus Nivolumab and Ipilimumab for Treatment-Naïve Advanced Non-Small Cell Lung Cancer Without Driver Gene Alterations: JCOG2007 (NIPPON Study). <i>Clinical Lung Cancer</i> , 2022, 23, e285-e288.	1.1	12
1543	PD-L1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer in PD-L1 Positive Patients: A Safety Data Network Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2021, 10, 4583.	1.0	3
1544	Efficacy of immune checkpoint inhibitors in non-small cell lung cancer with uncommon histology: a propensity-score-matched analysis. <i>BMC Pulmonary Medicine</i> , 2021, 21, 309.	0.8	2
1545	First-line treatment options for advanced non-small cell lung cancer patients with PD-L1 $\geq 50\%$: a systematic review and network meta-analysis. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 1345-1355.	2.0	5
1546	IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain. <i>Journal of Thoracic Oncology</i> , 2022, 17, 309-323.	0.5	114
1548	First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update. <i>ESMO Open</i> , 2021, 6, 100273.	2.0	91
1549	Programmed death-ligand 1 expression and tumor-infiltrating lymphocytes in non-small cell lung cancer: association with clinicopathologic parameters. <i>Journal of Pathology and Translational Medicine</i> , 2021, 55, 398-405.	0.4	1
1550	Clinical Management and Outcome of Grade III Pneumonitis after Chemoradioimmunotherapy for Inoperable Stage III Non-Small Cell Lung Cancer—A Prospective Longitudinal Assessment. <i>Diagnostics</i> , 2021, 11, 1968.	1.3	5
1552	Budget Impact Analysis of Comprehensive Genomic Profiling in Patients With Advanced Non-Small-Cell Lung Cancer. <i>JCO Precision Oncology</i> , 2021, 5, 1611-1624.	1.5	7
1553	Review of the recent clinical trials for PD-1/PD-L1 based lung cancer immunotherapy. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 1355-1370.	1.1	6
1554	Do Lipid-based Nanoparticles Hold Promise for Advancing the Clinical Translation of Anticancer Alkaloids?. <i>Cancers</i> , 2021, 13, 5346.	1.7	11
1555	The <i>RNA</i> binding protein <i>La</i> / <i>SSB</i> associates with radiation-induced <i>DNA</i> double-strand breaks in lung cancer cell lines. <i>Cancer Reports</i> , 2022, 5, e1543.	0.6	3
1556	Body composition and inflammation impact in non-small-cell lung cancer patients treated by first-line immunotherapy. <i>Immunotherapy</i> , 2021, 13, 1501-1519.	1.0	5
1557	Prognostic impact of chronological age on efficacy of immune checkpoint inhibitors in non-small cell lung cancer: Real-world data from 86%173 patients. <i>Thoracic Cancer</i> , 2021, 12, 2943-2948.	0.8	7
1558	Cyclophosphamide enhances the antitumor potency of GITR engagement by increasing oligoclonal cytotoxic T cell fitness. <i>JCI Insight</i> , 2021, 6, .	2.3	2
1559	First-line nab paclitaxel plus carboplatin for patients with advanced non-small cell lung cancer: Results of the NEPTUN study. <i>Cancer Medicine</i> , 2021, 10, 8127-8137.	1.3	1
1560	The Abscopal Effect: A Review of Pre-Clinical and Clinical Advances. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11061.	1.8	49

#	ARTICLE	IF	CITATIONS
1561	Long-term outcomes in extensive disease small cell lung cancer patients treated without immune checkpoint inhibitors. Japanese Journal of Clinical Oncology, 2021, 51, 1736-1743.	0.6	1
1562	Immunotherapeutic Advances for NSCLC. Biologics: Targets and Therapy, 2021, Volume 15, 399-417.	3.0	9
1563	Immune checkpoint inhibitors for cancer and venous thromboembolic events. European Journal of Cancer, 2021, 158, 99-110.	1.3	35
1564	Combining immune checkpoint inhibitors with chemotherapy in advanced solid tumours: A review. European Journal of Cancer, 2021, 158, 47-62.	1.3	32
1565	Non-small cell lung cancer: Emerging molecular targeted and immunotherapeutic agents. Biochimica Et Biophysica Acta: Reviews on Cancer, 2021, 1876, 188636.	3.3	27
1566	Treating disease progression with osimertinib in EGFR-mutated non-small-cell lung cancer: novel targeted agents and combination strategies. ESMO Open, 2021, 6, 100280.	2.0	29
1567	Myricetin exhibit selective anti-lymphoma activity by targeting BTK and is effective via oral administration in vivo. Phytomedicine, 2021, 93, 153802.	2.3	7
1569	Updates in the Systemic Treatment of Hepatocellular Carcinoma. Oncology & Hematology Review, 2018, 14, 76.	0.2	0
1570	Antiangiogenic therapy of lung cancer. Onkologie (Czech Republic), 2018, 12, 231-234.	0.0	0
1571	éžâ°ç°èfžè,°ç™CEã®æ²»ç™,â€•Updateâ€•. Japanese Journal of Lung Cancer, 2018, 58, 907-910.	0.0	0
1572	Immunotherapies in lung cancer. , 2019, , 227-231.		0
1573	Unmet Needs and Future Outlook of Mesothelioma Management. , 2019, , 331-340.		0
1574	The Role of the VEGF Signaling Pathway in Tumor Angiogenesis. , 2019, , 1-16.		0
1575	Updates in Lung Cancer 2018â€”What the Pulmonologist Needs to Know. Oncology & Hematology Review, 2019, 15, 20.	0.2	0
1576	Targeting Angiogenesis in Malignant Pleural Mesothelioma. , 2019, , 235-242.		0
1577	Les avancÃ©es dans la prise en charge des cancers bronchopulmonaires : ce qui change pour le rÃ©animateur. Medecine Intensive Reanimation, 2019, 28, 290-299.	0.1	0
1578	Disease progression in non-small cell lung cancer on immune-checkpoint inhibition, what are the options?. Precision Cancer Medicine, 0, 2, 13-13.	1.8	1
1580	Current Status and Future Direction of Immune Checkpoint Inhibitors. Japanese Journal of Lung Cancer, 2019, 59, 217-223.	0.0	0

#	ARTICLE	IF	CITATIONS
1582	Internal Medicine, 2019, 108, 1772-1776.	0.0	0
1583	Clinicopathological correlation of immune response in human cancers. <i>Oncotarget</i> , 2019, 10, 5859-5870.	0.8	0
1584	Características clínicas y patológicas de cáncer de pulmón. <i>Revista Colombiana De Hematología Y Oncología</i> , 2019, 6, 23-27.	0.0	0
1586	Immune-Therapy Standards Of Care. <i>International Journal of Pulmonary & Respiratory Sciences</i> , 2019, 4, .	0.1	0
1587	Tratamiento de cáncer de pulmón metastásico (estadio IV) : segundo consenso de expertos, Asociación Colombiana de Hematología y Oncología (ACHO), 2019.. <i>Revista Colombiana De Hematología Y Oncología</i> , 2019, 6, 10-22.	0.0	0
1588	Les CBNPC de stades avancées hors addiction oncogénique: les traitements systémiques de deuxième ligne. <i>Revue Des Maladies Respiratoires Actualites</i> , 2019, 11, 355-363.	0.0	0
1589	First-line pembrolizumab in programmed death ligand 1 positive non-small cell lung cancer. <i>Translational Cancer Research</i> , 2019, 8, 2514-2516.	0.4	3
1590	The role of immune checkpoint inhibitors (ICI) in the treatment of metastatic non-small cell lung carcinoma in the elderly. <i>Annals of Translational Medicine</i> , 2019, 7, S383-S383.	0.7	2
1591	Progress in individualized treatment for <i>EGFR</i>-mutated advanced non-small cell lung cancer. <i>Proceedings of the Japan Academy Series B: Physical and Biological Sciences</i> , 2020, 96, 266-272.	1.6	4
1593	Clinical efficacy, predictive biomarkers and response patterns of immunotherapy combinations for patients with cancer. <i>Future Oncology</i> , 2020, 16, 1659-1664.	1.1	2
1596	Efficacy of first-line atezolizumab combination therapy in patients with non-small cell lung cancer receiving proton pump inhibitors: post hoc analysis of IMPower150. <i>British Journal of Cancer</i> , 2022, 126, 42-47.	2.9	34
1597	The role of vascular endothelial growth factor inhibitors in the treatment of epithelial ovarian cancer. <i>British Journal of Cancer</i> , 2021, , .	2.9	3
1598	The Dual Effect of the BMP9-ALK1 Pathway in Blood Vessels: An Opportunity for Cancer Therapy Improvement?. <i>Cancers</i> , 2021, 13, 5412.	1.7	11
1599	Bayesian Design for Identifying Cohort-Specific Optimal Dose Combinations Based on Multiple Endpoints: Application to a Phase I Trial in Non-Small Cell Lung Cancer. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 11452.	1.2	1
1600	Immune checkpoint inhibition for the treatment of cancers: An update and critical review of ongoing clinical trials. <i>Clinical Immunology</i> , 2021, 232, 108873.	1.4	19
1601	Immunotherapy for Stage III NSCLC: Durvalumab and Beyond. <i>Lung Cancer: Targets and Therapy</i> , 2021, Volume 12, 123-131.	1.3	4
1602	Cancers bronchiques. , 2020, , 139-146.e2.		0
1603	EPHA5 mutations predict survival after immunotherapy in lung adenocarcinoma. <i>Aging</i> , 2021, 13, 598-618.	1.4	10

#	ARTICLE	IF	CITATIONS
1604	Is hyperprogressive disease a specific phenomenon of immunotherapy?. Exploration of Targeted Anti-tumor Therapy, 2020, 1, .	0.5	1
1605	CM227/CM9-LA: evidence supporting ipilimumab-based immunotherapy in the first-line treatment of metastatic NSCLC. Precision Cancer Medicine, 0, 3, 34-34.	1.8	0
1606	To treat or not to treat: A rare case of response to pembrolizumab-based immunotherapy+chemotherapy in non-small cell lung cancer with acute liver failure due to multiple bile duct metastases. Thoracic Cancer, 2021, 12, 553-556.	0.8	2
1607	Experience of targeted therapy for ALK positive non-small cell lung cancer – a clinical case. Meditsinskiy Sovet, 2020, , 181-186.	0.1	0
1608	A narrative review of evolving roles of radiotherapy in advanced non-small cell lung cancer: from palliative care to active player. Translational Lung Cancer Research, 2020, 9, 2479-2493.	1.3	10
1609	The role of nivolumab combined to immunotherapy and/or chemotherapy in the first-line treatment of advanced Non Small Cell Lung Cancer. Expert Opinion on Biological Therapy, 2021, 21, 303-309.	1.4	3
1610	Remarkable response to combined immunochemotherapy in patients with metastatic triple-negative breast cancer. Immunotherapy, 2020, 12, 1293-1302.	1.0	0
1611	Survival benefit from immunocheckpoint inhibitors in stage IV non-small cell lung cancer patients with brain metastases: A National Cancer Database propensity-matched analysis. Cancer Medicine, 2021, 10, 923-932.	1.3	6
1612	Tratamiento de cáncer de pulmón metastásico (estadio IV) : segundo consenso de expertos, Asociación Colombiana de Hematología y Oncología (ACHO), 2019.. Revista Colombiana De Hematología Y Oncología, 2019, 6, 10-22.	0.0	0
1613	Malignome des Respirationstrakts. , 2020, , 565-608.		0
1614	Therapy Response Imaging in Thoracic Malignancy. Medical Radiology, 2020, , 79-97.	0.0	0
1615	Facing the First-line in Metastatic Non-small-cell Lung Cancer – Immunotherapy and Chemotherapy. European Oncology and Haematology, 2020, 16, 39.	0.0	0
1617	Neue Arzneimittel 2019. , 2020, , 43-150.		2
1618	Critical Review of EGFR-Mutated NSCLC: What We Do and Do Not Know. Healthbook TIMES Oncology Hematology, 2020, , 20-35.	0.1	3
1619	In search of goldilocks: the quest to optimize combination drug strategies for the management of advanced stage non-small-cell lung cancer. Translational Cancer Research, 2020, 9, 1311-1318.	0.4	0
1620	First-Line Therapy for Metastatic Non-Small Cell Lung Cancer: State-of-the-Art Targeted Therapy and Immunotherapy Approaches. Journal of the Advanced Practitioner in Oncology, 2020, 11, 260-265.	0.2	1
1621	Tumor-Specific and Tumor-Agnostic Molecular Signatures Associated With Response to Immune Checkpoint Inhibitors. JCO Precision Oncology, 2021, 5, 1625-1638.	1.5	10
1622	Tumor PD-L1 and VEGF Expression, and CD8 T Cell Infiltration Predict Clinical Response to Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer. Anticancer Research, 2021, 41, 5469-5475.	0.5	4

#	ARTICLE	IF	CITATIONS
1623	Advances in systemic therapy for non-small cell lung cancer. <i>BMJ, The</i> , 2021, 375, n2363.	3.0	134
1624	Pretreatment Platelet Count and Neutrophil/Lymphocyte Ratio Are Predictive Markers for Carboplatin Plus Pemetrexed Therapy-induced Thrombocytopenia. <i>Anticancer Research</i> , 2021, 41, 5729-5737.	0.5	0
1625	Immunotherapy in the First-Line Setting in Wild-Type NSCLC. <i>Current Oncology</i> , 2021, 28, 4457-4470.	0.9	10
1626	Peritumoral CD90+CD73+ cells possess immunosuppressive features in human non-small cell lung cancer. <i>EBioMedicine</i> , 2021, 73, 103664.	2.7	5
1627	Prophylactic cranial irradiation (PCI), hippocampal avoidance (HA) whole brain radiotherapy (WBRT) and stereotactic radiosurgery (SRS) in small cell lung cancer (SCLC): Where do we stand?. <i>Lung Cancer</i> , 2021, 162, 96-105.	0.9	17
1628	Immunotherapy in Nonsmall Cell Lung Cancer (Basket of Choices). <i>Indian Journal of Medical and Paediatric Oncology</i> , 2020, 41, 587-590.	0.1	0
1629	Combination of Jumentaihoto and chemotherapy improves the prognosis of patients with postoperative recurrence of non-small cell lung cancer. <i>Molecular and Clinical Oncology</i> , 2020, 13, 13.	0.4	5
1630	Sequencing Therapy for Patients With Lung Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 945-948.	2.3	0
1631	Predictive Biomarkers for Immune Checkpoint Inhibitors in Advanced Non-small Cell Lung Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2020, 26, 507-516.	1.0	4
1632	Immunotherapy Use in Patients With Lung Cancer and Comorbidities. <i>Cancer Journal (Sudbury, Mass)</i> , 2020, 26, 525-536.	1.0	12
1634	Advisory Council on combined immunochemotherapy for urothelial cancer. <i>Onkourologiya</i> , 2020, 16, 209-211.	0.1	0
1635	Cytotoxic Chemotherapy in the Era of Immunotherapy for Lung Cancer. <i>Japanese Journal of Lung Cancer</i> , 2020, 60, 913-916.	0.0	0
1636	Immunotherapy induced enterocolitis and gastritis – What to do and when?. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2020, 48-49, 101703.	1.0	8
1641	Overexpression of B7-H3 as an opportunity for targeted therapy in head and neck cancers. <i>American Journal of Translational Research (discontinued)</i> , 2019, 11, 5183-5196.	0.0	6
1644	Infiltration of CD8 FOXP3 T cells, CD8 T cells, and FOXP3 T cells in non-small cell lung cancer microenvironment. <i>International Journal of Clinical and Experimental Pathology</i> , 2020, 13, 880-888.	0.5	11
1645	Novel genetic variants of and involved in immunoregulatory interactions are associated with non-small cell lung cancer survival. <i>American Journal of Cancer Research</i> , 2020, 10, 1770-1784.	1.4	2
1647	4-1BB co-stimulation further enhances anti-PD-1-mediated reinvigoration of exhausted CD39 CD8 T cells from primary and metastatic sites of epithelial ovarian cancers. , 2020, 8, .		7
1650	Immunotherapy in non-small cell lung cancer: Update and new insights. <i>Journal of Clinical and Translational Research</i> , 2021, 7, 1-21.	0.3	16

#	ARTICLE	IF	CITATIONS
1651	Prolonged Complete Response of Early Stage Primary Adenocarcinoma of the Lung to Nivolumab Monotherapy. , 2021, 4, .		0
1653	OUP accepted manuscript. Japanese Journal of Clinical Oncology, 2022, 52, 53-64.	0.6	0
1654	Which treatment after first line therapy in NSCLC patients without genetic alterations in the era of immunotherapy?. Critical Reviews in Oncology/Hematology, 2022, 169, 103538.	2.0	13
1655	Epidermal growth factor receptor exon 20 insertion variants in non-small cell lung cancer patients. Critical Reviews in Oncology/Hematology, 2022, 169, 103536.	2.0	6
1657	Bridging Radiotherapy to Immunotherapy: The IFNâ€“JAKâ€“STAT Axis. International Journal of Molecular Sciences, 2021, 22, 12295.	1.8	13
1658	Combining CTLA-4 and angiopoietin-2 blockade in patients with advanced melanoma: a phase I trial. , 2021, 9, e003318.		7
1660	Role of Immune Checkpoint Inhibitor Therapy in Advanced EGFR-Mutant Non-Small Cell Lung Cancer. Frontiers in Oncology, 2021, 11, 751209.	1.3	10
1661	New challenges in the combination of radiotherapy and immunotherapy in non-small cell lung cancer. World Journal of Clinical Oncology, 2021, 12, 983-999.	0.9	2
1662	Angiogenesis inhibition in lung cancer: emerging novel strategies. Current Opinion in Oncology, 2022, 34, 107-114.	1.1	4
1663	Impact of Value Frameworks on the Magnitude of Clinical Benefit: Evaluating a Decade of Randomized Trials for Systemic Therapy in Solid Malignancies. Current Oncology, 2021, 28, 4894-4928.	0.9	0
1664	Dual immunological blockade in the treatment of metastatic non-small cell lung cancer: reality and perspectives. Journal of Modern Oncology, 2021, 23, 428-435.	0.1	0
1665	Malignant neoplasm of the bronchi and lung: Russian clinical guidelines. Journal of Modern Oncology, 2021, 23, 369-402.	0.1	5
1666	Tailoring maintenance chemotherapy upon response to induction chemotherapy as compared with pemetrexed continuation maintenance in advanced non-squamous NSCLC patients: results of the IFCT-GFPC-1101 multicenter randomized phase III trial. Lung Cancer, 2021, 164, 84-90.	0.9	0
1667	Immune Checkpoint Inhibitors With or Without Bone-Targeted Therapy in NSCLC Patients With Bone Metastases and Prognostic Significance of Neutrophil-to-Lymphocyte Ratio. Frontiers in Immunology, 2021, 12, 697298.	2.2	13
1668	Impact of maintenance therapy following induction immunochemotherapy for untreated advanced non-small cell lung cancer patients. Journal of Cancer Research and Clinical Oncology, 2022, 148, 2985-2994.	1.2	1
1669	Impact of docetaxel plus ramucirumab in a secondâ€“line setting after chemoimmunotherapy in patients with nonâ€“smallâ€“cell lung cancer: A retrospective study. Thoracic Cancer, 2022, 13, 173-181.	0.8	10
1670	Chemotherapy Plus Immunotherapy Versus Chemotherapy Plus Bevacizumab Versus Chemotherapy Alone in EGFR-Mutant NSCLC After Progression on Osimertinib. Clinical Lung Cancer, 2022, 23, e210-e221.	1.1	11
1671	Clinical Outcomes of Chemotherapeutic Molecules as Single and Multiple Agents in Advanced Non-Small-Cell Lung Carcinoma (NSCLC) Patients. Medicina (Lithuania), 2021, 57, 1252.	0.8	5

#	ARTICLE	IF	CITATIONS
1672	Cancer bio-immunotherapy XVII annual NIBIT (Italian Network for Tumor Biotherapy) meeting, October 11-13 2019, Verona, Italy. <i>Cancer Immunology, Immunotherapy</i> , 2021, , 1.	2.0	0
1673	ICI Monotherapy or Combination Therapy in the Treatment of NSCLC: How to Choose Among Multiple Options. <i>Japanese Journal of Lung Cancer</i> , 2021, 61, 847-849.	0.0	0
1674	Discontinuation of immune checkpoint inhibitor (ICI) above 18 months of treatment in real-life patients with advanced non-small cell lung cancer (NSCLC): INTEPI, a multicentric retrospective study. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 1719-1731.	2.0	21
1675	Low peripheral blood derived neutrophil-to-lymphocyte ratio (dNLR) is associated with increased tumor T-cell infiltration and favorable outcomes to first-line pembrolizumab in non-small cell lung cancer. , 2021, 9, e003536.		45
1676	Low Carbohydrate Diets in Cancer Therapeutics: Current Evidence. <i>Frontiers in Nutrition</i> , 2021, 8, 662952.	1.6	2
1677	Immunotherapy in the First-Line Treatment of NSCLC: Current Status and Future Directions in China. <i>Frontiers in Oncology</i> , 2021, 11, 757993.	1.3	23
1678	Efficacy and Safety of Different Doses of Bevacizumab Combined With Pemetrexed and Platinum in First-Line Treatment of Advanced NSCLC: A Retrospective-Real World Study. <i>Frontiers in Pharmacology</i> , 2021, 12, 727102.	1.6	0
1679	CCTG BR34: A Randomized Phase 2 Trial of Durvalumab and Tremelimumab With or Without Platinum-Based Chemotherapy in Patients With Metastatic NSCLC. <i>Journal of Thoracic Oncology</i> , 2022, 17, 434-445.	0.5	21
1680	Weighted Approach for Estimating Effects in Principal Strata with Missing Data for a Categorical Post-Baseline Variable in Randomized Controlled Trials. <i>Statistics in Biopharmaceutical Research</i> , 0, , 1-29.	0.6	5
1681	First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer. <i>Annals of Oncology</i> , 2022, 33, 169-180.	0.6	118
1682	Pushing Past the Blockade: Advancements in T Cell-Based Cancer Immunotherapies. <i>Frontiers in Immunology</i> , 2021, 12, 777073.	2.2	5
1683	Rapidly Progressive Lung Sarcomatoid Carcinoma Managed with Doxorubicin Plus Ifosfamide and Pemetrexed. <i>Case Reports in Oncology</i> , 2021, 14, 1677-1681.	0.3	1
1684	Reprogramming NK cells and macrophages via combined antibody and cytokine therapy primes tumors for elimination by checkpoint blockade. <i>Cell Reports</i> , 2021, 37, 110021.	2.9	21
1685	Phase II Study of the Modified Weekly Nab-paclitaxel Regimen in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2021, 44, 613-618.	0.6	2
1686	Immunotherapy in Non-Small Cell Lung Cancer With Actionable Mutations Other Than EGFR. <i>Frontiers in Oncology</i> , 2021, 11, 750657.	1.3	32
1687	Impact of treatment timing and sequence of immune checkpoint inhibitors and anti-angiogenic agents for advanced non-small cell lung cancer: A systematic review and meta-analysis. <i>Lung Cancer</i> , 2021, 162, 175-184.	0.9	6
1688	Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trials. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 361-369.	1.9	68
1689	Health care resource utilization and costs associated with advanced or metastatic nonsmall cell lung cancer in the United States. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2022, 28, 255-265.	0.5	3

#	ARTICLE	IF	CITATIONS
1690	Tumor metastasis: Mechanistic insights and therapeutic interventions. <i>MedComm</i> , 2021, 2, 587-617.	3.1	42
1691	Real-World Effectiveness and Prognostic Factors Analysis of Stages Iâ€“III Non-Small Cell Lung Cancer Following Neoadjuvant Chemo-Immunotherapy or Neoadjuvant Chemotherapy. <i>Annals of Thoracic and Cardiovascular Surgery</i> , 2022, 28, 111-120.	0.3	9
1692	PD-L1 Expression in Chinese Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): A Multi-Center Retrospective Observational Study. <i>Journal of Cancer</i> , 2021, 12, 7390-7398.	1.2	6
1693	Influence of GSTP1 Polymorphism on the Clinical Outcomes of Patients With Advanced NSCLC Receiving First-Line Bevacizumab-Based Regimen: A Real-World Retrospective Study. <i>Clinical Medicine Insights: Oncology</i> , 2021, 15, 117955492110591.	0.6	0
1694	A Systematic Analysis of Post-Protocol Therapy in First Line Checkpoint Inhibitor Trials. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1695	Immunotherapy in Lung Cancer: Are the Promises of Long-Term Benefit Finally Met?. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1342, 113-142.	0.8	5
1696	Chemotherapy With or Without Bevacizumab Should Be the Standard of Care for First-Line Unresectable Epithelioid Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2022, 17, 34-37.	0.5	6
1697	Immune-related Thyroid Dysfunction (irTD) in Non-small Cell Lung Cancer (NSCLC) Correlates With Response and Survival. <i>Cancer Diagnosis & Prognosis</i> , 2022, 2, 55-63.	0.3	2
1698	Soluble PD-L1 works as a decoy in lung cancer immunotherapy via alternative polyadenylation. <i>JCI Insight</i> , 2022, 7, .	2.3	20
1699	Anti-hypoxia nanosized drug delivery systems improving cancer therapy. <i>Nano Today</i> , 2022, 42, 101376.	6.2	12
1700	First-line immunotherapy in advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an International Expert Panel Meeting by the Italian Association of Thoracic Oncology. <i>ESMO Open</i> , 2022, 7, 100355.	2.0	20
1701	The combination of immune checkpoint inhibitors and chemotherapy in advanced non-small-cell lung cancer: the rational choice. <i>Immunotherapy</i> , 2022, 14, 155-167.	1.0	7
1702	The efficacy and safety of immune checkpoint inhibitors combined with antiangiogenic drugs in renal cell carcinomas: a systematic review and meta-analysis. <i>Translational Cancer Research</i> , 2020, 9, 6780-6791.	0.4	2
1703	Ability of the Glasgow Prognostic Score to predict the tolerability and efficacy of platinum-combination chemotherapy among elderly patients with advanced non-small cell lung cancer. <i>Journal of Medical Investigation</i> , 2021, 68, 260-264.	0.2	2
1704	Study on the Changes of Immune Factors in Different Stages of Non-Small Cell Lung Cancer Chemotherapy. <i>Advances in Lung Cancer (Irvine)</i> , 2021, 10, 57-64.	0.2	0
1705	Immune checkpoint inhibitors in neoadjuvant therapy of non-small cell lung cancer: a systematic review and meta-analysis. <i>Journal of Thoracic Disease</i> , 2022, 14, 333-342.	0.6	8
1706	Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Progress, Challenges, and Prospects. <i>Cells</i> , 2022, 11, 320.	1.8	43
1707	Interactions Between Anti-Angiogenic Therapy and Immunotherapy in Glioblastoma. <i>Frontiers in Oncology</i> , 2021, 11, 812916.	1.3	13

#	ARTICLE	IF	CITATIONS
1708	Pretreatment Fibrinogen-Albumin Ratio (FAR) Associated with Treatment Response and Survival in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Anti-PD-1 Therapy Plus Platinum-Based Combination Chemotherapy. <i>Cancer Management and Research</i> , 2022, Volume 14, 377-386.	0.9	3
1709	Safety and Tolerability of Carboplatin and Paclitaxel in Cancer Patients with HIV (AMC-078), an AIDS Malignancy Consortium (AMC) Study. <i>Oncologist</i> , 2022, 27, 623-e624.	1.9	2
1710	Management of Oligoprogression in Patients with Metastatic NSCLC Harboring ALK Rearrangements. <i>Cancers</i> , 2022, 14, 718.	1.7	5
1711	Immune checkpoint-targeted antibodies: a room for dose and schedule optimization?. <i>Journal of Hematology and Oncology</i> , 2022, 15, 6.	6.9	17
1712	Interrogating the interplay of angiogenesis and immunity in metastatic colorectal cancer. <i>World Journal of Methodology</i> , 2022, 12, 43-53.	1.1	7
1713	Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 1312-1322.	0.8	42
1714	Peripheral neuropathy and headache in cancer patients treated with immunotherapy and immuno-oncology combinations: the MOUSEION-02 study. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2021, 17, 1455-1466.	1.5	7
1715	A phase II, open-label, single-arm trial of carboplatin plus etoposide with bevacizumab and atezolizumab in patients with extended-stage small-cell lung cancer (CeLEBrATE study): background, design and rationale. <i>Future Oncology</i> , 2022, 18, 771-779.	1.1	3
1716	A short-term follow-up CT based radiomics approach to predict response to immunotherapy in advanced non-small-cell lung cancer. <i>Oncolimmunology</i> , 2022, 11, 2028962.	2.1	26
1717	Patient and Caregiver Preferences for First-Line Treatments of Metastatic Non-Small Cell Lung Cancer: A Discrete Choice Experiment. <i>Patient Preference and Adherence</i> , 2022, Volume 16, 123-135.	0.8	2
1718	Combination strategies with PD-1/PD-L1 blockade: current advances and future directions. <i>Molecular Cancer</i> , 2022, 21, 28.	7.9	393
1719	Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier. <i>Cancer Cell International</i> , 2022, 22, 2.	1.8	83
1720	Managing Resistance to Immune Checkpoint Inhibitors in Lung Cancer: Treatment and Novel Strategies. <i>Journal of Clinical Oncology</i> , 2022, 40, 598-610.	0.8	94
1721	Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants. <i>Cancer Discovery</i> , 2022, 12, 924-937.	7.7	110
1722	Complications following novel therapies for non-small cell lung cancer. <i>Journal of Internal Medicine</i> , 2022, 291, 732-754.	2.7	6
1723	Chemotherapy plus single/double immunotherapy in the treatment of non-oncogene addicted advanced non-small cell lung cancer: where do we stand and where are we going?. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 183-189.	1.1	4
1724	Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies. , 2022, 10, e003024.		15
1725	Novel Molecular Determinants of Response or Resistance to Immune Checkpoint Inhibitor Therapies in Melanoma. <i>Frontiers in Immunology</i> , 2021, 12, 798474.	2.2	10

#	ARTICLE	IF	CITATIONS
1726	Inflammatory Thoracic Aortic Aneurysm in a Patient with Advanced Lung Adenocarcinoma Treated with Pembrolizumab. <i>Internal Medicine</i> , 2022, 61, 2339-2341.	0.3	4
1727	Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade. <i>Frontiers in Immunology</i> , 2021, 12, 799455.	2.2	76
1728	Cancer cell-expressed BTNL2 facilitates tumour immune escape via engagement with IL-17A-producing $\gamma\delta$ T cells. <i>Nature Communications</i> , 2022, 13, 231.	5.8	14
1729	Risk factors for pneumonitis in patients with non-small cell lung cancer treated with immune checkpoint inhibitors plus chemotherapy: A retrospective analysis. <i>Thoracic Cancer</i> , 2022, 13, 724-731.	0.8	10
1730	Predictable Clinical Benefits without Evidence of Synergy in Trials of Combination Therapies with Immune-Checkpoint Inhibitors. <i>Clinical Cancer Research</i> , 2022, 28, 368-377.	3.2	40
1731	First-line osimertinib treatment in a patient with lung adenocarcinoma with coexisting epidermal growth factor receptor G719S and de novo T790M mutations. <i>Thoracic Cancer</i> , 2022, 13, 771-774.	0.8	3
1732	Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations. <i>Journal of Clinical Oncology</i> , 2022, 40, 611-625.	0.8	242
1733	A case of PD-L1 negative advanced pulmonary sarcomatoid carcinoma effectively treated with atezolizumab, carboplatin, paclitaxel, and bevacizumab. <i>Respiratory Medicine Case Reports</i> , 2022, 36, 101579.	0.2	0
1734	Tumors resurrect an embryonic vascular program to escape immunity. <i>Science Immunology</i> , 2022, 7, eabm6388.	5.6	27
1735	Efficacy and safety of ramucirumab and docetaxel in previously treated patients with squamous cell lung cancer: a multicenter retrospective cohort study. <i>Investigational New Drugs</i> , 2022, 40, 634-642.	1.2	8
1736	Safety Related to the Timing of Radiotherapy and Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer: A Single Institutional Experience. <i>Current Oncology</i> , 2022, 29, 221-230.	0.9	2
1737	Thymic Polypeptide Fraction Biomodulina T Decreases Exhausted and Terminally Differentiated EMRA T Cells in Advanced Lung Cancer Patients Treated With Platinum-Based Chemotherapy. <i>Frontiers in Oncology</i> , 2022, 12, 823287.	1.3	4
1738	Bevacizumab's Association With a Decreased Risk of Brain Metastases in ECOG-ACRIN E1505, a Phase 3 Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab in Surgically Resected NSCLC. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100274.	0.6	1
1739	Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase Fusion-Positive Lung Cancers. <i>JCO Precision Oncology</i> , 2022, 6, e2100418.	1.5	29
1740	Squamous cell carcinoma of the lung: improving the detection and management of immune-related adverse events. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 203-213.	1.1	4
1741	Cost-effectiveness of immune checkpoint inhibitors in the treatment of non-small-cell lung cancer as a second line in Taiwan. <i>Future Oncology</i> , 2022, , .	1.1	1
1742	Addition of immune checkpoint inhibitors to chemotherapy versus chemotherapy alone in first-line metastatic triple-negative breast cancer: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2022, 104, 102352.	3.4	17
1743	Phase II study of atezolizumab with bevacizumab for non-squamous non-small cell lung cancer with high PD-L1 expression (@Be Study). , 2022, 10, e004025.		22

#	ARTICLE	IF	CITATIONS
1744	Chemoimmunotherapy for EGFR-Mutant NSCLC: Still No Clear Answer. <i>Journal of Thoracic Oncology</i> , 2022, 17, 179-181.	0.5	5
1745	Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial. <i>Lancet Oncology</i> , The, 2022, 23, 279-291.	5.1	118
1746	Survival outcomes of alternate dosing schedule of pemetrexed as maintenance therapy in NSCLC: Single institution experience. <i>Lung Cancer</i> , 2022, 165, 49-53.	0.9	2
1747	ALK fusion variant 3a/b, concomitant mutations, and high PD-L1 expression were associated with unfavorable clinical response to second-generation ALK TKIs in patients with advanced ALK-rearranged non-small cell lung cancer (GASTO 1061). <i>Lung Cancer</i> , 2022, 165, 54-62.	0.9	6
1748	Role and impact of immune checkpoint inhibitors in neoadjuvant treatment for NSCLC. <i>Cancer Treatment Reviews</i> , 2022, 104, 102350.	3.4	18
1749	The immune modifying effects of chemotherapy and advances in chemo-immunotherapy. , 2022, 236, 108111.		25
1750	Immunotherapy resistance of lung cancer. <i>Cancer Drug Resistance (Alhambra, Calif)</i> , 2022, 5, 114-128.	0.9	0
1751	Association of Personal Characteristics and Effectiveness of Immunotherapy in Late-Stage Non-Small Cell Lung Cancer: A Systematic Review. <i>JNCI Cancer Spectrum</i> , 2022, 6, .	1.4	1
1752	Disrupting cancer angiogenesis and immune checkpoint networks for improved tumor immunity. <i>Seminars in Cancer Biology</i> , 2022, 86, 981-996.	4.3	15
1753	First-Line Treatment of Advanced Non-Small-Cell Lung Cancer with Immune-Checkpoint Inhibitors: New Combinations and Long-Term Data. <i>BioDrugs</i> , 2022, 36, 137-151.	2.2	6
1754	Immunotherapy in Lung Cancer: Current Landscape and Future Directions. <i>Frontiers in Immunology</i> , 2022, 13, 823618.	2.2	105
1755	Prognostic Nutritional Index and Lung Immune Prognostic Index as Prognostic Predictors for Combination Therapies of Immune Checkpoint Inhibitors and Cytotoxic Anticancer Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer. <i>Diagnostics</i> , 2022, 12, 423.	1.3	17
1756	Current therapy and development of therapeutic agents for lung cancer. , 2022, 1, 100015.		8
1757	Generalizability of immune checkpoint inhibitor trials to real-world patients with advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2022, 166, 40-48.	0.9	7
1758	The role of PET molecular imaging in immune checkpoint inhibitor therapy in lung cancer: Precision medicine and visual monitoring. <i>European Journal of Radiology</i> , 2022, 149, 110200.	1.2	5
1759	4-1BB co-stimulation further enhances anti-PD-1-mediated reinvigoration of exhausted CD39 ⁺ CD8 T cells from primary and metastatic sites of epithelial ovarian cancers. , 2020, 8, e001650.		35
1761	Identification of drug combinations for lung cancer patients whose tumors are unresponsive to targeted therapy: clinical bases and future directions. <i>Expert Review of Precision Medicine and Drug Development</i> , 2022, 7, 29-38.	0.4	0
1762	Immune Checkpoint Inhibitors in 10 Years: Contribution of Basic Research and Clinical Application in Cancer Immunotherapy. <i>Immune Network</i> , 2022, 22, e2.	1.6	53

#	ARTICLE	IF	CITATIONS
1763	Research progress in immunotherapy of NSCLC with EGFR sensitive mutations. <i>Oncology Research</i> , 2022, , .	0.6	0
1765	Patient-derived functional organoids as a personalized approach for drug screening against hepatobiliary cancers. <i>Advances in Cancer Research</i> , 2022, , 319-341.	1.9	2
1766	Neurological complications of lung cancer. , 2022, , 243-276.		0
1767	Safety and Efficacy of Nivolumab Plus Bevacizumab, Paclitaxel for HER2-Negative Metastatic Breast Cancer: Primary Result and Biomarker Data of a Phase 2 Trial. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1768	C-MET Inhibitors as New Members of the NSCLC Treatment Armamentariumâ€”A Pooled Analysis. <i>Advances in Lung Cancer (Irvine)</i> , 2022, 11, 1-13.	0.2	0
1769	Atezolizumab-induced Encephalitis in a Patient with Hepatocellular Carcinoma: A Case Report and Literature Review. <i>Internal Medicine</i> , 2022, , .	0.3	4
1770	The Research Progress of Antiangiogenic Therapy, Immune Therapy and Tumor Microenvironment. <i>Frontiers in Immunology</i> , 2022, 13, 802846.	2.2	44
1771	PD-L1 expression as a prognostic marker in patients treated with chemotherapy for metastatic non-small-cell lung cancer. <i>Future Oncology</i> , 2022, 18, 1793-1799.	1.1	6
1772	Brain metastases, patterns of intracranial progression, and the clinical value of upfront cranial radiotherapy in patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors. <i>Translational Lung Cancer Research</i> , 2022, 11, 173-187.	1.3	6
1773	Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cellâ€™Mediated Antitumor Immune Responses. <i>Cancer Immunology Research</i> , 2022, 10, 420-436.	1.6	17
1774	Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma. , 2022, 10, e003026.		38
1775	Triple Negative Breast Cancer: Updates on Classification and Treatment in 2021. <i>Cancers</i> , 2022, 14, 1253.	1.7	69
1776	Safety and efficacy of nivolumab plus recombinant human endostatin in previously treated advanced non-small-cell lung cancer. <i>Translational Lung Cancer Research</i> , 2022, 11, 201-212.	1.3	10
1777	First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in advanced non-small cell lung cancer: a subanalysis of Asian patients in CheckMate 9LA. <i>International Journal of Clinical Oncology</i> , 2022, 27, 695-706.	1.0	11
1778	First-line Afatinib in Patients With Non-small-cell Lung Cancer With Uncommon EGFR Mutations in South Korea. <i>Anticancer Research</i> , 2022, 42, 1615-1622.	0.5	4
1779	Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 819-831.	1.2	14
1780	Efficacy of Atezolizumab in Patients With Advanced NSCLC Receiving Concomitant Antibiotic or Proton Pump Inhibitor Treatment: Pooled Analysis of Five Randomized Control Trials. <i>Journal of Thoracic Oncology</i> , 2022, 17, 758-767.	0.5	22
1781	Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small-cell lung cancer (Nsq-NSCLC) with PD-L1-high expression using real-world data. <i>Annals of Oncology</i> , 2022, 33, 511-521.	0.6	36

#	ARTICLE	IF	CITATIONS
1782	Murine fecal microbiota transfer models selectively colonize human microbes and reveal transcriptional programs associated with response to neoadjuvant checkpoint inhibitors. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 2405-2420.	2.0	10
1783	Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial. , 2022, 10, e003027.		45
1784	Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer. <i>JAMA Network Open</i> , 2022, 5, e2149040.	2.8	48
1785	Cancer immunotherapy by immune checkpoint blockade and its advanced application using bio-nanomaterials. <i>Seminars in Cancer Biology</i> , 2022, 86, 909-922.	4.3	26
1786	Penpulimab, an anti-PD1 IgG1 antibody in the treatment of advanced or metastatic upper gastrointestinal cancers. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 2371-2379.	2.0	4
1787	Reduced FEV1 as Prognostic Factors in Patients With Advanced NSCLC Receiving Immune Checkpoint Inhibitors. <i>Frontiers in Medicine</i> , 2022, 9, 860733.	1.2	2
1788	Protein-Protein Binding Free Energy Predictions with the MM/PBSA Approach Complemented with the Gaussian-Based Method for Entropy Estimation. <i>ACS Omega</i> , 2022, 7, 11057-11067.	1.6	9
1789	Graded Prognostic Assessment (GPA) for Patients With Lung Cancer and Brain Metastases: Initial Report of the Small Cell Lung Cancer GPA and Update of the Non-Small Cell Lung Cancer GPA Including the Effect of Programmed Death Ligand 1 and Other Prognostic Factors. <i>International Journal of Radiation Oncology Biology Physics</i> . 2022. 114. 60-74.	0.4	33
1790	Efficacy of platinum agents for stage III non-small-cell lung cancer following platinum-based chemoradiotherapy: a retrospective study. <i>BMC Cancer</i> , 2022, 22, 342.	1.1	2
1791	Revolutionization in Cancer Therapeutics via Targeting Major Immune Checkpoints PD-1, PD-L1 and CTLA-4. <i>Pharmaceuticals</i> , 2022, 15, 335.	1.7	35
1792	High Intensity Aerobic exercise training and Immune cell Mobilization in patients with lung cancer (HI) Tj ETQq0 0 0 rBT /Overlock 10 T	1.1	10
1793	Multifunctional Lipid Bilayer Nanocarriers for Cancer Immunotherapy in Heterogeneous Tumor Microenvironments, Combining Immunogenic Cell Death Stimuli with Immune Modulatory Drugs. <i>ACS Nano</i> , 2022, 16, 5184-5232.	7.3	32
1794	Partial Response After Toripalimab Plus Anlotinib for Advanced Metaplastic Breast Carcinoma: A Case Report. <i>Frontiers in Endocrinology</i> , 2022, 13, 810747.	1.5	4
1795	The role of long non-coding RNAs in angiogenesis and anti-angiogenic therapy resistance in cancer. <i>Molecular Therapy - Nucleic Acids</i> , 2022, 28, 397-407.	2.3	14
1796	Characterization of Somatic Mutations That Affect Neoantigens in Non-Small Cell Lung Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 749461.	2.2	11
1797	Combined Immunotherapy with Chemotherapy versus Bevacizumab with Chemotherapy in First-Line Treatment of Driver-Gene-Negative Non-Squamous Non-Small Cell Lung Cancer: An Updated Systematic Review and Network Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2022, 11, 1655.	1.0	6
1798	Evaluating management of progressive disease for control arm patients in trials of first line PD-1 or PD-L1 inhibitor-based treatment for metastatic solid tumours. <i>European Journal of Cancer</i> , 2022, 164, 95-104.	1.3	0
1799	Trends in treatment patterns and survival outcomes in advanced non-small cell lung cancer: a Canadian population-based real-world analysis. <i>BMC Cancer</i> , 2022, 22, 255.	1.1	11

#	ARTICLE	IF	CITATIONS
1800	Anti-drug antibodies in the current management of cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 89, 577-584.	1.1	2
1801	Applications of Circulating Tumor DNA in Immune Checkpoint Inhibition: Emerging Roles and Future Perspectives. <i>Frontiers in Oncology</i> , 2022, 12, 836891.	1.3	5
1802	Pan-Cancer Analyses Confirmed the Ferroptosis-Related Gene SLC7A11 as a Prognostic Biomarker for Cancer. <i>International Journal of General Medicine</i> , 2022, Volume 15, 2501-2513.	0.8	10
1803	Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer. <i>Cancer Cell</i> , 2022, 40, 289-300.e4.	7.7	148
1804	Clinical and economic impact of “ROS1-testing” strategy compared to a “no-ROS1-testing” strategy in advanced NSCLC in Spain. <i>BMC Cancer</i> , 2022, 22, 292.	1.1	2
1805	Predictive biomarkers of response to immune checkpoint inhibitors in hepatocellular carcinoma. <i>Expert Review of Molecular Diagnostics</i> , 2022, 22, 253-264.	1.5	20
1806	Camrelizumab Plus Apatinib in Treatment-Naive Patients With Advanced Nonsquamous NSCLC: A Multicenter, Open-Label, Single-Arm, Phase 2 Trial. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100312.	0.6	7
1807	Advanced Biomaterials for Cell-Specific Modulation and Restore of Cancer Immunotherapy. <i>Advanced Science</i> , 2022, 9, e2200027.	5.6	26
1808	Predictive Markers for Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer. <i>Journal of Clinical Medicine</i> , 2022, 11, 1855.	1.0	11
1809	Generalizability of ORIENT-11 trial results to a US standard of care cohort with advanced non-small-cell lung cancer. <i>Future Oncology</i> , 2022, , .	1.1	2
1810	Risk of Immune-Related Pneumonitis with PD-1/PD-L1 Inhibitors in Different Cancer Types and Treatment Regimens: A Systematic Review and Meta-Analysis of 22 Randomized Controlled Trials. <i>Chemotherapy</i> , 2023, 68, 1-15.	0.8	0
1811	Safety of salvage lung resection after immunotherapy for unresectable non-small cell lung cancer. <i>General Thoracic and Cardiovascular Surgery</i> , 2022, 70, 812-817.	0.4	10
1812	Rethinking the Status of Chemotherapy Combined With the Addition of Cytotoxic T-Lymphocyte-Associated Antigen 4 Inhibition and Programmed Death 1 or Programmed Death-Ligand 1 Blockade. <i>Journal of Thoracic Oncology</i> , 2022, 17, 341-344.	0.5	0
1813	Case Report: Neuromyelitis Optica After Treatment of Uveal Melanoma With Nivolumab and Ipilimumab. <i>Frontiers in Oncology</i> , 2022, 12, 806501.	1.3	10
1814	Durvalumab as Consolidation Therapy in Post-Multimodal Interventional Treatment for Patients with Advanced Solid Tumors: A Preliminary Study. <i>Journal of Oncology</i> , 2022, 2022, 1-10.	0.6	0
1815	¹²⁴ I-Labeled Monoclonal Antibody and Fragment for the Noninvasive Evaluation of Tumor PD-L1 Expression <i>In Vivo</i> . <i>Molecular Pharmaceutics</i> , 2022, 19, 3551-3562.	2.3	11
1816	Interest of the Addition of Taxanes to Standard Treatment in First-Line Advanced HER2 Positive Gastroesophageal Adenocarcinoma in Selective Patients. <i>Frontiers in Oncology</i> , 2022, 12, 763926.	1.3	0
1817	Immunotherapy-based combination strategies for treatment of EGFR-TKI-resistant non-small-cell lung cancer. <i>Future Oncology</i> , 2022, 18, 1757-1775.	1.1	14

#	ARTICLE	IF	CITATIONS
1818	Metastasis prevention: targeting causes and roots. <i>Clinical and Experimental Metastasis</i> , 2022, 39, 505-519.	1.7	8
1819	Can Previous Chemotherapy Affect the Outcome of Nivolumab Treatment in Non-small Cell Lung Cancer?. <i>Anticancer Research</i> , 2022, 42, 1987-1995.	0.5	2
1820	Inferring gene expression from cell-free DNA fragmentation profiles. <i>Nature Biotechnology</i> , 2022, 40, 585-597.	9.4	63
1821	Combined angiogenesis and PD-1 inhibition for immunomodulatory TNBC: concept exploration and biomarker analysis in the FUTURE-C-Plus trial. <i>Molecular Cancer</i> , 2022, 21, 84.	7.9	34
1822	What Is Long-Term Survival and Which First-Line Immunotherapy Brings Long-Term Survival for Advanced Wild-Type Non-Small Cell Lung Cancer: A Network Meta-Analysis Based on Integrated Analysis. <i>Frontiers in Immunology</i> , 2022, 13, 764643.	2.2	3
1823	Bone metastasis attenuates efficacy of immune checkpoint inhibitors and displays "cold" immune characteristics in Non-small cell lung cancer. <i>Lung Cancer</i> , 2022, 166, 189-196.	0.9	10
1824	Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons. <i>Cell Communication and Signaling</i> , 2022, 20, 44.	2.7	109
1825	The impact of a pathologist's personality on the interobserver variability and diagnostic accuracy of predictive PD-L1 immunohistochemistry in lung cancer. <i>Lung Cancer</i> , 2022, 166, 143-149.	0.9	12
1826	Organoid Models for Precision Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2022, 13, 770465.	2.2	23
1827	Circulating Immune Cell and Outcome Analysis from the Phase II Study of PD-L1 Blockade with Durvalumab for Newly Diagnosed and Recurrent Glioblastoma. <i>Clinical Cancer Research</i> , 2022, 28, 2567-2578.	3.2	20
1828	Imaging immunity in patients with cancer using positron emission tomography. <i>Npj Precision Oncology</i> , 2022, 6, 24.	2.3	13
1829	Allelic variation in HLA-DRB1 is associated with development of antibodies in cancer patients treated with atezolizumab that are neutralizing in vitro. <i>Clinical and Translational Science</i> , 2022, 15, 1393-1399.	1.5	6
1830	Dermatological adverse events associated with immune checkpoint inhibitor-based combinations of anticancer therapies: a systematic review. <i>Immunotherapy</i> , 2022, 14, 489-503.	1.0	1
1831	Non-Invasive Measurement Using Deep Learning Algorithm Based on Multi-Source Features Fusion to Predict PD-L1 Expression and Survival in NSCLC. <i>Frontiers in Immunology</i> , 2022, 13, 828560.	2.2	18
1832	Biomarkers of systemic inflammation predict survival with first-line immune checkpoint inhibitors in non-small-cell lung cancer. <i>ESMO Open</i> , 2022, 7, 100445.	2.0	26
1833	Survival after recurrence following surgical resected non-small cell lung cancer: A multicenter, prospective cohort study. <i>JTCVS Open</i> , 2022, 10, 370-381.	0.2	6
1834	Casticin and chrysosplenol D from <i>Artemisia annua</i> L. induce apoptosis by inhibiting topoisomerase II β in human non-small-cell lung cancer cells. <i>Phytomedicine</i> , 2022, 100, 154095.	2.3	9
1835	Immunotherapy in Patients with Advanced Non-Small Cell Lung Cancer Lacking Driver Mutations and Future Perspectives. <i>Cancers</i> , 2022, 14, 122.	1.7	16

#	ARTICLE	IF	CITATIONS
1836	Current Immunotherapeutic Strategies Targeting the PD-1/PD-L1 Axis in Non-Small Cell Lung Cancer with Oncogenic Driver Mutations. <i>International Journal of Molecular Sciences</i> , 2022, 23, 245.	1.8	6
1837	Sex-Based Clinical Outcome in Advanced NSCLC Patients Undergoing PD-1/PD-L1 Inhibitor Therapy—A Retrospective Bi-Centric Cohort Study. <i>Cancers</i> , 2022, 14, 93.	1.7	7
1838	Correlations between peripheral blood biomarkers and clinical outcomes in advanced non-small cell lung cancer patients who received immunotherapy-based treatments. <i>Translational Lung Cancer Research</i> , 2021, 10, 4477-4493.	1.3	14
1839	Patient-Derived Explants as a Precision Medicine Patient-Proximal Testing Platform Informing Cancer Management. <i>Frontiers in Oncology</i> , 2021, 11, 767697.	1.3	18
1840	Phase Ib Study of Atezolizumab Plus Interferon- γ with or without Bevacizumab in Patients with Metastatic Renal Cell Carcinoma and Other Solid Tumors. <i>Current Oncology</i> , 2021, 28, 5466-5479.	0.9	2
1841	What is the current role of immunotherapy in EGFR mutant advanced NSCLC?. <i>Lung Cancer</i> , 2021, , .	0.9	0
1842	Therapeutic advances in non-small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy. <i>MedComm</i> , 2021, 2, 692-729.	3.1	38
1843	Cost-Effectiveness of Nivolumab Plus Ipilimumab With and Without Chemotherapy for Advanced Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 760686.	1.3	8
1844	First-Line Pembrolizumab Mono- or Combination Therapy of Non-Small Cell Lung Cancer: Baseline Metabolic Biomarkers Predict Outcomes. <i>Cancers</i> , 2021, 13, 6096.	1.7	14
1845	A cascade targeting strategy based on modified bacterial vesicles for enhancing cancer immunotherapy. <i>Journal of Nanobiotechnology</i> , 2021, 19, 434.	4.2	8
1846	Pembrolizumab monotherapy versus pembrolizumab plus chemotherapy in patients with non-small cell lung cancer: A multicenter retrospective trial. <i>Thoracic Cancer</i> , 2022, 13, 228-235.	0.8	7
1847	Anti-VEGF antibody triggers the effect of anti-PD-L1 antibody in PD-L1 ^{low} and immune desert-like mouse tumors. <i>Oncology Reports</i> , 2021, 47, .	1.2	10
1848	Immunotherapy in non-small cell lung cancer: rationale, recent advances and future perspectives. <i>Precision Clinical Medicine</i> , 2021, 4, 258-270.	1.3	18
1849	Immune checkpoint inhibitor-related adverse events in lung cancer: Real-world incidence and management practices of 1905 patients in China. <i>Thoracic Cancer</i> , 2022, 13, 412-422.	0.8	19
1851	Cost-Effectiveness Analysis of Camrelizumab Plus Chemotherapy vs. Chemotherapy Alone as the First-Line Treatment in Patients With III-B-IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Without EGFR and ALK Alteration from a Perspective of Health - Care System in China. <i>Frontiers in Pharmacology</i> , 2021, 12, 735536.	1.6	18
1852	Assessment of Treatment Effects and Long-term Benefits in Immune Checkpoint Inhibitor Trials Using the Flexible Parametric Cure Model. <i>JAMA Network Open</i> , 2021, 4, e2139573.	2.8	8
1853	Electrolyte Abnormalities Associated With The Use of Atezolizumab – A Systematic Review. <i>Journal of Community Hospital Internal Medicine Perspectives</i> , 2022, 12, 35-44.	0.4	1
1854	PD-1/PD-L1 Inhibitor-Associated Myocarditis: Epidemiology, Characteristics, Diagnosis, Treatment, and Potential Mechanism. <i>Frontiers in Pharmacology</i> , 2022, 13, 835510.	1.6	10

#	ARTICLE	IF	CITATIONS
1855	The Role of Myeloid Cells in Hepatotoxicity Related to Cancer Immunotherapy. <i>Cancers</i> , 2022, 14, 1913.	1.7	7
1856	Effectiveness and Safety of Neoadjuvant Immunotherapy Combined with Chemotherapy in Resectable Non-Small Cell Lung Cancer: A Meta-Analysis. <i>Indian Journal of Surgery</i> , 0, , 1.	0.2	0
1857	Clinical efficacy and safety of pemetrexed with or without either Bevacizumab or Pembrolizumab in patients with metastatic nonsquamous non-small cell carcinoma. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2022, , .	0.7	0
1858	The use of immunotherapy in older patients with advanced non-small cell lung cancer. <i>Cancer Treatment Reviews</i> , 2022, 106, 102394.	3.4	16
1859	Pharmacological ascorbate improves the response to platinum-based chemotherapy in advanced stage non-small cell lung cancer. <i>Redox Biology</i> , 2022, 53, 102318.	3.9	8
1860	The efficacy and safety of immune checkpoint inhibitor plus chemotherapy in patients with advanced non-small-cell lung cancer: a meta-analysis. <i>Investigational New Drugs</i> , 2022, 40, 810-817.	1.2	5
1861	Organ-specific metastatic landscape dissects PD-(L)1 blockade efficacy in advanced non-small cell lung cancer: applicability from clinical trials to real-world practice. <i>BMC Medicine</i> , 2022, 20, 120.	2.3	5
1862	Bevacizumab Plus Atezolizumab After Progression on Atezolizumab Monotherapy in Pretreated Patients With NSCLC: An Open-Label, Two-Stage, Phase 2 Trial. <i>Journal of Thoracic Oncology</i> , 2022, 17, 900-908.	0.5	23
1863	Frailty and checkpoint inhibitor toxicity in older patients with melanoma. <i>Cancer</i> , 2022, 128, 2746-2752.	2.0	12
1864	Hyperprogression, a challenge of PD-1/PD-L1 inhibitors treatments: potential mechanisms and coping strategies. <i>Biomedicine and Pharmacotherapy</i> , 2022, 150, 112949.	2.5	6
1907	Incidence of hepatotoxicity associated with addition of immune checkpoint blockade to systemic solid tumor therapy: a meta-analysis of phase 3 randomized controlled trials. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 2837-2848.	2.0	5
1908	Surufatinib plus toripalimab in patients with advanced solid tumors: a single-arm, open-label, phase 1 trial. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 779-789.	1.2	10
1909	Anti-angiogenesis revisited: reshaping the treatment landscape of advanced non-small cell lung cancer. <i>Archives of Pharmacal Research</i> , 2022, 45, 263-279.	2.7	11
1910	IOLite: phase 1b trial of doublet/triplet combinations of dostarlimab with niraparib, carboplatin and paclitaxel, with or without bevacizumab in patients with advanced cancer. , 2022, 10, e003924.		8
1911	Research progress in immune checkpoint inhibitors in the treatment of oncogenedriven advanced nonsmall cell lung cancer. <i>Journal of Central South University (Medical Sciences)</i> , 2020, 45, 418-425.	0.1	0
1923	Microscale thermophoresis analysis of the molecular interaction between small nuclear ribonucleoprotein polypeptide G and the RING finger domain of RBBP6 towards anti-cancer drug discovery.. <i>American Journal of Translational Research (discontinued)</i> , 2021, 13, 12775-12785.	0.0	0
1924	Expression and Prognostic Significance of c-Myc, ALK, ROS1, BRAF, and PD-L1 Among Patients With Non-Small Cell Lung Cancer. <i>Clinical Medicine Insights: Oncology</i> , 2022, 16, 117955492210927.	0.6	1
1925	Phase 2 study of first-line pembrolizumab monotherapy in elderly patients with non-small cell lung cancer expressing high <sc>PD-L1</sc>. <i>Thoracic Cancer</i> , 2022, 13, 1611-1618.	0.8	4

#	ARTICLE	IF	CITATIONS
1926	CDC25C as a Predictive Biomarker for Immune Checkpoint Inhibitors in Patients With Lung Adenocarcinoma. <i>Frontiers in Oncology</i> , 2022, 12, 867788.	1.3	3
1927	Effect and outcomes analysis of anlotinib in non-small cell lung cancer patients with liver metastasis: results from the ALTER 0303 phase 3 randomized clinical trial. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 1417-1424.	1.2	4
1928	Efficacy of Immune Checkpoint Inhibitors in SMARCA4-Deficient Thoracic Tumor. <i>Clinical Lung Cancer</i> , 2022, 23, 386-392.	1.1	15
1929	Atezolizumab in the first-line treatment of metastatic non-small cell lung cancer. Clinical experience of the drug application. Case report. <i>Journal of Modern Oncology</i> , 2022, 24, 50-60.	0.1	0
1930	Targeting nucleotide metabolism: a promising approach to enhance cancer immunotherapy. <i>Journal of Hematology and Oncology</i> , 2022, 15, 45.	6.9	43
1931	Understanding the lived experience of lung cancer: a European social media listening study. <i>BMC Cancer</i> , 2022, 22, 475.	1.1	8
1932	Overcoming Immune Resistance With Radiation Therapy in Prostate Cancer. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	5
1933	Treatment-Related Adverse Events of Combination EGFR Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor in EGFR-Mutant Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2022, 14, 2157.	1.7	7
1936	Optimal Therapy Design With Tumor Microenvironment Normalization. <i>AICHE Journal</i> , 0, , .	1.8	1
1937	Real-World longitudinal practice patterns in the use of PD-1 and PD-L1 inhibitors as First-Line therapy in patients with Non-Small cell lung cancer in the United States. <i>Cancer Medicine</i> , 2022, , .	1.3	2
1938	A Somatic Mutation Signature Predicts the Best Overall Response to Anti-programmed Cell Death Protein-1 Treatment in Epidermal Growth Factor Receptor/Anaplastic Lymphoma Kinase-Negative Non-squamous Non-small Cell Lung Cancer. <i>Frontiers in Medicine</i> , 2022, 9, 808378.	1.2	5
1939	Replication of Overall Survival, Progression-Free Survival, and Overall Response in Chemotherapy Arms of Non-Small Cell Lung Cancer Trials Using Real-World Data. <i>Clinical Cancer Research</i> , 2022, 28, 2844-2853.	3.2	8
1940	Development of a Clinically Oriented Model to Predict Antitumor Effects after PD-1/PD-L1 Inhibitor Therapy. <i>Journal of Oncology</i> , 2022, 2022, 1-11.	0.6	2
1941	Long-term survival of patients with non-small cell lung cancer treated with immune checkpoint inhibitor monotherapy in real-world settings. <i>Clinical Lung Cancer</i> , 2022, , .	1.1	7
1942	Liquid Biopsy and Non-small-cell Lung Cancer: Expecting More Fluid Management of Patients. <i>Current Pharmaceutical Biotechnology</i> , 2022, 23, .	0.9	0
1943	Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 499-514.	12.5	140
1944	Rheumatic immune-and nonimmune-related adverse events in phase 3 clinical trials assessing PD-(L)1 checkpoint inhibitors for lung cancer: A systematic review and meta-analysis. <i>Joint Bone Spine</i> , 2022, 89, 105403.	0.8	1
1945	Activin-A, Growth Differentiation Factor-11 and Transforming Growth Factor- β 2 as predictive biomarkers for platinum chemotherapy in advanced non-small cell lung cancer. <i>Cancer Treatment and Research Communications</i> , 2022, 32, 100576.	0.7	1

#	ARTICLE	IF	CITATIONS
1946	Can Natural Products be Used to Overcome the Limitations of Colorectal Cancer Immunotherapy?. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	1
1947	Association between bevacizumab with cancer drug therapies and drug-induced interstitial lung disease in patients with solid tumor: A systematic review and meta-analysis of randomized clinical trials. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 174, 103703.	2.0	2
1948	PCR-based analysis of PD-L1 RNA expression in lung cancer: comparison with commonly used immunohistochemical assays. <i>Annals of Diagnostic Pathology</i> , 2022, 59, 151968.	0.6	5
1949	Tumor Growth Inhibition-Overall Survival (TGI-OS) Model for Subgroup Analysis Based on Post-Randomization Factors: Application for Anti-drug Antibody (ADA) Subgroup Analysis of Atezolizumab in the IMpower150 Study. <i>AAPS Journal</i> , 2022, 24, 58.	2.2	2
1950	Different In Situ Immune Patterns between Primary Tumor and Lymph Node in Non-Small-Cell Lung Cancer: Potential Impact on Neoadjuvant Immunotherapy. <i>Journal of Immunology Research</i> , 2022, 2022, 1-14.	0.9	2
1951	Atezolizumab plus carboplatin and nabâ€paclitaxel versus carboplatin and nabâ€paclitaxel as treatments for Chinese, treatmentâ€naÃve, stage IV, nonâ€squamous, nonâ€smallâ€cell lung cancer patients: A retrospective analysis. <i>Pharmacology Research and Perspectives</i> , 2022, 10, e00941.	1.1	1
1953	The roles of TGF-Î² and VEGF pathways in the suppression of antitumor immunity in melanoma and other solid tumors. , 2022, 240, 108211.		21
1954	Incidence of fatigue associated with immune checkpoint inhibitors in patients with cancer: a meta-analysis. <i>ESMO Open</i> , 2022, 7, 100474.	2.0	3
1955	Combination Immunotherapy in the First-line Setting for Non-small-cell Lung Cancer. <i>Japanese Journal of Lung Cancer</i> , 2022, 62, 75-80.	0.0	0
1956	Combined application of bevacizumab and PD-1 blockade displays durable treatment effects by increasing the infiltration and cytotoxic function of CD8⁺T cells in lung cancer. <i>Immunotherapy</i> , 2022, 14, 695-708.	1.0	7
1957	The Strategies and Mechanisms of Immune Checkpoint Inhibitors for Brain Metastases in NSCLC. <i>Frontiers in Pharmacology</i> , 2022, 13, .	1.6	3
1958	Oncological Treatment-Related Fatigue in Oncogeriatrics: A Scoping Review. <i>Cancers</i> , 2022, 14, 2470.	1.7	4
1959	A prognostic model using the neutrophil-albumin ratio and PG-SGA to predict overall survival in advanced palliative lung cancer. <i>BMC Palliative Care</i> , 2022, 21, 81.	0.8	5
1960	Safety and Efficacy of Dostarlimab in Patients With Recurrent/Advanced Nonâ€small Cell Lung Cancer: Results from Cohort E of the Phase I GARNET Trial. <i>Clinical Lung Cancer</i> , 2022, 23, e415-e427.	1.1	7
1961	Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: Focus on novel therapies. <i>Lung Cancer</i> , 2022, 170, 41-51.	0.9	33
1962	Firstâ€line immunotherapy or angiogenesis inhibitor combined with chemotherapy for advanced nonâ€small cell lung cancer with <i>EGFR</i> exon 20 insertions: Realâ€world evidence from China. <i>Cancer Medicine</i> , 2023, 12, 335-344.	1.3	5
1963	Treatment Strategies for Non-Small Cell Lung Cancer Harboring Common and Uncommon EGFR Mutations: Drug Sensitivity Based on Exon Classification, and Structure-Function Analysis. <i>Cancers</i> , 2022, 14, 2519.	1.7	8
1964	A phase II clinical trial of combination nivolumab, ipilimumab, and paclitaxel in patients with untreated metastatic non-small cell lung cancer: The OPTIMAL Trial. <i>JTO Clinical and Research Reports</i> , 2022, , 100337.	0.6	0

#	ARTICLE	IF	CITATIONS
1965	Clinically approved combination immunotherapy: Current status, limitations, and future perspective. <i>Current Research in Immunology</i> , 2022, 3, 118-127.	1.2	20
1966	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma. , 2022, 10, e003956.		16
1967	Evaluation of the EdgeSeq Precision Immuno-Oncology Panel for Gene Expression Profiling From Clinical Formalin-Fixed Paraffin-Embedded Tumor Specimens. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, .	1.8	3
1968	Combination of SABR With Anti-PD-1 in Oligoprogressive Non-Small Cell Lung Cancer and Melanoma: Results of a Prospective Multicenter Observational Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 114, 655-665.	0.4	15
1969	Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer. <i>Nature Communications</i> , 2022, 13, .	5.8	33
1970	Pulmonary Pleomorphic Carcinoma Harboring EGFR Mutation Successfully Treated with Osimertinib: A Case Report. <i>Medicina (Lithuania)</i> , 2022, 58, 706.	0.8	1
1971	Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Nonâ€“Small-Cell Lung Cancer Previously Treated With Immunotherapyâ€“Lung-MAP S1800A. <i>Journal of Clinical Oncology</i> , 2022, 40, 2295-2307.	0.8	84
1972	Upper Gastrointestinal Tract IrAEs: A Case Report About Sintilimab-Induced Acute Erosive Hemorrhagic Gastritis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
1973	Pembrolizumabâ€“induced aseptic meningitis in a patient with nonâ€“small cell lung cancer: A case report and literature review of aseptic meningitis as an immuneâ€“related adverse event. <i>Molecular and Clinical Oncology</i> , 2022, 17, .	0.4	2
1974	Lung-MAP: A Collaborative Roadmap to Improve Cancer Outcomes. <i>Journal of Clinical Oncology</i> , 2022, 40, 2285-2287.	0.8	1
1975	Efficacy of Immune Checkpoint Inhibitor With or Without Chemotherapy for Nonsquamous NSCLC With Malignant Pleural Effusion: A Retrospective Multicenter Cohort Study. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100355.	0.6	5
1977	Phase II study of nanoparticle albumin-bound paclitaxel monotherapy for relapsed non-small cell lung cancer with patient-reported outcomes (NLCTG1302). <i>Translational Lung Cancer Research</i> , 2022, 11, 1359-1368.	1.3	3
1979	Network meta-analysis of immune-oncology monotherapy as first-line treatment for advanced non-small-cell lung cancer in patients with PD-L1 expression â©¼50%. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211050.	1.4	1
1980	VEGF/VEGFR-Targeted Therapy and Immunotherapy in Non-small Cell Lung Cancer: Targeting the Tumor Microenvironment. <i>International Journal of Biological Sciences</i> , 2022, 18, 3845-3858.	2.6	64
1982	Modern treatment of ALK-positive non-small cell lung cancer. <i>South Russian Journal of Cancer</i> , 2022, 3, 41-51.	0.1	0
1983	The Applicability of the Results in the Asian Population of ORIENT-11 to a Western Population According to the ICH-E5 Framework. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
1984	Brief Report: Safety and Antitumor Activity of Alectinib Plus Atezolizumab From a Phase 1b Study in Advanced ALK-Positive NSCLC. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100367.	0.6	13
1985	The LINC00261/MiR105-5p/SELL axis is involved in dysfunction of B cell and is associated with overall survival in hepatocellular carcinoma. <i>PeerJ</i> , 0, 10, e12588.	0.9	5

#	ARTICLE	IF	CITATIONS
1986	VÎ ³ 2 x PD-L1, a Bispecific Antibody Targeting Both the VÎ ³ 2 TCR and PD-L1, Improves the Anti-Tumor Response of VÎ ³ 2VÎ ² T Cell. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
1987	Autophagy, ferroptosis, pyroptosis, and necroptosis in tumor immunotherapy. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	230
1988	Is the Efficacy of Adding Ramucirumab to Docetaxel Related to a History of Immune Checkpoint Inhibitors in the Real-World Clinical Practice?. <i>Cancers</i> , 2022, 14, 2970.	1.7	3
1989	Efficacy of Atezolizumab for Advanced Non-Small Cell Lung Cancer Based on Clinical and Molecular Features: A Meta-Analysis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
1991	Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities. <i>Nature Reviews Drug Discovery</i> , 2022, 21, 529-540.	21.5	134
1992	Prognostic role of neutrophil-to-lymphocyte ratio and EPSILoN score in advanced non-small-cell lung cancer patients treated with first-line chemo-immunotherapy. <i>Future Oncology</i> , 2022, 18, 2593-2604.	1.1	3
1993	Programmed Cell Death Protein 1/Programmed Cell Death Protein Ligand 1 Immunosuppressants in Advanced Non-Small Cell Lung Cancer Research Progress in Treatment. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	0
1994	Depletion of Mannose Receptorâ€“Positive Tumor-associated Macrophages via a Peptide-targeted Star-shaped Polyglutamate Inhibits Breast Cancer Progression in Mice. <i>Cancer Research Communications</i> , 2022, 2, 533-551.	0.7	7
1995	Efficacy comparison of immune treating strategies for NSCLC patients with negative PD-L1 expression. <i>Expert Review of Clinical Immunology</i> , 2022, 18, 759-771.	1.3	1
1996	Molecular Link between DNA Damage Response and Microtubule Dynamics. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6986.	1.8	14
1997	A Phase 2 Study of Docetaxel, Ramucirumab, and Pembrolizumab for Patients With Metastatic or Recurrent Nonâ€“Small-Cell Lung Cancer (NSCLC) who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade. <i>Clinical Lung Cancer</i> , 2022, 23, e400-e404.	1.1	4
1998	Emergence of the CD226 Axis in Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	13
1999	Association of High Tumor Mutation Burden in Nonâ€“Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels. <i>JAMA Oncology</i> , 2022, 8, 1160.	3.4	117
2000	Correlations between Objective Response Rate and Survival-based Endpoints in First-line Advanced Non-Small Cell Lung Cancer: a Systematic Review and Meta-analysis. <i>Lung Cancer</i> , 2022, , .	0.9	5
2001	Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma. <i>Nature Medicine</i> , 2022, 28, 1599-1611.	15.2	185
2003	Successful Treatment of Metastatic Gallbladder Carcinoma with PD-L1 Expression by the Combination of PD-1 Inhibitor Plus Bevacizumab with Chemotherapy: A Case Report. <i>OncoTargets and Therapy</i> , 0, Volume 15, 629-636.	1.0	2
2004	Impact of Adding Vascular Endothelial Growth Factor Inhibitor to Immune Checkpoint Inhibitor Therapy. <i>Journal of Thoracic Oncology</i> , 2022, 17, 865-866.	0.5	0
2005	Safety and efficacy of nivolumab plus bevacizumab, paclitaxel for HER2-negative metastatic breast cancer: Primary results and biomarker data from a phase 2 trial (WJOG9917B). <i>European Journal of Cancer</i> , 2022, 171, 193-202.	1.3	11

#	ARTICLE	IF	CITATIONS
2006	Hematological Toxicity in Lung Cancer. <i>Medical Radiology</i> , 2022, , .	0.0	0
2007	A Review of Concurrent Chemo/Radiation, Immunotherapy, Radiation Planning, and Biomarkers for Locally Advanced Non-small Cell Lung Cancer and Their Role in the Development of ECOG-ACRIN EA5181. <i>Clinical Lung Cancer</i> , 2022, 23, 547-560.	1.1	2
2008	Genetic variations in the ATP-binding cassette transporter ABCC10 are associated with neutropenia in Japanese patients with lung cancer treated with nanoparticle albumin-bound paclitaxel. <i>Investigational New Drugs</i> , 0, , .	1.2	0
2009	Lack of Efficacy of Immune Checkpoint Inhibitors in Cancer Patients Older Than 75?. <i>Journal of Immunotherapy</i> , 0, Publish Ahead of Print, .	1.2	0
2010	Charting roadmaps towards novel and safe synergistic immunotherapy combinations. <i>Nature Cancer</i> , 2022, 3, 665-680.	5.7	18
2011	Immunotherapy in NSCLC Patients with Brain Metastases. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7068.	1.8	12
2012	Immunotherapy for Non-small Cell Lung Cancer: Current Agents and Potential Molecular Targets. <i>Anticancer Research</i> , 2022, 42, 3275-3284.	0.5	3
2013	CD8+ T-cell Responses Are Boosted by Dual PD-1/VEGFR2 Blockade after EGFR Inhibition in <i>i>Egfr</i>-Mutant Lung Cancer. <i>Cancer Immunology Research</i>, 2022, 10, 1111-1126.</i>	1.6	10
2014	Non-small cell lung cancer in the era of immunotherapy. <i>Seminars in Oncology</i> , 2022, 49, 337-343.	0.8	1
2015	Advanced non-small-cell lung cancer: how to manage non-oncogene disease. <i>Drugs in Context</i> , 0, 11, 1-14.	1.0	2
2016	Risk of Rash in PD-1 or PD-L1-Related Cancer Clinical Trials: A Systematic Review and Meta-Analysis. <i>Journal of Oncology</i> , 2022, 2022, 1-27.	0.6	5
2017	<i><small>Non</small> cell lung cancer with tumor proportion score<math>\geq 90\%Thoracic Cancer</i> , 2022, 13, 2450-2458.	0.8	4
2018	Clinically-meaningful improvements in therapy for unresectable NSCLC. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 927-937.	1.1	6
2019	Clinical impact of tumour burden on the efficacy of PD-1 / PD-L1 inhibitors plus chemotherapy in non-small cell lung cancer. <i>Cancer Medicine</i> , 0, , .	1.3	1
2020	Mechanisms of resistance to immune checkpoint inhibitors. <i>Cancer Science</i> , 2022, 113, 3303-3312.	1.7	12
2021	The Multi-Dimensional Biomarker Landscape in Cancer Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7839.	1.8	13
2022	Engineered natural killer cells impede the immunometabolic CD73-adenosine axis in solid tumors. <i>ELife</i> , 0, 11, .	2.8	11
2023	Real-world data analysis of immune checkpoint inhibitors in stage III-IV adenocarcinoma and squamous cell carcinoma. <i>BMC Cancer</i> , 2022, 22, .	1.1	4

#	ARTICLE	IF	CITATIONS
2024	Non-small-cell lung cancer: how to manage RET-positive disease. <i>Drugs in Context</i> , 0, 11, 1-12.	1.0	5
2025	Emerging strategies to overcome resistance to third-generation EGFR inhibitors. <i>Journal of Hematology and Oncology</i> , 2022, 15, .	6.9	48
2026	Association of thyroid transcription factor-1 with the efficacy of immune-checkpoint inhibitors in patients with advanced lung adenocarcinoma. <i>Thoracic Cancer</i> , 2022, 13, 2309-2317.	0.8	7
2027	Limited Benefit from the Addition of Immunotherapy to Chemotherapy in TKI-Refractory EGFR-Mutant Lung Adenocarcinoma. <i>Cancers</i> , 2022, 14, 3473.	1.7	5
2028	Resistance to TKIs in EGFR-Mutated Non-Small Cell Lung Cancer: From Mechanisms to New Therapeutic Strategies. <i>Cancers</i> , 2022, 14, 3337.	1.7	21
2029	Efficacy and safety of immune checkpoint inhibitors in post-TKI NSCLC patients harboring EGFR mutations. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 2937-2949.	1.2	3
2030	Treatment with a VEGFR-2 antibody results in intra-tumor immune modulation and enhances anti-tumor efficacy of PD-L1 blockade in syngeneic murine tumor models. <i>PLoS ONE</i> , 2022, 17, e0268244.	1.1	3
2031	The Predictive Value of Pretreatment Lactate Dehydrogenase and Derived Neutrophil-to-Lymphocyte Ratio in Advanced Non-Small Cell Lung Cancer Patients Treated With PD-1/PD-L1 Inhibitors: A Meta-Analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	9
2032	Efficacy outcomes and prognostic factors from real-world patients with advanced non-small-cell lung cancer treated with first-line chemoimmunotherapy: The Spinnaker retrospective study. <i>International Immunopharmacology</i> , 2022, 110, 108985.	1.7	14
2033	Normalization of tumor vasculature: A potential strategy to increase the efficiency of immune checkpoint blockades in cancers. <i>International Immunopharmacology</i> , 2022, 110, 108968.	1.7	2
2035	The gut microbiome, immune check point inhibition and immune-related adverse events in non-small cell lung cancer. <i>Cancer and Metastasis Reviews</i> , 2022, 41, 347-366.	2.7	11
2036	Immune Checkpoint Inhibitor Rechallenge After Prior Immune Toxicity. <i>Current Treatment Options in Oncology</i> , 2022, 23, 1153-1168.	1.3	7
2037	Identification of Ferroptosis-Related lncRNA Pairs for Predicting the Prognosis of Head and Neck Squamous Cell Carcinoma. <i>Journal of Oncology</i> , 2022, 2022, 1-13.	0.6	0
2039	Anaplastic lymphoma kinase-special immunity and immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
2040	A phase II trial of Atezolizumab plus Carboplatin plus Pemetrexed plus Bevacizumab in the treatment of patients with stage IV non-squamous non-small cell lung cancer: Big Ten Cancer Research Consortium (BTCRC)- LUN 17-139. <i>Clinical Lung Cancer</i> , 2022, , .	1.1	3
2041	Persistent Ethnicity-Associated Disparity in Antitumor Effectiveness of Immune Checkpoint Inhibitors Despite Equal Access. <i>Cancer Research Communications</i> , 2022, 2, 806-813.	0.7	7
2042	Short bevacizumab infusion as an effective and safe treatment for colorectal cancer. <i>Molecular and Clinical Oncology</i> , 2022, 17, .	0.4	3
2043	Positive Correlation of Peripheral CD8+ T Lymphocytes with Immune-Related Adverse Events and Combinational Prognostic Value in Advanced Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors. <i>Cancers</i> , 2022, 14, 3568.	1.7	2

#	ARTICLE	IF	CITATIONS
2044	Immunotherapy of Lung Cancer. <i>Medical Radiology</i> , 2022, , .	0.0	29
2045	Renal Toxicities in Cancer Patients Receiving Immune-Checkpoint Inhibitors: A Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2022, 11, 4373.	1.0	1
2046	Enhanced Inhibitory Effect of DC-CIK Cells on Lung Adenocarcinoma via Anti-Tim-3 Antibody and Antiprogrammed Cell Death-1 Antibody and Possible Mechanism. <i>Evidence-based Complementary and Alternative Medicine</i> , 2022, 2022, 1-11.	0.5	2
2047	Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial. <i>Lancet Oncology, The</i> , 2022, 23, 1167-1179.	5.1	79
2048	Is there a place for chemotherapy in first line of treatment for metastatic NSCLC in era of immunotherapy?. <i>Medical Alphabet</i> , 2022, , 18-21.	0.0	0
2049	Combination regimens in EGFR-mutated lung cancer: can we get ORIENT-ed?. <i>Lancet Oncology, The</i> , 2022, 23, 1113-1114.	5.1	0
2050	Therapeutic targeting of VEGF and/or TGF- β 2 to enhance anti-PD-(L)1 therapy: The evidence from clinical trials. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
2051	Blood Immune Cell Biomarkers in Lung Cancer Patients Undergoing Treatment with a Combination of Chemotherapy and Immune Checkpoint Blockade. <i>Cancers</i> , 2022, 14, 3690.	1.7	6
2052	Immunotherapy for EGFR-mutant advanced non-small-cell lung cancer: Current status, possible mechanisms and application prospects. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
2053	Immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer: A review. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	5
2054	Regulated cell death in cancer: from pathogenesis to treatment. <i>Chinese Medical Journal</i> , 2023, 136, 653-665.	0.9	14
2055	Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With Non- α -Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors. <i>JCO Precision Oncology</i> , 2022, , .	1.5	26
2056	Pulmonary Lymphangitis Carcinomatosa Mimicking Immunotherapy-Related Interstitial Pneumonitis: A Case Report. <i>Case Reports in Oncology</i> , 0, , 732-737.	0.3	0
2057	Evaluation of the Molecular Landscape in PD-L1 Positive Metastatic NSCLC: Data from Campania, Italy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8541.	1.8	2
2058	Immunotherapy in non-small cell lung cancer: Past, present, and future directions. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	32
2059	Clinical studies of Atezolizumab contributing to FDA approvals. , 0, 8, 390-395.		0
2060	A Randomized Comparison of Nivolumab versus Nivolumab + Docetaxel for Previously Treated Advanced or Recurrent ICI-Na α -ve Non- α -Small Cell Lung Cancer: TORC1630. <i>Clinical Cancer Research</i> , 2022, 28, 4402-4409.	3.2	11
2061	Predicting systemic therapy toxicity in older adult patients with advanced non-small cell lung cancer: A prospective multicenter study of National Hospital Organization in Japan. <i>Journal of Geriatric Oncology</i> , 2022, 13, 1216-1222.	0.5	3

#	ARTICLE	IF	CITATIONS
2062	Immunotherapy-chemotherapy combinations for non-small cell lung cancer: current trends and future perspectives. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 1259-1273.	1.4	9
2063	The exploration of three different treatment models of osimertinib plus antiangiogenic agents in non-small cell lung cancer: A real-world study. <i>Thoracic Cancer</i> , 2022, 13, 2641-2649.	0.8	2
2064	Efficacy and safety of combined immunotherapy and antiangiogenesis with or without chemotherapy for advanced non-small-cell lung cancer: A systematic review and pooled analysis from 23 prospective studies. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	4
2065	Anti-Angiogenic Therapy in ALK Rearranged Non-Small Cell Lung Cancer (NSCLC). <i>International Journal of Molecular Sciences</i> , 2022, 23, 8863.	1.8	4
2066	Effective low-dose Anlotinib induces long-term tumor vascular normalization and improves anti-PD-1 therapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	12
2067	Immune-based combination therapy to convert immunologically cold tumors into hot tumors: an update and new insights. <i>Acta Pharmacologica Sinica</i> , 2023, 44, 288-307.	2.8	14
2068	PD-L1 expression, tumor mutational burden, and immune cell infiltration in non-small cell lung cancer patients with epithelial growth factor receptor mutations. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
2069	Molecular Mechanisms and Future Implications of VEGF/VEGFR in Cancer Therapy. <i>Clinical Cancer Research</i> , 2023, 29, 30-39.	3.2	53
2070	Synergistic effect of combining sunitinib with a peptide-based vaccine in cancer treatment after microenvironment remodeling. <i>Oncolimmunology</i> , 2022, 11, .	2.1	1
2071	Prognostic Potential of Metabolic Activity on 18F-FDG Accumulation in Advanced NSCLC Receiving Combining Chemotherapy Plus PD-1 Blockade. <i>Journal of Immunotherapy</i> , 2022, 45, 349-357.	1.2	4
2072	Emerging PD-1/PD-L1 targeting immunotherapy in non-small cell lung cancer: Current status and future perspective in Japan, US, EU, and China. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	8
2073	From rough to precise: PD-L1 evaluation for predicting the efficacy of PD-1/PD-L1 blockades. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	20
2074	The expanding role for small molecules in immuno-oncology. <i>Nature Reviews Drug Discovery</i> , 2022, 21, 821-840.	21.5	50
2075	Insomnia in patients treated with checkpoint inhibitors for cancer: A meta-analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
2076	Advances in the Treatment of Postoperative Recurrence of Non-Small Cell Lung Cancer and Their Impact on Survival in Asian Patients. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2022, , .	0.4	1
2077	Selective suppression of melanoma lacking IFN- γ pathway by JAK inhibition depends on T cells and host TNF signaling. <i>Nature Communications</i> , 2022, 13, .	5.8	11
2078	Suppression of VEGFD expression by S-nitrosylation promotes the development of lung adenocarcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, .	3.5	5
2079	Choosing the optimal immunotherapeutic strategies for non-small cell lung cancer based on clinical factors. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4

#	ARTICLE	IF	CITATIONS
2080	Bourgeoning Cancer Targets. Recent Patents on Anti-Cancer Drug Discovery, 2023, 18, 147-160.	0.8	2
2081	Comparison of real-world data (RWD) analysis on efficacy and post-progression outcomes with pembrolizumab plus chemo vs chemo alone in metastatic non-squamous non-small cell lung cancer with PD-L1 $\geq 50\%$. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
2082	The Efficacy of Immune Checkpoint Inhibitors vs. Chemotherapy for KRAS-Mutant or EGFR-Mutant Non-Small-Cell Lung Cancers: A Meta-Analysis Based on Randomized Controlled Trials. <i>Disease Markers</i> , 2022, 2022, 1-11.	0.6	3
2083	Immunotherapy in Advanced NSCLC Without Driver Mutations: Available Therapeutic Alternatives After Progression and Future Treatment Options. <i>Clinical Lung Cancer</i> , 2022, 23, 643-658.	1.1	5
2084	The role of immunotherapy plus chemotherapy versus chemotherapy alone as first-line treatment for advanced non-small cell lung cancer: an updated systematic review and meta-analysis of randomized controlled trials. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 1127-1140.	1.1	1
2085	Sintilimab combined with apatinib plus capecitabine in the treatment of unresectable hepatocellular carcinoma: A prospective, open-label, single-arm, phase II clinical study. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
2086	A Multi-Center Real-World Experience of IMpower150 in Oncogene Driven Tumors and CNS Metastases. <i>Clinical Lung Cancer</i> , 2022, 23, 702-708.	1.1	2
2087	Is ICI-based therapy better than chemotherapy for metastatic NSCLC patients who develop EGFR-TKI resistance? A real-world investigation. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	5
2088	Chemotherapy reinforces anti-tumor immune response and enhances clinical efficacy of immune checkpoint inhibitors. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
2089	Targeting $KRAS$: Crossroads of Signaling and Immune Inhibition. <i>Journal of Immunotherapy and Precision Oncology</i> , 2022, 5, 68-78.	0.6	6
2090	Bevacizumab Plus Atezolizumab in Pretreated Progressive and Metastatic NSCLC. <i>Journal of Thoracic Oncology</i> , 2022, 17, e71-e72.	0.5	0
2091	Olaparib maintenance versus placebo monotherapy in patients with advanced non-small cell lung cancer (PIN): A multicentre, randomised, controlled, phase 2 trial. <i>EClinicalMedicine</i> , 2022, 52, 101595.	3.2	14
2092	The Clinical Significance of Deglycosylated PD-L1 Level Detection Using 28-8 Monoclonal Antibody in Lung Adenocarcinoma. <i>International Journal of General Medicine</i> , 0, Volume 15, 7383-7393.	0.8	1
2093	FBW7-mediated ubiquitination and destruction of PD-1 protein primes sensitivity to anti-PD-1 immunotherapy in non-small cell lung cancer. , 2022, 10, e005116.		12
2094	$EGFR$ Mutations and PD-L1 Expression in Early-Stage Non-Small Cell Lung Cancer: A Real-World Data From a Single Center in Brazil. <i>Oncologist</i> , 0, , .	1.9	1
2095	Two phase I studies of BI 836880, a vascular endothelial growth factor/angiopoietin-2 inhibitor, administered once every 3 weeks or once weekly in patients with advanced solid tumors. <i>ESMO Open</i> , 2022, 7, 100576.	2.0	4
2096	The efficacy of immune checkpoint inhibitors in elderly patients: a meta-analysis and meta-regression. <i>ESMO Open</i> , 2022, 7, 100577.	2.0	11
2097	Prognostic scores including peripheral blood-derived inflammatory indices in patients with advanced non-small-cell lung cancer treated with immune checkpoint inhibitors. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 179, 103806.	2.0	14

#	ARTICLE	IF	CITATIONS
2098	Ramucirumab plus atezolizumab in patients with stage IV non-small cell lung cancer previously treated with immune checkpoint inhibitors. <i>Lung Cancer</i> , 2022, 173, 101-106.	0.9	6
2099	Data of programmed death-ligand 1 expression and VEGF: Nivolumab, bevacizumab and paclitaxel For HER2-negative metastatic breast cancer. <i>Data in Brief</i> , 2022, 45, 108558.	0.5	1
2100	Discrepancies Between the Cost of Advanced Lung Cancer Treatment and How Much Is Reimbursed by the Brazilian Public Healthcare System. <i>Value in Health Regional Issues</i> , 2023, 33, 1-6.	0.5	0
2101	Immunotherapy in soft tissue and bone sarcoma: unraveling the barriers to effectiveness. <i>Theranostics</i> , 2022, 12, 6106-6129.	4.6	14
2102	Chemotherapy for Lung Cancer. <i>Medical Radiology</i> , 2022, , .	0.0	0
2103	Immune checkpoint inhibitor (ICI)-induced hepatitis diagnosed by liver biopsy followed by ICI-free chemotherapy leading to therapeutic effect: A case of lung cancer treatment. <i>Respiratory Medicine Case Reports</i> , 2022, 40, 101753.	0.2	1
2104	Development and validation of a prognostic risk signature for lung adenocarcinoma constructed by six ferroptosis, necroptosis, and pyroptosis-related lncRNAs. <i>Journal of Thoracic Disease</i> , 2022, 14, 3955-3974.	0.6	2
2105	Checkpoint Inhibitors in Non-small Cell Lung Cancer: Potentials and Challenges. , 2022, , .		0
2106	Translational Research in Lung Cancer. <i>Medical Radiology</i> , 2022, , .	0.0	0
2107	Available Immunotherapy Drugs in Oncology. <i>Current Clinical Pathology</i> , 2022, , 5-23.	0.0	0
2108	Targeting N6-methyladenosine RNA modification combined with immune checkpoint Inhibitors: A new approach for cancer therapy. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 5150-5161.	1.9	5
2109	Reassessing vascular endothelial growth factor (VEGF) in anti-angiogenic cancer therapy. <i>Cancer Treatment and Research Communications</i> , 2022, 32, 100620.	0.7	23
2110	Clinical outcomes of Atezolizumab Therapy for Previously-Treated Advanced-Stage Non-Small Cell Lung Cancer: A Real-World Study in Taiwan. <i>Journal of Cancer</i> , 2022, 13, 2922-2932.	1.2	0
2111	Gemcitabine combined with apatinib and toripalimab in recurrent or metastatic nasopharyngeal carcinoma. <i>Med</i> , 2022, 3, 664-681.e6.	2.2	5
2112	A David and Goliath set-up: a qualitative study of the challenges of ensuring the introduction of cost-effective new cancer medicines in Finland. <i>Journal of Pharmaceutical Policy and Practice</i> , 2022, 15, .	1.1	0
2113	Cox Proportional Hazard Ratios Overestimate Survival Benefit of Immune Checkpoint Inhibitors: Cox-TEL Adjustment and Meta-Analyses of Programmed Death-Ligand 1 Expression and Immune Checkpoint Inhibitor Survival Benefit. <i>Journal of Thoracic Oncology</i> , 2022, 17, 1365-1374.	0.5	0
2114	Tobacco Use and Response to Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Cancer. <i>Current Oncology</i> , 2022, 29, 6260-6276.	0.9	6
2115	A retrospective study for prognostic significance of type II diabetes mellitus and hemoglobin A1c levels in non-small cell lung cancer patients treated with pembrolizumab. <i>Translational Lung Cancer Research</i> , 2022, 11, 1619-1630.	1.3	3

#	ARTICLE	IF	CITATIONS
2116	Safety of First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817. <i>Journal of Thoracic Oncology</i> , 2023, 18, 79-92.	0.5	11
2117	Clinical Strategies Targeting the Tumor Microenvironment of Pancreatic Ductal Adenocarcinoma. <i>Cancers</i> , 2022, 14, 4209.	1.7	9
2118	What does radiomics do in <scp>PD-L1</scp> blockade therapy of <scp>NSCLC</scp> patients?. <i>Thoracic Cancer</i> , 2022, 13, 2669-2680.	0.8	2
2119	Immune checkpoint inhibitor-induced arthralgia is tightly associated with improved overall survival in cancer patients. <i>Rheumatology</i> , 2023, 62, 1451-1459.	0.9	1
2120	Editorial: Beyond chemotherapy and immunotherapy in thoracic malignancies: Overcoming resistance by tackling new molecular pathways. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
2121	Overcoming the cardiac toxicities of cancer therapy immune checkpoint inhibitors. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	5
2122	Recent advances in immune checkpoint inhibitors for non-small lung cancer treatment. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
2123	Unveiling the tumor immune microenvironment of organ-specific melanoma metastatic sites. , 2022, 10, e004884.		15
2124	Benefits from Adjuvant Chemotherapy in Patients with Resected Non-Small Cell Lung Cancer: Possibility of Stratification by Gene Amplification of ACTN4 According to Evaluation of Metastatic Ability. <i>Cancers</i> , 2022, 14, 4363.	1.7	2
2125	Characteristics of the immune microenvironment and their clinical significance in non-small cell lung cancer patients with ALK-rearranged mutation. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
2126	Current Landscape of Therapeutic Resistance in Lung Cancer and Promising Strategies to Overcome Resistance. <i>Cancers</i> , 2022, 14, 4562.	1.7	15
2127	Non-small cell lung cancer in China. <i>Cancer Communications</i> , 2022, 42, 937-970.	3.7	129
2128	Biomarkers for immune checkpoint inhibitors in solid tumors. <i>Clinical and Translational Oncology</i> , 2023, 25, 126-136.	1.2	3
2129	Enhancing therapeutic anti-cancer responses by combining immune checkpoint and tyrosine kinase inhibition. <i>Molecular Cancer</i> , 2022, 21, .	7.9	5
2130	Clinical predictive value of na-ve and memory T cells in advanced NSCLC. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	13
2131	PD-1 inhibitor plus chemotherapy versus bevacizumab plus chemotherapy in patients with advanced non-squamous non-small-cell lung cancer: a pooled analysis of three randomised trials. <i>BMJ Open Respiratory Research</i> , 2022, 9, e001294.	1.2	0
2132	Mass cytometry-based peripheral blood analysis as a novel tool for early detection of solid tumours: a multicentre study. <i>Gut</i> , 2023, 72, 996-1006.	6.1	4
2133	Effects of a Novel Beta Lactam Compound, MC-100093, on the Expression of Glutamate Transporters/Receptors and Ethanol Drinking Behavior of Alcohol-Preferring Rats. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2022, 383, 208-216.	1.3	4

#	ARTICLE	IF	CITATIONS
2134	Thyroid-related adverse events induced by immune checkpoint inhibitors. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	9
2135	Immune checkpoint inhibitors for non-small cell lung cancer patients on steroid or non-steroidal anti-inflammatory drugs treatmentâ€”therapeutic indication or therapeutic efficacy?. <i>Translational Cancer Research</i> , 2022, 11, 3003-3005.	0.4	0
2136	Immunobiology of high-grade serous ovarian cancer: lessons for clinical translation. <i>Nature Reviews Cancer</i> , 2022, 22, 640-656.	12.8	38
2137	Efficacy of Disitamab Vedotin in a heavily pre-treated HER2 positive lung adenocarcinoma patient: case report and literature review. <i>Heliyon</i> , 2022, 8, e10581.	1.4	2
2138	Cost-benefit analysis of ALK diagnosis vs. non-diagnosis in patients with advanced nonâ€”small cell lung cancer in Spain. <i>Global & Regional Health Technology Assessment</i> , 0, 9, 82-90.	0.2	0
2139	The Interaction of the IFNÎ³/JAK/STAT1 and JAK/STAT3 Signalling Pathways in EGFR-Mutated Lung Adenocarcinoma Cells. <i>Journal of Oncology</i> , 2022, 2022, 1-16.	0.6	1
2140	Combination of Tumor Mutational Burden and DNA Damage Repair Gene Mutations with Stromal/Immune Scores Improved Prognosis Stratification in Patients with Lung Adenocarcinoma. <i>Journal of Oncology</i> , 2022, 2022, 1-12.	0.6	2
2141	Current perspectives of the Japanese Esophageal Oncology Group on the development of immunotherapy for esophageal cancer. <i>Japanese Journal of Clinical Oncology</i> , 0, , .	0.6	2
2142	Association of sarcopenia with survival in advanced NSCLC patients receiving concurrent immunotherapy and chemotherapy. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	8
2143	PD-1 inhibition plus platinum-based chemotherapy (PBC) or PBC alone in the first-line treatment of locally advanced or metastatic pulmonary lymphoepithelioma-like carcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
2144	A Biomolecular Toolbox for Precision Nanomotors. <i>Advanced Materials</i> , 0, , 2205746.	11.1	11
2145	Pancreatic injury following immune checkpoint inhibitors: A systematic review and meta-analysis. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	5
2146	Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial. <i>Nature Medicine</i> , 2022, 28, 2155-2161.	15.2	93
2147	Mechanism investigation of Caspase-8/GSDMC dependent immunogenic cell death induced by Ophiopogonin B in NSCLC cells. <i>Pharmacological Research Modern Chinese Medicine</i> , 2022, 4, 100157.	0.5	0
2148	Radiotherapy improves the outcomes of immunotherapy with Sintilimab in non-small-cell lung cancer: A real-world analysis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
2149	Results from the IMpower132 China cohort: Atezolizumab plus platinumâ€”based chemotherapy in advanced nonâ€”small cell lung cancer. <i>Cancer Medicine</i> , 0, , .	1.3	3
2150	Efficacy of Immunotherapy Combined with Antiangiogenic Therapy in Treatment-Failure Patients with Advanced Carcinoma Ex Pleomorphic Adenoma of the Submandibular Gland: A Case Report. <i>Current Oncology</i> , 2022, 29, 6334-6341.	0.9	1
2151	Harnessing the immune system by targeting immune checkpoints: Providing new hope for Oncotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6

#	ARTICLE	IF	CITATIONS
2152	Phase II study of carboplatin/nab-paclitaxel/atezolizumab combination therapy for advanced nonsquamous non-small cell lung cancer patients with impaired renal function: RESTART trial. <i>BMC Cancer</i> , 2022, 22, .	1.1	0
2153	Impact of treatment line on risks and benefits of immune checkpoint inhibitor in patients with advanced non-small cell lung cancer and interstitial lung disease: a systematic review and meta-analysis of cohort studies. <i>Translational Lung Cancer Research</i> , 2022, 11, 1835-1846.	1.3	2
2154	Anti-tumour potential of PD-L1 post-translational modifications. <i>Immunology</i> , 2022, 167, 471-481.	2.0	10
2155	Probability of Study Success (PrSS) Evaluation Based on Multiple Endpoints in Late Phase Oncology Drug Development. <i>Statistics in Biopharmaceutical Research</i> , 0, , 1-34.	0.6	0
2156	Multiscale profiling of protease activity in cancer. <i>Nature Communications</i> , 2022, 13, .	5.8	15
2157	Signaling pathways and targeted therapies in lung squamous cell carcinoma: mechanisms and clinical trials. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	33
2158	Emerging immune checkpoint inhibitors for the treatment of non-small cell lung cancer. <i>Expert Opinion on Emerging Drugs</i> , 2022, 27, 289-300.	1.0	5
2159	Adebrelimab (SHR-1316) in Combination With Chemotherapy as Perioperative Treatment in Patients With Resectable Stage II to III NSCLCs: An Open-Label, Multicenter, Phase 1b Trial. <i>Journal of Thoracic Oncology</i> , 2023, 18, 194-203.	0.5	12
2160	A phase Ib study of camrelizumab in combination with apatinib and fuzuloparib in patients with recurrent or metastatic triple-negative breast cancer. <i>BMC Medicine</i> , 2022, 20, .	2.3	11
2161	There Is No Unmet Need for Another Programmed Cell Death Protein-1 or Programmed Death-Ligand 1 Inhibitor for Metastatic NSCLC. <i>Journal of Thoracic Oncology</i> , 2022, 17, 1171-1174.	0.5	1
2162	Strategies to overcome DC dysregulation in the tumor microenvironment. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	19
2163	Comparison of next-generation sequencing and cobas EGFR mutation test v2 in detecting EGFR mutations. <i>Thoracic Cancer</i> , 2022, 13, 3217-3224.	0.8	6
2164	CT-based radiomics in predicting pathological response in non-small cell lung cancer patients receiving neoadjuvant immunotherapy. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	8
2165	Efficacy of Chemoimmunotherapy in NSCLC Patients With Brain Metastasis With or Without Prior Brain Radiotherapy. <i>Anticancer Research</i> , 2022, 42, 4805-4812.	0.5	2
2166	Surgical results of the Lung Cancer Mutation Consortium 3 trial: A phase II multicenter single-arm study to investigate the efficacy and safety of atezolizumab as neoadjuvant therapy in patients with stages IB-select IIIB resectable non-small cell lung cancer. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2023, 165, 828-839.e5.	0.4	13
2167	PD-1/PD-L1 combined with LAG3 is associated with clinical activity of immune checkpoint inhibitors in metastatic primary pulmonary lymphoepithelioma-like carcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
2168	Clinical implications of the interaction between PD-1/PD-L1 and PI3K/AKT/mTOR pathway in progression and treatment of non-small cell lung cancer. <i>Journal of Cancer</i> , 2022, 13, 3434-3443.	1.2	16
2169	Research Trends and Emerging Hotspots of Lung Cancer Surgery during 2012-2021: A 10-Year Bibliometric and Network Analysis. <i>Health Data Science</i> , 2022, 2022, .	1.1	0

#	ARTICLE	IF	CITATIONS
2170	NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC. <i>Journal of Thoracic Oncology</i> , 2023, 18, 106-119.	0.5	21
2172	Nivolumabâ€induced radiation recall pneumonitis in nonâ€small cell lung cancer patients with thoracic radiation therapy. <i>Cancer Science</i> , 0, , .	1.7	3
2173	Current status of immunotherapy for non-small cell lung cancer. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	11
2174	Pharmacodynamic and Antitumor Activity of BI 836880, a Dual Vascular Endothelial Growth Factor and Angiopoietin 2 Inhibitor, Alone and Combined with Programmed Cell Death Protein-1 Inhibition. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2023, 384, 331-342.	1.3	3
2175	History and Evidence of Immune Checkpoint Inhibitors in the Respiratory Field. <i>Nihon Kikan Shokudoka Gakkai Kaiho</i> , 2022, 73, 325-331.	0.0	0
2176	The Role of Chemotherapy Plus Immune Checkpoint Inhibitors in Oncogenic-Driven NSCLC: A University of California Lung Cancer Consortium Retrospective Study. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100427.	0.6	3
2179	Vidutolimod in Combination With Atezolizumab With and Without Radiation Therapy in Patientsâ€With Programmed Cell Death Protein 1 or Programmed Death-Ligand 1 Blockadeâ€Resistant Advanced NSCLC. <i>JTO Clinical and Research Reports</i> , 2023, 4, 100423.	0.6	1
2180	Translational Research in Cancer Immunotherapies. <i>Japanese Journal of Lung Cancer</i> , 2022, 62, 363-370.	0.0	0
2182	Trans-Arterial Chemoembolization Plus Systemic Treatments for Hepatocellular Carcinoma: An Update. <i>Journal of Personalized Medicine</i> , 2022, 12, 1788.	1.1	9
2184	The Overview of Perspectives of Clinical Application of Liquid Biopsy in Non-Small-Cell Lung Cancer. <i>Life</i> , 2022, 12, 1640.	1.1	5
2185	Characteristics of tumor microenvironment and novel immunotherapeutic strategies for non-small cell lung cancer. <i>Journal of the National Cancer Center</i> , 2022, 2, 243-262.	3.0	5
2187	The influence of pharmaceutical care in patients with advanced non-small-cell lung cancer receiving combination cytotoxic chemotherapy and PD-1/PD-L1 inhibitors. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	0
2188	Nintedanib plus docetaxel after progression on first-line immunochemotherapy in patients with lung adenocarcinoma: Cohort C of the non-interventional study, VARGADO. <i>Translational Lung Cancer Research</i> , 2022, 11, 2010-2021.	1.3	6
2189	Clinical implications of T cell exhaustion for cancer immunotherapy. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 775-790.	12.5	182
2191	Novel small 99mTc-labeled affibody molecular probe for PD-L1 receptor imaging. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
2192	Pharmacotherapy for Advanced Non-Small Cell Lung Cancer with Performance Status 2 without Druggable Gene Alterations: Could Immune Checkpoint Inhibitors Be a Game Changer?. <i>Cancers</i> , 2022, 14, 4861.	1.7	1
2193	Sâ€1 eliminates <sc>MDSCs</sc> and enhances the efficacy of <sc>PD</sc>â€1 blockade via regulation of tumorâ€derived Bv8 and <sc>S100A8</sc> in thoracic tumor. <i>Cancer Science</i> , 2023, 114, 384-398.	1.7	6
2194	A systematic review and network meta-analysis of first-line immune checkpoint inhibitor combination therapies in patients with advanced non-squamous non-small cell lung cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5

#	ARTICLE	IF	CITATIONS
2197	Potential of VEGFR2 expression as a predictive marker of PD-1 blockade in patients with advanced NSCLC. <i>Oncology Reports</i> , 2022, 48, .	1.2	4
2198	The efficacy and safety of immune checkpoint inhibitors combined with chemotherapy or anti-angiogenic therapy as a second-line or later treatment option for advanced non-small cell lung cancer: a retrospective comparative cohort study. <i>Translational Lung Cancer Research</i> , 2022, 11, 2111-2124.	1.3	2
2199	DDX17 promotes the growth and metastasis of lung adenocarcinoma. <i>Cell Death Discovery</i> , 2022, 8, .	2.0	4
2200	Gut microbiota diversity and specific composition during immunotherapy in responders with non-small cell lung cancer. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	9
2202	Adverse reactions associated with immune checkpoint inhibitors and bevacizumab: A pharmacovigilance analysis. <i>International Journal of Cancer</i> , 2023, 152, 480-495.	2.3	11
2203	Immune Checkpoint Inhibitors Do Not Increase Short-Term Risk of Hypertension in Cancer Patients: a Systematic Literature Review and Meta-Analysis. <i>Hypertension</i> , 2022, 79, 2611-2621.	1.3	16
2204	Cost of illness of stage IV non-small cell lung cancer (NSCLC) positive for programmed cell death ligand 1 (PD-L1) in the US. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 0, , 1-7.	0.7	0
2205	Acute kidney injury in advanced lung cancer patients treated with PD-1 inhibitors: a single center observational study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 5061-5070.	1.2	7
2206	Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study. <i>Journal of Clinical Oncology</i> , 2023, 41, 1213-1227.	0.8	107
2207	Immune checkpoint inhibitor therapy and elevated levels of C-reactive protein associated with COVID-19 aggravation in patients with lung cancer. <i>Journal of Pharmaceutical Health Care and Sciences</i> , 2022, 8, .	0.4	1
2208	Predictors of survival to immunotherapy and chemoimmunotherapy in non-small cell lung cancer: A meta-analysis. <i>Journal of the National Cancer Institute</i> , 2023, 115, 29-42.	3.0	7
2209	The treatment in patients with unresectable locally advanced non-small cell lung cancer: Explorations on hot issues. <i>Cancer Letters</i> , 2022, 551, 215947.	3.2	1
2210	Subgroup analyses in randomized phase III trials of systemic treatments in patients with advanced solid tumours: a systematic review of trials published between 2017 and 2020. <i>ESMO Open</i> , 2022, 7, 100593.	2.0	2
2211	The impact of microbiota on PD-1/PD-L1 inhibitor therapy outcomes: A focus on solid tumors. <i>Life Sciences</i> , 2022, 310, 121138.	2.0	14
2212	RAS: Circuitry and therapeutic targeting. <i>Cellular Signalling</i> , 2023, 101, 110505.	1.7	1
2213	Adenocarcinoma of the uterine corpus and sarcomas of the uterus. , 2023, , 125-174.e30.		0
2214	Tetramer-aided sorting and single-cell RNA sequencing facilitate transcriptional profiling of antigen-specific CD8+ T cells. <i>Translational Oncology</i> , 2023, 27, 101559.	1.7	1
2215	Immune checkpoint inhibitor (ICI)-induced hepatitis diagnosed by liver biopsy followed by ICI-free chemotherapy leading to therapeutic effect: A case of lung cancer treatment. <i>Respiratory Medicine Case Reports</i> , 2022, 40, 101773.	0.2	1

#	ARTICLE	IF	CITATIONS
2216	Deep learning to estimate durable clinical benefit and prognosis from patients with non-small cell lung cancer treated with PD-1/PD-L1 blockade. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
2217	A single center analysis of first-line treatment in advanced KRAS mutant non-small cell lung cancer: real-world practice. <i>BMC Cancer</i> , 2022, 22, .	1.1	1
2218	Multiplexed imaging of tumor immune microenvironmental markers in locally advanced or metastatic non-small cell lung cancer characterizes the features of response to PD-1 blockade plus chemotherapy. <i>Cancer Communications</i> , 2022, 42, 1331-1346.	3.7	10
2219	How to manage KRAS G12C-mutated advanced non-small-cell lung cancer. , 0, 11, 1-11.		4
2220	Biomarkers in the management of lung cancer: changing the practice of thoracic oncology. <i>Clinical Chemistry and Laboratory Medicine</i> , 2023, 61, 906-920.	1.4	4
2221	Classical ALK G1202R resistance mutation was identified in a lung adenocarcinoma patient with rare LOC388942-ALK fusion after sequential treatment with ALK-TKIs and anlotinib: a case report. <i>Annals of Translational Medicine</i> , 2022, 10, 1180-1180.	0.7	2
2222	Emerging evidence of immunotherapy for colorectal cancer. <i>Annals of Gastroenterological Surgery</i> , 2023, 7, 216-224.	1.2	4
2223	Effect of histology on the efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer: A systematic review and meta-analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
2224	Development of a novel immune-related lncRNA prognostic signature for patients with hepatocellular carcinoma. <i>BMC Gastroenterology</i> , 2022, 22, .	0.8	1
2225	Editorial: Impact of immunotherapy in lung cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
2226	Distribution and concordance of PD-L1 expression by routine 22C3 assays in East-Asian patients with non-small cell lung cancer. <i>Respiratory Research</i> , 2022, 23, .	1.4	6
2227	Immune checkpoint inhibitor-related adverse cardiac events in patients with lung cancer: a systematic review and meta-analysis. <i>Cancer Cell International</i> , 2022, 22, .	1.8	5
2228	Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis. <i>Annals of Oncology</i> , 2023, 34, 173-185.	0.6	8
2229	Folate Receptor-Mediated Delivery of Cas9 RNP for Enhanced Immune Checkpoint Disruption in Cancer Cells. <i>Small</i> , 2023, 19, .	5.2	12
2230	Anti-Tumor Efficacy of Anti-PD-1/PD-L1 Antibodies in Combination With Other Anticancer Drugs in Solid Tumors: A Systematic Review and Meta-Analysis. <i>Cancer Control</i> , 2022, 29, 107327482211406.	0.7	0
2231	Delayed-onset immune-related adverse events involving the thyroid gland by immune checkpoint inhibitors in combination with chemotherapy: a case report and retrospective cohort study. <i>Endocrine Journal</i> , 2023, 70, 323-332.	0.7	3
2232	A potential treatment option for transformed small-cell lung cancer on PD-L1 inhibitor-based combination therapy improved survival. <i>Lung Cancer</i> , 2023, 175, 68-78.	0.9	7
2233	A comparison of cancer vaccine adjuvants in clinical trials. <i>Cancer Treatment and Research Communications</i> , 2023, 34, 100667.	0.7	2

#	ARTICLE	IF	CITATIONS
2234	PD-1/PD-L1 inhibitor activity in patients with gene-rearrangement positive non-small cell lung cancer— an IMMUNOTARGET case series. <i>Translational Lung Cancer Research</i> , 2021, .	1.3	1
2235	The Use of Immunotherapy in Cancer Patients with Autoimmune Diseases. , 2023, , 267-286.		0
2236	Tumor glycolytic profiling through ¹⁸ F-FDG PET/CT predicts immune checkpoint inhibitor efficacy in advanced NSCLC. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211383.	1.4	2
2238	Comparison of the efficacy and safety in the treatment strategies between chemotherapy combined with antiangiogenic and with immune checkpoint inhibitors in advanced non-small cell lung cancer patients with negative PD-L1 expression: A network meta-analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
2239	Design and reporting of phase III oncology trials with prospective biomarker validation. <i>Journal of the National Cancer Institute</i> , 0, , .	3.0	1
2240	Immune-Related Adverse Events in Advanced Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibition in Combination With Chemotherapy: A Brief Report. <i>Clinical Lung Cancer</i> , 2022, , .	1.1	1
2241	An EGFR L858R mutation identified in 1862 Chinese NSCLC patients can be a promising neoantigen vaccine therapeutic strategy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
2242	The roles of metabolic profiles and intracellular signaling pathways of tumor microenvironment cells in angiogenesis of solid tumors. <i>Cell Communication and Signaling</i> , 2022, 20, .	2.7	18
2243	Increased tumor glycolysis is associated with decreased immune infiltration across human solid tumors. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
2244	Rechallenge of immune checkpoint inhibitors in a case with adverse events inducing myasthenia gravis. , 2022, 10, e005970.		2
2245	Malignant neoplasm of the bronchi and lung: Russian clinical guidelines. <i>Journal of Modern Oncology</i> , 2022, 24, 269-304.	0.1	2
2246	Crosstalk of four kinds of cell deaths defines subtypes of cutaneous melanoma for precise immunotherapy and chemotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
2247	Extended use of rh-endostatin improves prognosis in patients with advanced non-small cell lung cancer: an analysis of retrospective study. <i>Journal of Thoracic Disease</i> , 2022, 14, 4416-4426.	0.6	2
2248	The Safety and Efficacy of Preoperative Immunotherapy Combined with Chemotherapy in Patients with Stage IIIA-III B Lung Squamous Cell Carcinoma. <i>Thoracic and Cardiovascular Surgeon</i> , 0, , .	0.4	0
2249	Re-administration of immune checkpoint inhibitors for patients with non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2022, 11, 2170-2174.	1.3	0
2250	Retroviral Replicating Vector Toca 511 (Vocimagene Amiretrorepvec) for Prodrug Activator Gene Therapy of Lung Cancer. <i>Cancers</i> , 2022, 14, 5820.	1.7	1
2251	Case report: Durable response after pembrolizumab in combination with radiation - induced abscopal effect in platinum - refractory metastatic endometrial clear cell carcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
2252	PD-1/PD-L1 inhibitors plus anti-angiogenic agents with or without chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy as second or later-line treatment for patients with advanced non-small cell lung cancer: A real-world retrospective cohort study. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2

#	ARTICLE	IF	CITATIONS
2254	PEOPLE (NCT03447678), a first-line phase II pembrolizumab trial, in negative and low PD-L1 advanced NSCLC: clinical outcomes and association with circulating immune biomarkers. <i>ESMO Open</i> , 2022, 7, 100645.	2.0	3
2256	Clinical Outcomes in COVID-19 Patients Treated with Immunotherapy. <i>Cancers</i> , 2022, 14, 5954.	1.7	0
2257	Proinflammatory activity of VEGF-targeted treatment through reversal of tumor endothelial cell anergy. <i>Angiogenesis</i> , 2023, 26, 279-293.	3.7	12
2258	Associating Immunotherapy and Targeted Therapies: Facts and Hopes. <i>Clinical Cancer Research</i> , 2023, 29, 1183-1193.	3.2	3
2259	Immune Checkpoint Inhibitor Therapy in Oncology. <i>JACC: CardioOncology</i> , 2022, 4, 579-597.	1.7	25
2260	Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF- β 2 and PD-L1, in Patients with Non-Small Cell Lung Cancer Resistant or Refractory to Immune Checkpoint Inhibitors. <i>Oncologist</i> , 2023, 28, 258-267.	1.9	7
2261	Rational combinations of targeted cancer therapies: background, advances and challenges. <i>Nature Reviews Drug Discovery</i> , 2023, 22, 213-234.	21.5	69
2262	Targeting cell death pathways for cancer therapy: recent developments in necroptosis, pyroptosis, ferroptosis, and cuproptosis research. <i>Journal of Hematology and Oncology</i> , 2022, 15, .	6.9	138
2264	Atezolizumab Plus Bevacizumab as First-line Treatment for Patients With Metastatic Nonsquamous Non-Small Cell Lung Cancer With High Tumor Mutation Burden. <i>JAMA Oncology</i> , 2023, 9, 344.	3.4	13
2265	Immunoregulatory framework and the role of miRNA in the pathogenesis of NSCLC – A systematic review. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
2266	The prospect of tumor microenvironment-modulating therapeutical strategies. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	7
2267	Current status and challenges of immunotherapy in ALK rearranged NSCLC. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
2269	From targeted therapy to a novel way: Immunogenic cell death in lung cancer. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	2
2270	Global research landscape and trends of lung cancer immunotherapy: A bibliometric analysis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
2271	Targeting the EGF receptor family in non-small cell lung cancer – increased complexity and future perspectives. <i>Cancer Biology and Medicine</i> , 2022, 19, 1543-1564.	1.4	12
2272	Clinical and technical insights of tumour mutational burden in non-small cell lung cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2023, 182, 103891.	2.0	6
2273	Tolerability and efficacy of chemoimmunotherapy when administered with a corticosteroid-free anti-emetic regimen. <i>Journal of Oncology Pharmacy Practice</i> , 0, , 107815522211465.	0.5	0
2274	Neoadjuvant Immunotherapy in Oncogene-Positive Non-Small Cell Lung Cancer: A Multicenter Study. <i>Annals of Thoracic Surgery</i> , 2023, 116, 703-710.	0.7	5

#	ARTICLE	IF	CITATIONS
2275	ANK2 as a novel predictive biomarker for immune checkpoint inhibitors and its correlation with antitumor immunity in lung adenocarcinoma. <i>BMC Pulmonary Medicine</i> , 2022, 22, .	0.8	0
2276	Prognostic factors of toxicity of immune checkpoint inhibitors in nonsmall cell lung cancer and small cell lung cancer patients: The <sc>ToxImmune</sc> study. <i>Cancer Reports</i> , 2023, 6, .	0.6	2
2277	Suppression of Tumor or Host Intrinsic CMTM6 Drives Antitumor Cytotoxicity in a PD-L1â€“Independent Manner. <i>Cancer Immunology Research</i> , 2023, 11, 241-260.	1.6	3
2278	The Effect of Pleural Effusion on Prognosis in Patients with Non-Small Cell Lung Cancer Undergoing Immunochemotherapy: A Retrospective Observational Study. <i>Cancers</i> , 2022, 14, 6184.	1.7	3
2279	Current treatment approaches for brain metastases in <i>ALK</i>/<i>ROS1</i>/<i>NTRK</i>-positive non-small-cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2023, 23, 29-41.	1.1	1
2280	spaCI: deciphering spatial cellular communications through adaptive graph model. <i>Briefings in Bioinformatics</i> , 2023, 24, .	3.2	28
2281	Nonâ€“small cell lung cancer carrying PBRM1 mutation suggests an immunologically cold phenotype leading to immunotherapy failure even with high TMB. <i>Scientific Reports</i> , 2022, 12, .	1.6	2
2282	Radiopharmaceuticals heat anti-tumor immunity. <i>Theranostics</i> , 2023, 13, 767-786.	4.6	4
2284	Investigation of racial differences in survival from non-small cell lung cancer with immunotherapy use: A Texas study. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
2285	Clinical Progress and Prospect of Traditional Chinese Medicine Combined with Immune Checkpoint Inhibitors in the Treatment of Non-Small Cell Lung Cancer. <i>Advances in Clinical Medicine</i> , 2022, 12, 11735-11739.	0.0	0
2286	Evolution of treatment patterns and survival outcomes in patients with advanced non-small cell lung cancer treated at Frankfurt University Hospital in 2012â€“2018. <i>BMC Pulmonary Medicine</i> , 2023, 23, .	0.8	0
2287	Camrelizumab Plus Carboplatin and Pemetrexed as First-Line Treatment for Advanced Nonsquamous NSCLC: Extended Follow-Up of CameL Phase 3 Trial. <i>Journal of Thoracic Oncology</i> , 2023, 18, 628-639.	0.5	6
2288	Long-term comparative efficacy and safety of nivolumab plus ipilimumab relative to other first-line therapies for advanced non-small-cell lung cancer: A systematic literature review and network meta-analysis. <i>Lung Cancer</i> , 2023, 177, 11-20.	0.9	8
2289	Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 1365-1379.	2.0	93
2290	Therapeutic antibodies for precise cancer immunotherapy: current and future perspectives. <i>Medical Review</i> , 2023, 2, 555-569.	0.3	6
2291	Mechanisms of Resistance to Immunotherapies in Cancer. , 2023, , 1-30.		0
2292	Configuring Therapeutic Aspects of Immune Checkpoints in Lung Cancer. <i>Cancers</i> , 2023, 15, 543.	1.7	8
2293	A Subset of PD-1-Expressing CD56bright NK Cells Identifies Patients with Good Response to Immune Checkpoint Inhibitors in Lung Cancer. <i>Cancers</i> , 2023, 15, 329.	1.7	8

#	ARTICLE	IF	CITATIONS
2294	Predictive Nomogram for Hyperprogressive Disease During Anti-PD-1/PD-L1 Treatment in Patients with Advanced Non-Small Cell Lung Cancer. <i>ImmunoTargets and Therapy</i> , 0, Volume 12, 1-16.	2.7	1
2295	Tumor Dynamic Model-Based Decision Support for Phase Ib/II Combination Studies: A Retrospective Assessment Based on Resampling of the Phase III Study IMpower150. <i>Clinical Cancer Research</i> , 2023, 29, 1047-1055.	3.2	5
2296	At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC. <i>Nature Reviews Clinical Oncology</i> , 2023, 20, 143-159.	12.5	29
2298	Increasing cure rates of solid tumors by immune checkpoint inhibitors. <i>Experimental Hematology and Oncology</i> , 2023, 12, .	2.0	17
2299	Bevacizumab biosimilar candidate TAB008 compared to Avastin® in patients with locally advanced, metastatic EGFR wild-type non-squamous non-small cell lung cancer: a randomized, double-blind, multicenter study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 5907-5914.	1.2	1
2300	Therapeutic strategies for non-small cell lung cancer: Experimental models and emerging biomarkers to monitor drug efficacies. , 2023, 242, 108347.		4
2301	Multistate Pharmacometric Model to Define the Impact of Second-Line Immunotherapies on the Survival Outcome of the IMpower131 Study. <i>Clinical Pharmacology and Therapeutics</i> , 2023, 113, 851-858.	2.3	5
2302	In Silico Re-Optimization of Atezolizumab Dosing Using Population Pharmacokinetic Simulation and Exposure-Response Simulation. <i>Journal of Clinical Pharmacology</i> , 2023, 63, 672-680.	1.0	3
2303	<sc>Câ€PLAN</sc> index as a prognostic factor for patients with previously untreated advanced non-small cell lung cancer who received combination immunotherapy: A multicenter retrospective study. <i>Thoracic Cancer</i> , 2023, 14, 636-642.	0.8	2
2304	Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2023, 34, 358-376.	0.6	94
2305	BTN2A1-BRAF fusion may be a novel mechanism of resistance to osimertinib in lung adenocarcinoma: a case report. <i>Translational Cancer Research</i> , 2023, 12, 186-193.	0.4	3
2306	A network meta-analysis of immunotherapy-based treatments for advanced nonsquamous non-small cell lung cancer. <i>Journal of Comparative Effectiveness Research</i> , 0, , .	0.6	0
2307	The imbalance between NKG2A and NKG2D expression is involved in NK cell immunosuppression and tumor progression of patients with hepatitis B virus-related hepatocellular carcinoma. <i>Hepatology Research</i> , 2023, 53, 417-431.	1.8	3
2308	Research Progress in Prognostic Markers of Immunotherapy for Non-Small Cell Lung Cancer. <i>Advances in Clinical Medicine</i> , 2023, 13, 264-271.	0.0	0
2309	Wnt/ β -Catenin Signaling and Resistance to Immune Checkpoint Inhibitors: From Non-Small-Cell Lung Cancer to Other Cancers. <i>Biomedicines</i> , 2023, 11, 190.	1.4	9
2310	The Effects of Clonal Heterogeneity on Cancer Immunosurveillance. <i>Annual Review of Cancer Biology</i> , 2023, 7, 131-147.	2.3	3
2311	Avelumab in Combination With Cetuximab and Chemotherapy as First-Line Treatment for Patients With Advanced Squamous Non-Small Cell Lung Cancer. <i>JTO Clinical and Research Reports</i> , 2023, , 100461.	0.6	0
2312	Attribution of value for combination immune checkpoint inhibitors in non-small cell lung cancer. <i>Journal of Cancer Policy</i> , 2023, 35, 100382.	0.6	1

#	ARTICLE	IF	CITATIONS
2313	Serum-derived exosomal miR-125a-3p predicts the response to anti-programmed cell death-1/programmed cell death-ligand 1 monotherapy in patients with non-small cell lung cancer. <i>Gene</i> , 2023, 857, 147177.	1.0	2
2314	pfRNAsâ€”A Novel Class of Small Non-coding RNAs With Real Translational Potential. <i>Journal of Surgical Research</i> , 2023, 284, 237-244.	0.8	3
2315	Anti-Programmed Death Receptor 1 Signalling Immunotherapy as a Part of Curative Intent Strategies for Stages I-III Non-Small Cell Lung Cancer. <i>European Medical Journal Respiratory</i> , 0, , 109-116.	1.0	1
2316	Emerging Biomarkers in Immune Oncology to Guide Lung Cancer Management. <i>Targeted Oncology</i> , 0, , .	1.7	1
2317	Tumor Response, Disease Control, and Progression-Free Survival as Surrogate Endpoints in Trials Evaluating Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: Study- and Patient-Level Analyses. <i>Cancers</i> , 2023, 15, 185.	1.7	0
2318	Advancements in Cancer Immunotherapies. <i>Vaccines</i> , 2023, 11, 59.	2.1	8
2319	Impact of Results of TTF-1 Immunostaining on Efficacy of Platinum-Doublet Chemotherapy in Japanese Patients with Nonsquamous Non-Small-Cell Lung Cancer. <i>Journal of Clinical Medicine</i> , 2023, 12, 137.	1.0	0
2320	Comparison of Chemotherapy Plus Pembrolizumab vs. Chemotherapy Alone in EGFR-Mutant Nonâ€”small-Cell Lung Cancer Patients. <i>Clinical Lung Cancer</i> , 2023, 24, 278-286.	1.1	3
2321	The Role of Immune Checkpoint Inhibitors in Cancer Therapy. <i>Clinics and Practice</i> , 2023, 13, 22-40.	0.6	14
2322	The Association between Baseline Proton Pump Inhibitors, Immune Checkpoint Inhibitors, and Chemotherapy: A Systematic Review with Network Meta-Analysis. <i>Cancers</i> , 2023, 15, 284.	1.7	7
2323	Impact of Liver Metastases and Number of Metastatic Sites on Immune-Checkpoint Inhibitors Efficacy in Patients with Different Solid Tumors: A Retrospective Study. <i>Biomedicines</i> , 2023, 11, 83.	1.4	3
2324	A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel with or without atezolizumab in triple negative breast cancer (TNBC) - NCI 10013. <i>Npj Breast Cancer</i> , 2022, 8, .	2.3	8
2325	Nanoenabled Tumor Energy Metabolism Disorder via Sonodynamic Therapy for Multidrug Resistance Reversal and Metastasis Inhibition. <i>ACS Applied Materials & Interfaces</i> , 2023, 15, 309-326.	4.0	7
2326	Trends in real-world biomarker testing and overall survival in US patients with advanced non-small-cell lung cancer. <i>Future Oncology</i> , 2022, 18, 4385-4397.	1.1	3
2327	Antibiotic Treatment is an Independent Poor Risk Factor in NSCLC But Not in Melanoma Patients Who had Received Anti-PD-1/L1 Monotherapy. <i>Clinical Lung Cancer</i> , 2023, , .	1.1	2
2329	Bevacizumab-Induced Thrombotic Microangiopathy (TMA) in Metastatic Lung Adenocarcinoma Patients Receiving Nivolumab Combined with Bevacizumab, Carboplatin and Paclitaxel: Two Case Reports. <i>Clinics and Practice</i> , 2023, 13, 200-205.	0.6	2
2330	Tumor immunology. , 2023, , 245-452.		0
2332	Insight into autophagy in platinum resistance of cancer. <i>International Journal of Clinical Oncology</i> , 2023, 28, 354-362.	1.0	2

#	ARTICLE	IF	CITATIONS
2333	Association of immune-related adverse events and efficacy in advanced non-small-cell lung cancer: a systematic review and meta-analysis. <i>Immunotherapy</i> , 2023, 15, 209-220.	1.0	5
2334	Hypertransaminasemia in cancer patients receiving immunotherapy and immune-based combinations: the MOUSEION-05 study. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 1381-1394.	2.0	3
2335	Cost-effectiveness of first-line immunotherapies for advanced non-small cell lung cancer. <i>Cancer Medicine</i> , 0, , .	1.3	2
2336	Real-world Efficacy and Safety of Atezolizumab Plus Bevacizumab, Paclitaxel and Carboplatin for First-line Treatment of Japanese Patients With Metastatic Non-squamous Non-small Cell Lung Cancer. <i>Anticancer Research</i> , 2023, 43, 713-724.	0.5	4
2337	Peripheral blood lymphocytes differentiation patterns in responses / outcomes to immune checkpoint blockade therapies in non-small cell lung cancer: a retrospective study. <i>BMC Cancer</i> , 2023, 23, .	1.1	3
2338	The combined effect and mechanism of antiangiogenic drugs and PD-L1 inhibitor on cell apoptosis in triple negative breast cancer. <i>Annals of Translational Medicine</i> , 2023, 11, 83-83.	0.7	1
2339	Impact of Frailty on Outcomes of First-Line Pembrolizumab Monotherapy in a Real-World Population with Advanced Non-Small Cell Lung Cancer. <i>Biology</i> , 2023, 12, 191.	1.3	0
2340	Role of antiangiogenic agents in first-line treatment for advanced NSCLC in the era of immunotherapy. <i>BMC Cancer</i> , 2023, 23, .	1.1	6
2341	Genomic Instability and Protumoral Inflammation Are Associated with Primary Resistance to Anti-PD-1 + Antiangiogenesis in Malignant Pleural Mesothelioma. <i>Cancer Discovery</i> , 2023, 13, 858-879.	7.7	4
2342	Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2023, 34, 339-357.	0.6	118
2343	NEPTUNE China cohort: First-line durvalumab plus tremelimumab in Chinese patients with metastatic non-small-cell lung cancer. <i>Lung Cancer</i> , 2023, 178, 87-95.	0.9	0
2344	Regulation of Inflammasome by microRNAs in Triple-Negative Breast Cancer: New Opportunities for Therapy. <i>International Journal of Molecular Sciences</i> , 2023, 24, 3245.	1.8	0
2345	Treatments for brain metastases from EGFR/ALK-negative/unselected NSCLC: A network meta-analysis. <i>Open Medicine (Poland)</i> , 2023, 18, .	0.6	0
2346	Clinical Observation of Immunotherapy Combined with Antiangiogenic Targeted Drugs in the Treatment of 20 Cases Advanced Hepatocellular Carcinoma. <i>Advances in Clinical Medicine</i> , 2023, 13, 2575-2580.	0.0	0
2347	Risk factors indicating immune-related adverse events with combination chemotherapy with immune checkpoint inhibitors and platinum agents in patients with non-small cell lung cancer: a multicenter retrospective study. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 2169-2178.	2.0	1
2348	Radiation Recall Pneumonitis Anticipates Bilateral Immune-Induced Pneumonitis in Non-Small Cell Lung Cancer. <i>Journal of Clinical Medicine</i> , 2023, 12, 1266.	1.0	1
2349	Efficacy and outcomes of ramucirumab and docetaxel in patients with metastatic non-small cell lung cancer after disease progression on immune checkpoint inhibitor therapy: Results of a monocentric, retrospective analysis. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	1
2350	New Therapies on the Horizon. <i>Hematology/Oncology Clinics of North America</i> , 2023, , .	0.9	1

#	ARTICLE	IF	CITATIONS
2351	Low Risk of Hyperprogression with First-Line Chemoimmunotherapy for Advanced Non-Small Cell Lung Cancer: Pooled Analysis of 7 Clinical Trials. <i>Oncologist</i> , 2023, 28, e205-e211.	1.9	4
2352	Improvement strategy for immune checkpoint blockade: A focus on the combination with immunogenic cell death inducers. <i>Cancer Letters</i> , 2023, 562, 216167.	3.2	5
2353	Advances in the application of immune checkpoint inhibitors in gynecological tumors. <i>International Immunopharmacology</i> , 2023, 117, 109774.	1.7	5
2354	Soluble interleukin-2 receptor as a predictive biomarker for poor efficacy of combination treatment with anti-PD-1/PD-L1 antibodies and chemotherapy in non-small cell lung cancer patients. <i>Investigational New Drugs</i> , 0, , .	1.2	0
2355	Multicentre real-world data of ramucirumab plus docetaxel after combined platinum-based chemotherapy with programmed death-1 blockade in advanced non-small cell lung cancer: NEJ051 (REACTIVE study). <i>European Journal of Cancer</i> , 2023, 184, 62-72.	1.3	9
2356	Comprehensive evaluation of surrogate endpoints to predict overall survival in trials with PD1/PD-L1 immune checkpoint inhibitors plus chemotherapy. <i>Cancer Treatment Reviews</i> , 2023, 116, 102542.	3.4	1
2357	Anti-angiogenic agents for NSCLC following first-line immunotherapy: Rationale, recent updates, and future perspectives. <i>Lung Cancer</i> , 2023, 179, 107173.	0.9	7
2358	CD163 Monoclonal Antibody Modified Polymer Prodrug Nanoparticles for Targeting Tumor-Associated Macrophages (TAMs) to Enhance Anti-Tumor Effects. <i>Pharmaceutics</i> , 2023, 15, 1241.	2.0	0
2359	Treatment Strategies for Non-Small Cell Lung Cancer with Common EGFR Mutations: A Review of the History of EGFR TKIs Approval and Emerging Data. <i>Cancers</i> , 2023, 15, 629.	1.7	7
2360	Adjuvant immunotherapy in early-stage resectable non-small cell lung cancer: A new milestone. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	4
2361	A phase II study (WJOG12819L) to assess the efficacy of osimertinib in patients with EGFR mutation-positive NSCLC in whom systemic disease (T790M-negative) progressed after treatment with first- or second-generation EGFR TKIs and platinum-based chemotherapy. <i>Lung Cancer</i> , 2023, 177, 44-50.	0.9	2
2362	Atezolizumab with or without bevacizumab and platinum-pemetrexed in patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies: A multicentre phase II open-label non-randomised study GFPC 06-2018. <i>European Journal of Cancer</i> , 2023, 183, 38-48.	1.3	8
2364	Management of Locally Advanced or Metastatic Combined Hepatocellular Cholangiocarcinoma. <i>Cancers</i> , 2023, 15, 988.	1.7	1
2365	The Combination of Immune Checkpoint Blockade with Tumor Vessel Normalization as a Promising Therapeutic Strategy for Breast Cancer: An Overview of Preclinical and Clinical Studies. <i>International Journal of Molecular Sciences</i> , 2023, 24, 3226.	1.8	3
2366	Sintilimab plus chemotherapy for first-line treatment of advanced or metastatic nonsquamous non-small-cell lung cancer: network meta-analysis. <i>Immunotherapy</i> , 2023, 15, 293-309.	1.0	2
2367	Efficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancer. <i>Nature Communications</i> , 2023, 14, .	5.8	18
2368	Immunotherapy progress and clinical strategy of unresectable locally advanced non-small cell lung cancer. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	2
2369	The development and implementation of EGFR inhibitors in advanced NSCLC. , 2023, , 13-36.		0

#	ARTICLE	IF	CITATIONS
2370	Overall survival and role of programmed death ligand 1 expression in patients with metastatic non-small-cell lung cancer and immunotherapy: an observational study from central Switzerland. <i>Swiss Medical Weekly</i> , 2023, 153, 40039.	0.8	0
2371	The Interaction of Programmed Cell Death Protein and Its Ligands with Non-Coding RNAs in Neoplasms: Emerging Anticancer Immunotherapeutics. <i>Processes</i> , 2023, 11, 538.	1.3	0
2372	Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2023, 18, 731-743.	0.5	15
2373	Circulating Biomarkers for Prediction of Immunotherapy Response in NSCLC. <i>Biomedicines</i> , 2023, 11, 508.	1.4	3
2374	Clinical Characteristics and Pharmacokinetics Change of Long-Term Responders to Antiprogrammed Cell Death Protein 1 Inhibitor Among Patients With Advanced NSCLC. <i>JTO Clinical and Research Reports</i> , 2023, 4, 100474.	0.6	0
2375	Sequencing strategies with ramucirumab and docetaxel following prior treatments for advanced non-small cell lung cancer: a multicenter retrospective cohort study. <i>European Journal of Clinical Pharmacology</i> , 2023, 79, 503-511.	0.8	2
2376	Efficacy and safety of immune checkpoint inhibitors combined with recombinant human endostatin and chemotherapy as the first-line treatment of advanced non-small-cell lung cancer. <i>Future Oncology</i> , 2023, 19, 147-158.	1.1	0
2377	Prognostic Associations of Concomitant Antibiotic Use in Patients with Advanced NSCLC Treated with Atezolizumab: Sensitivity Analysis of a Pooled Investigation of Five Randomised Control Trials. <i>Biomedicines</i> , 2023, 11, 528.	1.4	0
2378	The interplay between inflammatory cytokines and cardiometabolic disease: bi-directional mendelian randomisation study. , 2023, 2, e000157.		4
2379	Controversies in NSCLC: which second-line strategy after chemo-immunotherapy?. <i>ESMO Open</i> , 2023, 8, 100879.	2.0	2
2380	Immunotherapy for Metastatic Non-Small Cell Lung Cancer: Therapeutic Advances and Biomarkers. <i>Current Oncology</i> , 2023, 30, 2366-2387.	0.9	5
2381	ALK-positive lung cancer: a moving target. <i>Nature Cancer</i> , 2023, 4, 330-343.	5.7	24
2382	Association of Immune-Related Adverse Events With Efficacy of Atezolizumab in Patients With Nonâ€Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2023, 9, 527.	3.4	37
2383	Durable response of tislelizumab plus cisplatin, nab-paclitaxel followed by concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: A case report. <i>Medicine (United States)</i> , 2023, 102, e32924.	0.4	0
2384	Angiogenic inhibitor preâ€administration improves the therapeutic effects of immunotherapy. <i>Cancer Medicine</i> , 2023, 12, 9760-9773.	1.3	3
2385	Standard versus lowâ€dose nabâ€paclitaxel in previously treated patients with advanced nonâ€small cell lung cancer: A randomized phase <sc>II</sc> trial (<sc>JMTO LC14</sc>â€01). <i>Cancer Medicine</i> , 2023, 12, 9133-9143.	1.3	2
2386	Cell adhesion molecules and immunotherapy in advanced non-small cell lung cancer: Current process and potential application. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
2387	Economic burden of locoregional and metastatic relapses in resectable early-stage non-small cell lung cancer in Spain. <i>BMC Pulmonary Medicine</i> , 2023, 23, .	0.8	1

#	ARTICLE	IF	CITATIONS
2388	Lung cancer immunotherapy: progress, pitfalls, and promises. <i>Molecular Cancer</i> , 2023, 22, .	7.9	104
2389	Predictive biomarkers for PD-1/PD-L1 checkpoint inhibitor response in NSCLC: an analysis of clinical trial and real-world data. , 2023, 11, e006464.		4
2390	MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy. <i>Journal of Thoracic Oncology</i> , 2023, 18, 907-921.	0.5	7
2391	Immune-related adverse events as potential surrogates of immune checkpoint inhibitorsâ€™ efficacy: a systematic review and meta-analysis of randomized studies. <i>ESMO Open</i> , 2023, 8, 100787.	2.0	13
2392	LOREALAUS: LOrlatinib REAL-World AUStralian Experience in Advanced ALK-Rearranged NSCLC. <i>JTO Clinical and Research Reports</i> , 2023, 4, 100490.	0.6	0
2393	JAG1 is correlated to suppressive immune microenvironment and predicts immunotherapy resistance in lung adenocarcinoma. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	1
2394	Narrative review: immunotherapy in anaplastic lymphoma kinase (ALK)+ lung cancerâ€™ current status and future directions. <i>Translational Lung Cancer Research</i> , 2023, 12, 322-336.	1.3	1
2395	Optimal first-line treatment for metastatic ALK+ non-small cell lung cancerâ€™ a narrative review. <i>Translational Lung Cancer Research</i> , 2023, 12, 369-378.	1.3	3
2396	Durable Response to Chemoimmunotherapy of a Lung Adenocarcinoma Harboring a MET Exon 14 Skipping Mutation. <i>Cureus</i> , 2023, , .	0.2	0
2397	Immunotherapy in Elderly Patients Affected by Non-Small Cell Lung Cancer: A Narrative Review. <i>Journal of Clinical Medicine</i> , 2023, 12, 1833.	1.0	4
2399	A Closer Look at EGFR Inhibitor Resistance in Non-Small Cell Lung Cancer through the Lens of Precision Medicine. <i>Journal of Clinical Medicine</i> , 2023, 12, 1936.	1.0	3
2400	Pretreatment levels of serum alkaline phosphatase are associated with the prognosis of patients with nonâ€™small cell lung cancer receiving immune checkpoint inhibitors. <i>Oncology Letters</i> , 2023, 25, .	0.8	2
2401	Identification of fibrocyte cluster in tumors reveals the role in antitumor immunity by PD-L1 blockade. <i>Cell Reports</i> , 2023, 42, 112162.	2.9	8
2402	Safety and clinical activity of atezolizumab plus erlotinib in patients with non-small-cell lung cancer. <i>ESMO Open</i> , 2023, 8, 101160.	2.0	3
2403	Safety and Efficacy of Bojungikki-Tang in Advanced NSCLC Patients Receiving Treatment with Immune Checkpoint Inhibitors: Protocol for a Multicenter, Double-Blind, Randomized, Placebo-Controlled Pilot Trial. <i>International Journal of Environmental Research and Public Health</i> , 2023, 20, 4507.	1.2	1
2404	CDK4/6 inhibition triggers ICAM1-driven immune response and sensitizes LKB1 mutant lung cancer to immunotherapy. <i>Nature Communications</i> , 2023, 14, .	5.8	14
2405	Nomogram prediction for the risk of venous thromboembolism in patients with lung cancer. <i>Cancer Cell International</i> , 2023, 23, .	1.8	6
2406	Infections in lung cancer patients undergoing immunotherapy and targeted therapy: An overview on the current scenario. <i>Critical Reviews in Oncology/Hematology</i> , 2023, 184, 103954.	2.0	3

#	ARTICLE	IF	CITATIONS
2407	Immune checkpoint inhibitor-associated toxicity in advanced non-small cell lung cancer: An updated understanding of risk factors. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	2
2409	Immune checkpoint inhibitors related respiratory disorders in patients with lung cancer: A meta-analysis of randomized controlled trials. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	0
2410	Clinical Efficacy and Safety of Immunotherapy Retreatment in Metastatic Cervical Cancer: A Retrospective Study. <i>OncoTargets and Therapy</i> , 0, Volume 16, 157-163.	1.0	2
2411	Cost-effectiveness of adjuvant atezolizumab versus best supportive care in the treatment of patients with resectable early-stage non-small cell lung cancer and overexpression of PD-L1. <i>Journal of Medical Economics</i> , 2023, 26, 445-453.	1.0	2
2412	Current Advances in Immune Checkpoint Therapy. , 0, , .		0
2413	Anti-PD-(L)1 therapy of non-small cell lung cancerâ€“A summary of clinical trials and current progresses. <i>Heliyon</i> , 2023, 9, e14566.	1.4	2
2414	Prognostic Model of Baseline Medications plus Neutrophil-to-lymphocyte Ratio in Patients with Advanced Non-small-cell Lung Cancer Receiving Immune Checkpoint Inhibitor plus Platinum Doublet: A Multicenter Retrospective Study. <i>Journal of Cancer</i> , 2023, 14, 676-688.	1.2	0
2415	Strategies targeting PD-L1 expression and associated opportunities for cancer combination therapy. <i>Theranostics</i> , 2023, 13, 1520-1544.	4.6	19
2416	Lung cancer management in low and middle-income countries - current challenges and potential solutions. <i>International Journal of Cancer Care and Delivery</i> , 2023, 3, .	0.0	0
2417	Immune checkpoint inhibitors in metastatic NSCLC: challenges and future directions (CME article). <i>International Journal of Cancer Care and Delivery</i> , 2023, 3, .	0.0	0
2418	A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer. <i>Nature Medicine</i> , 2023, 29, 859-868.	15.2	30
2420	Neurotoxicity following atezolizumab in a patient with tolerated rechallenge*. <i>Therapie</i> , 2023, , .	0.6	0
2421	Efficacy of immunotherapy in oncogene-driven non-small-cell lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2023, 15, 175883592311614.	1.4	8
2422	Strategies to overcome resistance to ALK inhibitors in non-small cell lung cancer: a narrative review. <i>Translational Lung Cancer Research</i> , 2023, 12, 615-628.	1.3	6
2423	Classification of Tumor Immune Microenvironment According to Programmed Death-Ligand 1 Expression and Immune Infiltration Predicts Response to Immunotherapy Plus Chemotherapy in Advanced Patients With NSCLC. <i>Journal of Thoracic Oncology</i> , 2023, 18, 869-881.	0.5	14
2424	Aging microenvironment and antitumor immunity for geriatric oncology: the landscape and future implications. <i>Journal of Hematology and Oncology</i> , 2023, 16, .	6.9	5
2425	Combi-TED: a new trial testing Tedopi [®] with docetaxel or nivolumab in metastatic non-small-cell lung cancer progressing after first line. <i>Future Oncology</i> , 2022, 18, 4457-4464.	1.1	1
2426	Immunotherapy combined with rh-endostatin improved clinical outcomes over immunotherapy plus chemotherapy for second-line treatment of advanced NSCLC. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	2

#	ARTICLE	IF	CITATIONS
2427	Immunotherapy in the first-line treatment of elderly patients with advanced non-small-cell lung cancer: results of an International Experts Panel Meeting by the Italian Association of Thoracic Oncology (AIOT). <i>ESMO Open</i> , 2023, 8, 101192.	2.0	7
2428	Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer. <i>New England Journal of Medicine</i> , 2023, 388, 2145-2158.	13.9	139
2429	Efficacy and safety of a triple combination of atezolizumab, bevacizumab plus GEMOX for advanced biliary tract cancer: a multicenter, single-arm, retrospective study. <i>Therapeutic Advances in Gastroenterology</i> , 2023, 16, 175628482311606.	1.4	4
2430	Immunotherapy efficacy predictive tool for lung adenocarcinoma based on neural network. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	0
2431	Cemiplimab Plus Chemotherapy Versus Chemotherapy Alone in Advanced NSCLC: 2-Year Follow-Up From the Phase 3 EMPOWER-Lung 3 Part 2 Trial. <i>Journal of Thoracic Oncology</i> , 2023, 18, 755-768.	0.5	13
2432	All-round counterattack to conquer lung cancer. <i>Journal of the Korean Medical Association</i> , 2023, 66, 154-158.	0.1	0
2433	Randomized Clinical Trials: Pitfalls in Design, Analysis, Presentation, and Interpretation. <i>Medical Radiology</i> , 2023, , .	0.0	0
2434	Costâ€“effectiveness of adjuvant atezolizumab for patients with stage IIâ€“III A PD-L1+ non-small-cell lung cancer. <i>Immunotherapy</i> , 2023, 15, 573-581.	1.0	1
2435	Anlotinib succeeded in rescue therapy for hyperprogression induced by immune checkpoint inhibitors: a case report. <i>Immunotherapy</i> , 2023, 15, 631-639.	1.0	2
2436	Immunotherapy resistance in non-small-cell lung cancer: From mechanism to clinical strategies. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	8
2437	Role of Surgical Pathologist for the Detection of Immuno-oncologic Predictive Factors in Non-small Cell Lung Cancers. <i>Advances in Anatomic Pathology</i> , 2023, 30, 174-194.	2.4	0
2438	Survival of NSCLC Patients Treated with Cimavax-EGF as Switch Maintenance in the Real-World Scenario. <i>Journal of Cancer</i> , 2023, 14, 874-879.	1.2	3
2439	Cancer organoids: A platform in basic and translational research. <i>Genes and Diseases</i> , 2024, 11, 614-632.	1.5	4
2440	The toxicity associated with combining immune check point inhibitors with tyrosine kinase inhibitors in patients with non-small cell lung cancer. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	2
2441	High Expression of MHC Class I Overcomes Cancer Immunotherapy Resistance Due to IFNÎ³ Signaling Pathway Defects. <i>Cancer Immunology Research</i> , 2023, 11, 895-908.	1.6	6
2442	Incidence of serious adverse events caused by tyrosine kinase inhibitor treatment following immune checkpoint inhibitor therapy in advanced NSCLC patients with oncogenic driver alterations. <i>Cancer Immunology, Immunotherapy</i> , 0, , .	2.0	1
2443	Pathological angiogenesis: mechanisms and therapeutic strategies. <i>Angiogenesis</i> , 2023, 26, 313-347.	3.7	50
2444	The Role of Immunotherapy in the First-Line Treatment of Elderly Advanced Non-Small Cell Lung Cancer. <i>Cancers</i> , 2023, 15, 2319.	1.7	1

#	ARTICLE	IF	CITATIONS
2446	Identifying optimal first-line immune checkpoint inhibitors based regimens for advanced non-small cell lung cancer without oncogenic driver mutations: A systematic review and network meta-analysis. PLoS ONE, 2023, 18, e0283719.	1.1	1
2447	Clinical benefit of platinum doublet combination therapy in older adults with advanced non-small cell lung cancer: A prospective multicenter study by the National Hospital Organization in Japan. Thoracic Cancer, 0, , .	0.8	0
2448	Targeting Angiogenesis in the Era of Biliary Tract Cancer Immunotherapy: Biological Rationale, Clinical Implications, and Future Research Avenues. Cancers, 2023, 15, 2376.	1.7	1
2449	Lung carcinoma with small intestinal metastases and gastrointestinal bleeding: A rare case report. Oncology Letters, 2023, 25, .	0.8	0
2450	Advances in the Treatment of Rare Epidermal Growth Factor Receptor Mutations in Advanced Nonsmall-Cell Lung Cancer. Technology in Cancer Research and Treatment, 2023, 22, 153303382311684.	0.8	0
2452	Evaluating the effect of PD-1 inhibitors on left ventricular function in lung cancer with noninvasive myocardial work. Quantitative Imaging in Medicine and Surgery, 2023, .	1.1	1
2455	Harnessing Phagocytosis for Cancer Treatment. Physiology, 0, , .	4.0	0
2473	The clinical application of immuno-therapeutics. , 2024, , 237-288.e7.		0
2538	Immunotherapy of Biliary Tract Cancer. , 2023, , .		0
2555	The complementarity of DDR, nucleic acids and anti-tumour immunity. Nature, 2023, 619, 475-486.	13.7	13
2570	Small-Molecule Inhibitors of Protein-Protein Interactions as Therapeutics. , 2023, , 343-428.		0
2598	Immune checkpoint targeting antibodies hold promise for combinatorial cancer therapeutics. Clinical and Experimental Medicine, 2023, 23, 4297-4322.	1.9	2
2603	Diagnosis and treatment of anaplastic lymphoma kinase (ALK) rearranged non-small cell lung cancer. , 2024, , 253-268.		0
2619	The Revolution of Lung Cancer Therapeutics. , 2023, , 235-249.		0
2626	Modern therapies of nonsmall cell lung cancer. Journal of Applied Genetics, 2023, 64, 695-711.	1.0	3
2636	Immunotherapy for Non-small Cell Lung Cancer. , 2023, , 1-25.		0
2644	Second-line therapy in advanced non-small cell lung cancer. , 2024, , 195-216.		0
2646	First-line therapy. , 2024, , 175-194.		0

#	ARTICLE	IF	CITATIONS
2649	Treatment of Stage IV Non-small Cell Lung Cancer. <i>Respiratory Medicine</i> , 2023, , 165-186.	0.1	0
2657	PD-1 and PD-L1 inhibitors in cold colorectal cancer: challenges and strategies. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 3875-3893.	2.0	4
2705	Lung Cancer in Elderly: Patient-Centered Approach for Optimal Delivery of Care. , 2024, , 1-17.		0
2708	The SWI/SNF Complex: A Frequently Mutated Chromatin Remodeling Complex in Cancer. <i>Cancer Treatment and Research</i> , 2023, , 211-244.	0.2	1
2755	The cardiac-related adverse events of PD-1/PD-L1 immunotherapy in advanced or metastatic lung cancer: a RCT-based meta-analysis. <i>Supportive Care in Cancer</i> , 2024, 32, .	1.0	0
2772	Malignome des Respirationstrakts. , 2024, , 601-646.		0
2775	Lung Cancer in Elderly: Patient-Centered Approach for Optimal Delivery of Care. , 2024, , 869-884.		0
2800	Important Biomarkers for Better Evaluation of Checkpoint Inhibitors and Other Immunotherapies in Lung Cancer. , 2024, , 331-351.		0
2801	Current and Future Perspectives of Combining Chemotherapy and Stereotactic Body Radiation Therapy with Immunotherapy in the Treatment of Lung Cancer. , 2024, , 265-295.		0